[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f_eHKwanh2ocCCvpJAO4P0utCHrLiXXma3Jo8IuU-wLs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"Peking Union Medical College",[6,4],"Peking Union Medical College Hospital",1149,false,360,67,1201465,272,576,[15,18,21,24,26,28,31,34],{"name":16,"count":17},"Breast Cancer",45,{"name":19,"count":20},"Pancreatic Cancer",17,{"name":22,"count":23},"Aplastic Anemia",15,{"name":25,"count":23},"Cervical Cancer",{"name":27,"count":23},"Hepatocellular Carcinoma",{"name":29,"count":30},"Lung Cancer",13,{"name":32,"count":33},"Surgery",11,{"name":35,"count":33},"Pelvic Organ Prolapse",[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05052619","Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes","2023-07-01","Preventive use of advanced antibiotics",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05383716","Neoadjuvant\u002FAdjuvant Pembrolizumab Plus Chemotherapy","2023-12-08","Pembrolizumab",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04736589","Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway","2024-02-02","Inetetamab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05507112","TIME in Immunotherapy Combined With nCRT for Rectal Cancer","2024-07-01","PD-1 inhibitor",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05603559","177Lu-P17-087\u002F177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer","2024-09-05","1.1 GBq (30 mCi) of 177Lu-P17-087",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT06039891","Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer","2024-10-01","Nimotuzumab、Tislelizumab",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT05013086","177Lu-AB-3PRGD2 in Patients With Integrin αVβ3 Positive Tumors","2024-10-30","1.48 GBq of 177Lu-AB-3PRGD2",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05996406","Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)","2024-11-13","Venetoclax",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06518850","Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension","2024-12-31","Rifaximin",{"nctId":83,"briefTitle":84,"date":80,"intervention":85},"NCT06926192","Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa","Surgery combined with secukinumab",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,213,342,389,502,545,567,604,635,684,714,736,765,796,826,855,873,902,920,938,965,993,1011,1029,1055,1073,1100,1118,1144,1162,1187,1213,1239,1265,1283,1306,1332,1350,1377,1395,1419,1443,1467,1485,1514,1544,1562,1586,1604,1659,1723,1779,1804,1837,1884,1928,1958,1982,2000,2025,2043,2069,2092,2120,2138,2156,2181,2204,2222,2240,2267,2285,2311,2329,2397,2439,2530,2595,2706,2782,2844,2893,2940,2962,2992,3026,3048,3070,3135,3180,3229,3251,3347,3387,3414,3482,3516,3566,3602,3631,3653,3687,3709,3734,3752,3770,3788,3812,3830,3849,3875,3898,3918,3936,3962,3980,3998,4022,4047,4091,4109,4127,4145,4163,4181,4199,4217,4235,4253,4271,4289,4307,4325,4343,4361,4379,4397,4415,4433,4458,4483,4501,4519,4542,4564,4589,4614,4638,4662,4687,4705,4723,4747,4765,4790,4808,4831,4854,4881,4909,4927,4945,4963,4985,5011,5029,5052,5081,5099,5124,5142,5164,5190,5208,5226,5253,5271,5289,5311,5333,5357,5379,5447,5493,5527,5564,5602,5628,5650,5711,5733,5756,5777,5799,5828,5883,5909,5932,5955,5979,6000,6018,6042,6065,6088,6111,6129,6155,6173,6192,6217,6235,6253,6278,6296,6318,6340,6364,6386,6424,6462,6493,6515,6552,6574,6596,6645,6674,6710,6737,6760,6778,6802,6824,6850,6868,6886,6904,6931,6949,6973,6991,7015,7033,7053,7075,7100,7118,7142,7165,7189,7211,7235,7257,7277,7299,7322,7340,7362,7385,7409,7436,7454,7476,7494,7512,7530,7556,7579,7602,7626,7648,7671,7730,7764,7794,7820,7853,7882,7922,7957,7979,8014,8041,8078,8104,8131,8149,8175,8193,8217,8235,8258,8284,8310,8334,8352,8377,8395,8413,8436,8461,8486,8511,8529,8551,8574,8599,8623,8651,8669,8687,8714,8732,8750,8768,8786,8812,8830,8853,8878,8896,8920,8945,8963,8989,9007,9025,9048,9072,9090,9116,9134,9159,9183,9201,9226,9251,9269,9290,9308,9326,9344,9362,9380,9403,9421,9439,9463,9486,9510,9528,9546,9564,9587,9605,9623,9641,9659,9681,9714,9736,9758,9791,9818,9843,9871,9901,9924,9948,9966,9988,10012,10036,10061,10079,10097,10120,10141,10159,10181,10199,10221,10239,10257,10275,10299,10317,10341,10365,10390,10413,10431,10449,10467,10491,10514,10538,10556,10574,10600,10618,10640,10667,10706,10740,10783,10811,10841,10866,10892,10924,10946,10968,11000,11027,11056,11074,11092,11115,11137,11161,11179,11197,11215,11238,11256,11274,11299,11324,11342,11360,11383,11401,11423,11447,11465,11483,11501,11519,11543,11561,11585,11609,11627,11651,11674,11692,11715,11738,11762,11783,11805,11823,11847,11869,11890,11908,11933,11951,11969,11987,12009,12032,12050,12075,12093,12111,12129,12151,12169,12190,12211,12234,12256,12278,12301,12319,12342,12364,12388,12414,12439,12463,12485,12503,12528,12546,12570,12593,12617,12640,12678,12710,12738,12762,12780,12798,12822,12848,12866,12884,12902,12920,12942,12965,12989,13007,13031,13052,13074,13099,13120,13143,13165,13183,13201,13219,13264,13286,13308,13332,13355,13377,13399,13420,13442,13460,13483,13506,13528,13549,13570,13594,13618,13636,13659,13682,13700,13725,13749,13771,13793,13816,13852,13887,13923,13952,13982,14004,14031,14053,14089,14121,14155,14182,14209,14238,14273,14295,14313,14342,14364,14390,14416,14434,14456,14474,14499,14517,14539,14563,14588,14606,14630,14648,14672,14690,14716,14741,14765,14786,14809,14834,14852,14877,14895,14918,14941,14963,14981,15004,15029,15053,15074,15096,15119,15137,15155,15173,15199,15222,15240,15262,15280,15304,15322,15345,15368,15394,15417,15435,15459,15477,15501,15519,15537,15555,15578,15602,15620,15642,15660,15686,15708,15726,15752,15770,15793,15811,15829,15854,15878,15896,15914,15936,15958,15979,15997,16019,16044,16062,16080],{"intervention":95,"totalTrials":96,"cells":97},"Chemotherapy",8,{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":148,"PHASE4":185,"NA":200},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":147,"soonestReadout":139},[105,120,134],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":119},"NCT06353061","Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer","UNKNOWN",[89],"2025-08-01","2026-02-01","2024-04-15",51,[25,115,116,117,118],"Radiotherapy","Metformin","Hypoxia","PET\u002FCT",[116,95],{"nctId":121,"briefTitle":122,"status":108,"phases":123,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":131},"NCT05935579","Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer",[89],"2023-12-30","2024-12-30","2022-12-14",40,[129,130],"Biliary Tract Neoplasms","Immunotherapy",[132,133,95],"Durvalumab","Lenvatinib Oral Product",{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":145},"NCT06941766","Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors","RECRUITING",[88,89],"2027-04-16","2028-04-16","2025-04-15",20,[144],"Intermediate Trophoblastic Tumor",[146,95],"QL1706",1,{"trials":149,"activeCount":184,"soonestReadout":50},[150,160,171],{"nctId":48,"briefTitle":49,"status":151,"phases":152,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NOT_YET_RECRUITING",[90],"2027-02-02","2021-02-02",270,[16],[51,158,159,95],"Rapamycin","Pyrotinib",{"nctId":161,"briefTitle":162,"status":137,"phases":163,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT06907602","Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma",[89,90],"2026-12-31","2028-12-31","2024-01-12",120,[169],"Locally Advanced Esophageal Squamous Cell Carcinoma",[95,130],{"nctId":172,"briefTitle":173,"status":151,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":183},"NCT05524389","Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions",[90],"2026-12-01","2027-06-30","2022-12-01",624,[180,181,182],"Endometrial Cancer","Adjuvant Radiotherapy","Molecular Classification",[95],3,{"trials":186,"activeCount":147,"soonestReadout":191},[187],{"nctId":188,"briefTitle":189,"status":151,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":199},"NCT05429515","Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury",[91],"2032-07-01","2032-12-01","2022-07-01",50,[196,197,198],"Multiple Myeloma","Acute Kidney Injury","Hemodiafiltration With Ultrafiltrate Regeneration (HFR)",[95],{"trials":201,"activeCount":147,"soonestReadout":206},[202],{"nctId":203,"briefTitle":204,"status":151,"phases":205,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":211},"NCT07114666","XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer",[92],"2029-08","2030-08","2025-08-18",12,[19],[212,95],"XH001",{"intervention":214,"totalTrials":215,"cells":216},"Rituximab",10,{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":304,"PHASE4":327,"NA":340},{"trials":218,"activeCount":100},[],{"trials":220,"activeCount":100},[],{"trials":222,"activeCount":147,"soonestReadout":255},[223,236,251,262,273,283,292],{"nctId":224,"briefTitle":225,"status":108,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":194,"conditions":230,"interventions":232},"NCT05390749","Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL",[89],"2024-04-01","2026-04-01","2022-04-11",[231],"Primary Central Nervous System Lymphoma",[233,234,214,235],"Orelabrutinib","Pomalidomide","Methotrexate",{"nctId":237,"briefTitle":238,"status":108,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":142,"conditions":243,"interventions":245},"NCT04899570","Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma",[89],"2023-04-01","2025-04-01","2021-04-01",[244],"Intravascular Large B-Cell Lymphoma",[246,214,247,248,249,250],"Zanubrutinib","Cyclophosphamide","Epirubicin","Vindesine","Prednisone",{"nctId":252,"briefTitle":253,"status":151,"phases":254,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":259,"interventions":261},"NCT06973811","ZR-MTX for PIOL Phase II Trial",[89],"2027-10-30","2029-10-30","2025-05-10",47,[260],"Primary Intraocular Lymphoma",[235,214,246,235],{"nctId":263,"briefTitle":264,"status":108,"phases":265,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT04899453","Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL",[89],"2022-08-01","2024-08-01","2020-08-01",42,[271],"Primary Vitreoretinal Lymphoma",[235,214,246],{"nctId":274,"briefTitle":275,"status":108,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":258,"conditions":280,"interventions":281},"NCT04120350","R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib\u002FII Stuty",[88,89],"2022-08","2024-08","2019-08-16",[231],[235,214,282],"Lenalidomide",{"nctId":284,"briefTitle":285,"status":108,"phases":286,"primaryCompletion":287,"completion":288,"start":289,"enrollment":269,"conditions":290,"interventions":291},"NCT03746223","Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma",[89],"2020-11-15","2025-10-15","2018-11-15",[260],[235,214,282],{"nctId":293,"briefTitle":294,"status":108,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT03700229","Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A",[89],"2019-10-15","2020-04-15","2018-10-10",22,[301],"Acquired Hemophilia A",[303,214],"Bortezomib",{"trials":305,"activeCount":147,"soonestReadout":322},[306,318],{"nctId":307,"briefTitle":308,"status":309,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":209,"conditions":314,"interventions":316},"NCT04743739","Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN","TERMINATED",[90],"2022-12-20","2024-12-20","2021-04-14",[315],"Idiopathic Membranous Nephropathy",[214,317],"cyclosporine",{"nctId":319,"briefTitle":320,"status":137,"phases":321,"primaryCompletion":322,"completion":323,"start":313,"enrollment":324,"conditions":325,"interventions":326},"NCT04745728","Different Immunosuppressive Treatment in iMN",[90],"2027-12","2029-12",200,[315],[250,247,214],{"trials":328,"activeCount":147,"soonestReadout":333},[329],{"nctId":330,"briefTitle":331,"status":137,"phases":332,"primaryCompletion":333,"completion":164,"start":334,"enrollment":23,"conditions":335,"interventions":338},"NCT06410833","Belimumab After Rituximab in Resistant Primary Juvenile SS",[91],"2025-12-31","2024-03-09",[336,337],"Sjogren's Syndrome","Pediatric ALL",[214,339],"Belimumab",{"trials":341,"activeCount":100},[],{"intervention":343,"totalTrials":184,"cells":344},"Traditional Chinese Medicine",{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":373,"NA":387},{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":100},[],{"trials":350,"activeCount":100},[],{"trials":352,"activeCount":372,"soonestReadout":175},[353,361],{"nctId":354,"briefTitle":355,"status":137,"phases":356,"primaryCompletion":175,"completion":164,"start":312,"enrollment":357,"conditions":358,"interventions":360},"NCT07376824","Clinical and Metabolomics Studies on the Improvement of Ovarian Reserve by Acupoint Photodynamic Therapy and Traditional Chinese Medicine Treatment",[90],90,[359],"Diminished Ovarian Reserve (DOR)",[343],{"nctId":362,"briefTitle":363,"status":151,"phases":364,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},"NCT07296614","Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy",[90],"2028-07-30","2025-12-25",320,[359,369],"Infertility",[371,343],"Western Medicine",2,{"trials":374,"activeCount":147,"soonestReadout":379},[375],{"nctId":376,"briefTitle":377,"status":137,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":384},"NCT07580950","The Research of Integrated Traditional Chinese and Western Medicine on Hypothalamic Amenorrhea",[91],"2028-06-30","2025-10-22",210,[383],"Functional Hypothalamic Amenorrhea",[385,386],"traditional Chinese medicine","Western medicine",{"trials":388,"activeCount":100},[],{"intervention":390,"totalTrials":96,"cells":391},"Aspirin",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":438,"PHASE4":452,"NA":500},{"trials":393,"activeCount":100},[],{"trials":395,"activeCount":100},[],{"trials":397,"activeCount":147,"soonestReadout":416},[398,412,423],{"nctId":399,"briefTitle":400,"status":108,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":410},"NCT03356769","Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex",[89],"2021-11-20","2017-11-20",98,[406,390,407,408,409],"Tuberous Sclerosis Complex","Epilepsy","Cognitive Decline","Skin Lesions",[390,411],"AED",{"nctId":413,"briefTitle":414,"status":137,"phases":415,"primaryCompletion":416,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":421},"NCT06478537","TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination",[89],"2027-06-20","2024-06-20",56,[420],"Immune Thrombocytopenia",[422,390],"Hetrombopag Olamine",{"nctId":424,"briefTitle":425,"status":108,"phases":426,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":434},"NCT04434365","Effect of Berberine for Endothelial Function and Intestinal Microflora in Patients With Coronary Artery Disease",[88,89],"2019-11-18","2020-12-30","2019-06-21",24,[432,433],"Stable Coronary Artery Disease","Percutaneous Coronary Intervention",[435,390,436,437],"Berberine","Clopidogrel","Statin",{"trials":439,"activeCount":100},[440],{"nctId":441,"briefTitle":442,"status":443,"phases":444,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":448,"interventions":450},"NCT06037889","Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)","COMPLETED",[90],"2026-02-26","2023-11-09",516,[449],"Branch Atheromatous Disease",[451,390,436],"Tirofiban",{"trials":453,"activeCount":147,"soonestReadout":458},[454,466,479,490],{"nctId":455,"briefTitle":456,"status":137,"phases":457,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT03378934","Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention",[91],"2026-06","2026-08","2018-09-26",64,[463,433],"Coronary Artery Disease",[435,465,390,436],"Standard treatment",{"nctId":467,"briefTitle":468,"status":108,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":477},"NCT00724724","The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial",[91],"2011-06","2011-08","2008-08",1000,[475,476],"Stroke","Transient Ischemic Attack",[478,390],"Butylphthalide Soft",{"nctId":480,"briefTitle":481,"status":108,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":489},"NCT04631627","Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort",[91],"2021-12-30","2022-08-30","2020-11-16",1500,[488],"Preeclampsia",[390],{"nctId":491,"briefTitle":492,"status":443,"phases":493,"primaryCompletion":494,"completion":494,"start":495,"enrollment":127,"conditions":496,"interventions":498},"NCT02748330","Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention",[91],"2018-12","2016-06",[463,497],"Diabetes Mellitus, Type 2",[499,436,390],"Ticagrelor",{"trials":501,"activeCount":100},[],{"intervention":503,"totalTrials":184,"cells":504},"Romiplostim",{"EARLY_PHASE1":505,"PHASE1":507,"PHASE2":509,"PHASE3":511,"PHASE4":513,"NA":543},{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":100},[],{"trials":512,"activeCount":100},[],{"trials":514,"activeCount":372,"soonestReadout":539},[515,523,535],{"nctId":516,"briefTitle":517,"status":151,"phases":518,"primaryCompletion":519,"completion":333,"start":520,"enrollment":127,"conditions":521,"interventions":522},"NCT06516484","Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study",[91],"2025-07-31","2024-07-30",[22],[503],{"nctId":524,"briefTitle":525,"status":108,"phases":526,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":531,"interventions":533},"NCT06009497","Romiplostim in Combination With CsA vs. CsA in the Treatment of Newly Diagnosed NSAA",[91],"2024-12","2025-12","2023-08",44,[532],"Non Severe Aplastic Anemia",[503,534],"Ciclosporin",{"nctId":536,"briefTitle":537,"status":151,"phases":538,"primaryCompletion":539,"completion":333,"start":540,"enrollment":127,"conditions":541,"interventions":542},"NCT06535685","A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA",[91],"2025-03-30","2024-08-02",[22],[503],{"trials":544,"activeCount":100},[],{"intervention":386,"totalTrials":372,"cells":546},{"EARLY_PHASE1":547,"PHASE1":549,"PHASE2":551,"PHASE3":553,"PHASE4":559,"NA":565},{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":147,"soonestReadout":365},[555],{"nctId":362,"briefTitle":363,"status":151,"phases":556,"primaryCompletion":365,"completion":365,"start":366,"enrollment":367,"conditions":557,"interventions":558},[90],[359,369],[371,343],{"trials":560,"activeCount":147,"soonestReadout":379},[561],{"nctId":376,"briefTitle":377,"status":137,"phases":562,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":563,"interventions":564},[91],[383],[385,386],{"trials":566,"activeCount":100},[],{"intervention":568,"totalTrials":372,"cells":569},"Cyclosporin A",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":574,"PHASE3":587,"PHASE4":589,"NA":602},{"trials":571,"activeCount":100},[],{"trials":573,"activeCount":100},[],{"trials":575,"activeCount":147,"soonestReadout":580},[576],{"nctId":577,"briefTitle":578,"status":137,"phases":579,"primaryCompletion":580,"completion":581,"start":582,"enrollment":127,"conditions":583,"interventions":585},"NCT06802055","Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory\u002FIntolerant to Cyclosporin A",[89],"2026-01","2027-01","2025-01-25",[584],"Aplastic Anaemia",[586,568],"Sirolimus",{"trials":588,"activeCount":100},[],{"trials":590,"activeCount":147,"soonestReadout":595},[591],{"nctId":592,"briefTitle":593,"status":151,"phases":594,"primaryCompletion":595,"completion":596,"start":520,"enrollment":597,"conditions":598,"interventions":600},"NCT06525948","Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA",[91],"2025-06-30","2025-12-30",54,[22,599],"Transfusion-dependent Anemia",[601,568],"rhTPO",{"trials":603,"activeCount":100},[],{"intervention":436,"totalTrials":605,"cells":606},4,{"EARLY_PHASE1":607,"PHASE1":609,"PHASE2":611,"PHASE3":617,"PHASE4":623,"NA":633},{"trials":608,"activeCount":100},[],{"trials":610,"activeCount":100},[],{"trials":612,"activeCount":100},[613],{"nctId":424,"briefTitle":425,"status":108,"phases":614,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":615,"interventions":616},[88,89],[432,433],[435,390,436,437],{"trials":618,"activeCount":100},[619],{"nctId":441,"briefTitle":442,"status":443,"phases":620,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":621,"interventions":622},[90],[449],[451,390,436],{"trials":624,"activeCount":147,"soonestReadout":458},[625,629],{"nctId":455,"briefTitle":456,"status":137,"phases":626,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":627,"interventions":628},[91],[463,433],[435,465,390,436],{"nctId":491,"briefTitle":492,"status":443,"phases":630,"primaryCompletion":494,"completion":494,"start":495,"enrollment":127,"conditions":631,"interventions":632},[91],[463,497],[499,436,390],{"trials":634,"activeCount":100},[],{"intervention":636,"totalTrials":184,"cells":637},"Anlotinib",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":666,"PHASE4":668,"NA":682},{"trials":639,"activeCount":100},[],{"trials":641,"activeCount":100},[],{"trials":643,"activeCount":100},[644,654],{"nctId":645,"briefTitle":646,"status":108,"phases":647,"primaryCompletion":227,"completion":228,"start":648,"enrollment":649,"conditions":650,"interventions":652},"NCT05306847","Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer",[89],"2022-04-01",93,[651],"Carcinoma, Non-Small-Cell Lung",[653,636],"Sintilimab",{"nctId":655,"briefTitle":656,"status":108,"phases":657,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT04970914","Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003",[89],"2022-08-23","2023-08-23","2021-11-05",32,[663],"Colorectal Cancer",[636,665],"Penpulimab",{"trials":667,"activeCount":100},[],{"trials":669,"activeCount":147,"soonestReadout":674},[670],{"nctId":671,"briefTitle":672,"status":151,"phases":673,"primaryCompletion":674,"completion":675,"start":141,"enrollment":194,"conditions":676,"interventions":678},"NCT06931145","Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer",[91],"2027-04-30","2027-12-31",[677],"Extensive-stage Small Cell Lung Cancer",[679,636,680,681],"Benmelstobart","Carboplatin or cisplatin","Etoposide",{"trials":683,"activeCount":100},[],{"intervention":437,"totalTrials":372,"cells":685},{"EARLY_PHASE1":686,"PHASE1":688,"PHASE2":690,"PHASE3":696,"PHASE4":698,"NA":712},{"trials":687,"activeCount":100},[],{"trials":689,"activeCount":100},[],{"trials":691,"activeCount":100},[692],{"nctId":424,"briefTitle":425,"status":108,"phases":693,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":694,"interventions":695},[88,89],[432,433],[435,390,436,437],{"trials":697,"activeCount":100},[],{"trials":699,"activeCount":147,"soonestReadout":675},[700],{"nctId":701,"briefTitle":702,"status":137,"phases":703,"primaryCompletion":675,"completion":165,"start":704,"enrollment":705,"conditions":706,"interventions":710},"NCT06902740","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis",[91],"2025-09-01",300,[707,708,709],"Intracranial Atherosclerosis","Intracranial Artery Stenosis","Atherosclerotic Plaque",[711,437],"Recaticimab and Statin",{"trials":713,"activeCount":100},[],{"intervention":435,"totalTrials":372,"cells":715},{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":726,"PHASE4":728,"NA":734},{"trials":717,"activeCount":100},[],{"trials":719,"activeCount":100},[],{"trials":721,"activeCount":100},[722],{"nctId":424,"briefTitle":425,"status":108,"phases":723,"primaryCompletion":427,"completion":428,"start":429,"enrollment":430,"conditions":724,"interventions":725},[88,89],[432,433],[435,390,436,437],{"trials":727,"activeCount":100},[],{"trials":729,"activeCount":147,"soonestReadout":458},[730],{"nctId":455,"briefTitle":456,"status":137,"phases":731,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":732,"interventions":733},[91],[463,433],[435,465,390,436],{"trials":735,"activeCount":100},[],{"intervention":339,"totalTrials":372,"cells":737},{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":763},{"trials":739,"activeCount":100},[],{"trials":741,"activeCount":100},[],{"trials":743,"activeCount":100},[],{"trials":745,"activeCount":100},[],{"trials":747,"activeCount":147,"soonestReadout":333},[748,752],{"nctId":330,"briefTitle":331,"status":137,"phases":749,"primaryCompletion":333,"completion":164,"start":334,"enrollment":23,"conditions":750,"interventions":751},[91],[336,337],[214,339],{"nctId":753,"briefTitle":754,"status":443,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":761},"NCT04956484","Belimumab In Early Systemic Lupus Erythematosus",[91],"2022-04-08","2021-09-01",16,[760],"Lupus Erythematosus, Systemic",[339,762],"Standard of care",{"trials":764,"activeCount":100},[],{"intervention":680,"totalTrials":372,"cells":766},{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":786,"PHASE4":788,"NA":794},{"trials":768,"activeCount":100},[],{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[773],{"nctId":774,"briefTitle":775,"status":443,"phases":776,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":781,"interventions":783},"NCT05302011","Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma",[89],"2023-03-30","2023-06-30","2020-06-01",28,[782],"Esophageal Squamous Cell Carcinoma",[46,784,785],"Carboplatin or Cisplatin","Docetaxel",{"trials":787,"activeCount":100},[],{"trials":789,"activeCount":147,"soonestReadout":674},[790],{"nctId":671,"briefTitle":672,"status":151,"phases":791,"primaryCompletion":674,"completion":675,"start":141,"enrollment":194,"conditions":792,"interventions":793},[91],[677],[679,636,680,681],{"trials":795,"activeCount":100},[],{"intervention":681,"totalTrials":372,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":816,"PHASE4":818,"NA":824},{"trials":799,"activeCount":100},[],{"trials":801,"activeCount":100},[],{"trials":803,"activeCount":100},[804],{"nctId":805,"briefTitle":806,"status":108,"phases":807,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":814},"NCT02987244","Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma",[88,89],"2020-03","2023-03","2016-03",100,[813],"T Cell Non-Hodgkin's Lymphoma",[815,247,248,249,681,250],"Chidamide",{"trials":817,"activeCount":100},[],{"trials":819,"activeCount":147,"soonestReadout":674},[820],{"nctId":671,"briefTitle":672,"status":151,"phases":821,"primaryCompletion":674,"completion":675,"start":141,"enrollment":194,"conditions":822,"interventions":823},[91],[677],[679,636,680,681],{"trials":825,"activeCount":100},[],{"intervention":601,"totalTrials":372,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":834,"PHASE4":847,"NA":853},{"trials":829,"activeCount":100},[],{"trials":831,"activeCount":100},[],{"trials":833,"activeCount":100},[],{"trials":835,"activeCount":100},[836],{"nctId":837,"briefTitle":838,"status":108,"phases":839,"primaryCompletion":840,"completion":841,"start":842,"enrollment":167,"conditions":843,"interventions":846},"NCT01805648","Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP",[90],"2013-08","2013-12","2011-02",[844,420,845],"Thrombocytopenia","Idiopathic Thrombocytopenic Purpura",[601],{"trials":848,"activeCount":147,"soonestReadout":595},[849],{"nctId":592,"briefTitle":593,"status":151,"phases":850,"primaryCompletion":595,"completion":596,"start":520,"enrollment":597,"conditions":851,"interventions":852},[91],[22,599],[601,568],{"trials":854,"activeCount":100},[],{"intervention":711,"totalTrials":147,"cells":856},{"EARLY_PHASE1":857,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":871},{"trials":858,"activeCount":100},[],{"trials":860,"activeCount":100},[],{"trials":862,"activeCount":100},[],{"trials":864,"activeCount":100},[],{"trials":866,"activeCount":147,"soonestReadout":675},[867],{"nctId":701,"briefTitle":702,"status":137,"phases":868,"primaryCompletion":675,"completion":165,"start":704,"enrollment":705,"conditions":869,"interventions":870},[91],[707,708,709],[711,437],{"trials":872,"activeCount":100},[],{"intervention":874,"totalTrials":147,"cells":875},"Rosuvastatin",{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":900},{"trials":877,"activeCount":100},[],{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[],{"trials":885,"activeCount":147,"soonestReadout":890},[886],{"nctId":887,"briefTitle":888,"status":151,"phases":889,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":894,"interventions":897},"NCT07605130","Efficacy and Safety Study of Digital Cognitive Training and PCSK9 Inhibitor-Enhanced Lipid-lowering Strategy in Patients With Intracranial Atherosclerotic Stenosis: A 2×2 Randomized Controlled Trial",[91],"2028-09-30","2029-07-31","2026-05-25",420,[895,896],"Intracranial Arteriosclerosis","Cognitive Impairment",[874,898,899],"Ezetimibe","Recaticimab",{"trials":901,"activeCount":100},[],{"intervention":898,"totalTrials":147,"cells":903},{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":918},{"trials":905,"activeCount":100},[],{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"trials":913,"activeCount":147,"soonestReadout":890},[914],{"nctId":887,"briefTitle":888,"status":151,"phases":915,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":916,"interventions":917},[91],[895,896],[874,898,899],{"trials":919,"activeCount":100},[],{"intervention":899,"totalTrials":147,"cells":921},{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":936},{"trials":923,"activeCount":100},[],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[],{"trials":931,"activeCount":147,"soonestReadout":890},[932],{"nctId":887,"briefTitle":888,"status":151,"phases":933,"primaryCompletion":890,"completion":891,"start":892,"enrollment":893,"conditions":934,"interventions":935},[91],[895,896],[874,898,899],{"trials":937,"activeCount":100},[],{"intervention":939,"totalTrials":147,"cells":940},"Subcutaneous injection of Secukinumab",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":945,"PHASE3":947,"PHASE4":949,"NA":963},{"trials":942,"activeCount":100},[],{"trials":944,"activeCount":100},[],{"trials":946,"activeCount":100},[],{"trials":948,"activeCount":100},[],{"trials":950,"activeCount":147,"soonestReadout":955},[951],{"nctId":952,"briefTitle":953,"status":151,"phases":954,"primaryCompletion":955,"completion":164,"start":956,"enrollment":957,"conditions":958,"interventions":962},"NCT07261072","Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS",[91],"2026-11-30","2025-12-01",30,[959,960,961],"Hidradenitis Suppurativa (HS)","Hidradenitis Suppurativa (Acne Inversa)","Secukinumab",[939],{"trials":964,"activeCount":100},[],{"intervention":966,"totalTrials":147,"cells":967},"FLCWK",{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":976,"NA":991},{"trials":969,"activeCount":100},[],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"trials":975,"activeCount":100},[],{"trials":977,"activeCount":147,"soonestReadout":982},[978],{"nctId":979,"briefTitle":980,"status":151,"phases":981,"primaryCompletion":982,"completion":983,"start":984,"enrollment":194,"conditions":985,"interventions":990},"NCT07061184","Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial",[91],"2027-11","2028-05","2025-11",[986,987,988,989],"Irritable Bowel Syndrome - Diarrhoea","Traditional Chinese Medicine (TCM)","N of 1 Study Design","Efficacy and Safety",[966],{"trials":992,"activeCount":100},[],{"intervention":465,"totalTrials":147,"cells":994},{"EARLY_PHASE1":995,"PHASE1":997,"PHASE2":999,"PHASE3":1001,"PHASE4":1003,"NA":1009},{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"trials":1002,"activeCount":100},[],{"trials":1004,"activeCount":147,"soonestReadout":458},[1005],{"nctId":455,"briefTitle":456,"status":137,"phases":1006,"primaryCompletion":458,"completion":459,"start":460,"enrollment":461,"conditions":1007,"interventions":1008},[91],[463,433],[435,465,390,436],{"trials":1010,"activeCount":100},[],{"intervention":679,"totalTrials":147,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1027},{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[],{"trials":1018,"activeCount":100},[],{"trials":1020,"activeCount":100},[],{"trials":1022,"activeCount":147,"soonestReadout":674},[1023],{"nctId":671,"briefTitle":672,"status":151,"phases":1024,"primaryCompletion":674,"completion":675,"start":141,"enrollment":194,"conditions":1025,"interventions":1026},[91],[677],[679,636,680,681],{"trials":1028,"activeCount":100},[],{"intervention":1030,"totalTrials":147,"cells":1031},"Compound sodium acetate ringer",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1053},{"trials":1033,"activeCount":100},[],{"trials":1035,"activeCount":100},[],{"trials":1037,"activeCount":100},[],{"trials":1039,"activeCount":100},[],{"trials":1041,"activeCount":147,"soonestReadout":1046},[1042],{"nctId":1043,"briefTitle":1044,"status":151,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":266,"enrollment":1048,"conditions":1049,"interventions":1051},"NCT05463471","Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients",[91],"2025-12-12","2027-12-12",500,[1050],"Shock",[1030,1052],"Albumin",{"trials":1054,"activeCount":100},[],{"intervention":1052,"totalTrials":147,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1065,"NA":1071},{"trials":1058,"activeCount":100},[],{"trials":1060,"activeCount":100},[],{"trials":1062,"activeCount":100},[],{"trials":1064,"activeCount":100},[],{"trials":1066,"activeCount":147,"soonestReadout":1046},[1067],{"nctId":1043,"briefTitle":1044,"status":151,"phases":1068,"primaryCompletion":1046,"completion":1047,"start":266,"enrollment":1048,"conditions":1069,"interventions":1070},[91],[1050],[1030,1052],{"trials":1072,"activeCount":100},[],{"intervention":1074,"totalTrials":147,"cells":1075},"Rucacuzumab plus standard therapy",{"EARLY_PHASE1":1076,"PHASE1":1078,"PHASE2":1080,"PHASE3":1082,"PHASE4":1084,"NA":1098},{"trials":1077,"activeCount":100},[],{"trials":1079,"activeCount":100},[],{"trials":1081,"activeCount":100},[],{"trials":1083,"activeCount":100},[],{"trials":1085,"activeCount":147,"soonestReadout":165},[1086],{"nctId":1087,"briefTitle":1088,"status":151,"phases":1089,"primaryCompletion":165,"completion":1090,"start":1091,"enrollment":1092,"conditions":1093,"interventions":1096},"NCT07466251","PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke",[91],"2029-12-31","2026-09-01",1212,[1094,1095,709],"Acute Ischemic Stroke AIS","Intracranial Atherosclerosis ICAS",[1074,1097],"Recaticimab plus placebo in combination with standard therapy",{"trials":1099,"activeCount":100},[],{"intervention":1097,"totalTrials":147,"cells":1101},{"EARLY_PHASE1":1102,"PHASE1":1104,"PHASE2":1106,"PHASE3":1108,"PHASE4":1110,"NA":1116},{"trials":1103,"activeCount":100},[],{"trials":1105,"activeCount":100},[],{"trials":1107,"activeCount":100},[],{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":147,"soonestReadout":165},[1112],{"nctId":1087,"briefTitle":1088,"status":151,"phases":1113,"primaryCompletion":165,"completion":1090,"start":1091,"enrollment":1092,"conditions":1114,"interventions":1115},[91],[1094,1095,709],[1074,1097],{"trials":1117,"activeCount":100},[],{"intervention":1119,"totalTrials":147,"cells":1120},"Isatuximab, bortezomib, lenalidomide, dexamethason",{"EARLY_PHASE1":1121,"PHASE1":1123,"PHASE2":1125,"PHASE3":1127,"PHASE4":1129,"NA":1142},{"trials":1122,"activeCount":100},[],{"trials":1124,"activeCount":100},[],{"trials":1126,"activeCount":100},[],{"trials":1128,"activeCount":100},[],{"trials":1130,"activeCount":147,"soonestReadout":1135},[1131],{"nctId":1132,"briefTitle":1133,"status":151,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1140},"NCT07334535","Isa-VRD in TIE HRMM",[91],"2028-07","2029-01","2026-01-30",117,[196],[1119,1141],"Bortezomib, Lenalidomide, Dexamethasone",{"trials":1143,"activeCount":100},[],{"intervention":1141,"totalTrials":147,"cells":1145},{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1154,"NA":1160},{"trials":1147,"activeCount":100},[],{"trials":1149,"activeCount":100},[],{"trials":1151,"activeCount":100},[],{"trials":1153,"activeCount":100},[],{"trials":1155,"activeCount":147,"soonestReadout":1135},[1156],{"nctId":1132,"briefTitle":1133,"status":151,"phases":1157,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1158,"interventions":1159},[91],[196],[1119,1141],{"trials":1161,"activeCount":100},[],{"intervention":1163,"totalTrials":147,"cells":1164},"Janus Kinase Inhibitor",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1185},{"trials":1166,"activeCount":100},[],{"trials":1168,"activeCount":100},[],{"trials":1170,"activeCount":100},[],{"trials":1172,"activeCount":100},[],{"trials":1174,"activeCount":147,"soonestReadout":1180},[1175],{"nctId":1176,"briefTitle":1177,"status":1178,"phases":1179,"primaryCompletion":1180,"completion":1181,"start":65,"enrollment":957,"conditions":1182,"interventions":1184},"NCT06660329","Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome","ENROLLING_BY_INVITATION",[91],"2027-10-01","2028-10-01",[1183],"Blau Syndrome",[1163],{"trials":1186,"activeCount":100},[],{"intervention":1188,"totalTrials":147,"cells":1189},"intravenous ondansetron",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1194,"PHASE3":1196,"PHASE4":1198,"NA":1211},{"trials":1191,"activeCount":100},[],{"trials":1193,"activeCount":100},[],{"trials":1195,"activeCount":100},[],{"trials":1197,"activeCount":100},[],{"trials":1199,"activeCount":147,"soonestReadout":1204},[1200],{"nctId":1201,"briefTitle":1202,"status":151,"phases":1203,"primaryCompletion":1204,"completion":458,"start":1205,"enrollment":1206,"conditions":1207,"interventions":1210},"NCT07336680","Effect of Ondansetron on Patient Tolerance, Efficacy and Endoscopist Workload in Unsedated Endoscopy for Upper Gastrointestinal Bleeding",[91],"2026-05","2026-01-01",80,[1208,1209],"Esophagogastroduodenoscopy","Upper Gastrointestinal Bleeding (UGIB)",[1188],{"trials":1212,"activeCount":100},[],{"intervention":1214,"totalTrials":147,"cells":1215},"Jinfeng Pill",{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1220,"PHASE3":1222,"PHASE4":1224,"NA":1237},{"trials":1217,"activeCount":100},[],{"trials":1219,"activeCount":100},[],{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":147,"soonestReadout":1231},[1226],{"nctId":1227,"briefTitle":1228,"status":1229,"phases":1230,"primaryCompletion":1231,"completion":1231,"start":1232,"enrollment":1233,"conditions":1234,"interventions":1236},"NCT06823830","Clinical、metabolomics and the Study of Intestinal Flora of Jinfeng Pills in the Treatment of Polycystic Ovary Syndrome","ACTIVE_NOT_RECRUITING",[91],"2025-02-28","2023-09-01",105,[1235],"Polycystic Ovary Syndrome",[1214],{"trials":1238,"activeCount":100},[],{"intervention":1240,"totalTrials":147,"cells":1241},"ondansetron and dyclonine hydrochloride",{"EARLY_PHASE1":1242,"PHASE1":1244,"PHASE2":1246,"PHASE3":1248,"PHASE4":1250,"NA":1263},{"trials":1243,"activeCount":100},[],{"trials":1245,"activeCount":100},[],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[],{"trials":1251,"activeCount":147,"soonestReadout":1256},[1252],{"nctId":1253,"briefTitle":1254,"status":1229,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":127,"conditions":1259,"interventions":1261},"NCT07264738","Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study",[91],"2025-09-28","2026-06-10","2025-07-01",[1260],"Esophagogastroduodensocopy (EGD) Procedure",[1240,1262],"dyclonine hydrochloride only",{"trials":1264,"activeCount":100},[],{"intervention":1262,"totalTrials":147,"cells":1266},{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1273,"PHASE4":1275,"NA":1281},{"trials":1268,"activeCount":100},[],{"trials":1270,"activeCount":100},[],{"trials":1272,"activeCount":100},[],{"trials":1274,"activeCount":100},[],{"trials":1276,"activeCount":147,"soonestReadout":1256},[1277],{"nctId":1253,"briefTitle":1254,"status":1229,"phases":1278,"primaryCompletion":1256,"completion":1257,"start":1258,"enrollment":127,"conditions":1279,"interventions":1280},[91],[1260],[1240,1262],{"trials":1282,"activeCount":100},[],{"intervention":1284,"totalTrials":147,"cells":1285},"Traditional Chinese Medicine Formulation",{"EARLY_PHASE1":1286,"PHASE1":1288,"PHASE2":1290,"PHASE3":1292,"PHASE4":1294,"NA":1304},{"trials":1287,"activeCount":100},[],{"trials":1289,"activeCount":100},[],{"trials":1291,"activeCount":100},[],{"trials":1293,"activeCount":100},[],{"trials":1295,"activeCount":147,"soonestReadout":379},[1296],{"nctId":1297,"briefTitle":1298,"status":151,"phases":1299,"primaryCompletion":379,"completion":165,"start":1300,"enrollment":486,"conditions":1301,"interventions":1303},"NCT07396701","Chinese Adaptive Randomised Pneumonia Trial With Respiratory Failure",[91],"2026-02-20",[1302],"Severe Pneumonia With Respiratory Failure",[1284],{"trials":1305,"activeCount":100},[],{"intervention":1307,"totalTrials":147,"cells":1308},"Ferric derisomaltose",{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1330},{"trials":1310,"activeCount":100},[],{"trials":1312,"activeCount":100},[],{"trials":1314,"activeCount":100},[],{"trials":1316,"activeCount":100},[],{"trials":1318,"activeCount":147,"soonestReadout":528},[1319],{"nctId":1320,"briefTitle":1321,"status":137,"phases":1322,"primaryCompletion":528,"completion":528,"start":1323,"enrollment":167,"conditions":1324,"interventions":1328},"NCT05714007","The Effects of Ferric Derisomaltose on Postoperative Anemia in Spinal Deformity Surgery",[91],"2023-08-31",[1325,32,1326,1327],"Perioperative Anemia","Spinal Deformity","Adult",[1307,1329],"Ferrous succinate",{"trials":1331,"activeCount":100},[],{"intervention":1329,"totalTrials":147,"cells":1333},{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1340,"PHASE4":1342,"NA":1348},{"trials":1335,"activeCount":100},[],{"trials":1337,"activeCount":100},[],{"trials":1339,"activeCount":100},[],{"trials":1341,"activeCount":100},[],{"trials":1343,"activeCount":147,"soonestReadout":528},[1344],{"nctId":1320,"briefTitle":1321,"status":137,"phases":1345,"primaryCompletion":528,"completion":528,"start":1323,"enrollment":167,"conditions":1346,"interventions":1347},[91],[1325,32,1326,1327],[1307,1329],{"trials":1349,"activeCount":100},[],{"intervention":1351,"totalTrials":147,"cells":1352},"Tegileridine",{"EARLY_PHASE1":1353,"PHASE1":1355,"PHASE2":1357,"PHASE3":1359,"PHASE4":1361,"NA":1375},{"trials":1354,"activeCount":100},[],{"trials":1356,"activeCount":100},[],{"trials":1358,"activeCount":100},[],{"trials":1360,"activeCount":100},[],{"trials":1362,"activeCount":147,"soonestReadout":176},[1363],{"nctId":1364,"briefTitle":1365,"status":151,"phases":1366,"primaryCompletion":176,"completion":1367,"start":1205,"enrollment":1368,"conditions":1369,"interventions":1373},"NCT07229495","Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery",[91],"2027-09-30",171,[1370,1371,1372],"Scoliosis; Adolescence","Pain After Surgery","Analgesia, Patient-controlled",[1351,1374],"morphine",{"trials":1376,"activeCount":100},[],{"intervention":1374,"totalTrials":147,"cells":1378},{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1387,"NA":1393},{"trials":1380,"activeCount":100},[],{"trials":1382,"activeCount":100},[],{"trials":1384,"activeCount":100},[],{"trials":1386,"activeCount":100},[],{"trials":1388,"activeCount":147,"soonestReadout":176},[1389],{"nctId":1364,"briefTitle":1365,"status":151,"phases":1390,"primaryCompletion":176,"completion":1367,"start":1205,"enrollment":1368,"conditions":1391,"interventions":1392},[91],[1370,1371,1372],[1351,1374],{"trials":1394,"activeCount":100},[],{"intervention":1396,"totalTrials":147,"cells":1397},"Adalimumab plus different doses of oral glucocorticosteroid",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1404,"PHASE4":1406,"NA":1417},{"trials":1399,"activeCount":100},[],{"trials":1401,"activeCount":100},[],{"trials":1403,"activeCount":100},[],{"trials":1405,"activeCount":100},[],{"trials":1407,"activeCount":147,"soonestReadout":164},[1408],{"nctId":1409,"briefTitle":1410,"status":151,"phases":1411,"primaryCompletion":164,"completion":164,"start":1412,"enrollment":1413,"conditions":1414,"interventions":1416},"NCT05105347","Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis",[91],"2021-11-10",130,[1415],"Uveitis",[1396],{"trials":1418,"activeCount":100},[],{"intervention":1420,"totalTrials":147,"cells":1421},"ursodeoxycholic acid",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1426,"PHASE3":1428,"PHASE4":1430,"NA":1441},{"trials":1423,"activeCount":100},[],{"trials":1425,"activeCount":100},[],{"trials":1427,"activeCount":100},[],{"trials":1429,"activeCount":100},[],{"trials":1431,"activeCount":147,"soonestReadout":1436},[1432],{"nctId":1433,"briefTitle":1434,"status":137,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1437,"enrollment":357,"conditions":1438,"interventions":1440},"NCT04650243","Clinical Research of Tapering UDCA in PBC Patients With a Complete Response",[91],"2025-05","2020-01-21",[1439],"Primary Biliary Cholangitis",[1420],{"trials":1442,"activeCount":100},[],{"intervention":1444,"totalTrials":147,"cells":1445},"Dexmedetomidine",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1450,"PHASE3":1452,"PHASE4":1454,"NA":1465},{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[],{"trials":1451,"activeCount":100},[],{"trials":1453,"activeCount":100},[],{"trials":1455,"activeCount":147,"soonestReadout":176},[1456],{"nctId":1457,"briefTitle":1458,"status":1178,"phases":1459,"primaryCompletion":176,"completion":176,"start":1258,"enrollment":1460,"conditions":1461,"interventions":1463},"NCT06849466","Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain",[91],364,[1462],"Chronic Post-Surgical Pain",[1444,1464],"Saline solution",{"trials":1466,"activeCount":100},[],{"intervention":1464,"totalTrials":147,"cells":1468},{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1483},{"trials":1470,"activeCount":100},[],{"trials":1472,"activeCount":100},[],{"trials":1474,"activeCount":100},[],{"trials":1476,"activeCount":100},[],{"trials":1478,"activeCount":147,"soonestReadout":176},[1479],{"nctId":1457,"briefTitle":1458,"status":1178,"phases":1480,"primaryCompletion":176,"completion":176,"start":1258,"enrollment":1460,"conditions":1481,"interventions":1482},[91],[1462],[1444,1464],{"trials":1484,"activeCount":100},[],{"intervention":1486,"totalTrials":147,"cells":1487},"Semaglutide",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1512},{"trials":1489,"activeCount":100},[],{"trials":1491,"activeCount":100},[],{"trials":1493,"activeCount":100},[],{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":147,"soonestReadout":1502},[1498],{"nctId":1499,"briefTitle":1500,"status":151,"phases":1501,"primaryCompletion":1502,"completion":1503,"start":1504,"enrollment":1505,"conditions":1506,"interventions":1511},"NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis",[91],"2028-09","2028-12","2026-09",396,[1507,1508,1509,1510],"Hypertriglyceridemia Induced Acute Pancreatitis","Recurrent Acute Pancreatitis","Pancreatitis Relapsing","Hypertriglyceridemia",[1486],{"trials":1513,"activeCount":100},[],{"intervention":1515,"totalTrials":147,"cells":1516},"Indomethacin SR",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1523,"PHASE4":1525,"NA":1542},{"trials":1518,"activeCount":100},[],{"trials":1520,"activeCount":100},[],{"trials":1522,"activeCount":100},[],{"trials":1524,"activeCount":100},[],{"trials":1526,"activeCount":147,"soonestReadout":1531},[1527],{"nctId":1528,"briefTitle":1529,"status":137,"phases":1530,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1534,"conditions":1535,"interventions":1540},"NCT03547232","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)",[91],"2028-06-01","2028-12-01","2024-12-01",1504,[1536,1537,1538,1539],"Acute Pancreatitis","Complication","Mortality Rate","Organ Failure, Multiple",[1515,1541],"Placebos",{"trials":1543,"activeCount":100},[],{"intervention":1541,"totalTrials":147,"cells":1545},{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1554,"NA":1560},{"trials":1547,"activeCount":100},[],{"trials":1549,"activeCount":100},[],{"trials":1551,"activeCount":100},[],{"trials":1553,"activeCount":100},[],{"trials":1555,"activeCount":147,"soonestReadout":1531},[1556],{"nctId":1528,"briefTitle":1529,"status":137,"phases":1557,"primaryCompletion":1531,"completion":1532,"start":1533,"enrollment":1534,"conditions":1558,"interventions":1559},[91],[1536,1537,1538,1539],[1515,1541],{"trials":1561,"activeCount":100},[],{"intervention":1563,"totalTrials":147,"cells":1564},"Oral ondansetron and dyclonine hydrochloride mucilage",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1571,"PHASE4":1573,"NA":1584},{"trials":1566,"activeCount":100},[],{"trials":1568,"activeCount":100},[],{"trials":1570,"activeCount":100},[],{"trials":1572,"activeCount":100},[],{"trials":1574,"activeCount":147,"soonestReadout":580},[1575],{"nctId":1576,"briefTitle":1577,"status":151,"phases":1578,"primaryCompletion":580,"completion":580,"start":1579,"enrollment":1580,"conditions":1581,"interventions":1582},"NCT06729307","Ondansetron Combined with Dyclonine Hydrochloride to Improve Patient Experience in Unsedated Esophagogastro-duodenoscopy",[91],"2025-01",260,[1260],[1563,1583],"Dyclonine hydrochloride mucilage",{"trials":1585,"activeCount":100},[],{"intervention":1583,"totalTrials":147,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1594,"PHASE4":1596,"NA":1602},{"trials":1589,"activeCount":100},[],{"trials":1591,"activeCount":100},[],{"trials":1593,"activeCount":100},[],{"trials":1595,"activeCount":100},[],{"trials":1597,"activeCount":147,"soonestReadout":580},[1598],{"nctId":1576,"briefTitle":1577,"status":151,"phases":1599,"primaryCompletion":580,"completion":580,"start":1579,"enrollment":1580,"conditions":1600,"interventions":1601},[91],[1260],[1563,1583],{"trials":1603,"activeCount":100},[],{"intervention":1605,"totalTrials":1606,"cells":1607},"Cyclosporine",5,{"EARLY_PHASE1":1608,"PHASE1":1610,"PHASE2":1612,"PHASE3":1633,"PHASE4":1646,"NA":1657},{"trials":1609,"activeCount":100},[],{"trials":1611,"activeCount":100},[],{"trials":1613,"activeCount":372,"soonestReadout":1503},[1614,1626],{"nctId":1615,"briefTitle":1616,"status":151,"phases":1617,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":1620,"interventions":1623},"NCT07523009","CsA+EPAG\u002FHPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA\u002FTD-NSAA",[89],"2026-04",43,[1621,1622],"Severe Aplastic Anemia (SAA)","Transfusion-dependent Non-severe Aplastic Anemia",[1605,1624,1625],"Thrombopoietin Receptor Agonist","Romiplostim N01",{"nctId":1627,"briefTitle":1628,"status":151,"phases":1629,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":1630,"interventions":1631},"NCT07558434","CsA+EPAG\u002FHPAG+Romiplostim N01 in Newly-diagnosed SAA\u002FTD-NSAA",[89],[1621,1622],[1605,1632,1625],"thrombopoietin receptor agonist",{"trials":1634,"activeCount":147,"soonestReadout":1503},[1635,1642],{"nctId":1636,"briefTitle":1637,"status":151,"phases":1638,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":357,"conditions":1639,"interventions":1640},"NCT07548671","Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA",[90],[1622],[1641,1605],"Enarodustat",{"nctId":307,"briefTitle":308,"status":309,"phases":1643,"primaryCompletion":311,"completion":312,"start":313,"enrollment":209,"conditions":1644,"interventions":1645},[90],[315],[214,317],{"trials":1647,"activeCount":100},[1648],{"nctId":1649,"briefTitle":1650,"status":108,"phases":1651,"primaryCompletion":1436,"completion":528,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1655},"NCT06424639","Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA",[91],"2024-05",58,[22],[1656,317],"Luspatercept",{"trials":1658,"activeCount":100},[],{"intervention":247,"totalTrials":1660,"cells":1661},6,{"EARLY_PHASE1":1662,"PHASE1":1664,"PHASE2":1666,"PHASE3":1702,"PHASE4":1719,"NA":1721},{"trials":1663,"activeCount":100},[],{"trials":1665,"activeCount":100},[],{"trials":1667,"activeCount":147,"soonestReadout":1691},[1668,1672,1676,1687],{"nctId":805,"briefTitle":806,"status":108,"phases":1669,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":1670,"interventions":1671},[88,89],[813],[815,247,248,249,681,250],{"nctId":237,"briefTitle":238,"status":108,"phases":1673,"primaryCompletion":240,"completion":241,"start":242,"enrollment":142,"conditions":1674,"interventions":1675},[89],[244],[246,214,247,248,249,250],{"nctId":1677,"briefTitle":1678,"status":108,"phases":1679,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":957,"conditions":1683,"interventions":1685},"NCT03982771","BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)",[89],"2022-01-01","2023-01-01","2019-01-01",[1684],"Idiopathic Multicentric Castleman's Disease",[303,247,1686],"Dexamethason",{"nctId":1688,"briefTitle":1689,"status":137,"phases":1690,"primaryCompletion":1691,"completion":1692,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1698},"NCT05845723","Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome",[89],"2026-06-01","2027-06-01","2023-06-01",81,[1696,1697],"Aneurysm","Behcet Syndrome, Vascular Type",[1699,1700,1701],"tocilizumab","tofacitinib","cyclophosphamide",{"trials":1703,"activeCount":147,"soonestReadout":322},[1704,1715],{"nctId":1705,"briefTitle":1706,"status":108,"phases":1707,"primaryCompletion":1708,"completion":841,"start":1709,"enrollment":1413,"conditions":1710,"interventions":1712},"NCT01646736","Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis",[89,90],"2013-07","2012-07",[1711],"Nephritis, Lupus",[1713,247,1714],"Tripterygium wilfordii Hook F","GC",{"nctId":319,"briefTitle":320,"status":137,"phases":1716,"primaryCompletion":322,"completion":323,"start":313,"enrollment":324,"conditions":1717,"interventions":1718},[90],[315],[250,247,214],{"trials":1720,"activeCount":100},[],{"trials":1722,"activeCount":100},[],{"intervention":159,"totalTrials":605,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1769,"PHASE4":1775,"NA":1777},{"trials":1726,"activeCount":100},[],{"trials":1728,"activeCount":100},[],{"trials":1730,"activeCount":147,"soonestReadout":164},[1731,1749,1760],{"nctId":1732,"briefTitle":1733,"status":108,"phases":1734,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":1739,"interventions":1746},"NCT03910712","Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive\u002F HR Positive MBC",[89],"2022-06-01","2023-12-01","2019-06-01",250,[1740,1741,1742,1743,1744,1745],"Breast Cancer Female","HER2-positive Breast Cancer","Hormone Receptor Positive Malignant Neoplasm of Breast","Metastatic Breast Cancer","Breast Diseases","Hormone Receptor Positive Tumor",[159,1747,1748],"Trastuzumab","Aromatase inhibitor",{"nctId":1750,"briefTitle":1751,"status":108,"phases":1752,"primaryCompletion":1753,"completion":1754,"start":1755,"enrollment":1756,"conditions":1757,"interventions":1759},"NCT03412383","Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer",[89],"2019-01-25","2019-06-25","2018-02-20",14,[16,1758],"HER2 Gene Mutation",[159],{"nctId":1761,"briefTitle":1762,"status":137,"phases":1763,"primaryCompletion":164,"completion":164,"start":1764,"enrollment":1765,"conditions":1766,"interventions":1768},"NCT05751018","Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified\u002FMutated Advanced Non-small Cell Lung Cancer",[89],"2021-12-08",18,[1767],"Non-small Cell Lung Cancer",[159],{"trials":1770,"activeCount":147,"soonestReadout":50},[1771],{"nctId":48,"briefTitle":49,"status":151,"phases":1772,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":1773,"interventions":1774},[90],[16],[51,158,159,95],{"trials":1776,"activeCount":100},[],{"trials":1778,"activeCount":100},[],{"intervention":1641,"totalTrials":372,"cells":1780},{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1800,"NA":1802},{"trials":1782,"activeCount":100},[],{"trials":1784,"activeCount":100},[],{"trials":1786,"activeCount":100},[],{"trials":1788,"activeCount":372,"soonestReadout":1503},[1789,1796],{"nctId":1790,"briefTitle":1791,"status":151,"phases":1792,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":357,"conditions":1793,"interventions":1794},"NCT07522996","Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA",[90],[1622],[1641,1795],"Cyclosporin",{"nctId":1636,"briefTitle":1637,"status":151,"phases":1797,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":357,"conditions":1798,"interventions":1799},[90],[1622],[1641,1605],{"trials":1801,"activeCount":100},[],{"trials":1803,"activeCount":100},[],{"intervention":1805,"totalTrials":372,"cells":1806},"Furmonertinib",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1822,"PHASE4":1833,"NA":1835},{"trials":1808,"activeCount":100},[],{"trials":1810,"activeCount":100},[],{"trials":1812,"activeCount":147,"soonestReadout":1817},[1813],{"nctId":1814,"briefTitle":1815,"status":137,"phases":1816,"primaryCompletion":1817,"completion":1817,"start":1818,"enrollment":1819,"conditions":1820,"interventions":1821},"NCT05445310","Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer",[89],"2026-07-01","2022-08-06",114,[1767],[1805],{"trials":1823,"activeCount":147,"soonestReadout":164},[1824],{"nctId":1825,"briefTitle":1826,"status":137,"phases":1827,"primaryCompletion":164,"completion":165,"start":1828,"enrollment":1829,"conditions":1830,"interventions":1832},"NCT06674343","Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations",[90],"2024-07-15",144,[1831],"Advanced or Metastatic Non-small Cell Lung Cancer",[1805],{"trials":1834,"activeCount":100},[],{"trials":1836,"activeCount":100},[],{"intervention":158,"totalTrials":605,"cells":1838},{"EARLY_PHASE1":1839,"PHASE1":1841,"PHASE2":1843,"PHASE3":1845,"PHASE4":1851,"NA":1882},{"trials":1840,"activeCount":100},[],{"trials":1842,"activeCount":100},[],{"trials":1844,"activeCount":100},[],{"trials":1846,"activeCount":147,"soonestReadout":50},[1847],{"nctId":48,"briefTitle":49,"status":151,"phases":1848,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":1849,"interventions":1850},[90],[16],[51,158,159,95],{"trials":1852,"activeCount":100},[1853,1865,1874],{"nctId":1854,"briefTitle":1855,"status":108,"phases":1856,"primaryCompletion":1857,"completion":1858,"start":1859,"enrollment":1860,"conditions":1861,"interventions":1863},"NCT03500367","Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis",[91],"2022-06-30","2022-12-31","2018-01-01",25,[1862],"Uterine Fibroids",[1864],"rapamycin",{"nctId":1866,"briefTitle":1867,"status":108,"phases":1868,"primaryCompletion":1680,"completion":193,"start":1869,"enrollment":142,"conditions":1870,"interventions":1873},"NCT03767660","Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous Malformation",[91],"2018-07-31",[1871,1872],"Blue Rubber Bleb Nevus Syndrome","Venous Malformation",[158],{"nctId":1875,"briefTitle":1876,"status":108,"phases":1877,"primaryCompletion":1680,"completion":193,"start":1878,"enrollment":215,"conditions":1879,"interventions":1881},"NCT03781050","Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers Syndrome",[91],"2018-09-16",[1880],"Peutz-Jeghers Syndrome",[158],{"trials":1883,"activeCount":100},[],{"intervention":1885,"totalTrials":184,"cells":1886},"Azacitidine",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1902,"PHASE4":1915,"NA":1926},{"trials":1888,"activeCount":100},[],{"trials":1890,"activeCount":100},[],{"trials":1892,"activeCount":100},[1893],{"nctId":1894,"briefTitle":1895,"status":108,"phases":1896,"primaryCompletion":1897,"completion":1898,"start":1680,"enrollment":142,"conditions":1899,"interventions":1901},"NCT05179213","Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma",[89],"2024-01-01","2024-05-01",[1900],"Angioimmunoblastic T-cell Lymphoma",[1885,815],{"trials":1903,"activeCount":147,"soonestReadout":1908},[1904],{"nctId":1905,"briefTitle":1906,"status":151,"phases":1907,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":1911,"conditions":1912,"interventions":1914},"NCT06927232","AZA+Lus VS AZA Monotherapy in HR-MDS",[90],"2026-01-31","2027-01-31","2025-04",86,[1913],"Higher-risk Myelodysplastic Syndrome",[1885,1656],{"trials":1916,"activeCount":100},[1917],{"nctId":1918,"briefTitle":1919,"status":108,"phases":1920,"primaryCompletion":278,"completion":1921,"start":529,"enrollment":1922,"conditions":1923,"interventions":1925},"NCT06004765","Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS",[91],"2025-08",138,[1924],"Myelodysplastic Syndromes",[282,1885],{"trials":1927,"activeCount":100},[],{"intervention":1656,"totalTrials":184,"cells":1929},{"EARLY_PHASE1":1930,"PHASE1":1932,"PHASE2":1934,"PHASE3":1936,"PHASE4":1942,"NA":1956},{"trials":1931,"activeCount":100},[],{"trials":1933,"activeCount":100},[],{"trials":1935,"activeCount":100},[],{"trials":1937,"activeCount":147,"soonestReadout":1908},[1938],{"nctId":1905,"briefTitle":1906,"status":151,"phases":1939,"primaryCompletion":1908,"completion":1909,"start":1910,"enrollment":1911,"conditions":1940,"interventions":1941},[90],[1913],[1885,1656],{"trials":1943,"activeCount":100},[1944,1952],{"nctId":1945,"briefTitle":1946,"status":108,"phases":1947,"primaryCompletion":278,"completion":1921,"start":529,"enrollment":1948,"conditions":1949,"interventions":1950},"NCT06006949","Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS",[91],62,[1924],[1951,1656],"Roxadustat",{"nctId":1649,"briefTitle":1650,"status":108,"phases":1953,"primaryCompletion":1436,"completion":528,"start":1652,"enrollment":1653,"conditions":1954,"interventions":1955},[91],[22],[1656,317],{"trials":1957,"activeCount":100},[],{"intervention":1959,"totalTrials":147,"cells":1960},"Azvudine",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1967,"PHASE4":1978,"NA":1980},{"trials":1962,"activeCount":100},[],{"trials":1964,"activeCount":100},[],{"trials":1966,"activeCount":100},[],{"trials":1968,"activeCount":147,"soonestReadout":595},[1969],{"nctId":1970,"briefTitle":1971,"status":137,"phases":1972,"primaryCompletion":595,"completion":333,"start":1973,"enrollment":1974,"conditions":1975,"interventions":1977},"NCT05689034","Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness",[89,90],"2023-04-19",1096,[1976],"COVID-19 Respiratory Infection",[1959],{"trials":1979,"activeCount":100},[],{"trials":1981,"activeCount":100},[],{"intervention":1795,"totalTrials":147,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1990,"PHASE4":1996,"NA":1998},{"trials":1985,"activeCount":100},[],{"trials":1987,"activeCount":100},[],{"trials":1989,"activeCount":100},[],{"trials":1991,"activeCount":147,"soonestReadout":1503},[1992],{"nctId":1790,"briefTitle":1791,"status":151,"phases":1993,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":357,"conditions":1994,"interventions":1995},[90],[1622],[1641,1795],{"trials":1997,"activeCount":100},[],{"trials":1999,"activeCount":100},[],{"intervention":2001,"totalTrials":147,"cells":2002},"The combination of Dalpiciclib with physician-selected endocrine therapy",{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2009,"PHASE4":2021,"NA":2023},{"trials":2004,"activeCount":100},[],{"trials":2006,"activeCount":100},[],{"trials":2008,"activeCount":100},[],{"trials":2010,"activeCount":147,"soonestReadout":333},[2011],{"nctId":2012,"briefTitle":2013,"status":137,"phases":2014,"primaryCompletion":333,"completion":2015,"start":2016,"enrollment":1206,"conditions":2017,"interventions":2019},"NCT05861830","Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4\u002F6 Inhibitor Failure (DAWNA-FES)",[90],"2026-06-30","2023-05-15",[2018],"Advanced Breast Cancer",[2001,2020],"Chemotherapy selected by the physician",{"trials":2022,"activeCount":100},[],{"trials":2024,"activeCount":100},[],{"intervention":2020,"totalTrials":147,"cells":2026},{"EARLY_PHASE1":2027,"PHASE1":2029,"PHASE2":2031,"PHASE3":2033,"PHASE4":2039,"NA":2041},{"trials":2028,"activeCount":100},[],{"trials":2030,"activeCount":100},[],{"trials":2032,"activeCount":100},[],{"trials":2034,"activeCount":147,"soonestReadout":333},[2035],{"nctId":2012,"briefTitle":2013,"status":137,"phases":2036,"primaryCompletion":333,"completion":2015,"start":2016,"enrollment":1206,"conditions":2037,"interventions":2038},[90],[2018],[2001,2020],{"trials":2040,"activeCount":100},[],{"trials":2042,"activeCount":100},[],{"intervention":2044,"totalTrials":147,"cells":2045},"EPAG-pfos",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2065,"NA":2067},{"trials":2047,"activeCount":100},[],{"trials":2049,"activeCount":100},[],{"trials":2051,"activeCount":100},[],{"trials":2053,"activeCount":147,"soonestReadout":2058},[2054],{"nctId":2055,"briefTitle":2056,"status":151,"phases":2057,"primaryCompletion":2058,"completion":2059,"start":2060,"enrollment":2061,"conditions":2062,"interventions":2064},"NCT07001397","Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA\u002FTD-NSAA",[90],"2026-03-23","2027-03-23","2025-06-23",70,[2063],"Aplastic Anemias",[2044],{"trials":2066,"activeCount":100},[],{"trials":2068,"activeCount":100},[],{"intervention":2070,"totalTrials":147,"cells":2071},"Bushen Tongzhi Formula",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2078,"PHASE4":2088,"NA":2090},{"trials":2073,"activeCount":100},[],{"trials":2075,"activeCount":100},[],{"trials":2077,"activeCount":100},[],{"trials":2079,"activeCount":147,"soonestReadout":2084},[2080],{"nctId":2081,"briefTitle":2082,"status":151,"phases":2083,"primaryCompletion":2084,"completion":1531,"start":1205,"enrollment":2085,"conditions":2086,"interventions":2087},"NCT07347340","Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian Reserve",[90],"2028-01-31",348,[359],[2070],{"trials":2089,"activeCount":100},[],{"trials":2091,"activeCount":100},[],{"intervention":2093,"totalTrials":147,"cells":2094},"5mg lenalidomide",{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2101,"PHASE4":2116,"NA":2118},{"trials":2096,"activeCount":100},[],{"trials":2098,"activeCount":100},[],{"trials":2100,"activeCount":100},[],{"trials":2102,"activeCount":147,"soonestReadout":2107},[2103],{"nctId":2104,"briefTitle":2105,"status":137,"phases":2106,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":2110,"conditions":2111,"interventions":2113},"NCT07068165","A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease",[89,90],"2028-07-20","2028-08-20","2025-07-07",198,[2112],"IgG4 Related Disease",[2093,2114,2115],"10mg lenalidomide","Prednisone monotherapy",{"trials":2117,"activeCount":100},[],{"trials":2119,"activeCount":100},[],{"intervention":2114,"totalTrials":147,"cells":2121},{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2134,"NA":2136},{"trials":2123,"activeCount":100},[],{"trials":2125,"activeCount":100},[],{"trials":2127,"activeCount":100},[],{"trials":2129,"activeCount":147,"soonestReadout":2107},[2130],{"nctId":2104,"briefTitle":2105,"status":137,"phases":2131,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":2110,"conditions":2132,"interventions":2133},[89,90],[2112],[2093,2114,2115],{"trials":2135,"activeCount":100},[],{"trials":2137,"activeCount":100},[],{"intervention":2115,"totalTrials":147,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2146,"PHASE4":2152,"NA":2154},{"trials":2141,"activeCount":100},[],{"trials":2143,"activeCount":100},[],{"trials":2145,"activeCount":100},[],{"trials":2147,"activeCount":147,"soonestReadout":2107},[2148],{"nctId":2104,"briefTitle":2105,"status":137,"phases":2149,"primaryCompletion":2107,"completion":2108,"start":2109,"enrollment":2110,"conditions":2150,"interventions":2151},[89,90],[2112],[2093,2114,2115],{"trials":2153,"activeCount":100},[],{"trials":2155,"activeCount":100},[],{"intervention":2157,"totalTrials":147,"cells":2158},"Butylphthalide",{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2163,"PHASE3":2165,"PHASE4":2177,"NA":2179},{"trials":2160,"activeCount":100},[],{"trials":2162,"activeCount":100},[],{"trials":2164,"activeCount":100},[],{"trials":2166,"activeCount":147,"soonestReadout":2171},[2167],{"nctId":2168,"briefTitle":2169,"status":151,"phases":2170,"primaryCompletion":2171,"completion":1181,"start":956,"enrollment":2172,"conditions":2173,"interventions":2176},"NCT07230587","Butylphthalide for Long-term Efficacy in Minor Stroke Study",[90],"2027-09-01",1200,[2174,2175],"Ischemic Stroke","Minor Stroke",[2157],{"trials":2178,"activeCount":100},[],{"trials":2180,"activeCount":100},[],{"intervention":2182,"totalTrials":147,"cells":2183},"Edaravone Dexborneol Sublingual",{"EARLY_PHASE1":2184,"PHASE1":2186,"PHASE2":2188,"PHASE3":2190,"PHASE4":2200,"NA":2202},{"trials":2185,"activeCount":100},[],{"trials":2187,"activeCount":100},[],{"trials":2189,"activeCount":100},[],{"trials":2191,"activeCount":147,"soonestReadout":1180},[2192],{"nctId":2193,"briefTitle":2194,"status":137,"phases":2195,"primaryCompletion":1180,"completion":1181,"start":110,"enrollment":2196,"conditions":2197,"interventions":2199},"NCT06674460","Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease",[90],600,[2198,2174],"Cerebral Small Vessel Disease",[2182],{"trials":2201,"activeCount":100},[],{"trials":2203,"activeCount":100},[],{"intervention":51,"totalTrials":147,"cells":2205},{"EARLY_PHASE1":2206,"PHASE1":2208,"PHASE2":2210,"PHASE3":2212,"PHASE4":2218,"NA":2220},{"trials":2207,"activeCount":100},[],{"trials":2209,"activeCount":100},[],{"trials":2211,"activeCount":100},[],{"trials":2213,"activeCount":147,"soonestReadout":50},[2214],{"nctId":48,"briefTitle":49,"status":151,"phases":2215,"primaryCompletion":50,"completion":153,"start":154,"enrollment":155,"conditions":2216,"interventions":2217},[90],[16],[51,158,159,95],{"trials":2219,"activeCount":100},[],{"trials":2221,"activeCount":100},[],{"intervention":130,"totalTrials":147,"cells":2223},{"EARLY_PHASE1":2224,"PHASE1":2226,"PHASE2":2228,"PHASE3":2230,"PHASE4":2236,"NA":2238},{"trials":2225,"activeCount":100},[],{"trials":2227,"activeCount":100},[],{"trials":2229,"activeCount":100},[],{"trials":2231,"activeCount":147,"soonestReadout":164},[2232],{"nctId":161,"briefTitle":162,"status":137,"phases":2233,"primaryCompletion":164,"completion":165,"start":166,"enrollment":167,"conditions":2234,"interventions":2235},[89,90],[169],[95,130],{"trials":2237,"activeCount":100},[],{"trials":2239,"activeCount":100},[],{"intervention":2241,"totalTrials":147,"cells":2242},"Moderated hypofractionated online adaptive radiotherapy",{"EARLY_PHASE1":2243,"PHASE1":2245,"PHASE2":2247,"PHASE3":2249,"PHASE4":2263,"NA":2265},{"trials":2244,"activeCount":100},[],{"trials":2246,"activeCount":100},[],{"trials":2248,"activeCount":100},[],{"trials":2250,"activeCount":147,"soonestReadout":2255},[2251],{"nctId":2252,"briefTitle":2253,"status":137,"phases":2254,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":2258,"conditions":2259,"interventions":2261},"NCT06641635","Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer",[90],"2026-10-31","2029-10-31","2024-11-19",440,[25,2260],"Adaptive Radiotherapy",[2241,2262],"Conventional radiotherapy",{"trials":2264,"activeCount":100},[],{"trials":2266,"activeCount":100},[],{"intervention":2262,"totalTrials":147,"cells":2268},{"EARLY_PHASE1":2269,"PHASE1":2271,"PHASE2":2273,"PHASE3":2275,"PHASE4":2281,"NA":2283},{"trials":2270,"activeCount":100},[],{"trials":2272,"activeCount":100},[],{"trials":2274,"activeCount":100},[],{"trials":2276,"activeCount":147,"soonestReadout":2255},[2277],{"nctId":2252,"briefTitle":2253,"status":137,"phases":2278,"primaryCompletion":2255,"completion":2256,"start":2257,"enrollment":2258,"conditions":2279,"interventions":2280},[90],[25,2260],[2241,2262],{"trials":2282,"activeCount":100},[],{"trials":2284,"activeCount":100},[],{"intervention":2286,"totalTrials":147,"cells":2287},"Organoid Drug Sensitivity Testing-Guided Therapy",{"EARLY_PHASE1":2288,"PHASE1":2290,"PHASE2":2292,"PHASE3":2294,"PHASE4":2307,"NA":2309},{"trials":2289,"activeCount":100},[],{"trials":2291,"activeCount":100},[],{"trials":2293,"activeCount":100},[],{"trials":2295,"activeCount":147,"soonestReadout":322},[2296],{"nctId":2297,"briefTitle":2298,"status":151,"phases":2299,"primaryCompletion":322,"completion":1503,"start":1921,"enrollment":2300,"conditions":2301,"interventions":2305},"NCT07106528","Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer",[89,90],128,[2302,2303,2304],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Extensive-stage Small Cell Lung Cancer (SCLC)","Small Cell Lung Cancer ( SCLC )",[2286,2306],"Topotecan",{"trials":2308,"activeCount":100},[],{"trials":2310,"activeCount":100},[],{"intervention":2306,"totalTrials":147,"cells":2312},{"EARLY_PHASE1":2313,"PHASE1":2315,"PHASE2":2317,"PHASE3":2319,"PHASE4":2325,"NA":2327},{"trials":2314,"activeCount":100},[],{"trials":2316,"activeCount":100},[],{"trials":2318,"activeCount":100},[],{"trials":2320,"activeCount":147,"soonestReadout":322},[2321],{"nctId":2297,"briefTitle":2298,"status":151,"phases":2322,"primaryCompletion":322,"completion":1503,"start":1921,"enrollment":2300,"conditions":2323,"interventions":2324},[89,90],[2302,2303,2304],[2286,2306],{"trials":2326,"activeCount":100},[],{"trials":2328,"activeCount":100},[],{"intervention":250,"totalTrials":2330,"cells":2331},7,{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2358,"PHASE4":2374,"NA":2386},{"trials":2333,"activeCount":100},[],{"trials":2335,"activeCount":100},[],{"trials":2337,"activeCount":100},[2338,2342,2346],{"nctId":805,"briefTitle":806,"status":108,"phases":2339,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":2340,"interventions":2341},[88,89],[813],[815,247,248,249,681,250],{"nctId":237,"briefTitle":238,"status":108,"phases":2343,"primaryCompletion":240,"completion":241,"start":242,"enrollment":142,"conditions":2344,"interventions":2345},[89],[244],[246,214,247,248,249,250],{"nctId":2347,"briefTitle":2348,"status":108,"phases":2349,"primaryCompletion":2350,"completion":2351,"start":2352,"enrollment":2353,"conditions":2354,"interventions":2356},"NCT02458196","Study of Treatment Response on IgG4 Related Disease (IgG4RD)",[89],"2017-06","2018-06","2015-04",60,[2355],"Autoimmune Disease",[250,2357],"Prednisone and Mycophenolate mofetil",{"trials":2359,"activeCount":147,"soonestReadout":322},[2360,2370],{"nctId":2361,"briefTitle":2362,"status":108,"phases":2363,"primaryCompletion":2364,"completion":2365,"start":2366,"enrollment":127,"conditions":2367,"interventions":2369},"NCT01758393","Glucocorticoids in Patients With IgG4-RD",[89,90],"2014-01","2014-04","2012-12",[2368],"IgG4-related Disease",[250],{"nctId":319,"briefTitle":320,"status":137,"phases":2371,"primaryCompletion":322,"completion":323,"start":313,"enrollment":324,"conditions":2372,"interventions":2373},[90],[315],[250,247,214],{"trials":2375,"activeCount":100},[2376],{"nctId":2377,"briefTitle":2378,"status":108,"phases":2379,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":2353,"conditions":2383,"interventions":2384},"NCT04660565","Belimumab Treatment for IgG4-related Disease",[91],"2022-12","2023-12","2021-01",[2368],[2385,250],"Prednisone and Belimumab",{"trials":2387,"activeCount":100},[2388],{"nctId":2389,"briefTitle":2390,"status":108,"phases":2391,"primaryCompletion":2392,"completion":2392,"start":2393,"enrollment":2061,"conditions":2394,"interventions":2395},"NCT03715699","Leflunomide Treatment for IgG4-RD",[92],"2020-12-31","2018-07-01",[2355],[250,2396],"Prednisone and Leflunomide",{"intervention":1625,"totalTrials":1606,"cells":2398},{"EARLY_PHASE1":2399,"PHASE1":2401,"PHASE2":2403,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2400,"activeCount":100},[],{"trials":2402,"activeCount":100},[],{"trials":2404,"activeCount":1606,"soonestReadout":2429},[2405,2409,2415,2421,2425],{"nctId":1615,"briefTitle":1616,"status":151,"phases":2406,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":2407,"interventions":2408},[89],[1621,1622],[1605,1624,1625],{"nctId":2410,"briefTitle":2411,"status":151,"phases":2412,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":2413,"interventions":2414},"NCT07572084","Romiplostim N01 in Chemoradiotherapy-induced Aplastic Anemia",[89],[22],[1625],{"nctId":2416,"briefTitle":2417,"status":151,"phases":2418,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":2419,"interventions":2420},"NCT07532408","Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA",[89],[22],[1625],{"nctId":1627,"briefTitle":1628,"status":151,"phases":2422,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":2423,"interventions":2424},[89],[1621,1622],[1605,1632,1625],{"nctId":2426,"briefTitle":2427,"status":151,"phases":2428,"primaryCompletion":2429,"completion":1181,"start":228,"enrollment":780,"conditions":2430,"interventions":2432},"NCT07400250","Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of Therapy",[89],"2026-10-01",[2431],"Primary Immune Thrombocytopenia (ITP)",[233,1625],{"trials":2434,"activeCount":100},[],{"trials":2436,"activeCount":100},[],{"trials":2438,"activeCount":100},[],{"intervention":2440,"totalTrials":2330,"cells":2441},"Lenvatinib",{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2524,"PHASE4":2526,"NA":2528},{"trials":2443,"activeCount":100},[],{"trials":2445,"activeCount":100},[],{"trials":2447,"activeCount":605,"soonestReadout":1691},[2448,2463,2475,2483,2491,2502,2513],{"nctId":2449,"briefTitle":2450,"status":151,"phases":2451,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2455,"conditions":2456,"interventions":2460},"NCT07159217","Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer",[89],"2027-05-31","2028-05-31","2025-08-30",65,[2457,2458,2440,2459],"Biliary Tract Cancer","Disitamab Vedotin","Immune Checkpoint Inhibitors",[2458,2440,46,2461,2462],"Toripalimab","Camrelizumab",{"nctId":2464,"briefTitle":2465,"status":137,"phases":2466,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":2468,"interventions":2470},"NCT07157969","ICIs and Anti-VEGF Antibody\u002FTKIs With or Without Interventional Therapy for Advanced HCC",[89],"2025-02-19",[2469],"HCC - Hepatocellular Carcinoma",[2440,46,2471,2472,2462,2473,2474,653],"Atezolizumab","Bevacizumab","Apatinib","Tislelizumab",{"nctId":2476,"briefTitle":2477,"status":108,"phases":2478,"primaryCompletion":278,"completion":278,"start":2479,"enrollment":2480,"conditions":2481,"interventions":2482},"NCT04443309","Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC",[88,89],"2020-09-11",53,[27],[2462,2440],{"nctId":2484,"briefTitle":2485,"status":137,"phases":2486,"primaryCompletion":2429,"completion":2429,"start":1898,"enrollment":705,"conditions":2487,"interventions":2488},"NCT07282262","An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.",[89],[2457],[2489,2440,2490],"Ivosidenib","PD-1\u002FPD-L1 inhibitor",{"nctId":2492,"briefTitle":2493,"status":108,"phases":2494,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":705,"conditions":2498,"interventions":2500},"NCT06362317","Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer",[89],"2025-03-06","2026-03-06","2024-03-06",[2499],"Biliary Tract Neoplasms Immunotherapy",[2461,2440,2501],"Gemox Chemotherapy（Gemox or GC）",{"nctId":2503,"briefTitle":2504,"status":443,"phases":2505,"primaryCompletion":2506,"completion":2507,"start":1859,"enrollment":2508,"conditions":2509,"interventions":2512},"NCT04656249","Lenvatinib in Patients With Previously Treated Advanced Biliary Tract Cancer",[89],"2020-12-01","2021-05-01",46,[2510,2457,2511],"Cholangiocarcinoma","Targeted Therapy",[2440],{"nctId":2514,"briefTitle":2515,"status":137,"phases":2516,"primaryCompletion":2517,"completion":2452,"start":2518,"enrollment":2519,"conditions":2520,"interventions":2522},"NCT07014150","Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma",[89],"2027-05-01","2025-06-10",33,[2521],"Hepatocellular Carcinoma Resectable",[2440,2523],"Iparomlimab and Tuvonralimab",{"trials":2525,"activeCount":100},[],{"trials":2527,"activeCount":100},[],{"trials":2529,"activeCount":100},[],{"intervention":2531,"totalTrials":1606,"cells":2532},"Dexamethasone",{"EARLY_PHASE1":2533,"PHASE1":2535,"PHASE2":2537,"PHASE3":2578,"PHASE4":2580,"NA":2582},{"trials":2534,"activeCount":100},[],{"trials":2536,"activeCount":100},[],{"trials":2538,"activeCount":184,"soonestReadout":75},[2539,2550,2561,2568],{"nctId":2540,"briefTitle":2541,"status":108,"phases":2542,"primaryCompletion":2543,"completion":2544,"start":2545,"enrollment":127,"conditions":2546,"interventions":2548},"NCT04474938","Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis",[89],"2023-06","2024-03","2021-05-24",[2547],"Amyloidosis; Systemic",[2549,303,2531],"Daratumumab",{"nctId":2551,"briefTitle":2552,"status":137,"phases":2553,"primaryCompletion":2554,"completion":2554,"start":2555,"enrollment":2556,"conditions":2557,"interventions":2559},"NCT06629818","Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)",[89],"2026-10-14","2024-10-15",36,[2558],"Light Chain (AL) Amyloidosis",[2560,76,2531],"Daratumumab 16 mg\u002Fkg",{"nctId":73,"briefTitle":74,"status":1229,"phases":2562,"primaryCompletion":75,"completion":2563,"start":2564,"enrollment":2556,"conditions":2565,"interventions":2567},[89],"2025-09","2023-09-07",[2558,2566,76],"CCND1 Translocation",[76,2531],{"nctId":2569,"briefTitle":2570,"status":137,"phases":2571,"primaryCompletion":1618,"completion":2572,"start":2573,"enrollment":2574,"conditions":2575,"interventions":2577},"NCT05248633","Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma",[89],"2026-10","2022-04-21",220,[2576],"Solitary Plasmacytoma",[303,282,2531],{"trials":2579,"activeCount":100},[],{"trials":2581,"activeCount":100},[],{"trials":2583,"activeCount":147,"soonestReadout":2588},[2584],{"nctId":2585,"briefTitle":2586,"status":137,"phases":2587,"primaryCompletion":2588,"completion":704,"start":112,"enrollment":705,"conditions":2589,"interventions":2591},"NCT06387823","Efficacy and Safety of Sivelestat Sodium and Dexamethasone in the Treatment of ARDS",[92],"2025-06-01",[2590],"Acute Respiratory Distress Syndrome",[2592,2531,2593,2594],"Sivelestat sodium","Sivelestat sodium placebo","Dexamethasone placebo",{"intervention":2596,"totalTrials":33,"cells":2597},"68Ga-FAPI",{"EARLY_PHASE1":2598,"PHASE1":2664,"PHASE2":2674,"PHASE3":2691,"PHASE4":2693,"NA":2695},{"trials":2599,"activeCount":147,"soonestReadout":333},[2600,2610,2619,2630,2640,2648,2655],{"nctId":2601,"briefTitle":2602,"status":108,"phases":2603,"primaryCompletion":2604,"completion":2605,"start":2606,"enrollment":2061,"conditions":2607,"interventions":2609},"NCT04596462","Characterizing SAPHO With 68Ga-FAPI PET\u002FCT",[87],"2021-06","2021-07","2020-06-08",[2608],"SAPHO Syndrome",[2596],{"nctId":2611,"briefTitle":2612,"status":108,"phases":2613,"primaryCompletion":2614,"completion":2614,"start":2615,"enrollment":811,"conditions":2616,"interventions":2618},"NCT05036759","68Ga-FAPI PET\u002FMR for Atherosclerosis",[87],"2023-08-30","2021-05-26",[2617],"Atherosclerosis",[2596],{"nctId":2620,"briefTitle":2621,"status":137,"phases":2622,"primaryCompletion":333,"completion":333,"start":2623,"enrollment":2353,"conditions":2624,"interventions":2626},"NCT05543954","68Ga-FAPI-RGD PET\u002FCT Imaging in the Lung Cancer Patients",[87],"2022-09-03",[2625],"Lung Neoplasms",[2627,2628,2596,2629],"68Ga-FAPI-RGD","18F-FDG","68Ga-RGD",{"nctId":2631,"briefTitle":2632,"status":108,"phases":2633,"primaryCompletion":2634,"completion":2635,"start":2636,"enrollment":142,"conditions":2637,"interventions":2639},"NCT05686876","FAPI-PET\u002FCT in Psoriatic Arthritis",[87],"2023-01-31","2023-02-28","2022-11-01",[2638],"Psoriatic Arthritis",[2596],{"nctId":2641,"briefTitle":2642,"status":108,"phases":2643,"primaryCompletion":1680,"completion":177,"start":2644,"enrollment":811,"conditions":2645,"interventions":2647},"NCT04514614","Characterizing Rheumatoid Arthritis With 68Ga-FAPI PET\u002FCT",[87],"2020-09-01",[2646],"Arthritis",[2596],{"nctId":2649,"briefTitle":2650,"status":108,"phases":2651,"primaryCompletion":1680,"completion":177,"start":268,"enrollment":811,"conditions":2652,"interventions":2654},"NCT04507932","Characterizing Inflammatory Bowel Disease With 68Ga-FAPI PET\u002FCT",[87],[2653],"Inflammatory Bowel Disease",[2596],{"nctId":2656,"briefTitle":2657,"status":108,"phases":2658,"primaryCompletion":2659,"completion":2660,"start":2661,"enrollment":811,"conditions":2662,"interventions":2663},"NCT04125511","Characterizing IgG4-RD With 68Ga-FAPI PET\u002FCT",[87],"2021-10-01","2021-12-01","2019-11-01",[2368],[2596],{"trials":2665,"activeCount":147,"soonestReadout":956},[2666],{"nctId":2667,"briefTitle":2668,"status":137,"phases":2669,"primaryCompletion":956,"completion":333,"start":2670,"enrollment":1206,"conditions":2671,"interventions":2673},"NCT05121779","Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT",[88],"2021-11-18",[2672],"Pulmonary Fibrosis",[2596,2628],{"trials":2675,"activeCount":147,"soonestReadout":704},[2676,2685],{"nctId":2677,"briefTitle":2678,"status":443,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":2681,"enrollment":1860,"conditions":2682,"interventions":2684},"NCT05275699","Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT",[88,89],"2023-02-01","2022-03-01",[2683],"Keloid",[2596],{"nctId":2686,"briefTitle":2687,"status":137,"phases":2688,"primaryCompletion":704,"completion":956,"start":55,"enrollment":2353,"conditions":2689,"interventions":2690},"NCT07062523","Analyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT",[88,89],[336],[2596],{"trials":2692,"activeCount":100},[],{"trials":2694,"activeCount":100},[],{"trials":2696,"activeCount":100},[2697],{"nctId":2698,"briefTitle":2699,"status":108,"phases":2700,"primaryCompletion":2701,"completion":1858,"start":2659,"enrollment":957,"conditions":2702,"interventions":2705},"NCT05499936","68Ga-FAPI PET\u002FCT for the Detection of Adenoid Cystic Carcinoma(ACC)",[92],"2022-10-01",[2703,2704],"68Ga-FAPI PET\u002FCT","Metastatic Adenoid Cystic Carcinoma",[2596],{"intervention":2462,"totalTrials":96,"cells":2707},{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2755,"PHASE4":2757,"NA":2759},{"trials":2709,"activeCount":100},[],{"trials":2711,"activeCount":100},[],{"trials":2713,"activeCount":372,"soonestReadout":1691},[2714,2718,2728,2732,2741,2745],{"nctId":2449,"briefTitle":2450,"status":151,"phases":2715,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2455,"conditions":2716,"interventions":2717},[89],[2457,2458,2440,2459],[2458,2440,46,2461,2462],{"nctId":2719,"briefTitle":2720,"status":443,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":142,"conditions":2725,"interventions":2727},"NCT04047017","Camrelizumab Combined With Apatinib for Recurrent Resistant GTN",[89],"2021-03-18","2021-05-15","2019-08-08",[2726],"Gestational Trophoblastic Disease",[2473,2462],{"nctId":2464,"briefTitle":2465,"status":137,"phases":2729,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":2730,"interventions":2731},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"nctId":2733,"briefTitle":2734,"status":108,"phases":2735,"primaryCompletion":2736,"completion":1857,"start":2737,"enrollment":780,"conditions":2738,"interventions":2740},"NCT04068974","Camrelizumab \u002FApatinib for Recurrent Platinum-resistant Ovarian Cancer",[89],"2021-06-30","2019-10-28",[2739],"Recurrent Platinum-resistant Ovarian Cancer",[2462,2473],{"nctId":2476,"briefTitle":2477,"status":108,"phases":2742,"primaryCompletion":278,"completion":278,"start":2479,"enrollment":2480,"conditions":2743,"interventions":2744},[88,89],[27],[2462,2440],{"nctId":2746,"briefTitle":2747,"status":108,"phases":2748,"primaryCompletion":124,"completion":2749,"start":2750,"enrollment":269,"conditions":2751,"interventions":2753},"NCT04583020","Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma",[89],"2023-12-31","2020-11-12",[2752],"Glioblastoma",[2462,2754],"Temozolomide",{"trials":2756,"activeCount":100},[],{"trials":2758,"activeCount":100},[],{"trials":2760,"activeCount":147,"soonestReadout":257},[2761,2770],{"nctId":2762,"briefTitle":2763,"status":137,"phases":2764,"primaryCompletion":257,"completion":2765,"start":1897,"enrollment":1765,"conditions":2766,"interventions":2769},"NCT06215677","Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer",[92],"2030-02-10",[2767,2768,130],"Colon Cancer","Mismatch Repair Deficiency",[2462],{"nctId":2771,"briefTitle":2772,"status":108,"phases":2773,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":2777,"interventions":2779},"NCT04771715","Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer",[],"2021-02-28","2021-03-31","2019-05-01",[2778],"Advanced Colorectal Carcinoma",[2780,2781,46,2462,653,2461,2474],"Regorafenib","Nivolumab",{"intervention":2461,"totalTrials":2330,"cells":2783},{"EARLY_PHASE1":2784,"PHASE1":2786,"PHASE2":2788,"PHASE3":2827,"PHASE4":2829,"NA":2831},{"trials":2785,"activeCount":100},[],{"trials":2787,"activeCount":100},[],{"trials":2789,"activeCount":372,"soonestReadout":1921},[2790,2794,2805,2809,2819],{"nctId":2449,"briefTitle":2450,"status":151,"phases":2791,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2455,"conditions":2792,"interventions":2793},[89],[2457,2458,2440,2459],[2458,2440,46,2461,2462],{"nctId":2795,"briefTitle":2796,"status":108,"phases":2797,"primaryCompletion":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2804},"NCT05803915","Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy",[89],"2024-09-30","2026-03-10","2023-05-01",57,[2803],"Oral Squamous Cell Carcinoma",[2461],{"nctId":2492,"briefTitle":2493,"status":108,"phases":2806,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":705,"conditions":2807,"interventions":2808},[89],[2499],[2461,2440,2501],{"nctId":2810,"briefTitle":2811,"status":108,"phases":2812,"primaryCompletion":177,"completion":1736,"start":2813,"enrollment":2814,"conditions":2815,"interventions":2816},"NCT04973904","Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer",[89],"2021-08-01",35,[25],[2461,2817,2818,2472],"Paclitaxel","Cisplatin",{"nctId":2820,"briefTitle":2821,"status":137,"phases":2822,"primaryCompletion":1921,"completion":1921,"start":527,"enrollment":20,"conditions":2823,"interventions":2825},"NCT06020755","Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7",[89],[2824],"Gestational Trophoblastic Neoplasia",[2461,2826],"Actinomycin-D",{"trials":2828,"activeCount":100},[],{"trials":2830,"activeCount":100},[],{"trials":2832,"activeCount":147,"soonestReadout":1921},[2833,2837],{"nctId":2771,"briefTitle":2772,"status":108,"phases":2834,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":2835,"interventions":2836},[],[2778],[2780,2781,46,2462,653,2461,2474],{"nctId":2838,"briefTitle":2839,"status":137,"phases":2840,"primaryCompletion":1921,"completion":1921,"start":2841,"enrollment":127,"conditions":2842,"interventions":2843},"NCT06028672","Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6",[92],"2023-09-12",[2824],[2461,2826],{"intervention":46,"totalTrials":1660,"cells":2845},{"EARLY_PHASE1":2846,"PHASE1":2848,"PHASE2":2850,"PHASE3":2883,"PHASE4":2885,"NA":2887},{"trials":2847,"activeCount":100},[],{"trials":2849,"activeCount":100},[],{"trials":2851,"activeCount":184,"soonestReadout":45},[2852,2856,2860,2864,2871],{"nctId":2449,"briefTitle":2450,"status":151,"phases":2853,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2455,"conditions":2854,"interventions":2855},[89],[2457,2458,2440,2459],[2458,2440,46,2461,2462],{"nctId":2464,"briefTitle":2465,"status":137,"phases":2857,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":2858,"interventions":2859},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"nctId":774,"briefTitle":775,"status":443,"phases":2861,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":2862,"interventions":2863},[89],[782],[46,784,785],{"nctId":43,"briefTitle":44,"status":1229,"phases":2865,"primaryCompletion":45,"completion":322,"start":193,"enrollment":1206,"conditions":2866,"interventions":2870},[89],[2867,2868,2869],"Non Small Cell Lung Cancer","Neoadjuvant Therapy","Immune Checkpoint Inhibitor",[46],{"nctId":2872,"briefTitle":2873,"status":108,"phases":2874,"primaryCompletion":2875,"completion":2876,"start":2877,"enrollment":2878,"conditions":2879,"interventions":2881},"NCT04164745","Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer",[89],"2021-11-16","2022-11-16","2019-11-16",49,[2880],"NSCLC",[2882,46],"Anlotinib, oral",{"trials":2884,"activeCount":100},[],{"trials":2886,"activeCount":100},[],{"trials":2888,"activeCount":100},[2889],{"nctId":2771,"briefTitle":2772,"status":108,"phases":2890,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":2891,"interventions":2892},[],[2778],[2780,2781,46,2462,653,2461,2474],{"intervention":2894,"totalTrials":184,"cells":2895},"Osimertinib",{"EARLY_PHASE1":2896,"PHASE1":2898,"PHASE2":2900,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2897,"activeCount":100},[],{"trials":2899,"activeCount":100},[],{"trials":2901,"activeCount":372,"soonestReadout":2906},[2902,2913,2924],{"nctId":2903,"briefTitle":2904,"status":151,"phases":2905,"primaryCompletion":2906,"completion":2907,"start":2908,"enrollment":2909,"conditions":2910,"interventions":2911},"NCT06752408","Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer",[89],"2027-01-16","2028-01-16","2024-12-17",316,[2867],[2912,2894],"Aumolertinib",{"nctId":2914,"briefTitle":2915,"status":108,"phases":2916,"primaryCompletion":2917,"completion":2918,"start":2919,"enrollment":1206,"conditions":2920,"interventions":2923},"NCT05458726","Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC",[89],"2022-07-31","2022-10-31","2020-09-15",[2921,2894,1767,2922],"EGFR T790M","ddPCR",[2894],{"nctId":2925,"briefTitle":2926,"status":151,"phases":2927,"primaryCompletion":2928,"completion":379,"start":1736,"enrollment":2929,"conditions":2930,"interventions":2932},"NCT06142617","A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.",[89],"2027-11-30",37,[2867,2869,2931],"EGFR Exon 21 Mutation",[2933,2894],"Pembrolizumab, pemetrexed, platinum",{"trials":2935,"activeCount":100},[],{"trials":2937,"activeCount":100},[],{"trials":2939,"activeCount":100},[],{"intervention":1624,"totalTrials":372,"cells":2941},{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2943,"activeCount":100},[],{"trials":2945,"activeCount":100},[],{"trials":2947,"activeCount":372,"soonestReadout":1503},[2948,2952],{"nctId":1615,"briefTitle":1616,"status":151,"phases":2949,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":2950,"interventions":2951},[89],[1621,1622],[1605,1624,1625],{"nctId":1627,"briefTitle":1628,"status":151,"phases":2953,"primaryCompletion":1503,"completion":323,"start":1618,"enrollment":1619,"conditions":2954,"interventions":2955},[89],[1621,1622],[1605,1632,1625],{"trials":2957,"activeCount":100},[],{"trials":2959,"activeCount":100},[],{"trials":2961,"activeCount":100},[],{"intervention":2963,"totalTrials":372,"cells":2964},"Teclistamab",{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2986,"PHASE4":2988,"NA":2990},{"trials":2966,"activeCount":100},[],{"trials":2968,"activeCount":100},[],{"trials":2970,"activeCount":372,"soonestReadout":164},[2971,2979],{"nctId":2972,"briefTitle":2973,"status":137,"phases":2974,"primaryCompletion":1909,"completion":675,"start":2975,"enrollment":2814,"conditions":2976,"interventions":2978},"NCT07079423","Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis",[89],"2025-06-28",[2977],"AL Amyloidosis",[2963],{"nctId":2980,"briefTitle":2981,"status":137,"phases":2982,"primaryCompletion":164,"completion":165,"start":2983,"enrollment":957,"conditions":2984,"interventions":2985},"NCT06935162","Teclistamab in Previously Treated AL Amyloidosis",[89],"2025-05-21",[2977],[2963],{"trials":2987,"activeCount":100},[],{"trials":2989,"activeCount":100},[],{"trials":2991,"activeCount":100},[],{"intervention":2993,"totalTrials":372,"cells":2994},"Single subcutaneous",{"EARLY_PHASE1":2995,"PHASE1":2997,"PHASE2":2999,"PHASE3":3020,"PHASE4":3022,"NA":3024},{"trials":2996,"activeCount":100},[],{"trials":2998,"activeCount":100},[],{"trials":3000,"activeCount":372,"soonestReadout":3005},[3001,3011],{"nctId":3002,"briefTitle":3003,"status":137,"phases":3004,"primaryCompletion":3005,"completion":2015,"start":3006,"enrollment":23,"conditions":3007,"interventions":3009},"NCT07530705","Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism",[88,89],"2026-05-31","2025-11-17",[3008],"Hypoparathyroidism",[2993,3010],"Multiple subcutaneous",{"nctId":3012,"briefTitle":3013,"status":137,"phases":3014,"primaryCompletion":3015,"completion":3016,"start":3017,"enrollment":2353,"conditions":3018,"interventions":3019},"NCT07540286","A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism",[89],"2030-04-30","2030-07-30","2026-04-13",[3008],[2993,3010],{"trials":3021,"activeCount":100},[],{"trials":3023,"activeCount":100},[],{"trials":3025,"activeCount":100},[],{"intervention":3010,"totalTrials":372,"cells":3027},{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3032,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3029,"activeCount":100},[],{"trials":3031,"activeCount":100},[],{"trials":3033,"activeCount":372,"soonestReadout":3005},[3034,3038],{"nctId":3002,"briefTitle":3003,"status":137,"phases":3035,"primaryCompletion":3005,"completion":2015,"start":3006,"enrollment":23,"conditions":3036,"interventions":3037},[88,89],[3008],[2993,3010],{"nctId":3012,"briefTitle":3013,"status":137,"phases":3039,"primaryCompletion":3015,"completion":3016,"start":3017,"enrollment":2353,"conditions":3040,"interventions":3041},[89],[3008],[2993,3010],{"trials":3043,"activeCount":100},[],{"trials":3045,"activeCount":100},[],{"trials":3047,"activeCount":100},[],{"intervention":76,"totalTrials":372,"cells":3049},{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3064,"PHASE4":3066,"NA":3068},{"trials":3051,"activeCount":100},[],{"trials":3053,"activeCount":100},[],{"trials":3055,"activeCount":372,"soonestReadout":75},[3056,3060],{"nctId":2551,"briefTitle":2552,"status":137,"phases":3057,"primaryCompletion":2554,"completion":2554,"start":2555,"enrollment":2556,"conditions":3058,"interventions":3059},[89],[2558],[2560,76,2531],{"nctId":73,"briefTitle":74,"status":1229,"phases":3061,"primaryCompletion":75,"completion":2563,"start":2564,"enrollment":2556,"conditions":3062,"interventions":3063},[89],[2558,2566,76],[76,2531],{"trials":3065,"activeCount":100},[],{"trials":3067,"activeCount":100},[],{"trials":3069,"activeCount":100},[],{"intervention":586,"totalTrials":1660,"cells":3071},{"EARLY_PHASE1":3072,"PHASE1":3074,"PHASE2":3076,"PHASE3":3091,"PHASE4":3103,"NA":3125},{"trials":3073,"activeCount":100},[],{"trials":3075,"activeCount":100},[],{"trials":3077,"activeCount":147,"soonestReadout":580},[3078,3087],{"nctId":3079,"briefTitle":3080,"status":108,"phases":3081,"primaryCompletion":3082,"completion":3082,"start":3083,"enrollment":215,"conditions":3084,"interventions":3086},"NCT03942926","The Efficacy and Safety of Sirolimus for Plastic Bronchitis",[89],"2020-05-05","2019-05-06",[3085],"Plastic Bronchitis",[586],{"nctId":577,"briefTitle":578,"status":137,"phases":3088,"primaryCompletion":580,"completion":581,"start":582,"enrollment":127,"conditions":3089,"interventions":3090},[89],[584],[586,568],{"trials":3092,"activeCount":100},[3093],{"nctId":3094,"briefTitle":3095,"status":108,"phases":3096,"primaryCompletion":778,"completion":3097,"start":2736,"enrollment":142,"conditions":3098,"interventions":3102},"NCT04892212","Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis",[89,90],"2023-10-30",[3099,3100,3101],"Lupus Nephritis","Immunosuppression","Effect of Drug",[586],{"trials":3104,"activeCount":100},[3105,3115],{"nctId":3106,"briefTitle":3107,"status":108,"phases":3108,"primaryCompletion":3109,"completion":648,"start":3110,"enrollment":127,"conditions":3111,"interventions":3113},"NCT03866681","Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNH",[91],"2021-03-01","2019-04-01",[3112],"Paroxysmal Nocturnal Hemoglobinuria",[3114],"sirolimus",{"nctId":3116,"briefTitle":3117,"status":108,"phases":3118,"primaryCompletion":3119,"completion":3120,"start":3121,"enrollment":142,"conditions":3122,"interventions":3124},"NCT03688191","Study of Sirolimus in CTD-TP in China",[91],"2018-12-31","2019-09-30","2017-09-21",[3123,844],"Connective Tissue Diseases",[586],{"trials":3126,"activeCount":147,"soonestReadout":528},[3127],{"nctId":3128,"briefTitle":3129,"status":137,"phases":3130,"primaryCompletion":528,"completion":528,"start":3131,"enrollment":299,"conditions":3132,"interventions":3134},"NCT05925023","Sirolimus in the Treatment of Refractory\u002FRelapsed wAIHA",[92],"2023-06-24",[3133],"Warm Autoimmune Hemolytic Anemia",[586],{"intervention":246,"totalTrials":1606,"cells":3136},{"EARLY_PHASE1":3137,"PHASE1":3139,"PHASE2":3141,"PHASE3":3163,"PHASE4":3165,"NA":3167},{"trials":3138,"activeCount":100},[],{"trials":3140,"activeCount":100},[],{"trials":3142,"activeCount":147,"soonestReadout":255},[3143,3151,3155,3159],{"nctId":3144,"briefTitle":3145,"status":108,"phases":3146,"primaryCompletion":3147,"completion":3147,"start":3148,"enrollment":957,"conditions":3149,"interventions":3150},"NCT04743687","Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial",[89],"2025-01-01","2021-01-01",[1684],[246],{"nctId":237,"briefTitle":238,"status":108,"phases":3152,"primaryCompletion":240,"completion":241,"start":242,"enrollment":142,"conditions":3153,"interventions":3154},[89],[244],[246,214,247,248,249,250],{"nctId":252,"briefTitle":253,"status":151,"phases":3156,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":3157,"interventions":3158},[89],[260],[235,214,246,235],{"nctId":263,"briefTitle":264,"status":108,"phases":3160,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":3161,"interventions":3162},[89],[271],[235,214,246],{"trials":3164,"activeCount":100},[],{"trials":3166,"activeCount":100},[],{"trials":3168,"activeCount":147,"soonestReadout":674},[3169],{"nctId":3170,"briefTitle":3171,"status":151,"phases":3172,"primaryCompletion":674,"completion":3173,"start":3174,"enrollment":3175,"conditions":3176,"interventions":3178},"NCT06942507","Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia",[92],"2029-04-30","2025-05-01",104,[3177],"Waldenström's Macroglobulinemia (WM)",[246,3179],"Bendamustine + Rituximab",{"intervention":3181,"totalTrials":605,"cells":3182},"Tocilizumab",{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3187,"PHASE3":3203,"PHASE4":3205,"NA":3217},{"trials":3184,"activeCount":100},[],{"trials":3186,"activeCount":100},[],{"trials":3188,"activeCount":147,"soonestReadout":1691},[3189,3199],{"nctId":3190,"briefTitle":3191,"status":108,"phases":3192,"primaryCompletion":3193,"completion":3193,"start":3194,"enrollment":3195,"conditions":3196,"interventions":3198},"NCT05181397","The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases",[89],"2022-09-01","2021-02-22",68,[3197],"Rapid Progressive Interstitial Lung Diseases",[3181],{"nctId":1688,"briefTitle":1689,"status":137,"phases":3200,"primaryCompletion":1691,"completion":1692,"start":1693,"enrollment":1694,"conditions":3201,"interventions":3202},[89],[1696,1697],[1699,1700,1701],{"trials":3204,"activeCount":100},[],{"trials":3206,"activeCount":100},[3207],{"nctId":3208,"briefTitle":3209,"status":108,"phases":3210,"primaryCompletion":3211,"completion":3211,"start":3212,"enrollment":127,"conditions":3213,"interventions":3215},"NCT04762784","A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis",[91],"2023-02-10","2020-07-01",[3214],"Idiopathic Retroperitoneal Fibrosis",[3181,3216],"Glucocorticoids",{"trials":3218,"activeCount":147,"soonestReadout":2572},[3219],{"nctId":3220,"briefTitle":3221,"status":137,"phases":3222,"primaryCompletion":2572,"completion":2572,"start":3223,"enrollment":3224,"conditions":3225,"interventions":3227},"NCT07377058","RCT of Tocilizumab for Anti-MDA5+DM",[92],"2025-11-01",110,[3226],"Dermatomyositis",[3181,3228],"Standard medical treatment",{"intervention":2826,"totalTrials":372,"cells":3230},{"EARLY_PHASE1":3231,"PHASE1":3233,"PHASE2":3235,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3232,"activeCount":100},[],{"trials":3234,"activeCount":100},[],{"trials":3236,"activeCount":147,"soonestReadout":1921},[3237],{"nctId":2820,"briefTitle":2821,"status":137,"phases":3238,"primaryCompletion":1921,"completion":1921,"start":527,"enrollment":20,"conditions":3239,"interventions":3240},[89],[2824],[2461,2826],{"trials":3242,"activeCount":100},[],{"trials":3244,"activeCount":100},[],{"trials":3246,"activeCount":147,"soonestReadout":1921},[3247],{"nctId":2838,"briefTitle":2839,"status":137,"phases":3248,"primaryCompletion":1921,"completion":1921,"start":2841,"enrollment":127,"conditions":3249,"interventions":3250},[92],[2824],[2461,2826],{"intervention":235,"totalTrials":33,"cells":3252},{"EARLY_PHASE1":3253,"PHASE1":3255,"PHASE2":3266,"PHASE3":3297,"PHASE4":3320,"NA":3345},{"trials":3254,"activeCount":100},[],{"trials":3256,"activeCount":100},[3257],{"nctId":3258,"briefTitle":3259,"status":108,"phases":3260,"primaryCompletion":2918,"completion":1858,"start":3261,"enrollment":2353,"conditions":3262,"interventions":3263},"NCT04967950","An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients",[88],"2021-07-15",[2638],[3264,3265,235],"Secukinumab 300 MG","Secukinumab 150 MG",{"trials":3267,"activeCount":147,"soonestReadout":255},[3268,3272,3281,3285,3289,3293],{"nctId":224,"briefTitle":225,"status":108,"phases":3269,"primaryCompletion":227,"completion":228,"start":229,"enrollment":194,"conditions":3270,"interventions":3271},[89],[231],[233,234,214,235],{"nctId":3273,"briefTitle":3274,"status":443,"phases":3275,"primaryCompletion":3276,"completion":3276,"start":2364,"enrollment":1619,"conditions":3277,"interventions":3279},"NCT02389400","Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis",[89],"2017-09",[3278],"Langerhans Cell Histiocytosis",[3280],"methotrexate",{"nctId":252,"briefTitle":253,"status":151,"phases":3282,"primaryCompletion":255,"completion":256,"start":257,"enrollment":258,"conditions":3283,"interventions":3284},[89],[260],[235,214,246,235],{"nctId":263,"briefTitle":264,"status":108,"phases":3286,"primaryCompletion":266,"completion":267,"start":268,"enrollment":269,"conditions":3287,"interventions":3288},[89],[271],[235,214,246],{"nctId":274,"briefTitle":275,"status":108,"phases":3290,"primaryCompletion":277,"completion":278,"start":279,"enrollment":258,"conditions":3291,"interventions":3292},[88,89],[231],[235,214,282],{"nctId":284,"briefTitle":285,"status":108,"phases":3294,"primaryCompletion":287,"completion":288,"start":289,"enrollment":269,"conditions":3295,"interventions":3296},[89],[260],[235,214,282],{"trials":3298,"activeCount":100},[3299,3310],{"nctId":3300,"briefTitle":3301,"status":108,"phases":3302,"primaryCompletion":3303,"completion":3303,"start":3304,"enrollment":3305,"conditions":3306,"interventions":3309},"NCT05054426","Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL",[90],"2025-10-08","2021-10-08",488,[3307,3308],"Diffuse Large B Cell Lymphoma","Central Nervous System Lymphoma",[235],{"nctId":3311,"briefTitle":3312,"status":443,"phases":3313,"primaryCompletion":3314,"completion":3314,"start":3315,"enrollment":3316,"conditions":3317,"interventions":3319},"NCT01613079","Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis",[89,90],"2013-06","2012-05",201,[3318],"Arthritis, Rheumatoid",[1713,235],{"trials":3321,"activeCount":100},[3322,3333],{"nctId":3323,"briefTitle":3324,"status":108,"phases":3325,"primaryCompletion":3326,"completion":3327,"start":3328,"enrollment":194,"conditions":3329,"interventions":3332},"NCT05015335","The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage",[91],"2022-07","2023-07","2021-08-19",[3330,3331],"Uveitis, Anterior","Adalimumab",[3331,235],{"nctId":3334,"briefTitle":3335,"status":443,"phases":3336,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":3341,"interventions":3342},"NCT03589833","Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA",[91],"2022-03-20","2022-07-27","2019-05-14",504,[3318],[3343,235,3344],"Tripterygium Wilfordii","Yisaipu",{"trials":3346,"activeCount":100},[],{"intervention":282,"totalTrials":1606,"cells":3348},{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3353,"PHASE3":3367,"PHASE4":3369,"NA":3385},{"trials":3350,"activeCount":100},[],{"trials":3352,"activeCount":100},[],{"trials":3354,"activeCount":147,"soonestReadout":1618},[3355,3359,3363],{"nctId":274,"briefTitle":275,"status":108,"phases":3356,"primaryCompletion":277,"completion":278,"start":279,"enrollment":258,"conditions":3357,"interventions":3358},[88,89],[231],[235,214,282],{"nctId":2569,"briefTitle":2570,"status":137,"phases":3360,"primaryCompletion":1618,"completion":2572,"start":2573,"enrollment":2574,"conditions":3361,"interventions":3362},[89],[2576],[303,282,2531],{"nctId":284,"briefTitle":285,"status":108,"phases":3364,"primaryCompletion":287,"completion":288,"start":289,"enrollment":269,"conditions":3365,"interventions":3366},[89],[260],[235,214,282],{"trials":3368,"activeCount":100},[],{"trials":3370,"activeCount":100},[3371,3381],{"nctId":3372,"briefTitle":3373,"status":443,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":3377,"conditions":3378,"interventions":3379},"NCT04217967","Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients",[91],"2024-06-30","2019-09-24",211,[196],[3380,282],"Ixazomib",{"nctId":1918,"briefTitle":1919,"status":108,"phases":3382,"primaryCompletion":278,"completion":1921,"start":529,"enrollment":1922,"conditions":3383,"interventions":3384},[91],[1924],[282,1885],{"trials":3386,"activeCount":100},[],{"intervention":3331,"totalTrials":372,"cells":3388},{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3393,"PHASE3":3404,"PHASE4":3406,"NA":3412},{"trials":3390,"activeCount":100},[],{"trials":3392,"activeCount":100},[],{"trials":3394,"activeCount":147,"soonestReadout":176},[3395],{"nctId":3396,"briefTitle":3397,"status":137,"phases":3398,"primaryCompletion":176,"completion":379,"start":3399,"enrollment":418,"conditions":3400,"interventions":3402},"NCT06849908","Baricitinib in the Treatment of Intestinal Behçet's Syndrome",[89],"2024-11-08",[3401],"Behcet Syndrome, Intestinal Type",[3403,3331],"Baricitinib",{"trials":3405,"activeCount":100},[],{"trials":3407,"activeCount":100},[3408],{"nctId":3323,"briefTitle":3324,"status":108,"phases":3409,"primaryCompletion":3326,"completion":3327,"start":3328,"enrollment":194,"conditions":3410,"interventions":3411},[91],[3330,3331],[3331,235],{"trials":3413,"activeCount":100},[],{"intervention":2473,"totalTrials":2330,"cells":3415},{"EARLY_PHASE1":3416,"PHASE1":3418,"PHASE2":3420,"PHASE3":3465,"PHASE4":3478,"NA":3480},{"trials":3417,"activeCount":100},[],{"trials":3419,"activeCount":100},[],{"trials":3421,"activeCount":147,"soonestReadout":1691},[3422,3432,3441,3445,3449,3453],{"nctId":3423,"briefTitle":3424,"status":108,"phases":3425,"primaryCompletion":2543,"completion":2543,"start":2606,"enrollment":2353,"conditions":3426,"interventions":3428},"NCT04453930","A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）",[89],[3427],"Small Cell Lung Carcinoma",[3429,3430,3431,2473],"Camrelizumab，an engineered anti-PD-1 antibody","Platinum","Irinotecan",{"nctId":3433,"briefTitle":3434,"status":443,"phases":3435,"primaryCompletion":3436,"completion":2774,"start":3437,"enrollment":142,"conditions":3438,"interventions":3440},"NCT02731352","Study of Apatinib in Patients With Differentiated Thyroid Cancer",[89],"2020-02-27","2016-03-11",[3439],"Thyroid Cancer",[2473,2473],{"nctId":2719,"briefTitle":2720,"status":443,"phases":3442,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":142,"conditions":3443,"interventions":3444},[89],[2726],[2473,2462],{"nctId":2464,"briefTitle":2465,"status":137,"phases":3446,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":3447,"interventions":3448},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"nctId":2733,"briefTitle":2734,"status":108,"phases":3450,"primaryCompletion":2736,"completion":1857,"start":2737,"enrollment":780,"conditions":3451,"interventions":3452},[89],[2739],[2462,2473],{"nctId":3454,"briefTitle":3455,"status":443,"phases":3456,"primaryCompletion":3457,"completion":3458,"start":3459,"enrollment":3460,"conditions":3461,"interventions":3464},"NCT03251443","A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma",[89],"2019-03-08","2019-05-08","2017-08-08",34,[3462,3463],"Intrahepatic Cholangiocarcinoma","Second-line Treatment",[2473],{"trials":3466,"activeCount":100},[3467],{"nctId":3468,"briefTitle":3469,"status":108,"phases":3470,"primaryCompletion":3471,"completion":2749,"start":3472,"enrollment":3473,"conditions":3474,"interventions":3476},"NCT03048877","Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer",[90],"2020-03-25","2016-12",118,[3475],"Differentiated Thyroid Cancer",[3477],"Apatinib Oral",{"trials":3479,"activeCount":100},[],{"trials":3481,"activeCount":100},[],{"intervention":3483,"totalTrials":372,"cells":3484},"Concurrent Chemotherapy",{"EARLY_PHASE1":3485,"PHASE1":3487,"PHASE2":3489,"PHASE3":3500,"PHASE4":3512,"NA":3514},{"trials":3486,"activeCount":100},[],{"trials":3488,"activeCount":100},[],{"trials":3490,"activeCount":147,"soonestReadout":175},[3491],{"nctId":3492,"briefTitle":3493,"status":151,"phases":3494,"primaryCompletion":175,"completion":1532,"start":3495,"enrollment":3496,"conditions":3497,"interventions":3499},"NCT07200141","Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer",[89],"2025-10-01",156,[3498],"Locally Advanced Rectal Adenocarcinoma",[3483],{"trials":3501,"activeCount":100},[3502],{"nctId":3503,"briefTitle":3504,"status":108,"phases":3505,"primaryCompletion":1735,"completion":2588,"start":3506,"enrollment":3507,"conditions":3508,"interventions":3510},"NCT03955367","Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer",[90],"2019-06-17",638,[3509],"Uterine Cervical Neoplasms",[3511],"Concurrent chemotherapy",{"trials":3513,"activeCount":100},[],{"trials":3515,"activeCount":100},[],{"intervention":3517,"totalTrials":605,"cells":3518},"68Ga-Pentixafor",{"EARLY_PHASE1":3519,"PHASE1":3545,"PHASE2":3547,"PHASE3":3560,"PHASE4":3562,"NA":3564},{"trials":3520,"activeCount":100},[3521,3529,3537],{"nctId":3522,"briefTitle":3523,"status":108,"phases":3524,"primaryCompletion":80,"completion":80,"start":3525,"enrollment":811,"conditions":3526,"interventions":3528},"NCT06086327","Application of 68Ga-Pentixafor PET\u002FCT for Thymoma",[87],"2023-06-22",[3527],"Thymoma",[3517],{"nctId":3530,"briefTitle":3531,"status":108,"phases":3532,"primaryCompletion":3533,"completion":2506,"start":1737,"enrollment":811,"conditions":3534,"interventions":3536},"NCT03436342","Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma",[87],"2020-03-01",[196,3535],"Lymphoma",[3517],{"nctId":3538,"briefTitle":3539,"status":108,"phases":3540,"primaryCompletion":278,"completion":278,"start":3541,"enrollment":811,"conditions":3542,"interventions":3543},"NCT05364177","68Ga-pentixather and 68Ga-pentixafor PET\u002FCT in Multiple Myeloma",[87],"2021-08-11",[196],[3544,3517],"68Ga-Pentixather",{"trials":3546,"activeCount":100},[],{"trials":3548,"activeCount":147,"soonestReadout":3553},[3549],{"nctId":3550,"briefTitle":3551,"status":137,"phases":3552,"primaryCompletion":3553,"completion":3554,"start":3555,"enrollment":3556,"conditions":3557,"interventions":3559},"NCT07350707","Diagnostic Value of CXCR4-targeted PET\u002FCT in ACTH-dependent and Independent Cushing's Syndrome",[88,89],"2026-03-01","2027-02-12","2023-06-12",160,[3558],"Cushing s Syndrome",[3517],{"trials":3561,"activeCount":100},[],{"trials":3563,"activeCount":100},[],{"trials":3565,"activeCount":100},[],{"intervention":56,"totalTrials":184,"cells":3567},{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3572,"PHASE3":3596,"PHASE4":3598,"NA":3600},{"trials":3569,"activeCount":100},[],{"trials":3571,"activeCount":100},[],{"trials":3573,"activeCount":147,"soonestReadout":55},[3574,3581,3588],{"nctId":3575,"briefTitle":3576,"status":108,"phases":3577,"primaryCompletion":3223,"completion":956,"start":2659,"enrollment":142,"conditions":3578,"interventions":3580},"NCT05048017","Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma",[89],[27,2780,3579],"PD-1 Inhibitor",[2780,56],{"nctId":3582,"briefTitle":3583,"status":108,"phases":3584,"primaryCompletion":778,"completion":778,"start":3585,"enrollment":2353,"conditions":3586,"interventions":3587},"NCT04941417","Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients",[89],"2020-11-24",[1767],[56],{"nctId":53,"briefTitle":54,"status":151,"phases":3589,"primaryCompletion":55,"completion":3590,"start":3591,"enrollment":811,"conditions":3592,"interventions":3594},[89],"2029-12-01","2022-09-20",[3593],"Locally Advanced Rectal Cancer",[56,3595],"Capecitabine",{"trials":3597,"activeCount":100},[],{"trials":3599,"activeCount":100},[],{"trials":3601,"activeCount":100},[],{"intervention":3403,"totalTrials":372,"cells":3603},{"EARLY_PHASE1":3604,"PHASE1":3606,"PHASE2":3608,"PHASE3":3625,"PHASE4":3627,"NA":3629},{"trials":3605,"activeCount":100},[],{"trials":3607,"activeCount":100},[],{"trials":3609,"activeCount":147,"soonestReadout":176},[3610,3621],{"nctId":3611,"briefTitle":3612,"status":443,"phases":3613,"primaryCompletion":3614,"completion":3615,"start":3616,"enrollment":3617,"conditions":3618,"interventions":3619},"NCT05016297","Efficacy and Safety of Baricitinib in Sjogren's Syndrome",[89],"2024-08-22","2024-11-22","2022-07-14",87,[336],[3403,3620],"Hydroxychloroquine",{"nctId":3396,"briefTitle":3397,"status":137,"phases":3622,"primaryCompletion":176,"completion":379,"start":3399,"enrollment":418,"conditions":3623,"interventions":3624},[89],[3401],[3403,3331],{"trials":3626,"activeCount":100},[],{"trials":3628,"activeCount":100},[],{"trials":3630,"activeCount":100},[],{"intervention":2472,"totalTrials":372,"cells":3632},{"EARLY_PHASE1":3633,"PHASE1":3635,"PHASE2":3637,"PHASE3":3647,"PHASE4":3649,"NA":3651},{"trials":3634,"activeCount":100},[],{"trials":3636,"activeCount":100},[],{"trials":3638,"activeCount":147,"soonestReadout":1691},[3639,3643],{"nctId":2464,"briefTitle":2465,"status":137,"phases":3640,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":3641,"interventions":3642},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"nctId":2810,"briefTitle":2811,"status":108,"phases":3644,"primaryCompletion":177,"completion":1736,"start":2813,"enrollment":2814,"conditions":3645,"interventions":3646},[89],[25],[2461,2817,2818,2472],{"trials":3648,"activeCount":100},[],{"trials":3650,"activeCount":100},[],{"trials":3652,"activeCount":100},[],{"intervention":3654,"totalTrials":372,"cells":3655},"Serplulimab",{"EARLY_PHASE1":3656,"PHASE1":3658,"PHASE2":3660,"PHASE3":3681,"PHASE4":3683,"NA":3685},{"trials":3657,"activeCount":100},[],{"trials":3659,"activeCount":100},[],{"trials":3661,"activeCount":147,"soonestReadout":3675},[3662,3671],{"nctId":3663,"briefTitle":3664,"status":108,"phases":3665,"primaryCompletion":3666,"completion":3667,"start":2680,"enrollment":2814,"conditions":3668,"interventions":3670},"NCT05918419","Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction",[89],"2024-06-01","2024-09-01",[3669],"Gastroesophageal Junction Adenocarcinoma",[3654],{"nctId":3672,"briefTitle":3673,"status":137,"phases":3674,"primaryCompletion":3675,"completion":675,"start":3676,"enrollment":3677,"conditions":3678,"interventions":3680},"NCT06295926","Serplulimab Combined With CCRT for LS-SCLC.",[89],"2027-01-25","2024-04-04",96,[3679],"Small Cell Lung Cancer",[3654],{"trials":3682,"activeCount":100},[],{"trials":3684,"activeCount":100},[],{"trials":3686,"activeCount":100},[],{"intervention":3688,"totalTrials":147,"cells":3689},"Linperlisib",{"EARLY_PHASE1":3690,"PHASE1":3692,"PHASE2":3694,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3691,"activeCount":100},[],{"trials":3693,"activeCount":100},[],{"trials":3695,"activeCount":147,"soonestReadout":333},[3696],{"nctId":3697,"briefTitle":3698,"status":151,"phases":3699,"primaryCompletion":333,"completion":164,"start":704,"enrollment":23,"conditions":3700,"interventions":3702},"NCT07031115","Linperlisib in the Treatment of aPRCA",[89],[3701],"Acquired Pure Red Cell Aplasia",[3688],{"trials":3704,"activeCount":100},[],{"trials":3706,"activeCount":100},[],{"trials":3708,"activeCount":100},[],{"intervention":3710,"totalTrials":147,"cells":3711},"68Ga-NY104 PET\u002FCT",{"EARLY_PHASE1":3712,"PHASE1":3714,"PHASE2":3716,"PHASE3":3728,"PHASE4":3730,"NA":3732},{"trials":3713,"activeCount":100},[],{"trials":3715,"activeCount":100},[],{"trials":3717,"activeCount":147,"soonestReadout":1504},[3718],{"nctId":3719,"briefTitle":3720,"status":137,"phases":3721,"primaryCompletion":1504,"completion":1502,"start":3722,"enrollment":127,"conditions":3723,"interventions":3725},"NCT06613269","68Ga-NY104 PET\u002FCT Guided Radiation Therapy in CcRCC.",[89],"2024-03-27",[3724],"Clear Cell Renal Cell Carcinoma",[3710,3726,3727],"18F-FDG PET\u002FCT","Systemic therapy",{"trials":3729,"activeCount":100},[],{"trials":3731,"activeCount":100},[],{"trials":3733,"activeCount":100},[],{"intervention":3726,"totalTrials":147,"cells":3735},{"EARLY_PHASE1":3736,"PHASE1":3738,"PHASE2":3740,"PHASE3":3746,"PHASE4":3748,"NA":3750},{"trials":3737,"activeCount":100},[],{"trials":3739,"activeCount":100},[],{"trials":3741,"activeCount":147,"soonestReadout":1504},[3742],{"nctId":3719,"briefTitle":3720,"status":137,"phases":3743,"primaryCompletion":1504,"completion":1502,"start":3722,"enrollment":127,"conditions":3744,"interventions":3745},[89],[3724],[3710,3726,3727],{"trials":3747,"activeCount":100},[],{"trials":3749,"activeCount":100},[],{"trials":3751,"activeCount":100},[],{"intervention":3727,"totalTrials":147,"cells":3753},{"EARLY_PHASE1":3754,"PHASE1":3756,"PHASE2":3758,"PHASE3":3764,"PHASE4":3766,"NA":3768},{"trials":3755,"activeCount":100},[],{"trials":3757,"activeCount":100},[],{"trials":3759,"activeCount":147,"soonestReadout":1504},[3760],{"nctId":3719,"briefTitle":3720,"status":137,"phases":3761,"primaryCompletion":1504,"completion":1502,"start":3722,"enrollment":127,"conditions":3762,"interventions":3763},[89],[3724],[3710,3726,3727],{"trials":3765,"activeCount":100},[],{"trials":3767,"activeCount":100},[],{"trials":3769,"activeCount":100},[],{"intervention":2458,"totalTrials":147,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3782,"PHASE4":3784,"NA":3786},{"trials":3773,"activeCount":100},[],{"trials":3775,"activeCount":100},[],{"trials":3777,"activeCount":147,"soonestReadout":2452},[3778],{"nctId":2449,"briefTitle":2450,"status":151,"phases":3779,"primaryCompletion":2452,"completion":2453,"start":2454,"enrollment":2455,"conditions":3780,"interventions":3781},[89],[2457,2458,2440,2459],[2458,2440,46,2461,2462],{"trials":3783,"activeCount":100},[],{"trials":3785,"activeCount":100},[],{"trials":3787,"activeCount":100},[],{"intervention":3789,"totalTrials":147,"cells":3790},"Camrelizumab plus apatinib CohortA",{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3795,"PHASE3":3806,"PHASE4":3808,"NA":3810},{"trials":3792,"activeCount":100},[],{"trials":3794,"activeCount":100},[],{"trials":3796,"activeCount":147,"soonestReadout":175},[3797],{"nctId":3798,"briefTitle":3799,"status":137,"phases":3800,"primaryCompletion":175,"completion":3801,"start":3802,"enrollment":2061,"conditions":3803,"interventions":3804},"NCT05139095","Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia",[89],"2027-01-01","2022-01-27",[2824],[3789,3805],"Camrelizumab plus apatinib Cohort B",{"trials":3807,"activeCount":100},[],{"trials":3809,"activeCount":100},[],{"trials":3811,"activeCount":100},[],{"intervention":3805,"totalTrials":147,"cells":3813},{"EARLY_PHASE1":3814,"PHASE1":3816,"PHASE2":3818,"PHASE3":3824,"PHASE4":3826,"NA":3828},{"trials":3815,"activeCount":100},[],{"trials":3817,"activeCount":100},[],{"trials":3819,"activeCount":147,"soonestReadout":175},[3820],{"nctId":3798,"briefTitle":3799,"status":137,"phases":3821,"primaryCompletion":175,"completion":3801,"start":3802,"enrollment":2061,"conditions":3822,"interventions":3823},[89],[2824],[3789,3805],{"trials":3825,"activeCount":100},[],{"trials":3827,"activeCount":100},[],{"trials":3829,"activeCount":100},[],{"intervention":81,"totalTrials":147,"cells":3831},{"EARLY_PHASE1":3832,"PHASE1":3834,"PHASE2":3836,"PHASE3":3843,"PHASE4":3845,"NA":3847},{"trials":3833,"activeCount":100},[],{"trials":3835,"activeCount":100},[],{"trials":3837,"activeCount":147,"soonestReadout":80},[3838],{"nctId":78,"briefTitle":79,"status":151,"phases":3839,"primaryCompletion":80,"completion":333,"start":267,"enrollment":957,"conditions":3840,"interventions":3842},[88,89],[3841],"Small Intestine Bacterial Overgrowth",[81],{"trials":3844,"activeCount":100},[],{"trials":3846,"activeCount":100},[],{"trials":3848,"activeCount":100},[],{"intervention":3850,"totalTrials":147,"cells":3851},"Azacitidine or Ruxolitinib combined with Selinexor",{"EARLY_PHASE1":3852,"PHASE1":3854,"PHASE2":3856,"PHASE3":3869,"PHASE4":3871,"NA":3873},{"trials":3853,"activeCount":100},[],{"trials":3855,"activeCount":100},[],{"trials":3857,"activeCount":147,"soonestReadout":3862},[3858],{"nctId":3859,"briefTitle":3860,"status":1178,"phases":3861,"primaryCompletion":3862,"completion":3863,"start":3864,"enrollment":3865,"conditions":3866,"interventions":3868},"NCT06664970","A Multicenter Study on the Treatment of MDS\u002FMPN Overlap Syndrome With AZA or Rux Combined With Selinexor",[89],"2025-09-30","2026-09-30","2024-11-06",39,[3867],"MDS",[3850],{"trials":3870,"activeCount":100},[],{"trials":3872,"activeCount":100},[],{"trials":3874,"activeCount":100},[],{"intervention":3876,"totalTrials":147,"cells":3877},"Durvalumab and Chemotherapy",{"EARLY_PHASE1":3878,"PHASE1":3880,"PHASE2":3882,"PHASE3":3892,"PHASE4":3894,"NA":3896},{"trials":3879,"activeCount":100},[],{"trials":3881,"activeCount":100},[],{"trials":3883,"activeCount":147,"soonestReadout":955},[3884],{"nctId":3885,"briefTitle":3886,"status":137,"phases":3887,"primaryCompletion":955,"completion":164,"start":3888,"enrollment":299,"conditions":3889,"interventions":3891},"NCT06070740","First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma",[89],"2023-11-01",[3890],"Gastrointestinal Neuroendocrine Carcinoma",[3876],{"trials":3893,"activeCount":100},[],{"trials":3895,"activeCount":100},[],{"trials":3897,"activeCount":100},[],{"intervention":66,"totalTrials":147,"cells":3899},{"EARLY_PHASE1":3900,"PHASE1":3902,"PHASE2":3904,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3901,"activeCount":100},[],{"trials":3903,"activeCount":100},[],{"trials":3905,"activeCount":147,"soonestReadout":65},[3906],{"nctId":63,"briefTitle":64,"status":151,"phases":3907,"primaryCompletion":65,"completion":1180,"start":3908,"enrollment":3909,"conditions":3910,"interventions":3911},[89],"2023-10-01",55,[25],[66],{"trials":3913,"activeCount":100},[],{"trials":3915,"activeCount":100},[],{"trials":3917,"activeCount":100},[],{"intervention":2912,"totalTrials":147,"cells":3919},{"EARLY_PHASE1":3920,"PHASE1":3922,"PHASE2":3924,"PHASE3":3930,"PHASE4":3932,"NA":3934},{"trials":3921,"activeCount":100},[],{"trials":3923,"activeCount":100},[],{"trials":3925,"activeCount":147,"soonestReadout":2906},[3926],{"nctId":2903,"briefTitle":2904,"status":151,"phases":3927,"primaryCompletion":2906,"completion":2907,"start":2908,"enrollment":2909,"conditions":3928,"interventions":3929},[89],[2867],[2912,2894],{"trials":3931,"activeCount":100},[],{"trials":3933,"activeCount":100},[],{"trials":3935,"activeCount":100},[],{"intervention":3937,"totalTrials":147,"cells":3938},"SHR-A1811 & Bevacizumab",{"EARLY_PHASE1":3939,"PHASE1":3941,"PHASE2":3943,"PHASE3":3956,"PHASE4":3958,"NA":3960},{"trials":3940,"activeCount":100},[],{"trials":3942,"activeCount":100},[],{"trials":3944,"activeCount":147,"soonestReadout":3949},[3945],{"nctId":3946,"briefTitle":3947,"status":151,"phases":3948,"primaryCompletion":3949,"completion":2084,"start":596,"enrollment":1206,"conditions":3950,"interventions":3954},"NCT07355764","MA-CRC-II-016 SHR-1811",[89],"2028-01-30",[3951,3952,2511,3953],"mCRC","HER2","Antibody-drug Conjugates",[3937,3955],"Chemotherapeutic Combinations",{"trials":3957,"activeCount":100},[],{"trials":3959,"activeCount":100},[],{"trials":3961,"activeCount":100},[],{"intervention":3955,"totalTrials":147,"cells":3963},{"EARLY_PHASE1":3964,"PHASE1":3966,"PHASE2":3968,"PHASE3":3974,"PHASE4":3976,"NA":3978},{"trials":3965,"activeCount":100},[],{"trials":3967,"activeCount":100},[],{"trials":3969,"activeCount":147,"soonestReadout":3949},[3970],{"nctId":3946,"briefTitle":3947,"status":151,"phases":3971,"primaryCompletion":3949,"completion":2084,"start":596,"enrollment":1206,"conditions":3972,"interventions":3973},[89],[3951,3952,2511,3953],[3937,3955],{"trials":3975,"activeCount":100},[],{"trials":3977,"activeCount":100},[],{"trials":3979,"activeCount":100},[],{"intervention":2471,"totalTrials":147,"cells":3981},{"EARLY_PHASE1":3982,"PHASE1":3984,"PHASE2":3986,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3983,"activeCount":100},[],{"trials":3985,"activeCount":100},[],{"trials":3987,"activeCount":147,"soonestReadout":1691},[3988],{"nctId":2464,"briefTitle":2465,"status":137,"phases":3989,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":3990,"interventions":3991},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"trials":3993,"activeCount":100},[],{"trials":3995,"activeCount":100},[],{"trials":3997,"activeCount":100},[],{"intervention":3999,"totalTrials":147,"cells":4000},"Tuvonralimab\u002FIparomlimab combination with GEMOX chemotherapy",{"EARLY_PHASE1":4001,"PHASE1":4003,"PHASE2":4005,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4002,"activeCount":100},[],{"trials":4004,"activeCount":100},[],{"trials":4006,"activeCount":147,"soonestReadout":4011},[4007],{"nctId":4008,"briefTitle":4009,"status":137,"phases":4010,"primaryCompletion":4011,"completion":4012,"start":4013,"enrollment":17,"conditions":4014,"interventions":4015},"NCT07267078","Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer",[89],"2028-01-25","2028-05-25","2025-05-25",[2457],[3999],{"trials":4017,"activeCount":100},[],{"trials":4019,"activeCount":100},[],{"trials":4021,"activeCount":100},[],{"intervention":4023,"totalTrials":147,"cells":4024},"Nimotuzumab+ NALIRIFOX",{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4029,"PHASE3":4041,"PHASE4":4043,"NA":4045},{"trials":4026,"activeCount":100},[],{"trials":4028,"activeCount":100},[],{"trials":4030,"activeCount":147,"soonestReadout":4035},[4031],{"nctId":4032,"briefTitle":4033,"status":1229,"phases":4034,"primaryCompletion":4035,"completion":4035,"start":4036,"enrollment":4037,"conditions":4038,"interventions":4040},"NCT06429904","Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer",[89],"2027-05","2024-05-15",31,[4039],"Locally Advanced Pancreatic Cancer",[4023],{"trials":4042,"activeCount":100},[],{"trials":4044,"activeCount":100},[],{"trials":4046,"activeCount":100},[],{"intervention":4048,"totalTrials":147,"cells":4049},"Cohort 3",{"EARLY_PHASE1":4050,"PHASE1":4052,"PHASE2":4054,"PHASE3":4085,"PHASE4":4087,"NA":4089},{"trials":4051,"activeCount":100},[],{"trials":4053,"activeCount":100},[],{"trials":4055,"activeCount":147,"soonestReadout":4060},[4056],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4059,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4062,"interventions":4065},"NCT06145308","Precision Treatment of Recurrent\u002FMetastatic Salivary Gland Carcinoma Guided by Molecular Typing",[89],"2028-07-10","2023-08-15",[4063,4064],"Salivary Gland Carcinoma","Precision Therapy",[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],"Cohort 1","Cohort 2","TROP2 ADC","TKI","Albumin-paclitaxel + platinum","Albumin-paclitaxel + carboplatin + apatinib + camrelizumab","albumin-bound paclitaxel+trastuzumab+pyrotinib","HER2,trastuzumab deruxtecan± pertuzumab","AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab","AR,AR antagonist +goserelin +docetaxel","ivonescimab + investigator-choice platinum doublet+","iparomlimab + tuvonralimab","cadonilimab","CDK4\u002F6 inhibitor+AI or fulvestrant","alpelisib+fulvestrant","PARP inhibitor","enfortumab vedotin","HER2, pyrotinib + pertuzumab\u002Ftrastuzumab","vebecotutamab ±lenvatinib",{"trials":4086,"activeCount":100},[],{"trials":4088,"activeCount":100},[],{"trials":4090,"activeCount":100},[],{"intervention":4068,"totalTrials":147,"cells":4092},{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4103,"PHASE4":4105,"NA":4107},{"trials":4094,"activeCount":100},[],{"trials":4096,"activeCount":100},[],{"trials":4098,"activeCount":147,"soonestReadout":4060},[4099],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4100,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4101,"interventions":4102},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4104,"activeCount":100},[],{"trials":4106,"activeCount":100},[],{"trials":4108,"activeCount":100},[],{"intervention":4069,"totalTrials":147,"cells":4110},{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4115,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4112,"activeCount":100},[],{"trials":4114,"activeCount":100},[],{"trials":4116,"activeCount":147,"soonestReadout":4060},[4117],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4118,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4119,"interventions":4120},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4122,"activeCount":100},[],{"trials":4124,"activeCount":100},[],{"trials":4126,"activeCount":100},[],{"intervention":4070,"totalTrials":147,"cells":4128},{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4133,"PHASE3":4139,"PHASE4":4141,"NA":4143},{"trials":4130,"activeCount":100},[],{"trials":4132,"activeCount":100},[],{"trials":4134,"activeCount":147,"soonestReadout":4060},[4135],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4136,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4137,"interventions":4138},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4140,"activeCount":100},[],{"trials":4142,"activeCount":100},[],{"trials":4144,"activeCount":100},[],{"intervention":4071,"totalTrials":147,"cells":4146},{"EARLY_PHASE1":4147,"PHASE1":4149,"PHASE2":4151,"PHASE3":4157,"PHASE4":4159,"NA":4161},{"trials":4148,"activeCount":100},[],{"trials":4150,"activeCount":100},[],{"trials":4152,"activeCount":147,"soonestReadout":4060},[4153],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4154,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4155,"interventions":4156},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4158,"activeCount":100},[],{"trials":4160,"activeCount":100},[],{"trials":4162,"activeCount":100},[],{"intervention":4072,"totalTrials":147,"cells":4164},{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4169,"PHASE3":4175,"PHASE4":4177,"NA":4179},{"trials":4166,"activeCount":100},[],{"trials":4168,"activeCount":100},[],{"trials":4170,"activeCount":147,"soonestReadout":4060},[4171],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4172,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4173,"interventions":4174},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4176,"activeCount":100},[],{"trials":4178,"activeCount":100},[],{"trials":4180,"activeCount":100},[],{"intervention":4073,"totalTrials":147,"cells":4182},{"EARLY_PHASE1":4183,"PHASE1":4185,"PHASE2":4187,"PHASE3":4193,"PHASE4":4195,"NA":4197},{"trials":4184,"activeCount":100},[],{"trials":4186,"activeCount":100},[],{"trials":4188,"activeCount":147,"soonestReadout":4060},[4189],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4190,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4191,"interventions":4192},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4194,"activeCount":100},[],{"trials":4196,"activeCount":100},[],{"trials":4198,"activeCount":100},[],{"intervention":4074,"totalTrials":147,"cells":4200},{"EARLY_PHASE1":4201,"PHASE1":4203,"PHASE2":4205,"PHASE3":4211,"PHASE4":4213,"NA":4215},{"trials":4202,"activeCount":100},[],{"trials":4204,"activeCount":100},[],{"trials":4206,"activeCount":147,"soonestReadout":4060},[4207],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4208,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4209,"interventions":4210},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4212,"activeCount":100},[],{"trials":4214,"activeCount":100},[],{"trials":4216,"activeCount":100},[],{"intervention":4075,"totalTrials":147,"cells":4218},{"EARLY_PHASE1":4219,"PHASE1":4221,"PHASE2":4223,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4220,"activeCount":100},[],{"trials":4222,"activeCount":100},[],{"trials":4224,"activeCount":147,"soonestReadout":4060},[4225],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4226,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4227,"interventions":4228},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4230,"activeCount":100},[],{"trials":4232,"activeCount":100},[],{"trials":4234,"activeCount":100},[],{"intervention":4076,"totalTrials":147,"cells":4236},{"EARLY_PHASE1":4237,"PHASE1":4239,"PHASE2":4241,"PHASE3":4247,"PHASE4":4249,"NA":4251},{"trials":4238,"activeCount":100},[],{"trials":4240,"activeCount":100},[],{"trials":4242,"activeCount":147,"soonestReadout":4060},[4243],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4244,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4245,"interventions":4246},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4248,"activeCount":100},[],{"trials":4250,"activeCount":100},[],{"trials":4252,"activeCount":100},[],{"intervention":4077,"totalTrials":147,"cells":4254},{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4259,"PHASE3":4265,"PHASE4":4267,"NA":4269},{"trials":4256,"activeCount":100},[],{"trials":4258,"activeCount":100},[],{"trials":4260,"activeCount":147,"soonestReadout":4060},[4261],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4262,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4263,"interventions":4264},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4266,"activeCount":100},[],{"trials":4268,"activeCount":100},[],{"trials":4270,"activeCount":100},[],{"intervention":4078,"totalTrials":147,"cells":4272},{"EARLY_PHASE1":4273,"PHASE1":4275,"PHASE2":4277,"PHASE3":4283,"PHASE4":4285,"NA":4287},{"trials":4274,"activeCount":100},[],{"trials":4276,"activeCount":100},[],{"trials":4278,"activeCount":147,"soonestReadout":4060},[4279],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4280,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4281,"interventions":4282},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4284,"activeCount":100},[],{"trials":4286,"activeCount":100},[],{"trials":4288,"activeCount":100},[],{"intervention":4079,"totalTrials":147,"cells":4290},{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4295,"PHASE3":4301,"PHASE4":4303,"NA":4305},{"trials":4292,"activeCount":100},[],{"trials":4294,"activeCount":100},[],{"trials":4296,"activeCount":147,"soonestReadout":4060},[4297],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4298,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4299,"interventions":4300},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4302,"activeCount":100},[],{"trials":4304,"activeCount":100},[],{"trials":4306,"activeCount":100},[],{"intervention":4080,"totalTrials":147,"cells":4308},{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4313,"PHASE3":4319,"PHASE4":4321,"NA":4323},{"trials":4310,"activeCount":100},[],{"trials":4312,"activeCount":100},[],{"trials":4314,"activeCount":147,"soonestReadout":4060},[4315],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4316,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4317,"interventions":4318},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4320,"activeCount":100},[],{"trials":4322,"activeCount":100},[],{"trials":4324,"activeCount":100},[],{"intervention":4081,"totalTrials":147,"cells":4326},{"EARLY_PHASE1":4327,"PHASE1":4329,"PHASE2":4331,"PHASE3":4337,"PHASE4":4339,"NA":4341},{"trials":4328,"activeCount":100},[],{"trials":4330,"activeCount":100},[],{"trials":4332,"activeCount":147,"soonestReadout":4060},[4333],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4334,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4335,"interventions":4336},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4338,"activeCount":100},[],{"trials":4340,"activeCount":100},[],{"trials":4342,"activeCount":100},[],{"intervention":4082,"totalTrials":147,"cells":4344},{"EARLY_PHASE1":4345,"PHASE1":4347,"PHASE2":4349,"PHASE3":4355,"PHASE4":4357,"NA":4359},{"trials":4346,"activeCount":100},[],{"trials":4348,"activeCount":100},[],{"trials":4350,"activeCount":147,"soonestReadout":4060},[4351],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4352,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4353,"interventions":4354},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4356,"activeCount":100},[],{"trials":4358,"activeCount":100},[],{"trials":4360,"activeCount":100},[],{"intervention":4083,"totalTrials":147,"cells":4362},{"EARLY_PHASE1":4363,"PHASE1":4365,"PHASE2":4367,"PHASE3":4373,"PHASE4":4375,"NA":4377},{"trials":4364,"activeCount":100},[],{"trials":4366,"activeCount":100},[],{"trials":4368,"activeCount":147,"soonestReadout":4060},[4369],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4370,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4371,"interventions":4372},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4374,"activeCount":100},[],{"trials":4376,"activeCount":100},[],{"trials":4378,"activeCount":100},[],{"intervention":4084,"totalTrials":147,"cells":4380},{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4382,"activeCount":100},[],{"trials":4384,"activeCount":100},[],{"trials":4386,"activeCount":147,"soonestReadout":4060},[4387],{"nctId":4057,"briefTitle":4058,"status":137,"phases":4388,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":4389,"interventions":4390},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":4392,"activeCount":100},[],{"trials":4394,"activeCount":100},[],{"trials":4396,"activeCount":100},[],{"intervention":2489,"totalTrials":147,"cells":4398},{"EARLY_PHASE1":4399,"PHASE1":4401,"PHASE2":4403,"PHASE3":4409,"PHASE4":4411,"NA":4413},{"trials":4400,"activeCount":100},[],{"trials":4402,"activeCount":100},[],{"trials":4404,"activeCount":147,"soonestReadout":2429},[4405],{"nctId":2484,"briefTitle":2485,"status":137,"phases":4406,"primaryCompletion":2429,"completion":2429,"start":1898,"enrollment":705,"conditions":4407,"interventions":4408},[89],[2457],[2489,2440,2490],{"trials":4410,"activeCount":100},[],{"trials":4412,"activeCount":100},[],{"trials":4414,"activeCount":100},[],{"intervention":2490,"totalTrials":147,"cells":4416},{"EARLY_PHASE1":4417,"PHASE1":4419,"PHASE2":4421,"PHASE3":4427,"PHASE4":4429,"NA":4431},{"trials":4418,"activeCount":100},[],{"trials":4420,"activeCount":100},[],{"trials":4422,"activeCount":147,"soonestReadout":2429},[4423],{"nctId":2484,"briefTitle":2485,"status":137,"phases":4424,"primaryCompletion":2429,"completion":2429,"start":1898,"enrollment":705,"conditions":4425,"interventions":4426},[89],[2457],[2489,2440,2490],{"trials":4428,"activeCount":100},[],{"trials":4430,"activeCount":100},[],{"trials":4432,"activeCount":100},[],{"intervention":4434,"totalTrials":147,"cells":4435},"Immunochemotherapy",{"EARLY_PHASE1":4436,"PHASE1":4438,"PHASE2":4440,"PHASE3":4452,"PHASE4":4454,"NA":4456},{"trials":4437,"activeCount":100},[],{"trials":4439,"activeCount":100},[],{"trials":4441,"activeCount":147,"soonestReadout":4446},[4442],{"nctId":4443,"briefTitle":4444,"status":137,"phases":4445,"primaryCompletion":4446,"completion":4447,"start":4448,"enrollment":2878,"conditions":4449,"interventions":4451},"NCT06824883","Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK\u002FT-Cell Lymphoma",[89],"2026-05-20","2027-05-20","2024-05-20",[4450],"Extranodal NK\u002FT-cell Lymphoma",[4434],{"trials":4453,"activeCount":100},[],{"trials":4455,"activeCount":100},[],{"trials":4457,"activeCount":100},[],{"intervention":4459,"totalTrials":147,"cells":4460},"Orelabrutinib-50",{"EARLY_PHASE1":4461,"PHASE1":4463,"PHASE2":4465,"PHASE3":4477,"PHASE4":4479,"NA":4481},{"trials":4462,"activeCount":100},[],{"trials":4464,"activeCount":100},[],{"trials":4466,"activeCount":147,"soonestReadout":4471},[4467],{"nctId":4468,"briefTitle":4469,"status":151,"phases":4470,"primaryCompletion":4471,"completion":4471,"start":3553,"enrollment":194,"conditions":4472,"interventions":4474},"NCT07453368","Orelabrutinib in the Treatment of Relapsed\u002FRefractory AIHA",[89],"2027-03-01",[4473],"Autoimmune Hemolytic Anemia (AIHA)",[4459,4475,4476],"Orelabrutinib-100","Orelabrutinib-150",{"trials":4478,"activeCount":100},[],{"trials":4480,"activeCount":100},[],{"trials":4482,"activeCount":100},[],{"intervention":4475,"totalTrials":147,"cells":4484},{"EARLY_PHASE1":4485,"PHASE1":4487,"PHASE2":4489,"PHASE3":4495,"PHASE4":4497,"NA":4499},{"trials":4486,"activeCount":100},[],{"trials":4488,"activeCount":100},[],{"trials":4490,"activeCount":147,"soonestReadout":4471},[4491],{"nctId":4468,"briefTitle":4469,"status":151,"phases":4492,"primaryCompletion":4471,"completion":4471,"start":3553,"enrollment":194,"conditions":4493,"interventions":4494},[89],[4473],[4459,4475,4476],{"trials":4496,"activeCount":100},[],{"trials":4498,"activeCount":100},[],{"trials":4500,"activeCount":100},[],{"intervention":4476,"totalTrials":147,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4513,"PHASE4":4515,"NA":4517},{"trials":4504,"activeCount":100},[],{"trials":4506,"activeCount":100},[],{"trials":4508,"activeCount":147,"soonestReadout":4471},[4509],{"nctId":4468,"briefTitle":4469,"status":151,"phases":4510,"primaryCompletion":4471,"completion":4471,"start":3553,"enrollment":194,"conditions":4511,"interventions":4512},[89],[4473],[4459,4475,4476],{"trials":4514,"activeCount":100},[],{"trials":4516,"activeCount":100},[],{"trials":4518,"activeCount":100},[],{"intervention":4520,"totalTrials":147,"cells":4521},"RC48 + Tislelizumab",{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4536,"PHASE4":4538,"NA":4540},{"trials":4523,"activeCount":100},[],{"trials":4525,"activeCount":100},[],{"trials":4527,"activeCount":147,"soonestReadout":1921},[4528],{"nctId":4529,"briefTitle":4530,"status":137,"phases":4531,"primaryCompletion":1921,"completion":459,"start":4532,"enrollment":957,"conditions":4533,"interventions":4535},"NCT06063018","RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer",[89],"2023-08-16",[4534],"Cervical Cancer Recurrent",[4520],{"trials":4537,"activeCount":100},[],{"trials":4539,"activeCount":100},[],{"trials":4541,"activeCount":100},[],{"intervention":4543,"totalTrials":147,"cells":4544},"Eliglustat Tartrate",{"EARLY_PHASE1":4545,"PHASE1":4547,"PHASE2":4549,"PHASE3":4558,"PHASE4":4560,"NA":4562},{"trials":4546,"activeCount":100},[],{"trials":4548,"activeCount":100},[],{"trials":4550,"activeCount":147,"soonestReadout":519},[4551],{"nctId":4552,"briefTitle":4553,"status":151,"phases":4554,"primaryCompletion":519,"completion":519,"start":267,"enrollment":1606,"conditions":4555,"interventions":4557},"NCT06523517","Efficacy and Safety of Eliglustat in Chinese Pediatric Patients With Gaucher Disease Type 1 and Type 3",[89],[4556],"Gaucher Disease",[4543],{"trials":4559,"activeCount":100},[],{"trials":4561,"activeCount":100},[],{"trials":4563,"activeCount":100},[],{"intervention":4565,"totalTrials":147,"cells":4566},"Elemene",{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4571,"PHASE3":4583,"PHASE4":4585,"NA":4587},{"trials":4568,"activeCount":100},[],{"trials":4570,"activeCount":100},[],{"trials":4572,"activeCount":147,"soonestReadout":4577},[4573],{"nctId":4574,"briefTitle":4575,"status":151,"phases":4576,"primaryCompletion":4577,"completion":4035,"start":4578,"enrollment":4579,"conditions":4580,"interventions":4582},"NCT05842746","Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma",[89],"2026-12","2023-05",74,[4581],"Glioblastoma, IDH-wildtype",[4565],{"trials":4584,"activeCount":100},[],{"trials":4586,"activeCount":100},[],{"trials":4588,"activeCount":100},[],{"intervention":4590,"totalTrials":147,"cells":4591},"Immune checkpoint inhibitor",{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4596,"PHASE3":4608,"PHASE4":4610,"NA":4612},{"trials":4593,"activeCount":100},[],{"trials":4595,"activeCount":100},[],{"trials":4597,"activeCount":147,"soonestReadout":4602},[4598],{"nctId":4599,"briefTitle":4600,"status":137,"phases":4601,"primaryCompletion":4602,"completion":4603,"start":4604,"enrollment":4605,"conditions":4606,"interventions":4607},"NCT06388031","ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI",[89],"2027-01-10","2027-12-10","2024-08-09",27,[1767],[4590],{"trials":4609,"activeCount":100},[],{"trials":4611,"activeCount":100},[],{"trials":4613,"activeCount":100},[],{"intervention":4615,"totalTrials":147,"cells":4616},"Surufatinib + envafolimab",{"EARLY_PHASE1":4617,"PHASE1":4619,"PHASE2":4621,"PHASE3":4632,"PHASE4":4634,"NA":4636},{"trials":4618,"activeCount":100},[],{"trials":4620,"activeCount":100},[],{"trials":4622,"activeCount":147,"soonestReadout":4627},[4623],{"nctId":4624,"briefTitle":4625,"status":151,"phases":4626,"primaryCompletion":4627,"completion":153,"start":4628,"enrollment":17,"conditions":4629,"interventions":4631},"NCT05722977","Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients",[89],"2026-02-02","2023-02-02",[4630],"Efficacy and Safety of Surufatinib Combined With Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma Patients",[4615],{"trials":4633,"activeCount":100},[],{"trials":4635,"activeCount":100},[],{"trials":4637,"activeCount":100},[],{"intervention":4639,"totalTrials":147,"cells":4640},"Envafolimab Injection, Axitinib",{"EARLY_PHASE1":4641,"PHASE1":4643,"PHASE2":4645,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4642,"activeCount":100},[],{"trials":4644,"activeCount":100},[],{"trials":4646,"activeCount":147,"soonestReadout":4651},[4647],{"nctId":4648,"briefTitle":4649,"status":151,"phases":4650,"primaryCompletion":4651,"completion":4652,"start":704,"enrollment":957,"conditions":4653,"interventions":4655},"NCT07159191","Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma",[89],"2027-02-20","2027-07-20",[4654],"Advanced Renal Cell Carcinoma (aRCC)",[4639],{"trials":4657,"activeCount":100},[],{"trials":4659,"activeCount":100},[],{"trials":4661,"activeCount":100},[],{"intervention":4663,"totalTrials":147,"cells":4664},"Pembrolizumab,Lenvatinib and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）",{"EARLY_PHASE1":4665,"PHASE1":4667,"PHASE2":4669,"PHASE3":4681,"PHASE4":4683,"NA":4685},{"trials":4666,"activeCount":100},[],{"trials":4668,"activeCount":100},[],{"trials":4670,"activeCount":147,"soonestReadout":333},[4671],{"nctId":4672,"briefTitle":4673,"status":137,"phases":4674,"primaryCompletion":333,"completion":4675,"start":4676,"enrollment":2353,"conditions":4677,"interventions":4678},"NCT06230471","Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer",[89],"2026-04-30","2023-01-09",[2499],[4663,4679,4680],"Pembrolizumab and Lenvatinib","Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin）",{"trials":4682,"activeCount":100},[],{"trials":4684,"activeCount":100},[],{"trials":4686,"activeCount":100},[],{"intervention":4679,"totalTrials":147,"cells":4688},{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4693,"PHASE3":4699,"PHASE4":4701,"NA":4703},{"trials":4690,"activeCount":100},[],{"trials":4692,"activeCount":100},[],{"trials":4694,"activeCount":147,"soonestReadout":333},[4695],{"nctId":4672,"briefTitle":4673,"status":137,"phases":4696,"primaryCompletion":333,"completion":4675,"start":4676,"enrollment":2353,"conditions":4697,"interventions":4698},[89],[2499],[4663,4679,4680],{"trials":4700,"activeCount":100},[],{"trials":4702,"activeCount":100},[],{"trials":4704,"activeCount":100},[],{"intervention":4680,"totalTrials":147,"cells":4706},{"EARLY_PHASE1":4707,"PHASE1":4709,"PHASE2":4711,"PHASE3":4717,"PHASE4":4719,"NA":4721},{"trials":4708,"activeCount":100},[],{"trials":4710,"activeCount":100},[],{"trials":4712,"activeCount":147,"soonestReadout":333},[4713],{"nctId":4672,"briefTitle":4673,"status":137,"phases":4714,"primaryCompletion":333,"completion":4675,"start":4676,"enrollment":2353,"conditions":4715,"interventions":4716},[89],[2499],[4663,4679,4680],{"trials":4718,"activeCount":100},[],{"trials":4720,"activeCount":100},[],{"trials":4722,"activeCount":100},[],{"intervention":4724,"totalTrials":147,"cells":4725},"Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX",{"EARLY_PHASE1":4726,"PHASE1":4728,"PHASE2":4730,"PHASE3":4741,"PHASE4":4743,"NA":4745},{"trials":4727,"activeCount":100},[],{"trials":4729,"activeCount":100},[],{"trials":4731,"activeCount":147,"soonestReadout":175},[4732],{"nctId":4733,"briefTitle":4734,"status":137,"phases":4735,"primaryCompletion":175,"completion":164,"start":4736,"enrollment":430,"conditions":4737,"interventions":4740},"NCT07108127","Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer",[89],"2025-06-20",[4738,4739],"Rectal Cancer","HER2-positive",[4724],{"trials":4742,"activeCount":100},[],{"trials":4744,"activeCount":100},[],{"trials":4746,"activeCount":100},[],{"intervention":422,"totalTrials":147,"cells":4748},{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4753,"PHASE3":4759,"PHASE4":4761,"NA":4763},{"trials":4750,"activeCount":100},[],{"trials":4752,"activeCount":100},[],{"trials":4754,"activeCount":147,"soonestReadout":416},[4755],{"nctId":413,"briefTitle":414,"status":137,"phases":4756,"primaryCompletion":416,"completion":416,"start":417,"enrollment":418,"conditions":4757,"interventions":4758},[89],[420],[422,390],{"trials":4760,"activeCount":100},[],{"trials":4762,"activeCount":100},[],{"trials":4764,"activeCount":100},[],{"intervention":4766,"totalTrials":147,"cells":4767},"antimetic drugs（ dexamethasone，ondansetron）",{"EARLY_PHASE1":4768,"PHASE1":4770,"PHASE2":4772,"PHASE3":4784,"PHASE4":4786,"NA":4788},{"trials":4769,"activeCount":100},[],{"trials":4771,"activeCount":100},[],{"trials":4773,"activeCount":147,"soonestReadout":4778},[4774],{"nctId":4775,"briefTitle":4776,"status":1229,"phases":4777,"primaryCompletion":4778,"completion":4779,"start":166,"enrollment":4780,"conditions":4781,"interventions":4783},"NCT06241547","PONV Prevention Via Percutaneous Nerve Electrical Stimulation on PC6",[89],"2026-01-10","2026-03-30",302,[4782],"Postoperative Nausea and Vomiting",[4766],{"trials":4785,"activeCount":100},[],{"trials":4787,"activeCount":100},[],{"trials":4789,"activeCount":100},[],{"intervention":2560,"totalTrials":147,"cells":4791},{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4802,"PHASE4":4804,"NA":4806},{"trials":4793,"activeCount":100},[],{"trials":4795,"activeCount":100},[],{"trials":4797,"activeCount":147,"soonestReadout":2554},[4798],{"nctId":2551,"briefTitle":2552,"status":137,"phases":4799,"primaryCompletion":2554,"completion":2554,"start":2555,"enrollment":2556,"conditions":4800,"interventions":4801},[89],[2558],[2560,76,2531],{"trials":4803,"activeCount":100},[],{"trials":4805,"activeCount":100},[],{"trials":4807,"activeCount":100},[],{"intervention":4809,"totalTrials":147,"cells":4810},"Cadonilimab lenvatinib",{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4815,"PHASE3":4825,"PHASE4":4827,"NA":4829},{"trials":4812,"activeCount":100},[],{"trials":4814,"activeCount":100},[],{"trials":4816,"activeCount":147,"soonestReadout":1579},[4817],{"nctId":4818,"briefTitle":4819,"status":137,"phases":4820,"primaryCompletion":1579,"completion":581,"start":4821,"enrollment":957,"conditions":4822,"interventions":4824},"NCT06215651","Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma",[89],"2024-03-11",[4823],"Cadonilimab and Lenvatinib",[4809],{"trials":4826,"activeCount":100},[],{"trials":4828,"activeCount":100},[],{"trials":4830,"activeCount":100},[],{"intervention":4832,"totalTrials":147,"cells":4833},"irinotecan liposome II combined with 5-FU\u002FLV and oxaliplatin",{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4848,"PHASE4":4850,"NA":4852},{"trials":4835,"activeCount":100},[],{"trials":4837,"activeCount":100},[],{"trials":4839,"activeCount":147,"soonestReadout":4675},[4840],{"nctId":4841,"briefTitle":4842,"status":137,"phases":4843,"primaryCompletion":4675,"completion":2015,"start":4844,"enrollment":17,"conditions":4845,"interventions":4847},"NCT06387810","Irinotecan Liposome II in Combination With 5-FU\u002FLV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer",[89],"2024-04-17",[4846],"Borderline Resectable Pancreatic Cancer",[4832],{"trials":4849,"activeCount":100},[],{"trials":4851,"activeCount":100},[],{"trials":4853,"activeCount":100},[],{"intervention":4855,"totalTrials":147,"cells":4856},"multi-kinase inhibitors in combination with bevacizumab",{"EARLY_PHASE1":4857,"PHASE1":4859,"PHASE2":4861,"PHASE3":4875,"PHASE4":4877,"NA":4879},{"trials":4858,"activeCount":100},[],{"trials":4860,"activeCount":100},[],{"trials":4862,"activeCount":147,"soonestReadout":458},[4863],{"nctId":4864,"briefTitle":4865,"status":151,"phases":4866,"primaryCompletion":458,"completion":581,"start":4867,"enrollment":4868,"conditions":4869,"interventions":4874},"NCT06041490","Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation",[89],"2023-09",88,[4870,4871,4872,4873],"Liver Transplant; Complications","Hepatocarcinoma","Recurrent Osteosarcoma","High-Risk Cancer",[4855],{"trials":4876,"activeCount":100},[],{"trials":4878,"activeCount":100},[],{"trials":4880,"activeCount":100},[],{"intervention":4882,"totalTrials":147,"cells":4883},"vedicitumomab (Edisil, RC48）",{"EARLY_PHASE1":4884,"PHASE1":4886,"PHASE2":4888,"PHASE3":4903,"PHASE4":4905,"NA":4907},{"trials":4885,"activeCount":100},[],{"trials":4887,"activeCount":100},[],{"trials":4889,"activeCount":147,"soonestReadout":4894},[4890],{"nctId":4891,"briefTitle":4892,"status":151,"phases":4893,"primaryCompletion":4894,"completion":4895,"start":4896,"enrollment":167,"conditions":4897,"interventions":4899},"NCT05898373","Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC",[88,89],"2025-06-06","2026-06-06","2023-06-07",[4898],"Salivary Gland Cancer",[4882,4900,4901,4902],"vedicitumomab in combination with pyrrolizidine","RC48 in combination with a platinum-based chemotherapeutic agent","RC48 in combination with teraplizumab",{"trials":4904,"activeCount":100},[],{"trials":4906,"activeCount":100},[],{"trials":4908,"activeCount":100},[],{"intervention":4900,"totalTrials":147,"cells":4910},{"EARLY_PHASE1":4911,"PHASE1":4913,"PHASE2":4915,"PHASE3":4921,"PHASE4":4923,"NA":4925},{"trials":4912,"activeCount":100},[],{"trials":4914,"activeCount":100},[],{"trials":4916,"activeCount":147,"soonestReadout":4894},[4917],{"nctId":4891,"briefTitle":4892,"status":151,"phases":4918,"primaryCompletion":4894,"completion":4895,"start":4896,"enrollment":167,"conditions":4919,"interventions":4920},[88,89],[4898],[4882,4900,4901,4902],{"trials":4922,"activeCount":100},[],{"trials":4924,"activeCount":100},[],{"trials":4926,"activeCount":100},[],{"intervention":4901,"totalTrials":147,"cells":4928},{"EARLY_PHASE1":4929,"PHASE1":4931,"PHASE2":4933,"PHASE3":4939,"PHASE4":4941,"NA":4943},{"trials":4930,"activeCount":100},[],{"trials":4932,"activeCount":100},[],{"trials":4934,"activeCount":147,"soonestReadout":4894},[4935],{"nctId":4891,"briefTitle":4892,"status":151,"phases":4936,"primaryCompletion":4894,"completion":4895,"start":4896,"enrollment":167,"conditions":4937,"interventions":4938},[88,89],[4898],[4882,4900,4901,4902],{"trials":4940,"activeCount":100},[],{"trials":4942,"activeCount":100},[],{"trials":4944,"activeCount":100},[],{"intervention":4902,"totalTrials":147,"cells":4946},{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4957,"PHASE4":4959,"NA":4961},{"trials":4948,"activeCount":100},[],{"trials":4950,"activeCount":100},[],{"trials":4952,"activeCount":147,"soonestReadout":4894},[4953],{"nctId":4891,"briefTitle":4892,"status":151,"phases":4954,"primaryCompletion":4894,"completion":4895,"start":4896,"enrollment":167,"conditions":4955,"interventions":4956},[88,89],[4898],[4882,4900,4901,4902],{"trials":4958,"activeCount":100},[],{"trials":4960,"activeCount":100},[],{"trials":4962,"activeCount":100},[],{"intervention":4964,"totalTrials":147,"cells":4965},"Orelabrutinib, obinutuzumab, lenalidomide",{"EARLY_PHASE1":4966,"PHASE1":4968,"PHASE2":4970,"PHASE3":4979,"PHASE4":4981,"NA":4983},{"trials":4967,"activeCount":100},[],{"trials":4969,"activeCount":100},[],{"trials":4971,"activeCount":147,"soonestReadout":1691},[4972],{"nctId":4973,"briefTitle":4974,"status":137,"phases":4975,"primaryCompletion":1691,"completion":1531,"start":417,"enrollment":17,"conditions":4976,"interventions":4978},"NCT06454968","Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.",[89],[4977],"Marginal Zone Lymphoma",[4964],{"trials":4980,"activeCount":100},[],{"trials":4982,"activeCount":100},[],{"trials":4984,"activeCount":100},[],{"intervention":4986,"totalTrials":147,"cells":4987},"Atezolizumab combined with bevacizumab combined with β- alanine",{"EARLY_PHASE1":4988,"PHASE1":4990,"PHASE2":4992,"PHASE3":5005,"PHASE4":5007,"NA":5009},{"trials":4989,"activeCount":100},[],{"trials":4991,"activeCount":100},[],{"trials":4993,"activeCount":147,"soonestReadout":4998},[4994],{"nctId":4995,"briefTitle":4996,"status":137,"phases":4997,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5002,"interventions":5003},"NCT07317414","β-alanine in the Treatment of Advanced Hepatocellular Carcinoma",[89],"2028-12-05","2030-12-05","2025-12-24",158,[27],[4986,5004],"Atezolizumab combined with bevacizumab",{"trials":5006,"activeCount":100},[],{"trials":5008,"activeCount":100},[],{"trials":5010,"activeCount":100},[],{"intervention":5004,"totalTrials":147,"cells":5012},{"EARLY_PHASE1":5013,"PHASE1":5015,"PHASE2":5017,"PHASE3":5023,"PHASE4":5025,"NA":5027},{"trials":5014,"activeCount":100},[],{"trials":5016,"activeCount":100},[],{"trials":5018,"activeCount":147,"soonestReadout":4998},[5019],{"nctId":4995,"briefTitle":4996,"status":137,"phases":5020,"primaryCompletion":4998,"completion":4999,"start":5000,"enrollment":5001,"conditions":5021,"interventions":5022},[89],[27],[4986,5004],{"trials":5024,"activeCount":100},[],{"trials":5026,"activeCount":100},[],{"trials":5028,"activeCount":100},[],{"intervention":5030,"totalTrials":147,"cells":5031},"Camrelizumab combination with Apatinib",{"EARLY_PHASE1":5032,"PHASE1":5034,"PHASE2":5036,"PHASE3":5046,"PHASE4":5048,"NA":5050},{"trials":5033,"activeCount":100},[],{"trials":5035,"activeCount":100},[],{"trials":5037,"activeCount":147,"soonestReadout":333},[5038],{"nctId":5039,"briefTitle":5040,"status":1229,"phases":5041,"primaryCompletion":333,"completion":333,"start":5042,"enrollment":142,"conditions":5043,"interventions":5045},"NCT04560127","Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer",[89],"2020-09-23",[5044],"Radioactive Iodine-refractory Differentiated Thyroid Cancer",[5030],{"trials":5047,"activeCount":100},[],{"trials":5049,"activeCount":100},[],{"trials":5051,"activeCount":100},[],{"intervention":5053,"totalTrials":147,"cells":5054},"Injection of 68Ga-NI-FAPI",{"EARLY_PHASE1":5055,"PHASE1":5057,"PHASE2":5059,"PHASE3":5075,"PHASE4":5077,"NA":5079},{"trials":5056,"activeCount":100},[],{"trials":5058,"activeCount":100},[],{"trials":5060,"activeCount":147,"soonestReadout":5065},[5061],{"nctId":5062,"briefTitle":5063,"status":137,"phases":5064,"primaryCompletion":5065,"completion":5066,"start":5067,"enrollment":957,"conditions":5068,"interventions":5074},"NCT07464132","Application of [68Ga]Ga-NI-FAPI-04 PET\u002FCT Imaging in Fibroblast Activation Protein Related Diseases",[88,89],"2027-02-17","2027-06-17","2025-12-17",[5069,5070,2672,5071,5072,5073],"Tumor","Cardiovascular Diseases","Rheumatic Immune Diseases Involving Large Blood Vessels","Hypertrophic Cardiomyopathy (HCM)","Other Hypoxic and Fibroblast Activated Diseases",[5053],{"trials":5076,"activeCount":100},[],{"trials":5078,"activeCount":100},[],{"trials":5080,"activeCount":100},[],{"intervention":2523,"totalTrials":147,"cells":5082},{"EARLY_PHASE1":5083,"PHASE1":5085,"PHASE2":5087,"PHASE3":5093,"PHASE4":5095,"NA":5097},{"trials":5084,"activeCount":100},[],{"trials":5086,"activeCount":100},[],{"trials":5088,"activeCount":147,"soonestReadout":2517},[5089],{"nctId":2514,"briefTitle":2515,"status":137,"phases":5090,"primaryCompletion":2517,"completion":2452,"start":2518,"enrollment":2519,"conditions":5091,"interventions":5092},[89],[2521],[2440,2523],{"trials":5094,"activeCount":100},[],{"trials":5096,"activeCount":100},[],{"trials":5098,"activeCount":100},[],{"intervention":5100,"totalTrials":147,"cells":5101},"Adebelimab Combined with Apatinib",{"EARLY_PHASE1":5102,"PHASE1":5104,"PHASE2":5106,"PHASE3":5118,"PHASE4":5120,"NA":5122},{"trials":5103,"activeCount":100},[],{"trials":5105,"activeCount":100},[],{"trials":5107,"activeCount":147,"soonestReadout":5112},[5108],{"nctId":5109,"briefTitle":5110,"status":151,"phases":5111,"primaryCompletion":5112,"completion":5112,"start":241,"enrollment":5113,"conditions":5114,"interventions":5116},"NCT06771154","Adebrelimab Plus Carboplatin\u002FPaclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent\u002FMetastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial",[89],"2029-04-01",140,[5115],"Recurrent\u002FMetastatic Endometrial Cancer",[5100,5117],"Adebelimab",{"trials":5119,"activeCount":100},[],{"trials":5121,"activeCount":100},[],{"trials":5123,"activeCount":100},[],{"intervention":5117,"totalTrials":147,"cells":5125},{"EARLY_PHASE1":5126,"PHASE1":5128,"PHASE2":5130,"PHASE3":5136,"PHASE4":5138,"NA":5140},{"trials":5127,"activeCount":100},[],{"trials":5129,"activeCount":100},[],{"trials":5131,"activeCount":147,"soonestReadout":5112},[5132],{"nctId":5109,"briefTitle":5110,"status":151,"phases":5133,"primaryCompletion":5112,"completion":5112,"start":241,"enrollment":5113,"conditions":5134,"interventions":5135},[89],[5115],[5100,5117],{"trials":5137,"activeCount":100},[],{"trials":5139,"activeCount":100},[],{"trials":5141,"activeCount":100},[],{"intervention":5143,"totalTrials":147,"cells":5144},"Golidocitinib plus CHOP",{"EARLY_PHASE1":5145,"PHASE1":5147,"PHASE2":5149,"PHASE3":5158,"PHASE4":5160,"NA":5162},{"trials":5146,"activeCount":100},[],{"trials":5148,"activeCount":100},[],{"trials":5150,"activeCount":147,"soonestReadout":1091},[5151],{"nctId":5152,"briefTitle":5153,"status":137,"phases":5154,"primaryCompletion":1091,"completion":2171,"start":3667,"enrollment":3195,"conditions":5155,"interventions":5157},"NCT06739265","Golidocitinib Plus CHOP in Newly Diagnosed PTCL",[88,89],[5156],"Peripheral T-cell Lymphoma",[5143],{"trials":5159,"activeCount":100},[],{"trials":5161,"activeCount":100},[],{"trials":5163,"activeCount":100},[],{"intervention":5165,"totalTrials":147,"cells":5166},"Al18F-NOTA-Pentixafor PET\u002FCT",{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5171,"PHASE3":5184,"PHASE4":5186,"NA":5188},{"trials":5168,"activeCount":100},[],{"trials":5170,"activeCount":100},[],{"trials":5172,"activeCount":147,"soonestReadout":5177},[5173],{"nctId":5174,"briefTitle":5175,"status":137,"phases":5176,"primaryCompletion":5177,"completion":5178,"start":124,"enrollment":5179,"conditions":5180,"interventions":5183},"NCT06773663","Application of Al18F-NOTA-Pentixafor PET\u002FCT for Primary Aldosteronism",[88,89],"2026-05-30","2026-10-30",150,[5181,5182],"Primary Aldosteronism","Primary Aldosteronism Due to Aldosterone Producing Adenoma",[5165],{"trials":5185,"activeCount":100},[],{"trials":5187,"activeCount":100},[],{"trials":5189,"activeCount":100},[],{"intervention":146,"totalTrials":147,"cells":5191},{"EARLY_PHASE1":5192,"PHASE1":5194,"PHASE2":5196,"PHASE3":5202,"PHASE4":5204,"NA":5206},{"trials":5193,"activeCount":100},[],{"trials":5195,"activeCount":100},[],{"trials":5197,"activeCount":147,"soonestReadout":139},[5198],{"nctId":135,"briefTitle":136,"status":137,"phases":5199,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":5200,"interventions":5201},[88,89],[144],[146,95],{"trials":5203,"activeCount":100},[],{"trials":5205,"activeCount":100},[],{"trials":5207,"activeCount":100},[],{"intervention":1700,"totalTrials":147,"cells":5209},{"EARLY_PHASE1":5210,"PHASE1":5212,"PHASE2":5214,"PHASE3":5220,"PHASE4":5222,"NA":5224},{"trials":5211,"activeCount":100},[],{"trials":5213,"activeCount":100},[],{"trials":5215,"activeCount":147,"soonestReadout":1691},[5216],{"nctId":1688,"briefTitle":1689,"status":137,"phases":5217,"primaryCompletion":1691,"completion":1692,"start":1693,"enrollment":1694,"conditions":5218,"interventions":5219},[89],[1696,1697],[1699,1700,1701],{"trials":5221,"activeCount":100},[],{"trials":5223,"activeCount":100},[],{"trials":5225,"activeCount":100},[],{"intervention":5227,"totalTrials":147,"cells":5228},"AK112+oxaliplatin+capecitabine",{"EARLY_PHASE1":5229,"PHASE1":5231,"PHASE2":5233,"PHASE3":5247,"PHASE4":5249,"NA":5251},{"trials":5230,"activeCount":100},[],{"trials":5232,"activeCount":100},[],{"trials":5234,"activeCount":147,"soonestReadout":5239},[5235],{"nctId":5236,"briefTitle":5237,"status":151,"phases":5238,"primaryCompletion":5239,"completion":5240,"start":5241,"enrollment":5242,"conditions":5243,"interventions":5245},"NCT07091227","Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G\u002FGEJ Adenocarcinoma",[89],"2026-07-20","2029-07-20","2025-07-20",66,[5244],"Gastric or Gastroesophageal Junction Adenocarcinoma",[5227,5246],"oxaliplatin+capecitabine",{"trials":5248,"activeCount":100},[],{"trials":5250,"activeCount":100},[],{"trials":5252,"activeCount":100},[],{"intervention":5246,"totalTrials":147,"cells":5254},{"EARLY_PHASE1":5255,"PHASE1":5257,"PHASE2":5259,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5256,"activeCount":100},[],{"trials":5258,"activeCount":100},[],{"trials":5260,"activeCount":147,"soonestReadout":5239},[5261],{"nctId":5236,"briefTitle":5237,"status":151,"phases":5262,"primaryCompletion":5239,"completion":5240,"start":5241,"enrollment":5242,"conditions":5263,"interventions":5264},[89],[5244],[5227,5246],{"trials":5266,"activeCount":100},[],{"trials":5268,"activeCount":100},[],{"trials":5270,"activeCount":100},[],{"intervention":2933,"totalTrials":147,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5283,"PHASE4":5285,"NA":5287},{"trials":5274,"activeCount":100},[],{"trials":5276,"activeCount":100},[],{"trials":5278,"activeCount":147,"soonestReadout":2928},[5279],{"nctId":2925,"briefTitle":2926,"status":151,"phases":5280,"primaryCompletion":2928,"completion":379,"start":1736,"enrollment":2929,"conditions":5281,"interventions":5282},[89],[2867,2869,2931],[2933,2894],{"trials":5284,"activeCount":100},[],{"trials":5286,"activeCount":100},[],{"trials":5288,"activeCount":100},[],{"intervention":5290,"totalTrials":147,"cells":5291},"Kangfupen (liquid dressing) retention enema administration",{"EARLY_PHASE1":5292,"PHASE1":5294,"PHASE2":5296,"PHASE3":5305,"PHASE4":5307,"NA":5309},{"trials":5293,"activeCount":100},[],{"trials":5295,"activeCount":100},[],{"trials":5297,"activeCount":147,"soonestReadout":1136},[5298],{"nctId":5299,"briefTitle":5300,"status":151,"phases":5301,"primaryCompletion":1136,"completion":1136,"start":1921,"enrollment":2455,"conditions":5302,"interventions":5304},"NCT07065175","KANGFUPEN Liquid Dressing for Chronic Radiation-Induced Rectal Injury",[89],[5303],"Chronic Radiation-induced Proctitis",[5290],{"trials":5306,"activeCount":100},[],{"trials":5308,"activeCount":100},[],{"trials":5310,"activeCount":100},[],{"intervention":5312,"totalTrials":147,"cells":5313},"Paclitaxel polymer micelle immunocombination",{"EARLY_PHASE1":5314,"PHASE1":5316,"PHASE2":5318,"PHASE3":5327,"PHASE4":5329,"NA":5331},{"trials":5315,"activeCount":100},[],{"trials":5317,"activeCount":100},[],{"trials":5319,"activeCount":147,"soonestReadout":333},[5320],{"nctId":5321,"briefTitle":5322,"status":137,"phases":5323,"primaryCompletion":333,"completion":1817,"start":1681,"enrollment":811,"conditions":5324,"interventions":5326},"NCT07159204","Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer",[89],[5325],"Biliary Tract Cancer (BTC)",[5312],{"trials":5328,"activeCount":100},[],{"trials":5330,"activeCount":100},[],{"trials":5332,"activeCount":100},[],{"intervention":5334,"totalTrials":147,"cells":5335},"Systemic treatment",{"EARLY_PHASE1":5336,"PHASE1":5338,"PHASE2":5340,"PHASE3":5351,"PHASE4":5353,"NA":5355},{"trials":5337,"activeCount":100},[],{"trials":5339,"activeCount":100},[],{"trials":5341,"activeCount":147,"soonestReadout":3801},[5342],{"nctId":5343,"briefTitle":5344,"status":1229,"phases":5345,"primaryCompletion":3801,"completion":5346,"start":3147,"enrollment":2353,"conditions":5347,"interventions":5350},"NCT07153952","RT for Adenocarcinoma\u002FAdenosquamous Carcinoma",[88,89],"2028-01-01",[5348,5349,115],"Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma",[5334],{"trials":5352,"activeCount":100},[],{"trials":5354,"activeCount":100},[],{"trials":5356,"activeCount":100},[],{"intervention":5358,"totalTrials":147,"cells":5359},"Roxadustat in combination with retinoic acid",{"EARLY_PHASE1":5360,"PHASE1":5362,"PHASE2":5364,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5361,"activeCount":100},[],{"trials":5363,"activeCount":100},[],{"trials":5365,"activeCount":147,"soonestReadout":5370},[5366],{"nctId":5367,"briefTitle":5368,"status":151,"phases":5369,"primaryCompletion":5370,"completion":4577,"start":529,"enrollment":1860,"conditions":5371,"interventions":5372},"NCT06020833","A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS",[88,89],"2025-10",[1924],[5358],{"trials":5374,"activeCount":100},[],{"trials":5376,"activeCount":100},[],{"trials":5378,"activeCount":100},[],{"intervention":653,"totalTrials":2330,"cells":5380},{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5385,"PHASE3":5437,"PHASE4":5439,"NA":5441},{"trials":5382,"activeCount":100},[],{"trials":5384,"activeCount":100},[],{"trials":5386,"activeCount":147,"soonestReadout":1691},[5387,5391,5395,5403,5413,5427],{"nctId":645,"briefTitle":646,"status":108,"phases":5388,"primaryCompletion":227,"completion":228,"start":648,"enrollment":649,"conditions":5389,"interventions":5390},[89],[651],[653,636],{"nctId":2464,"briefTitle":2465,"status":137,"phases":5392,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":5393,"interventions":5394},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"nctId":5396,"briefTitle":5397,"status":108,"phases":5398,"primaryCompletion":2380,"completion":527,"start":2661,"enrollment":5399,"conditions":5400,"interventions":5402},"NCT04296786","Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study",[89],52,[5401],"Cutaneous T-cell Lymphoma",[653,815],{"nctId":5404,"briefTitle":5405,"status":443,"phases":5406,"primaryCompletion":5407,"completion":5408,"start":5409,"enrollment":1756,"conditions":5410,"interventions":5412},"NCT04167657","SinTilimab After Radiation (STAR Study)",[89],"2023-11-30","2024-04-30","2019-04-15",[5411],"Carcinoma, Non-Small Cell Lung",[653],{"nctId":5414,"briefTitle":5415,"status":108,"phases":5416,"primaryCompletion":5417,"completion":5418,"start":5419,"enrollment":5420,"conditions":5421,"interventions":5426},"NCT05113355","Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm",[89],"2022-11-15","2024-11-15","2021-11-17",23,[5422,5423,5424,5425],"Neuroendocrine Tumors","Neuroendocrine Tumor Grade 3","Neuroendocrine Carcinoma","Neuroendocrine Neoplasm",[815,653],{"nctId":5428,"briefTitle":5429,"status":108,"phases":5430,"primaryCompletion":5431,"completion":5432,"start":5433,"enrollment":661,"conditions":5434,"interventions":5435},"NCT04899427","Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed\u002FRefractory Primary Central Nervous System Lymphoma",[89],"2023-03-24","2023-10-24","2021-03-24",[231],[5436,653,2474],"orelabrutinib",{"trials":5438,"activeCount":100},[],{"trials":5440,"activeCount":100},[],{"trials":5442,"activeCount":100},[5443],{"nctId":2771,"briefTitle":2772,"status":108,"phases":5444,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":5445,"interventions":5446},[],[2778],[2780,2781,46,2462,653,2461,2474],{"intervention":303,"totalTrials":1660,"cells":5448},{"EARLY_PHASE1":5449,"PHASE1":5451,"PHASE2":5453,"PHASE3":5471,"PHASE4":5473,"NA":5483},{"trials":5450,"activeCount":100},[],{"trials":5452,"activeCount":100},[],{"trials":5454,"activeCount":147,"soonestReadout":1618},[5455,5459,5463,5467],{"nctId":2540,"briefTitle":2541,"status":108,"phases":5456,"primaryCompletion":2543,"completion":2544,"start":2545,"enrollment":127,"conditions":5457,"interventions":5458},[89],[2547],[2549,303,2531],{"nctId":1677,"briefTitle":1678,"status":108,"phases":5460,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":957,"conditions":5461,"interventions":5462},[89],[1684],[303,247,1686],{"nctId":2569,"briefTitle":2570,"status":137,"phases":5464,"primaryCompletion":1618,"completion":2572,"start":2573,"enrollment":2574,"conditions":5465,"interventions":5466},[89],[2576],[303,282,2531],{"nctId":293,"briefTitle":294,"status":108,"phases":5468,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":5469,"interventions":5470},[89],[301],[303,214],{"trials":5472,"activeCount":100},[],{"trials":5474,"activeCount":100},[5475],{"nctId":5476,"briefTitle":5477,"status":108,"phases":5478,"primaryCompletion":5407,"completion":5479,"start":2660,"enrollment":957,"conditions":5480,"interventions":5482},"NCT05135442","Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP",[91],"2025-11-30",[5481],"Thrombotic Thrombocytopenic Purpura, Acquired",[303],{"trials":5484,"activeCount":100},[5485],{"nctId":5486,"briefTitle":5487,"status":108,"phases":5488,"primaryCompletion":3375,"completion":125,"start":5489,"enrollment":957,"conditions":5490,"interventions":5492},"NCT06215638","An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis",[92],"2023-03-01",[5491],"Rheumatoid Arthritis",[303],{"intervention":233,"totalTrials":605,"cells":5494},{"EARLY_PHASE1":5495,"PHASE1":5497,"PHASE2":5499,"PHASE3":5513,"PHASE4":5515,"NA":5517},{"trials":5496,"activeCount":100},[],{"trials":5498,"activeCount":100},[],{"trials":5500,"activeCount":147,"soonestReadout":2429},[5501,5505,5509],{"nctId":224,"briefTitle":225,"status":108,"phases":5502,"primaryCompletion":227,"completion":228,"start":229,"enrollment":194,"conditions":5503,"interventions":5504},[89],[231],[233,234,214,235],{"nctId":2426,"briefTitle":2427,"status":151,"phases":5506,"primaryCompletion":2429,"completion":1181,"start":228,"enrollment":780,"conditions":5507,"interventions":5508},[89],[2431],[233,1625],{"nctId":5428,"briefTitle":5429,"status":108,"phases":5510,"primaryCompletion":5431,"completion":5432,"start":5433,"enrollment":661,"conditions":5511,"interventions":5512},[89],[231],[5436,653,2474],{"trials":5514,"activeCount":100},[],{"trials":5516,"activeCount":100},[],{"trials":5518,"activeCount":100},[5519],{"nctId":5520,"briefTitle":5521,"status":108,"phases":5522,"primaryCompletion":529,"completion":529,"start":5523,"enrollment":5420,"conditions":5524,"interventions":5526},"NCT05284175","A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder",[92],"2022-04",[5525],"Neuromyelitis Optica Spectrum Disorder",[233],{"intervention":2474,"totalTrials":605,"cells":5528},{"EARLY_PHASE1":5529,"PHASE1":5531,"PHASE2":5533,"PHASE3":5554,"PHASE4":5556,"NA":5558},{"trials":5530,"activeCount":100},[],{"trials":5532,"activeCount":100},[],{"trials":5534,"activeCount":147,"soonestReadout":1691},[5535,5539,5550],{"nctId":2464,"briefTitle":2465,"status":137,"phases":5536,"primaryCompletion":1691,"completion":176,"start":2467,"enrollment":705,"conditions":5537,"interventions":5538},[89],[2469],[2440,46,2471,2472,2462,2473,2474,653],{"nctId":5540,"briefTitle":5541,"status":108,"phases":5542,"primaryCompletion":5543,"completion":4675,"start":5544,"enrollment":142,"conditions":5545,"interventions":5547},"NCT05822453","Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma",[89],"2025-04-30","2023-04-30",[5546],"Biliary Tract Carcinoma",[5548,5549,2474],"Gemcitabine","S1",{"nctId":5428,"briefTitle":5429,"status":108,"phases":5551,"primaryCompletion":5431,"completion":5432,"start":5433,"enrollment":661,"conditions":5552,"interventions":5553},[89],[231],[5436,653,2474],{"trials":5555,"activeCount":100},[],{"trials":5557,"activeCount":100},[],{"trials":5559,"activeCount":100},[5560],{"nctId":2771,"briefTitle":2772,"status":108,"phases":5561,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":5562,"interventions":5563},[],[2778],[2780,2781,46,2462,653,2461,2474],{"intervention":3595,"totalTrials":184,"cells":5565},{"EARLY_PHASE1":5566,"PHASE1":5568,"PHASE2":5570,"PHASE3":5583,"PHASE4":5585,"NA":5587},{"trials":5567,"activeCount":100},[],{"trials":5569,"activeCount":100},[],{"trials":5571,"activeCount":147,"soonestReadout":55},[5572,5579],{"nctId":5573,"briefTitle":5574,"status":108,"phases":5575,"primaryCompletion":5576,"start":2364,"enrollment":705,"conditions":5577,"interventions":5578},"NCT02838238","X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer",[89],"2020-01",[16],[3595],{"nctId":53,"briefTitle":54,"status":151,"phases":5580,"primaryCompletion":55,"completion":3590,"start":3591,"enrollment":811,"conditions":5581,"interventions":5582},[89],[3593],[56,3595],{"trials":5584,"activeCount":100},[],{"trials":5586,"activeCount":100},[],{"trials":5588,"activeCount":100},[5589],{"nctId":5590,"briefTitle":5591,"status":108,"phases":5592,"primaryCompletion":5593,"completion":5594,"start":5595,"enrollment":2172,"conditions":5596,"interventions":5599},"NCT03042000","Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid\u002FLow Rectal Cancer.",[92],"2020-12","2021-12","2017-02",[5597,5598],"Rectal Cancer, Adenocarcinoma","Neoadjuvant Chemoradiation",[5600,5601],"capecitabine with oxaliplatin","capecitabine",{"intervention":4066,"totalTrials":372,"cells":5603},{"EARLY_PHASE1":5604,"PHASE1":5606,"PHASE2":5608,"PHASE3":5614,"PHASE4":5616,"NA":5618},{"trials":5605,"activeCount":100},[],{"trials":5607,"activeCount":100},[],{"trials":5609,"activeCount":147,"soonestReadout":4060},[5610],{"nctId":4057,"briefTitle":4058,"status":137,"phases":5611,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":5612,"interventions":5613},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":5615,"activeCount":100},[],{"trials":5617,"activeCount":100},[],{"trials":5619,"activeCount":100},[5620],{"nctId":5621,"briefTitle":5622,"status":309,"phases":5623,"primaryCompletion":5624,"completion":4779,"start":1258,"enrollment":1606,"conditions":5625,"interventions":5627},"NCT07000344","A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor",[92],"2026-03-29",[5626],"Ovarian Cancer",[4066,4067],{"intervention":4067,"totalTrials":372,"cells":5629},{"EARLY_PHASE1":5630,"PHASE1":5632,"PHASE2":5634,"PHASE3":5640,"PHASE4":5642,"NA":5644},{"trials":5631,"activeCount":100},[],{"trials":5633,"activeCount":100},[],{"trials":5635,"activeCount":147,"soonestReadout":4060},[5636],{"nctId":4057,"briefTitle":4058,"status":137,"phases":5637,"primaryCompletion":4060,"completion":4060,"start":4061,"enrollment":3865,"conditions":5638,"interventions":5639},[89],[4063,4064],[4066,4067,4048,4068,4069,4070,4071,4072,4073,4074,4075,4076,4077,4078,4079,4080,4081,4082,4083,4084],{"trials":5641,"activeCount":100},[],{"trials":5643,"activeCount":100},[],{"trials":5645,"activeCount":100},[5646],{"nctId":5621,"briefTitle":5622,"status":309,"phases":5647,"primaryCompletion":5624,"completion":4779,"start":1258,"enrollment":1606,"conditions":5648,"interventions":5649},[92],[5626],[4066,4067],{"intervention":2628,"totalTrials":1660,"cells":5651},{"EARLY_PHASE1":5652,"PHASE1":5678,"PHASE2":5693,"PHASE3":5695,"PHASE4":5697,"NA":5699},{"trials":5653,"activeCount":372,"soonestReadout":333},[5654,5658,5670],{"nctId":2620,"briefTitle":2621,"status":137,"phases":5655,"primaryCompletion":333,"completion":333,"start":2623,"enrollment":2353,"conditions":5656,"interventions":5657},[87],[2625],[2627,2628,2596,2629],{"nctId":5659,"briefTitle":5660,"status":137,"phases":5661,"primaryCompletion":333,"completion":164,"start":5662,"enrollment":357,"conditions":5663,"interventions":5667},"NCT05549024","68Ga-RM26-RGD PET\u002FCT Imaging in the GRPR and αvβ3 Positive Tumor Patients",[87],"2022-08-16",[16,5664,5665,5666],"Prostate Cancer","Brain Tumor","PET\u002FCT Imaging",[5668,2628,5669,2629],"68Ga-RM26-RGD","68Ga-RM26",{"nctId":5671,"briefTitle":5672,"status":108,"phases":5673,"primaryCompletion":5674,"completion":5674,"start":5675,"enrollment":811,"conditions":5676,"interventions":5677},"NCT01665196","18F-FDG PET\u002FCT for IgG4-Related Disease",[87],"2017-12","2012-09",[2355],[2628],{"trials":5679,"activeCount":147,"soonestReadout":956},[5680,5684],{"nctId":2667,"briefTitle":2668,"status":137,"phases":5681,"primaryCompletion":956,"completion":333,"start":2670,"enrollment":1206,"conditions":5682,"interventions":5683},[88],[2672],[2596,2628],{"nctId":5685,"briefTitle":5686,"status":108,"phases":5687,"primaryCompletion":5688,"completion":5688,"start":5689,"enrollment":811,"conditions":5690,"interventions":5692},"NCT03404414","Detection of Functioning Pituitary Microadenoma: PET\u002FMRI Versus PET\u002FCT",[88],"2018-11","2013-02",[5691],"Pituitary Adenoma",[2628],{"trials":5694,"activeCount":100},[],{"trials":5696,"activeCount":100},[],{"trials":5698,"activeCount":100},[],{"trials":5700,"activeCount":100},[5701],{"nctId":5702,"briefTitle":5703,"status":443,"phases":5704,"primaryCompletion":5705,"completion":5706,"start":5707,"enrollment":269,"conditions":5708,"interventions":5709},"NCT05432947","68Ga-P16-093 and 18F-FDG PET\u002FCT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients",[92],"2022-09-04","2022-09-15","2022-04-14",[3724],[5710,2628],"68Ga-P16-093",{"intervention":5712,"totalTrials":147,"cells":5713},"TMT101",{"EARLY_PHASE1":5714,"PHASE1":5716,"PHASE2":5725,"PHASE3":5727,"PHASE4":5729,"NA":5731},{"trials":5715,"activeCount":100},[],{"trials":5717,"activeCount":147,"soonestReadout":956},[5718],{"nctId":5719,"briefTitle":5720,"status":137,"phases":5721,"primaryCompletion":956,"completion":1817,"start":5722,"enrollment":1765,"conditions":5723,"interventions":5724},"NCT06861543","The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)",[88],"2025-03-01",[1767],[5712],{"trials":5726,"activeCount":100},[],{"trials":5728,"activeCount":100},[],{"trials":5730,"activeCount":100},[],{"trials":5732,"activeCount":100},[],{"intervention":5734,"totalTrials":147,"cells":5735},"CAR-M-C-MET cell intraperitoneal",{"EARLY_PHASE1":5736,"PHASE1":5738,"PHASE2":5748,"PHASE3":5750,"PHASE4":5752,"NA":5754},{"trials":5737,"activeCount":100},[],{"trials":5739,"activeCount":147,"soonestReadout":1532},[5740],{"nctId":5741,"briefTitle":5742,"status":151,"phases":5743,"primaryCompletion":1532,"completion":3590,"start":5744,"enrollment":1765,"conditions":5745,"interventions":5747},"NCT07553793","Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients",[88],"2026-05-01",[19,5746],"Advanced Stage Cancer",[5734],{"trials":5749,"activeCount":100},[],{"trials":5751,"activeCount":100},[],{"trials":5753,"activeCount":100},[],{"trials":5755,"activeCount":100},[],{"intervention":5757,"totalTrials":147,"cells":5758},"TKI+Cardunilimab",{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5769,"PHASE3":5771,"PHASE4":5773,"NA":5775},{"trials":5760,"activeCount":100},[],{"trials":5762,"activeCount":147,"soonestReadout":1205},[5763],{"nctId":5764,"briefTitle":5765,"status":137,"phases":5766,"primaryCompletion":1205,"completion":3801,"start":4821,"enrollment":127,"conditions":5767,"interventions":5768},"NCT06363006","Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer",[88],[27],[5757],{"trials":5770,"activeCount":100},[],{"trials":5772,"activeCount":100},[],{"trials":5774,"activeCount":100},[],{"trials":5776,"activeCount":100},[],{"intervention":2629,"totalTrials":372,"cells":5778},{"EARLY_PHASE1":5779,"PHASE1":5789,"PHASE2":5791,"PHASE3":5793,"PHASE4":5795,"NA":5797},{"trials":5780,"activeCount":372,"soonestReadout":333},[5781,5785],{"nctId":2620,"briefTitle":2621,"status":137,"phases":5782,"primaryCompletion":333,"completion":333,"start":2623,"enrollment":2353,"conditions":5783,"interventions":5784},[87],[2625],[2627,2628,2596,2629],{"nctId":5659,"briefTitle":5660,"status":137,"phases":5786,"primaryCompletion":333,"completion":164,"start":5662,"enrollment":357,"conditions":5787,"interventions":5788},[87],[16,5664,5665,5666],[5668,2628,5669,2629],{"trials":5790,"activeCount":100},[],{"trials":5792,"activeCount":100},[],{"trials":5794,"activeCount":100},[],{"trials":5796,"activeCount":100},[],{"trials":5798,"activeCount":100},[],{"intervention":5800,"totalTrials":372,"cells":5801},"68GA-DOTA-dPNE",{"EARLY_PHASE1":5802,"PHASE1":5811,"PHASE2":5813,"PHASE3":5815,"PHASE4":5817,"NA":5819},{"trials":5803,"activeCount":147,"soonestReadout":956},[5804],{"nctId":5805,"briefTitle":5806,"status":137,"phases":5807,"primaryCompletion":956,"completion":956,"start":5808,"enrollment":194,"conditions":5809,"interventions":5810},"NCT06411678","Application of 68GA-labeled CD73 Targeting Probe PET\u002FCT Imaging in the Diagnosis of Breast Cancer",[87],"2024-05-10",[16],[5800],{"trials":5812,"activeCount":100},[],{"trials":5814,"activeCount":100},[],{"trials":5816,"activeCount":100},[],{"trials":5818,"activeCount":100},[],{"trials":5820,"activeCount":147,"soonestReadout":596},[5821],{"nctId":5822,"briefTitle":5823,"status":137,"phases":5824,"primaryCompletion":596,"completion":4779,"start":5722,"enrollment":194,"conditions":5825,"interventions":5827},"NCT06844110","Application of 68GA-labeled CD73 Targeting Probe PET\u002FCT Imaging in the Diagnosis of Malignant Tumor",[92],[5826],"Tumor Immunity",[5800],{"intervention":5829,"totalTrials":605,"cells":5830},"68Ga-DOTATATE",{"EARLY_PHASE1":5831,"PHASE1":5862,"PHASE2":5875,"PHASE3":5877,"PHASE4":5879,"NA":5881},{"trials":5832,"activeCount":147,"soonestReadout":2563},[5833,5841,5850],{"nctId":5834,"briefTitle":5835,"status":108,"phases":5836,"primaryCompletion":428,"completion":5837,"start":5838,"enrollment":811,"conditions":5839,"interventions":5840},"NCT04041882","68Ga-DOTATATE PET\u002FCT in Neuroendocrine Tumor",[87],"2022-01-30","2014-04-01",[5422],[5829],{"nctId":5842,"briefTitle":5843,"status":108,"phases":5844,"primaryCompletion":5674,"completion":5674,"start":5845,"enrollment":811,"conditions":5846,"interventions":5849},"NCT01524016","68Ga-DOTATATE PET\u002FCT in Oncogenic Osteomalacia",[87],"2011-12",[5847,5848],"Oncogenic Osteomalacia","Mesenchymal Tumor",[5829],{"nctId":5851,"briefTitle":5852,"status":137,"phases":5853,"primaryCompletion":2563,"completion":4577,"start":757,"enrollment":5179,"conditions":5854,"interventions":5859},"NCT05069220","18F-MFBG PET\u002FCT in the Evaluation of Neural Crest Tumor",[87],[5855,5856,5857,5858],"Neuroendocrine Tumor","Neuroblastoma","Pheochromocytoma","Paraganglioma",[5860,5861],"18F-MFBG","68Ga-Dotatate",{"trials":5863,"activeCount":100},[5864],{"nctId":5865,"briefTitle":5866,"status":108,"phases":5867,"primaryCompletion":5868,"completion":5869,"start":5870,"enrollment":194,"conditions":5871,"interventions":5873},"NCT04689893","Application of 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 PET\u002FCT in the Diagnosis and Evaluation of TIO",[88],"2021-03-15","2022-03-15","2020-03-15",[5872],"Tumor-Induced Osteomalacia",[5861,5874],"68Ga-DOTA-JR11",{"trials":5876,"activeCount":100},[],{"trials":5878,"activeCount":100},[],{"trials":5880,"activeCount":100},[],{"trials":5882,"activeCount":100},[],{"intervention":5669,"totalTrials":372,"cells":5884},{"EARLY_PHASE1":5885,"PHASE1":5899,"PHASE2":5901,"PHASE3":5903,"PHASE4":5905,"NA":5907},{"trials":5886,"activeCount":147,"soonestReadout":333},[5887,5891],{"nctId":5659,"briefTitle":5660,"status":137,"phases":5888,"primaryCompletion":333,"completion":164,"start":5662,"enrollment":357,"conditions":5889,"interventions":5890},[87],[16,5664,5665,5666],[5668,2628,5669,2629],{"nctId":5892,"briefTitle":5893,"status":108,"phases":5894,"primaryCompletion":5895,"completion":5895,"start":2701,"enrollment":957,"conditions":5896,"interventions":5898},"NCT06412952","68Ga-NOTA-RM26 PET\u002FCT in Glioma Patients",[87],"2024-05-31",[5897],"Glioma",[5669],{"trials":5900,"activeCount":100},[],{"trials":5902,"activeCount":100},[],{"trials":5904,"activeCount":100},[],{"trials":5906,"activeCount":100},[],{"trials":5908,"activeCount":100},[],{"intervention":5910,"totalTrials":147,"cells":5911},"GEN6050X intravenous",{"EARLY_PHASE1":5912,"PHASE1":5922,"PHASE2":5924,"PHASE3":5926,"PHASE4":5928,"NA":5930},{"trials":5913,"activeCount":147,"soonestReadout":528},[5914],{"nctId":5915,"briefTitle":5916,"status":1229,"phases":5917,"primaryCompletion":528,"completion":322,"start":5918,"enrollment":184,"conditions":5919,"interventions":5921},"NCT06392724","A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.",[87],"2024-07-05",[5920],"Duchenne Muscular Dystrophy (DMD)",[5910],{"trials":5923,"activeCount":100},[],{"trials":5925,"activeCount":100},[],{"trials":5927,"activeCount":100},[],{"trials":5929,"activeCount":100},[],{"trials":5931,"activeCount":100},[],{"intervention":5933,"totalTrials":147,"cells":5934},"177Lu-LNC1004",{"EARLY_PHASE1":5935,"PHASE1":5945,"PHASE2":5947,"PHASE3":5949,"PHASE4":5951,"NA":5953},{"trials":5936,"activeCount":147,"soonestReadout":2058},[5937],{"nctId":5938,"briefTitle":5939,"status":137,"phases":5940,"primaryCompletion":2058,"completion":2059,"start":5941,"enrollment":142,"conditions":5942,"interventions":5944},"NCT06898437","Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer",[87],"2025-03-24",[5943],"Radioiodine Refractory Differentiated Thyroid Cancer",[5933],{"trials":5946,"activeCount":100},[],{"trials":5948,"activeCount":100},[],{"trials":5950,"activeCount":100},[],{"trials":5952,"activeCount":100},[],{"trials":5954,"activeCount":100},[],{"intervention":5956,"totalTrials":147,"cells":5957},"177Lu-TATE-RGD",{"EARLY_PHASE1":5958,"PHASE1":5969,"PHASE2":5971,"PHASE3":5973,"PHASE4":5975,"NA":5977},{"trials":5959,"activeCount":147,"soonestReadout":5964},[5960],{"nctId":5961,"briefTitle":5962,"status":137,"phases":5963,"primaryCompletion":5964,"completion":5965,"start":3667,"enrollment":215,"conditions":5966,"interventions":5968},"NCT06632873","177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors",[87],"2025-01-30","2025-02-20",[5967],"SSTR2 and Integrin αVβ3 Positive Tumors",[5956],{"trials":5970,"activeCount":100},[],{"trials":5972,"activeCount":100},[],{"trials":5974,"activeCount":100},[],{"trials":5976,"activeCount":100},[],{"trials":5978,"activeCount":100},[],{"intervention":61,"totalTrials":147,"cells":5980},{"EARLY_PHASE1":5981,"PHASE1":5990,"PHASE2":5992,"PHASE3":5994,"PHASE4":5996,"NA":5998},{"trials":5982,"activeCount":147,"soonestReadout":60},[5983],{"nctId":58,"briefTitle":59,"status":137,"phases":5984,"primaryCompletion":60,"completion":5985,"start":1681,"enrollment":957,"conditions":5986,"interventions":5988},[87],"2026-10-04",[5987],"Metastatic Castration-resistant Prostate Cancer",[61,5989],"1.1 GBq (30 mCi) of 177Lu-P17-088",{"trials":5991,"activeCount":100},[],{"trials":5993,"activeCount":100},[],{"trials":5995,"activeCount":100},[],{"trials":5997,"activeCount":100},[],{"trials":5999,"activeCount":100},[],{"intervention":5989,"totalTrials":147,"cells":6001},{"EARLY_PHASE1":6002,"PHASE1":6008,"PHASE2":6010,"PHASE3":6012,"PHASE4":6014,"NA":6016},{"trials":6003,"activeCount":147,"soonestReadout":60},[6004],{"nctId":58,"briefTitle":59,"status":137,"phases":6005,"primaryCompletion":60,"completion":5985,"start":1681,"enrollment":957,"conditions":6006,"interventions":6007},[87],[5987],[61,5989],{"trials":6009,"activeCount":100},[],{"trials":6011,"activeCount":100},[],{"trials":6013,"activeCount":100},[],{"trials":6015,"activeCount":100},[],{"trials":6017,"activeCount":100},[],{"intervention":6019,"totalTrials":147,"cells":6020},"intravenous administration of PTH1-84 mRNA",{"EARLY_PHASE1":6021,"PHASE1":6032,"PHASE2":6034,"PHASE3":6036,"PHASE4":6038,"NA":6040},{"trials":6022,"activeCount":147,"soonestReadout":6027},[6023],{"nctId":6024,"briefTitle":6025,"status":137,"phases":6026,"primaryCompletion":6027,"completion":6028,"start":6029,"enrollment":1660,"conditions":6030,"interventions":6031},"NCT07197450","Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism",[87],"2026-07-15","2026-07-30","2025-05-20",[3008],[6019],{"trials":6033,"activeCount":100},[],{"trials":6035,"activeCount":100},[],{"trials":6037,"activeCount":100},[],{"trials":6039,"activeCount":100},[],{"trials":6041,"activeCount":100},[],{"intervention":6043,"totalTrials":147,"cells":6044},"18F-FCOB04",{"EARLY_PHASE1":6045,"PHASE1":6055,"PHASE2":6057,"PHASE3":6059,"PHASE4":6061,"NA":6063},{"trials":6046,"activeCount":147,"soonestReadout":164},[6047],{"nctId":6048,"briefTitle":6049,"status":151,"phases":6050,"primaryCompletion":164,"completion":164,"start":6051,"enrollment":127,"conditions":6052,"interventions":6054},"NCT07470710","Study on the Application of ¹⁸F-FCOB04, a MAO-B Targeted PET Imaging Agent, in Neurodegenerative Diseases",[87],"2026-03-09",[6053],"Neurodegenerative Diseases",[6043],{"trials":6056,"activeCount":100},[],{"trials":6058,"activeCount":100},[],{"trials":6060,"activeCount":100},[],{"trials":6062,"activeCount":100},[],{"trials":6064,"activeCount":100},[],{"intervention":6066,"totalTrials":147,"cells":6067},"BMD003",{"EARLY_PHASE1":6068,"PHASE1":6078,"PHASE2":6080,"PHASE3":6082,"PHASE4":6084,"NA":6086},{"trials":6069,"activeCount":147,"soonestReadout":4577},[6070],{"nctId":6071,"briefTitle":6072,"status":151,"phases":6073,"primaryCompletion":4577,"completion":322,"start":6074,"enrollment":430,"conditions":6075,"interventions":6077},"NCT07485543","Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years",[87],"2026-03",[6076],"Cystic Fibrosis",[6066],{"trials":6079,"activeCount":100},[],{"trials":6081,"activeCount":100},[],{"trials":6083,"activeCount":100},[],{"trials":6085,"activeCount":100},[],{"trials":6087,"activeCount":100},[],{"intervention":6089,"totalTrials":147,"cells":6090},"[68Ga]Ga-NOTA-RF",{"EARLY_PHASE1":6091,"PHASE1":6101,"PHASE2":6103,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6092,"activeCount":147,"soonestReadout":6097},[6093],{"nctId":6094,"briefTitle":6095,"status":1178,"phases":6096,"primaryCompletion":6097,"completion":6097,"start":3006,"enrollment":957,"conditions":6098,"interventions":6100},"NCT07254104","Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors",[87],"2026-10-13",[6099],"Pituitary Neoplasms",[6089],{"trials":6102,"activeCount":100},[],{"trials":6104,"activeCount":100},[],{"trials":6106,"activeCount":100},[],{"trials":6108,"activeCount":100},[],{"trials":6110,"activeCount":100},[],{"intervention":2627,"totalTrials":147,"cells":6112},{"EARLY_PHASE1":6113,"PHASE1":6119,"PHASE2":6121,"PHASE3":6123,"PHASE4":6125,"NA":6127},{"trials":6114,"activeCount":147,"soonestReadout":333},[6115],{"nctId":2620,"briefTitle":2621,"status":137,"phases":6116,"primaryCompletion":333,"completion":333,"start":2623,"enrollment":2353,"conditions":6117,"interventions":6118},[87],[2625],[2627,2628,2596,2629],{"trials":6120,"activeCount":100},[],{"trials":6122,"activeCount":100},[],{"trials":6124,"activeCount":100},[],{"trials":6126,"activeCount":100},[],{"trials":6128,"activeCount":100},[],{"intervention":6130,"totalTrials":147,"cells":6131},"68Ga-TATE-RGD",{"EARLY_PHASE1":6132,"PHASE1":6145,"PHASE2":6147,"PHASE3":6149,"PHASE4":6151,"NA":6153},{"trials":6133,"activeCount":147,"soonestReadout":6138},[6134],{"nctId":6135,"briefTitle":6136,"status":137,"phases":6137,"primaryCompletion":6138,"completion":596,"start":267,"enrollment":127,"conditions":6139,"interventions":6143},"NCT06632860","A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors",[87],"2025-12-20",[6140,6141,6142],"Iodine-resistant Thyroid Cancer","Meningioma","NETs",[6130,6144],"18-FDG",{"trials":6146,"activeCount":100},[],{"trials":6148,"activeCount":100},[],{"trials":6150,"activeCount":100},[],{"trials":6152,"activeCount":100},[],{"trials":6154,"activeCount":100},[],{"intervention":6144,"totalTrials":147,"cells":6156},{"EARLY_PHASE1":6157,"PHASE1":6163,"PHASE2":6165,"PHASE3":6167,"PHASE4":6169,"NA":6171},{"trials":6158,"activeCount":147,"soonestReadout":6138},[6159],{"nctId":6135,"briefTitle":6136,"status":137,"phases":6160,"primaryCompletion":6138,"completion":596,"start":267,"enrollment":127,"conditions":6161,"interventions":6162},[87],[6140,6141,6142],[6130,6144],{"trials":6164,"activeCount":100},[],{"trials":6166,"activeCount":100},[],{"trials":6168,"activeCount":100},[],{"trials":6170,"activeCount":100},[],{"trials":6172,"activeCount":100},[],{"intervention":71,"totalTrials":147,"cells":6174},{"EARLY_PHASE1":6175,"PHASE1":6182,"PHASE2":6184,"PHASE3":6186,"PHASE4":6188,"NA":6190},{"trials":6176,"activeCount":147,"soonestReadout":70},[6177],{"nctId":68,"briefTitle":69,"status":137,"phases":6178,"primaryCompletion":70,"completion":1533,"start":2659,"enrollment":215,"conditions":6179,"interventions":6181},[87],[6180],"Integrin αVβ3 Positive Tumors",[71],{"trials":6183,"activeCount":100},[],{"trials":6185,"activeCount":100},[],{"trials":6187,"activeCount":100},[],{"trials":6189,"activeCount":100},[],{"trials":6191,"activeCount":100},[],{"intervention":6193,"totalTrials":147,"cells":6194},"inhaled BMD003",{"EARLY_PHASE1":6195,"PHASE1":6207,"PHASE2":6209,"PHASE3":6211,"PHASE4":6213,"NA":6215},{"trials":6196,"activeCount":147,"soonestReadout":6201},[6197],{"nctId":6198,"briefTitle":6199,"status":151,"phases":6200,"primaryCompletion":6201,"completion":6202,"start":257,"enrollment":209,"conditions":6203,"interventions":6206},"NCT06963008","A Prospective, Single-center, Open-label Clinical Study to Evaluate the Safety and Efficacy of Inhaled BMD003(CFTR mRNA) in Chinese Adult Patients With Cystic Fibrosis",[87],"2026-05-10","2027-05-10",[6204,6205],"Cystic Fibrosis (CF)","Gene Therapy",[6193],{"trials":6208,"activeCount":100},[],{"trials":6210,"activeCount":100},[],{"trials":6212,"activeCount":100},[],{"trials":6214,"activeCount":100},[],{"trials":6216,"activeCount":100},[],{"intervention":5668,"totalTrials":147,"cells":6218},{"EARLY_PHASE1":6219,"PHASE1":6225,"PHASE2":6227,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6220,"activeCount":147,"soonestReadout":333},[6221],{"nctId":5659,"briefTitle":5660,"status":137,"phases":6222,"primaryCompletion":333,"completion":164,"start":5662,"enrollment":357,"conditions":6223,"interventions":6224},[87],[16,5664,5665,5666],[5668,2628,5669,2629],{"trials":6226,"activeCount":100},[],{"trials":6228,"activeCount":100},[],{"trials":6230,"activeCount":100},[],{"trials":6232,"activeCount":100},[],{"trials":6234,"activeCount":100},[],{"intervention":5860,"totalTrials":147,"cells":6236},{"EARLY_PHASE1":6237,"PHASE1":6243,"PHASE2":6245,"PHASE3":6247,"PHASE4":6249,"NA":6251},{"trials":6238,"activeCount":147,"soonestReadout":2563},[6239],{"nctId":5851,"briefTitle":5852,"status":137,"phases":6240,"primaryCompletion":2563,"completion":4577,"start":757,"enrollment":5179,"conditions":6241,"interventions":6242},[87],[5855,5856,5857,5858],[5860,5861],{"trials":6244,"activeCount":100},[],{"trials":6246,"activeCount":100},[],{"trials":6248,"activeCount":100},[],{"trials":6250,"activeCount":100},[],{"trials":6252,"activeCount":100},[],{"intervention":6254,"totalTrials":147,"cells":6255},"PUMCH-E101 Injection（Low dose）",{"EARLY_PHASE1":6256,"PHASE1":6268,"PHASE2":6270,"PHASE3":6272,"PHASE4":6274,"NA":6276},{"trials":6257,"activeCount":147,"soonestReadout":675},[6258],{"nctId":6259,"briefTitle":6260,"status":137,"phases":6261,"primaryCompletion":675,"completion":6262,"start":6263,"enrollment":215,"conditions":6264,"interventions":6266},"NCT06749639","Safety and Efficacy Study of PUMCH-E101 Injection in Subjects with RDH12 Retinopathy",[87],"2030-01-04","2024-09-20",[6265],"Inherited Retinal Diseases",[6254,6267],"PUMCH-E101 Injection（High dose）",{"trials":6269,"activeCount":100},[],{"trials":6271,"activeCount":100},[],{"trials":6273,"activeCount":100},[],{"trials":6275,"activeCount":100},[],{"trials":6277,"activeCount":100},[],{"intervention":6267,"totalTrials":147,"cells":6279},{"EARLY_PHASE1":6280,"PHASE1":6286,"PHASE2":6288,"PHASE3":6290,"PHASE4":6292,"NA":6294},{"trials":6281,"activeCount":147,"soonestReadout":675},[6282],{"nctId":6259,"briefTitle":6260,"status":137,"phases":6283,"primaryCompletion":675,"completion":6262,"start":6263,"enrollment":215,"conditions":6284,"interventions":6285},[87],[6265],[6254,6267],{"trials":6287,"activeCount":100},[],{"trials":6289,"activeCount":100},[],{"trials":6291,"activeCount":100},[],{"trials":6293,"activeCount":100},[],{"trials":6295,"activeCount":100},[],{"intervention":6297,"totalTrials":147,"cells":6298},"RAG-18",{"EARLY_PHASE1":6299,"PHASE1":6308,"PHASE2":6310,"PHASE3":6312,"PHASE4":6314,"NA":6316},{"trials":6300,"activeCount":147,"soonestReadout":6305},[6301],{"nctId":6302,"briefTitle":6303,"status":1229,"phases":6304,"primaryCompletion":6305,"completion":6305,"start":1046,"enrollment":209,"conditions":6306,"interventions":6307},"NCT07282652","A Study to Evaluate the Safety and Tolerability of RAG-18 in Pediatric Patients With Duchenne Muscular Dystrophy",[87],"2026-11",[5920],[6297],{"trials":6309,"activeCount":100},[],{"trials":6311,"activeCount":100},[],{"trials":6313,"activeCount":100},[],{"trials":6315,"activeCount":100},[],{"trials":6317,"activeCount":100},[],{"intervention":6319,"totalTrials":147,"cells":6320},"161Tb-LNC1011",{"EARLY_PHASE1":6321,"PHASE1":6330,"PHASE2":6332,"PHASE3":6334,"PHASE4":6336,"NA":6338},{"trials":6322,"activeCount":147,"soonestReadout":6327},[6323],{"nctId":6324,"briefTitle":6325,"status":151,"phases":6326,"primaryCompletion":6327,"completion":675,"start":1205,"enrollment":23,"conditions":6328,"interventions":6329},"NCT07381582","Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[87],"2027-10-31",[5664],[6319],{"trials":6331,"activeCount":100},[],{"trials":6333,"activeCount":100},[],{"trials":6335,"activeCount":100},[],{"trials":6337,"activeCount":100},[],{"trials":6339,"activeCount":100},[],{"intervention":6341,"totalTrials":147,"cells":6342},"68Ga-FAPI-RGD for PET \u002F CT scan and 177Lu-FAPI-RGD for therapy",{"EARLY_PHASE1":6343,"PHASE1":6354,"PHASE2":6356,"PHASE3":6358,"PHASE4":6360,"NA":6362},{"trials":6344,"activeCount":147,"soonestReadout":3147},[6345],{"nctId":6346,"briefTitle":6347,"status":137,"phases":6348,"primaryCompletion":3147,"completion":6349,"start":1898,"enrollment":23,"conditions":6350,"interventions":6353},"NCT06638034","Diagnosis of Metastatic Tumors on 68Ga-FAPI-RGD PET-CT and Radioligand Therapy With 177Lu-FAPI-RGD",[87],"2025-02-01",[6351,6352],"FAP- Expressing Positive Tumors","RGD- Expressing Positive Tumors",[6341],{"trials":6355,"activeCount":100},[],{"trials":6357,"activeCount":100},[],{"trials":6359,"activeCount":100},[],{"trials":6361,"activeCount":100},[],{"trials":6363,"activeCount":100},[],{"intervention":6365,"totalTrials":147,"cells":6366},"68Ga-FAPI for PET \u002F CT scan and 177Lu-EB-FAPI for therapy",{"EARLY_PHASE1":6367,"PHASE1":6376,"PHASE2":6378,"PHASE3":6380,"PHASE4":6382,"NA":6384},{"trials":6368,"activeCount":147,"soonestReadout":3147},[6369],{"nctId":6370,"briefTitle":6371,"status":137,"phases":6372,"primaryCompletion":3147,"completion":241,"start":1680,"enrollment":215,"conditions":6373,"interventions":6375},"NCT05400967","Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI",[87],[6374],"177Lu-EB-FAPI",[6365],{"trials":6377,"activeCount":100},[],{"trials":6379,"activeCount":100},[],{"trials":6381,"activeCount":100},[],{"trials":6383,"activeCount":100},[],{"trials":6385,"activeCount":100},[],{"intervention":2459,"totalTrials":184,"cells":6387},{"EARLY_PHASE1":6388,"PHASE1":6390,"PHASE2":6392,"PHASE3":6401,"PHASE4":6403,"NA":6405},{"trials":6389,"activeCount":100},[],{"trials":6391,"activeCount":100},[],{"trials":6393,"activeCount":100},[6394],{"nctId":6395,"briefTitle":6396,"status":108,"phases":6397,"primaryCompletion":124,"completion":267,"start":2660,"enrollment":194,"conditions":6398,"interventions":6400},"NCT06074029","Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy",[88,89],[2457,2869,6399],"Predictive Cancer Model",[2459],{"trials":6402,"activeCount":100},[],{"trials":6404,"activeCount":100},[],{"trials":6406,"activeCount":372,"soonestReadout":6411},[6407,6416],{"nctId":6408,"briefTitle":6409,"status":137,"phases":6410,"primaryCompletion":6411,"completion":6411,"start":6412,"enrollment":5242,"conditions":6413,"interventions":6415},"NCT07512518","Observational Cohort Study of Chronic Viral Infection in the Central Nervous System",[],"2030-10-25","2023-02-20",[6414,2459],"Progressive Multifocal Leukoencephalopathy",[2459],{"nctId":6417,"briefTitle":6418,"status":137,"phases":6419,"primaryCompletion":6420,"completion":6420,"start":1681,"enrollment":1048,"conditions":6421,"interventions":6423},"NCT07453342","Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge",[],"2033-12-31",[6422],"Immune-Related Adverse Events",[2459],{"intervention":6425,"totalTrials":184,"cells":6426},"Later-line therapy",{"EARLY_PHASE1":6427,"PHASE1":6429,"PHASE2":6431,"PHASE3":6433,"PHASE4":6435,"NA":6437},{"trials":6428,"activeCount":100},[],{"trials":6430,"activeCount":100},[],{"trials":6432,"activeCount":100},[],{"trials":6434,"activeCount":100},[],{"trials":6436,"activeCount":100},[],{"trials":6438,"activeCount":372,"soonestReadout":111},[6439,6447,6455],{"nctId":6440,"briefTitle":6441,"status":137,"phases":6442,"primaryCompletion":111,"completion":6443,"start":2680,"enrollment":811,"conditions":6444,"interventions":6446},"NCT05802407","The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer",[92],"2030-02-01",[19,6445],"Resectable Carcinoma",[6425],{"nctId":6448,"briefTitle":6449,"status":108,"phases":6450,"primaryCompletion":6349,"completion":6349,"start":2680,"enrollment":811,"conditions":6451,"interventions":6454},"NCT05802420","The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer",[92],[19,6452,6453],"Advanced Cancer","Metastatic Cancer",[6425],{"nctId":6456,"briefTitle":6457,"status":137,"phases":6458,"primaryCompletion":111,"completion":6443,"start":2680,"enrollment":811,"conditions":6459,"interventions":6461},"NCT05802394","The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer",[92],[19,6460],"Locally Advanced",[6425],{"intervention":6463,"totalTrials":372,"cells":6464},"Diagnostic Test: Al18F-NOTA-LM3",{"EARLY_PHASE1":6465,"PHASE1":6467,"PHASE2":6469,"PHASE3":6471,"PHASE4":6473,"NA":6475},{"trials":6466,"activeCount":100},[],{"trials":6468,"activeCount":100},[],{"trials":6470,"activeCount":100},[],{"trials":6472,"activeCount":100},[],{"trials":6474,"activeCount":100},[],{"trials":6476,"activeCount":372,"soonestReadout":333},[6477,6485],{"nctId":6478,"briefTitle":6479,"status":137,"phases":6480,"primaryCompletion":6481,"completion":5177,"start":777,"enrollment":127,"conditions":6482,"interventions":6483},"NCT07366099","Al18F-NOTA-LM3 PET\u002FCT in Patients With TIO",[92],"2026-02-28",[5872],[6463,6484],"Diagnostic Test: 68Ga-DOTATATE",{"nctId":6486,"briefTitle":6487,"status":137,"phases":6488,"primaryCompletion":333,"completion":3553,"start":6489,"enrollment":127,"conditions":6490,"interventions":6492},"NCT07288931","Al18F-NOTA-LM3 PET\u002FCT in Patients With Pheochromocytoma and Paraganglioma",[92],"2024-08-06",[6491],"Pheochromocytoma\u002FParaganglioma (PPGL)",[6463,6484],{"intervention":6484,"totalTrials":372,"cells":6494},{"EARLY_PHASE1":6495,"PHASE1":6497,"PHASE2":6499,"PHASE3":6501,"PHASE4":6503,"NA":6505},{"trials":6496,"activeCount":100},[],{"trials":6498,"activeCount":100},[],{"trials":6500,"activeCount":100},[],{"trials":6502,"activeCount":100},[],{"trials":6504,"activeCount":100},[],{"trials":6506,"activeCount":372,"soonestReadout":333},[6507,6511],{"nctId":6478,"briefTitle":6479,"status":137,"phases":6508,"primaryCompletion":6481,"completion":5177,"start":777,"enrollment":127,"conditions":6509,"interventions":6510},[92],[5872],[6463,6484],{"nctId":6486,"briefTitle":6487,"status":137,"phases":6512,"primaryCompletion":333,"completion":3553,"start":6489,"enrollment":127,"conditions":6513,"interventions":6514},[92],[6491],[6463,6484],{"intervention":6516,"totalTrials":372,"cells":6517},"Secondary prevention for atherosclerotic coronary artery disease",{"EARLY_PHASE1":6518,"PHASE1":6520,"PHASE2":6522,"PHASE3":6524,"PHASE4":6526,"NA":6528},{"trials":6519,"activeCount":100},[],{"trials":6521,"activeCount":100},[],{"trials":6523,"activeCount":100},[],{"trials":6525,"activeCount":100},[],{"trials":6527,"activeCount":100},[],{"trials":6529,"activeCount":372,"soonestReadout":1504},[6530,6545],{"nctId":6531,"briefTitle":6532,"status":137,"phases":6533,"primaryCompletion":1504,"completion":1504,"start":6534,"enrollment":3865,"conditions":6535,"interventions":6542},"NCT05860400","Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study",[],"2023-05-17",[463,6536,6537,6538,6539,6540,6541],"Coronary Artery Stenosis","Coronary Artery Restenosis","Coronary Artery Disease Progression","Inflammation","Inflammatory Disease","Inflammation Vascular",[6516,6543,6544],"Immunosuppressive therapy","Supportive therapies",{"nctId":6546,"briefTitle":6547,"status":137,"phases":6548,"primaryCompletion":4577,"completion":4577,"start":241,"enrollment":167,"conditions":6549,"interventions":6550},"NCT06845410","Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study",[],[463,6538,6536,6537,6539,6540,6541],[6516,6551,6544],"Immunosuppressive Therapy",{"intervention":6543,"totalTrials":372,"cells":6553},{"EARLY_PHASE1":6554,"PHASE1":6556,"PHASE2":6558,"PHASE3":6560,"PHASE4":6562,"NA":6564},{"trials":6555,"activeCount":100},[],{"trials":6557,"activeCount":100},[],{"trials":6559,"activeCount":100},[],{"trials":6561,"activeCount":100},[],{"trials":6563,"activeCount":100},[],{"trials":6565,"activeCount":372,"soonestReadout":1504},[6566,6570],{"nctId":6531,"briefTitle":6532,"status":137,"phases":6567,"primaryCompletion":1504,"completion":1504,"start":6534,"enrollment":3865,"conditions":6568,"interventions":6569},[],[463,6536,6537,6538,6539,6540,6541],[6516,6543,6544],{"nctId":6546,"briefTitle":6547,"status":137,"phases":6571,"primaryCompletion":4577,"completion":4577,"start":241,"enrollment":167,"conditions":6572,"interventions":6573},[],[463,6538,6536,6537,6539,6540,6541],[6516,6551,6544],{"intervention":6544,"totalTrials":372,"cells":6575},{"EARLY_PHASE1":6576,"PHASE1":6578,"PHASE2":6580,"PHASE3":6582,"PHASE4":6584,"NA":6586},{"trials":6577,"activeCount":100},[],{"trials":6579,"activeCount":100},[],{"trials":6581,"activeCount":100},[],{"trials":6583,"activeCount":100},[],{"trials":6585,"activeCount":100},[],{"trials":6587,"activeCount":372,"soonestReadout":1504},[6588,6592],{"nctId":6531,"briefTitle":6532,"status":137,"phases":6589,"primaryCompletion":1504,"completion":1504,"start":6534,"enrollment":3865,"conditions":6590,"interventions":6591},[],[463,6536,6537,6538,6539,6540,6541],[6516,6543,6544],{"nctId":6546,"briefTitle":6547,"status":137,"phases":6593,"primaryCompletion":4577,"completion":4577,"start":241,"enrollment":167,"conditions":6594,"interventions":6595},[],[463,6538,6536,6537,6539,6540,6541],[6516,6551,6544],{"intervention":5710,"totalTrials":1606,"cells":6597},{"EARLY_PHASE1":6598,"PHASE1":6600,"PHASE2":6602,"PHASE3":6619,"PHASE4":6629,"NA":6631},{"trials":6599,"activeCount":100},[],{"trials":6601,"activeCount":100},[],{"trials":6603,"activeCount":100},[6604,6611],{"nctId":6605,"briefTitle":6606,"status":108,"phases":6607,"primaryCompletion":2381,"completion":527,"start":6608,"enrollment":194,"conditions":6609,"interventions":6610},"NCT05569434","68Ga-P16-093 PET\u002FCT Imaging in Glioma Patients",[88,89],"2021-11-28",[5897],[5710],{"nctId":6612,"briefTitle":6613,"status":108,"phases":6614,"primaryCompletion":124,"completion":6615,"start":3908,"enrollment":127,"conditions":6616,"interventions":6618},"NCT06049368","68Ga-P16-093 PET\u002FCT Imaging in the Salivary Gland",[88,89],"2024-03-31",[6617],"Primary Sjögren Syndrome",[5710],{"trials":6620,"activeCount":100},[6621],{"nctId":6622,"briefTitle":6623,"status":108,"phases":6624,"primaryCompletion":2813,"completion":2701,"start":6625,"enrollment":194,"conditions":6626,"interventions":6627},"NCT04796467","68Ga-P16-093 and 68Ga-PSMA-617 PET\u002FCT Imaging in the Same Group of Prostate Cancer Patients",[89,90],"2020-10-01",[5664],[6628,5710],"68Ga-PSMA-617",{"trials":6630,"activeCount":100},[],{"trials":6632,"activeCount":147,"soonestReadout":3147},[6633,6637],{"nctId":5702,"briefTitle":5703,"status":443,"phases":6634,"primaryCompletion":5705,"completion":5706,"start":5707,"enrollment":269,"conditions":6635,"interventions":6636},[92],[3724],[5710,2628],{"nctId":6638,"briefTitle":6639,"status":137,"phases":6640,"primaryCompletion":3147,"completion":333,"start":6641,"enrollment":194,"conditions":6642,"interventions":6643},"NCT05324332","68Ga-P16-093 and 68Ga-PSMA-11 PET\u002FCT Imaging in the Same Group of Primary Prostate Cancer Patients",[92],"2022-04-15",[5664],[5710,6644],"68Ga-PSMA-11",{"intervention":3228,"totalTrials":372,"cells":6646},{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6653,"PHASE4":6655,"NA":6657},{"trials":6648,"activeCount":100},[],{"trials":6650,"activeCount":100},[],{"trials":6652,"activeCount":100},[],{"trials":6654,"activeCount":100},[],{"trials":6656,"activeCount":100},[],{"trials":6658,"activeCount":147,"soonestReadout":2572},[6659,6663],{"nctId":3220,"briefTitle":3221,"status":137,"phases":6660,"primaryCompletion":2572,"completion":2572,"start":3223,"enrollment":3224,"conditions":6661,"interventions":6662},[92],[3226],[3181,3228],{"nctId":6664,"briefTitle":6665,"status":443,"phases":6666,"primaryCompletion":6667,"completion":6668,"start":6669,"enrollment":705,"conditions":6670,"interventions":6673},"NCT00691314","Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis",[92],"2010-09","2010-12","2008-06",[475,476,2617,6671,6672],"Stenosis","Stents",[3228],{"intervention":6675,"totalTrials":372,"cells":6676},"Multi-component intervention package",{"EARLY_PHASE1":6677,"PHASE1":6679,"PHASE2":6681,"PHASE3":6683,"PHASE4":6685,"NA":6687},{"trials":6678,"activeCount":100},[],{"trials":6680,"activeCount":100},[],{"trials":6682,"activeCount":100},[],{"trials":6684,"activeCount":100},[],{"trials":6686,"activeCount":100},[],{"trials":6688,"activeCount":147,"soonestReadout":6693},[6689,6701],{"nctId":6690,"briefTitle":6691,"status":443,"phases":6692,"primaryCompletion":6693,"completion":6693,"start":6694,"enrollment":6695,"conditions":6696,"interventions":6700},"NCT06456996","Impact of Multi-Component Interventions on High Risk COPD Population",[92],"2026-03-31","2024-06-17",9319,[6697,6698,6699],"Multimorbidity","Population Medicine","Chronic Obstructive Pulmonary Disease",[6675],{"nctId":6702,"briefTitle":6703,"status":1229,"phases":6704,"primaryCompletion":6693,"completion":2015,"start":6694,"enrollment":6705,"conditions":6706,"interventions":6708},"NCT06457009","Impact of Multi-Component Intervention on Suspected Asthma Population",[92],7400,[6697,6707,6698],"Chronic Asthma",[6709],"Multi-component Intervention Package",{"intervention":6644,"totalTrials":372,"cells":6711},{"EARLY_PHASE1":6712,"PHASE1":6714,"PHASE2":6716,"PHASE3":6727,"PHASE4":6729,"NA":6731},{"trials":6713,"activeCount":100},[],{"trials":6715,"activeCount":100},[],{"trials":6717,"activeCount":100},[6718],{"nctId":6719,"briefTitle":6720,"status":108,"phases":6721,"primaryCompletion":177,"completion":177,"start":6722,"enrollment":957,"conditions":6723,"interventions":6725},"NCT05627778","68Ga-P15-041 and 68Ga-PSMA-11 PET\u002FCT Imaging in the Same Group of Prostate Bone Metastasis",[88,89],"2021-11-01",[6724],"Prostate Cancer Metastatic",[6644,6726],"68Ga-P15-041",{"trials":6728,"activeCount":100},[],{"trials":6730,"activeCount":100},[],{"trials":6732,"activeCount":147,"soonestReadout":3147},[6733],{"nctId":6638,"briefTitle":6639,"status":137,"phases":6734,"primaryCompletion":3147,"completion":333,"start":6641,"enrollment":194,"conditions":6735,"interventions":6736},[92],[5664],[5710,6644],{"intervention":6738,"totalTrials":147,"cells":6739},"pyrotinib combined with Capecitabine",{"EARLY_PHASE1":6740,"PHASE1":6742,"PHASE2":6744,"PHASE3":6746,"PHASE4":6748,"NA":6750},{"trials":6741,"activeCount":100},[],{"trials":6743,"activeCount":100},[],{"trials":6745,"activeCount":100},[],{"trials":6747,"activeCount":100},[],{"trials":6749,"activeCount":100},[],{"trials":6751,"activeCount":147,"soonestReadout":1692},[6752],{"nctId":6753,"briefTitle":6754,"status":137,"phases":6755,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":705,"conditions":6756,"interventions":6758},"NCT06035016","Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer",[],[1741,6757],"Early-stage Breast Cancer",[6738,6759],"treatment of physician's choice",{"intervention":6759,"totalTrials":147,"cells":6761},{"EARLY_PHASE1":6762,"PHASE1":6764,"PHASE2":6766,"PHASE3":6768,"PHASE4":6770,"NA":6772},{"trials":6763,"activeCount":100},[],{"trials":6765,"activeCount":100},[],{"trials":6767,"activeCount":100},[],{"trials":6769,"activeCount":100},[],{"trials":6771,"activeCount":100},[],{"trials":6773,"activeCount":147,"soonestReadout":1692},[6774],{"nctId":6753,"briefTitle":6754,"status":137,"phases":6775,"primaryCompletion":1692,"completion":1692,"start":1693,"enrollment":705,"conditions":6776,"interventions":6777},[],[1741,6757],[6738,6759],{"intervention":6779,"totalTrials":147,"cells":6780},"Ensartinib",{"EARLY_PHASE1":6781,"PHASE1":6783,"PHASE2":6785,"PHASE3":6787,"PHASE4":6789,"NA":6791},{"trials":6782,"activeCount":100},[],{"trials":6784,"activeCount":100},[],{"trials":6786,"activeCount":100},[],{"trials":6788,"activeCount":100},[],{"trials":6790,"activeCount":100},[],{"trials":6792,"activeCount":147,"soonestReadout":333},[6793],{"nctId":6794,"briefTitle":6795,"status":137,"phases":6796,"primaryCompletion":333,"completion":1532,"start":6797,"enrollment":6798,"conditions":6799,"interventions":6801},"NCT05498064","A Real World Study of Ensartinib in Advanced ALK-positive NSCLC",[],"2022-05-13",490,[651,6800,6779],"Anaplastic Lymphoma Kinase I1171N",[6779],{"intervention":6803,"totalTrials":147,"cells":6804},"Glofitamab",{"EARLY_PHASE1":6805,"PHASE1":6807,"PHASE2":6809,"PHASE3":6811,"PHASE4":6813,"NA":6815},{"trials":6806,"activeCount":100},[],{"trials":6808,"activeCount":100},[],{"trials":6810,"activeCount":100},[],{"trials":6812,"activeCount":100},[],{"trials":6814,"activeCount":100},[],{"trials":6816,"activeCount":147,"soonestReadout":675},[6817],{"nctId":6818,"briefTitle":6819,"status":137,"phases":6820,"primaryCompletion":675,"completion":165,"start":1897,"enrollment":142,"conditions":6821,"interventions":6823},"NCT06481826","Glofitamab in Chinese Patients With R\u002FR DLBCL",[],[6822],"DLBCL - Diffuse Large B Cell Lymphoma",[6803],{"intervention":6825,"totalTrials":147,"cells":6826},"1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01",{"EARLY_PHASE1":6827,"PHASE1":6829,"PHASE2":6831,"PHASE3":6833,"PHASE4":6835,"NA":6837},{"trials":6828,"activeCount":100},[],{"trials":6830,"activeCount":100},[],{"trials":6832,"activeCount":100},[],{"trials":6834,"activeCount":100},[],{"trials":6836,"activeCount":100},[],{"trials":6838,"activeCount":147,"soonestReadout":595},[6839],{"nctId":6840,"briefTitle":6841,"status":137,"phases":6842,"primaryCompletion":595,"completion":6843,"start":6844,"enrollment":6845,"conditions":6846,"interventions":6847},"NCT05613738","177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer",[92],"2025-11-15","2022-11-23",9,[5987],[6825,6848,6849],"1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01","2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01",{"intervention":6848,"totalTrials":147,"cells":6851},{"EARLY_PHASE1":6852,"PHASE1":6854,"PHASE2":6856,"PHASE3":6858,"PHASE4":6860,"NA":6862},{"trials":6853,"activeCount":100},[],{"trials":6855,"activeCount":100},[],{"trials":6857,"activeCount":100},[],{"trials":6859,"activeCount":100},[],{"trials":6861,"activeCount":100},[],{"trials":6863,"activeCount":147,"soonestReadout":595},[6864],{"nctId":6840,"briefTitle":6841,"status":137,"phases":6865,"primaryCompletion":595,"completion":6843,"start":6844,"enrollment":6845,"conditions":6866,"interventions":6867},[92],[5987],[6825,6848,6849],{"intervention":6849,"totalTrials":147,"cells":6869},{"EARLY_PHASE1":6870,"PHASE1":6872,"PHASE2":6874,"PHASE3":6876,"PHASE4":6878,"NA":6880},{"trials":6871,"activeCount":100},[],{"trials":6873,"activeCount":100},[],{"trials":6875,"activeCount":100},[],{"trials":6877,"activeCount":100},[],{"trials":6879,"activeCount":100},[],{"trials":6881,"activeCount":147,"soonestReadout":595},[6882],{"nctId":6840,"briefTitle":6841,"status":137,"phases":6883,"primaryCompletion":595,"completion":6843,"start":6844,"enrollment":6845,"conditions":6884,"interventions":6885},[92],[5987],[6825,6848,6849],{"intervention":212,"totalTrials":147,"cells":6887},{"EARLY_PHASE1":6888,"PHASE1":6890,"PHASE2":6892,"PHASE3":6894,"PHASE4":6896,"NA":6898},{"trials":6889,"activeCount":100},[],{"trials":6891,"activeCount":100},[],{"trials":6893,"activeCount":100},[],{"trials":6895,"activeCount":100},[],{"trials":6897,"activeCount":100},[],{"trials":6899,"activeCount":147,"soonestReadout":206},[6900],{"nctId":203,"briefTitle":204,"status":151,"phases":6901,"primaryCompletion":206,"completion":207,"start":208,"enrollment":209,"conditions":6902,"interventions":6903},[92],[19],[212,95],{"intervention":6905,"totalTrials":147,"cells":6906},"Three-drug chemotherapy group",{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6911,"PHASE3":6913,"PHASE4":6915,"NA":6917},{"trials":6908,"activeCount":100},[],{"trials":6910,"activeCount":100},[],{"trials":6912,"activeCount":100},[],{"trials":6914,"activeCount":100},[],{"trials":6916,"activeCount":100},[],{"trials":6918,"activeCount":147,"soonestReadout":6923},[6919],{"nctId":6920,"briefTitle":6921,"status":1229,"phases":6922,"primaryCompletion":6923,"completion":6924,"start":2555,"enrollment":2353,"conditions":6925,"interventions":6929},"NCT06867146","MRD in PAAD Adjuvant Therapy",[92],"2026-12-30","2027-12-30",[6926,6927,19,6928],"The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy","Molecular Residual Disease","Adjuvant Therapy",[6905,6930],"two-drug chemotherapy group",{"intervention":6930,"totalTrials":147,"cells":6932},{"EARLY_PHASE1":6933,"PHASE1":6935,"PHASE2":6937,"PHASE3":6939,"PHASE4":6941,"NA":6943},{"trials":6934,"activeCount":100},[],{"trials":6936,"activeCount":100},[],{"trials":6938,"activeCount":100},[],{"trials":6940,"activeCount":100},[],{"trials":6942,"activeCount":100},[],{"trials":6944,"activeCount":147,"soonestReadout":6923},[6945],{"nctId":6920,"briefTitle":6921,"status":1229,"phases":6946,"primaryCompletion":6923,"completion":6924,"start":2555,"enrollment":2353,"conditions":6947,"interventions":6948},[92],[6926,6927,19,6928],[6905,6930],{"intervention":6950,"totalTrials":147,"cells":6951},"Lactulose oral solution",{"EARLY_PHASE1":6952,"PHASE1":6954,"PHASE2":6956,"PHASE3":6958,"PHASE4":6960,"NA":6962},{"trials":6953,"activeCount":100},[],{"trials":6955,"activeCount":100},[],{"trials":6957,"activeCount":100},[],{"trials":6959,"activeCount":100},[],{"trials":6961,"activeCount":100},[],{"trials":6963,"activeCount":147,"soonestReadout":6028},[6964],{"nctId":6965,"briefTitle":6966,"status":137,"phases":6967,"primaryCompletion":6028,"completion":6028,"start":40,"enrollment":2353,"conditions":6968,"interventions":6971},"NCT07065942","Effects of Lactulose on Gut Microbiota and Metabolism in Diabetic Constipated Patients",[92],[6969,6970],"Diabetes Mellitus","Constipation - Functional",[6950,6972],"Live Combined B. Subtilis and E. Faecium Enteric-coated",{"intervention":6972,"totalTrials":147,"cells":6974},{"EARLY_PHASE1":6975,"PHASE1":6977,"PHASE2":6979,"PHASE3":6981,"PHASE4":6983,"NA":6985},{"trials":6976,"activeCount":100},[],{"trials":6978,"activeCount":100},[],{"trials":6980,"activeCount":100},[],{"trials":6982,"activeCount":100},[],{"trials":6984,"activeCount":100},[],{"trials":6986,"activeCount":147,"soonestReadout":6028},[6987],{"nctId":6965,"briefTitle":6966,"status":137,"phases":6988,"primaryCompletion":6028,"completion":6028,"start":40,"enrollment":2353,"conditions":6989,"interventions":6990},[92],[6969,6970],[6950,6972],{"intervention":6992,"totalTrials":147,"cells":6993},"Sodium Glycerophosphate 216 MG\u002FML",{"EARLY_PHASE1":6994,"PHASE1":6996,"PHASE2":6998,"PHASE3":7000,"PHASE4":7002,"NA":7004},{"trials":6995,"activeCount":100},[],{"trials":6997,"activeCount":100},[],{"trials":6999,"activeCount":100},[],{"trials":7001,"activeCount":100},[],{"trials":7003,"activeCount":100},[],{"trials":7005,"activeCount":147,"soonestReadout":241},[7006],{"nctId":7007,"briefTitle":7008,"status":137,"phases":7009,"primaryCompletion":241,"completion":110,"start":65,"enrollment":2061,"conditions":7010,"interventions":7014},"NCT06754670","Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning",[],[7011,7012,7013],"Mechanical Ventilation","Weaning Failure","Hypophosphatemia",[6992],{"intervention":3179,"totalTrials":147,"cells":7016},{"EARLY_PHASE1":7017,"PHASE1":7019,"PHASE2":7021,"PHASE3":7023,"PHASE4":7025,"NA":7027},{"trials":7018,"activeCount":100},[],{"trials":7020,"activeCount":100},[],{"trials":7022,"activeCount":100},[],{"trials":7024,"activeCount":100},[],{"trials":7026,"activeCount":100},[],{"trials":7028,"activeCount":147,"soonestReadout":674},[7029],{"nctId":3170,"briefTitle":3171,"status":151,"phases":7030,"primaryCompletion":674,"completion":3173,"start":3174,"enrollment":3175,"conditions":7031,"interventions":7032},[92],[3177],[246,3179],{"intervention":961,"totalTrials":147,"cells":7034},{"EARLY_PHASE1":7035,"PHASE1":7037,"PHASE2":7039,"PHASE3":7041,"PHASE4":7043,"NA":7045},{"trials":7036,"activeCount":100},[],{"trials":7038,"activeCount":100},[],{"trials":7040,"activeCount":100},[],{"trials":7042,"activeCount":100},[],{"trials":7044,"activeCount":100},[],{"trials":7046,"activeCount":147,"soonestReadout":1691},[7047],{"nctId":7048,"briefTitle":7049,"status":137,"phases":7050,"primaryCompletion":1691,"completion":1691,"start":2588,"enrollment":194,"conditions":7051,"interventions":7052},"NCT07109765","Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa",[],[959],[961],{"intervention":7054,"totalTrials":147,"cells":7055},"Rituxan treatment",{"EARLY_PHASE1":7056,"PHASE1":7058,"PHASE2":7060,"PHASE3":7062,"PHASE4":7064,"NA":7066},{"trials":7057,"activeCount":100},[],{"trials":7059,"activeCount":100},[],{"trials":7061,"activeCount":100},[],{"trials":7063,"activeCount":100},[],{"trials":7065,"activeCount":100},[],{"trials":7067,"activeCount":147,"soonestReadout":5177},[7068],{"nctId":7069,"briefTitle":7070,"status":151,"phases":7071,"primaryCompletion":5177,"completion":7072,"start":2058,"enrollment":1606,"conditions":7073,"interventions":7074},"NCT07475754","A Study to Evaluate the Safety and Tolerability of Rituxan in Duchenne Muscular Dystrophy",[92],"2027-04-23",[5920],[7054],{"intervention":7076,"totalTrials":147,"cells":7077},"Denosumab",{"EARLY_PHASE1":7078,"PHASE1":7080,"PHASE2":7082,"PHASE3":7084,"PHASE4":7086,"NA":7088},{"trials":7079,"activeCount":100},[],{"trials":7081,"activeCount":100},[],{"trials":7083,"activeCount":100},[],{"trials":7085,"activeCount":100},[],{"trials":7087,"activeCount":100},[],{"trials":7089,"activeCount":147,"soonestReadout":3863},[7090],{"nctId":7091,"briefTitle":7092,"status":137,"phases":7093,"primaryCompletion":3863,"completion":3863,"start":7094,"enrollment":7095,"conditions":7096,"interventions":7098},"NCT05866029","Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture",[92],"2023-05-26",2478,[7097],"Osteoporotic Fractures",[7076,7099],"Teriparatide",{"intervention":7099,"totalTrials":147,"cells":7101},{"EARLY_PHASE1":7102,"PHASE1":7104,"PHASE2":7106,"PHASE3":7108,"PHASE4":7110,"NA":7112},{"trials":7103,"activeCount":100},[],{"trials":7105,"activeCount":100},[],{"trials":7107,"activeCount":100},[],{"trials":7109,"activeCount":100},[],{"trials":7111,"activeCount":100},[],{"trials":7113,"activeCount":147,"soonestReadout":3863},[7114],{"nctId":7091,"briefTitle":7092,"status":137,"phases":7115,"primaryCompletion":3863,"completion":3863,"start":7094,"enrollment":7095,"conditions":7116,"interventions":7117},[92],[7097],[7076,7099],{"intervention":7119,"totalTrials":147,"cells":7120},"Home-based therapy",{"EARLY_PHASE1":7121,"PHASE1":7123,"PHASE2":7125,"PHASE3":7127,"PHASE4":7129,"NA":7131},{"trials":7122,"activeCount":100},[],{"trials":7124,"activeCount":100},[],{"trials":7126,"activeCount":100},[],{"trials":7128,"activeCount":100},[],{"trials":7130,"activeCount":100},[],{"trials":7132,"activeCount":147,"soonestReadout":7137},[7133],{"nctId":7134,"briefTitle":7135,"status":151,"phases":7136,"primaryCompletion":7137,"completion":7137,"start":7138,"enrollment":7139,"conditions":7140,"interventions":7141},"NCT06810024","Stroke Homecare and Recurrence Prevention",[92],"2026-04-26","2025-02-27",1614,[475],[7119],{"intervention":7143,"totalTrials":147,"cells":7144},"Lactulose oral solution treatment",{"EARLY_PHASE1":7145,"PHASE1":7147,"PHASE2":7149,"PHASE3":7151,"PHASE4":7153,"NA":7155},{"trials":7146,"activeCount":100},[],{"trials":7148,"activeCount":100},[],{"trials":7150,"activeCount":100},[],{"trials":7152,"activeCount":100},[],{"trials":7154,"activeCount":100},[],{"trials":7156,"activeCount":147,"soonestReadout":333},[7157],{"nctId":7158,"briefTitle":7159,"status":137,"phases":7160,"primaryCompletion":333,"completion":164,"start":7161,"enrollment":127,"conditions":7162,"interventions":7164},"NCT06802042","Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women",[92],"2025-01-09",[7163],"Functional Constipation (FC)",[7143],{"intervention":7166,"totalTrials":147,"cells":7167},"Irinotecan liposome II combination therapy regimen",{"EARLY_PHASE1":7168,"PHASE1":7170,"PHASE2":7172,"PHASE3":7174,"PHASE4":7176,"NA":7178},{"trials":7169,"activeCount":100},[],{"trials":7171,"activeCount":100},[],{"trials":7173,"activeCount":100},[],{"trials":7175,"activeCount":100},[],{"trials":7177,"activeCount":100},[],{"trials":7179,"activeCount":147,"soonestReadout":7184},[7180],{"nctId":7181,"briefTitle":7182,"status":137,"phases":7183,"primaryCompletion":7184,"completion":7184,"start":7185,"enrollment":7186,"conditions":7187,"interventions":7188},"NCT06375473","Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients",[],"2027-04-19","2024-04-19",3000,[19],[7166],{"intervention":7190,"totalTrials":147,"cells":7191},"Drug treatment",{"EARLY_PHASE1":7192,"PHASE1":7194,"PHASE2":7196,"PHASE3":7198,"PHASE4":7200,"NA":7202},{"trials":7193,"activeCount":100},[],{"trials":7195,"activeCount":100},[],{"trials":7197,"activeCount":100},[],{"trials":7199,"activeCount":100},[],{"trials":7201,"activeCount":100},[],{"trials":7203,"activeCount":147,"soonestReadout":675},[7204],{"nctId":7205,"briefTitle":7206,"status":137,"phases":7207,"primaryCompletion":675,"completion":165,"start":1897,"enrollment":811,"conditions":7208,"interventions":7210},"NCT07037472","Photoacoustic\u002FUltrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation",[92],[3226,7209],"Dermatomyositis With Calcinosis Cutis",[7190],{"intervention":7212,"totalTrials":147,"cells":7213},"Direct oral anticoagulant",{"EARLY_PHASE1":7214,"PHASE1":7216,"PHASE2":7218,"PHASE3":7220,"PHASE4":7222,"NA":7224},{"trials":7215,"activeCount":100},[],{"trials":7217,"activeCount":100},[],{"trials":7219,"activeCount":100},[],{"trials":7221,"activeCount":100},[],{"trials":7223,"activeCount":100},[],{"trials":7225,"activeCount":147,"soonestReadout":3863},[7226],{"nctId":7227,"briefTitle":7228,"status":137,"phases":7229,"primaryCompletion":3863,"completion":3863,"start":242,"enrollment":705,"conditions":7230,"interventions":7234},"NCT06194617","Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients",[],[7231,7232,7233],"Pulmonary Embolism","Venous Thromboembolism","Anticoagulant-induced Bleeding",[7212],{"intervention":7236,"totalTrials":147,"cells":7237},"Parsaclisib",{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7244,"PHASE4":7246,"NA":7248},{"trials":7239,"activeCount":100},[],{"trials":7241,"activeCount":100},[],{"trials":7243,"activeCount":100},[],{"trials":7245,"activeCount":100},[],{"trials":7247,"activeCount":100},[],{"trials":7249,"activeCount":147,"soonestReadout":3801},[7250],{"nctId":7251,"briefTitle":7252,"status":151,"phases":7253,"primaryCompletion":3801,"completion":3801,"start":704,"enrollment":299,"conditions":7254,"interventions":7256},"NCT07149818","A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed\u002FRefractory Autoimmune Hemolytic Anemia",[],[7255],"Autoimmune Hemolytic Anemia",[7236],{"intervention":85,"totalTrials":147,"cells":7258},{"EARLY_PHASE1":7259,"PHASE1":7261,"PHASE2":7263,"PHASE3":7265,"PHASE4":7267,"NA":7269},{"trials":7260,"activeCount":100},[],{"trials":7262,"activeCount":100},[],{"trials":7264,"activeCount":100},[],{"trials":7266,"activeCount":100},[],{"trials":7268,"activeCount":100},[],{"trials":7270,"activeCount":147,"soonestReadout":80},[7271],{"nctId":83,"briefTitle":84,"status":137,"phases":7272,"primaryCompletion":80,"completion":7273,"start":7274,"enrollment":811,"conditions":7275,"interventions":7276},[],"2025-06-21","2020-01-01",[959,960,961],[85],{"intervention":7278,"totalTrials":147,"cells":7279},"Rivaroxaban",{"EARLY_PHASE1":7280,"PHASE1":7282,"PHASE2":7284,"PHASE3":7286,"PHASE4":7288,"NA":7290},{"trials":7281,"activeCount":100},[],{"trials":7283,"activeCount":100},[],{"trials":7285,"activeCount":100},[],{"trials":7287,"activeCount":100},[],{"trials":7289,"activeCount":100},[],{"trials":7291,"activeCount":147,"soonestReadout":5178},[7292],{"nctId":7293,"briefTitle":7294,"status":137,"phases":7295,"primaryCompletion":5178,"completion":7296,"start":1897,"enrollment":705,"conditions":7297,"interventions":7298},"NCT06362343","The Study of Monitoring and Dosing Guidance of Direct Oral Anticoagulants Based on Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics",[],"2027-01-30",[7231],[7278],{"intervention":7300,"totalTrials":147,"cells":7301},"glucocorticoid plus iguratimod",{"EARLY_PHASE1":7302,"PHASE1":7304,"PHASE2":7306,"PHASE3":7308,"PHASE4":7310,"NA":7312},{"trials":7303,"activeCount":100},[],{"trials":7305,"activeCount":100},[],{"trials":7307,"activeCount":100},[],{"trials":7309,"activeCount":100},[],{"trials":7311,"activeCount":100},[],{"trials":7313,"activeCount":147,"soonestReadout":4675},[7314],{"nctId":7315,"briefTitle":7316,"status":137,"phases":7317,"primaryCompletion":4675,"completion":4675,"start":193,"enrollment":2353,"conditions":7318,"interventions":7320},"NCT05789030","Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement",[92],[7319],"Autoimmune Diseases",[7300,7321],"glucocorticoid plus leflunomide",{"intervention":7321,"totalTrials":147,"cells":7323},{"EARLY_PHASE1":7324,"PHASE1":7326,"PHASE2":7328,"PHASE3":7330,"PHASE4":7332,"NA":7334},{"trials":7325,"activeCount":100},[],{"trials":7327,"activeCount":100},[],{"trials":7329,"activeCount":100},[],{"trials":7331,"activeCount":100},[],{"trials":7333,"activeCount":100},[],{"trials":7335,"activeCount":147,"soonestReadout":4675},[7336],{"nctId":7315,"briefTitle":7316,"status":137,"phases":7337,"primaryCompletion":4675,"completion":4675,"start":193,"enrollment":2353,"conditions":7338,"interventions":7339},[92],[7319],[7300,7321],{"intervention":7341,"totalTrials":147,"cells":7342},"Multi-component Interventions",{"EARLY_PHASE1":7343,"PHASE1":7345,"PHASE2":7347,"PHASE3":7349,"PHASE4":7351,"NA":7353},{"trials":7344,"activeCount":100},[],{"trials":7346,"activeCount":100},[],{"trials":7348,"activeCount":100},[],{"trials":7350,"activeCount":100},[],{"trials":7352,"activeCount":100},[],{"trials":7354,"activeCount":147,"soonestReadout":6693},[7355],{"nctId":7356,"briefTitle":7357,"status":1229,"phases":7358,"primaryCompletion":6693,"completion":2015,"start":6694,"enrollment":6705,"conditions":7359,"interventions":7361},"NCT06458218","Impact of Multi-component Interventions on Populations With Mental Health Symptoms and High-risk COPD",[92],[6697,7360,7341],"Mental Health Issue",[7341],{"intervention":7363,"totalTrials":147,"cells":7364},"Multi-component intervention for smokers",{"EARLY_PHASE1":7365,"PHASE1":7367,"PHASE2":7369,"PHASE3":7371,"PHASE4":7373,"NA":7375},{"trials":7366,"activeCount":100},[],{"trials":7368,"activeCount":100},[],{"trials":7370,"activeCount":100},[],{"trials":7372,"activeCount":100},[],{"trials":7374,"activeCount":100},[],{"trials":7376,"activeCount":147,"soonestReadout":6693},[7377],{"nctId":7378,"briefTitle":7379,"status":1229,"phases":7380,"primaryCompletion":6693,"completion":2015,"start":6694,"enrollment":6705,"conditions":7381,"interventions":7384},"NCT06458205","Impact of Multi-Component Interventions on High-Risk COPD Smokers",[92],[6697,7382,7383],"Tobacco Use Cessation","Smoking Reduction",[7363],{"intervention":7386,"totalTrials":147,"cells":7387},"Steroid Drug",{"EARLY_PHASE1":7388,"PHASE1":7390,"PHASE2":7392,"PHASE3":7394,"PHASE4":7396,"NA":7398},{"trials":7389,"activeCount":100},[],{"trials":7391,"activeCount":100},[],{"trials":7393,"activeCount":100},[],{"trials":7395,"activeCount":100},[],{"trials":7397,"activeCount":100},[],{"trials":7399,"activeCount":147,"soonestReadout":3863},[7400],{"nctId":7401,"briefTitle":7402,"status":137,"phases":7403,"primaryCompletion":3863,"completion":3863,"start":7404,"enrollment":7405,"conditions":7406,"interventions":7408},"NCT06006832","A Prospective Cohort Study of Myasthenia Gravis in China",[],"2023-08-20",202,[7407],"Myasthenia Gravis",[7386],{"intervention":7410,"totalTrials":147,"cells":7411},"Denosumab treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients",{"EARLY_PHASE1":7412,"PHASE1":7414,"PHASE2":7416,"PHASE3":7418,"PHASE4":7420,"NA":7422},{"trials":7413,"activeCount":100},[],{"trials":7415,"activeCount":100},[],{"trials":7417,"activeCount":100},[],{"trials":7419,"activeCount":100},[],{"trials":7421,"activeCount":100},[],{"trials":7423,"activeCount":147,"soonestReadout":7428},[7424],{"nctId":7425,"briefTitle":7426,"status":151,"phases":7427,"primaryCompletion":7428,"completion":7428,"start":111,"enrollment":7429,"conditions":7430,"interventions":7434},"NCT07063797","Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes",[92],"2027-07-31",358,[7431,7432,7433],"Type 2 Diabetes","Osteoporosis","Fractures",[7410,7435],"Denosumab combined with eldecalcitol treatment in type 2 diabetes mellitus (T2DM) with osteoporosis patients",{"intervention":7435,"totalTrials":147,"cells":7437},{"EARLY_PHASE1":7438,"PHASE1":7440,"PHASE2":7442,"PHASE3":7444,"PHASE4":7446,"NA":7448},{"trials":7439,"activeCount":100},[],{"trials":7441,"activeCount":100},[],{"trials":7443,"activeCount":100},[],{"trials":7445,"activeCount":100},[],{"trials":7447,"activeCount":100},[],{"trials":7449,"activeCount":147,"soonestReadout":7428},[7450],{"nctId":7425,"briefTitle":7426,"status":151,"phases":7451,"primaryCompletion":7428,"completion":7428,"start":111,"enrollment":7429,"conditions":7452,"interventions":7453},[92],[7431,7432,7433],[7410,7435],{"intervention":7455,"totalTrials":147,"cells":7456},"Sugemalimab and Chemotherapy",{"EARLY_PHASE1":7457,"PHASE1":7459,"PHASE2":7461,"PHASE3":7463,"PHASE4":7465,"NA":7467},{"trials":7458,"activeCount":100},[],{"trials":7460,"activeCount":100},[],{"trials":7462,"activeCount":100},[],{"trials":7464,"activeCount":100},[],{"trials":7466,"activeCount":100},[],{"trials":7468,"activeCount":147,"soonestReadout":4035},[7469],{"nctId":7470,"briefTitle":7471,"status":137,"phases":7472,"primaryCompletion":4035,"completion":4035,"start":7473,"enrollment":5179,"conditions":7474,"interventions":7475},"NCT07247227","Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC",[92],"2023-10-10",[2880],[7455],{"intervention":2592,"totalTrials":147,"cells":7477},{"EARLY_PHASE1":7478,"PHASE1":7480,"PHASE2":7482,"PHASE3":7484,"PHASE4":7486,"NA":7488},{"trials":7479,"activeCount":100},[],{"trials":7481,"activeCount":100},[],{"trials":7483,"activeCount":100},[],{"trials":7485,"activeCount":100},[],{"trials":7487,"activeCount":100},[],{"trials":7489,"activeCount":147,"soonestReadout":2588},[7490],{"nctId":2585,"briefTitle":2586,"status":137,"phases":7491,"primaryCompletion":2588,"completion":704,"start":112,"enrollment":705,"conditions":7492,"interventions":7493},[92],[2590],[2592,2531,2593,2594],{"intervention":2593,"totalTrials":147,"cells":7495},{"EARLY_PHASE1":7496,"PHASE1":7498,"PHASE2":7500,"PHASE3":7502,"PHASE4":7504,"NA":7506},{"trials":7497,"activeCount":100},[],{"trials":7499,"activeCount":100},[],{"trials":7501,"activeCount":100},[],{"trials":7503,"activeCount":100},[],{"trials":7505,"activeCount":100},[],{"trials":7507,"activeCount":147,"soonestReadout":2588},[7508],{"nctId":2585,"briefTitle":2586,"status":137,"phases":7509,"primaryCompletion":2588,"completion":704,"start":112,"enrollment":705,"conditions":7510,"interventions":7511},[92],[2590],[2592,2531,2593,2594],{"intervention":2594,"totalTrials":147,"cells":7513},{"EARLY_PHASE1":7514,"PHASE1":7516,"PHASE2":7518,"PHASE3":7520,"PHASE4":7522,"NA":7524},{"trials":7515,"activeCount":100},[],{"trials":7517,"activeCount":100},[],{"trials":7519,"activeCount":100},[],{"trials":7521,"activeCount":100},[],{"trials":7523,"activeCount":100},[],{"trials":7525,"activeCount":147,"soonestReadout":2588},[7526],{"nctId":2585,"briefTitle":2586,"status":137,"phases":7527,"primaryCompletion":2588,"completion":704,"start":112,"enrollment":705,"conditions":7528,"interventions":7529},[92],[2590],[2592,2531,2593,2594],{"intervention":7531,"totalTrials":147,"cells":7532},"Any Chinese government-recommended COVID-19 booster vaccine",{"EARLY_PHASE1":7533,"PHASE1":7535,"PHASE2":7537,"PHASE3":7539,"PHASE4":7541,"NA":7543},{"trials":7534,"activeCount":100},[],{"trials":7536,"activeCount":100},[],{"trials":7538,"activeCount":100},[],{"trials":7540,"activeCount":100},[],{"trials":7542,"activeCount":100},[],{"trials":7544,"activeCount":147,"soonestReadout":7549},[7545],{"nctId":7546,"briefTitle":7547,"status":137,"phases":7548,"primaryCompletion":7549,"completion":7549,"start":45,"enrollment":7550,"conditions":7551,"interventions":7555},"NCT06168032","COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research",[92],"2026-12-08",1224,[7552,29,7553,7554,95,2869],"COVID-19 Recurrent","Vaccination","Antibody",[7531],{"intervention":7557,"totalTrials":147,"cells":7558},"Lenalidomide 10 mg",{"EARLY_PHASE1":7559,"PHASE1":7561,"PHASE2":7563,"PHASE3":7565,"PHASE4":7567,"NA":7569},{"trials":7560,"activeCount":100},[],{"trials":7562,"activeCount":100},[],{"trials":7564,"activeCount":100},[],{"trials":7566,"activeCount":100},[],{"trials":7568,"activeCount":100},[],{"trials":7570,"activeCount":147,"soonestReadout":7575},[7571],{"nctId":7572,"briefTitle":7573,"status":137,"phases":7574,"primaryCompletion":7575,"completion":333,"start":240,"enrollment":269,"conditions":7576,"interventions":7578},"NCT05449548","Lenalidomide in the Treatment of Mucosal Behçet's Syndrome",[92],"2025-10-30",[7577],"Oral Ulcer",[7557],{"intervention":7580,"totalTrials":147,"cells":7581},"QL1706 plus chemotherapy",{"EARLY_PHASE1":7582,"PHASE1":7584,"PHASE2":7586,"PHASE3":7588,"PHASE4":7590,"NA":7592},{"trials":7583,"activeCount":100},[],{"trials":7585,"activeCount":100},[],{"trials":7587,"activeCount":100},[],{"trials":7589,"activeCount":100},[],{"trials":7591,"activeCount":100},[],{"trials":7593,"activeCount":147,"soonestReadout":1503},[7594],{"nctId":7595,"briefTitle":7596,"status":137,"phases":7597,"primaryCompletion":1503,"completion":323,"start":7598,"enrollment":957,"conditions":7599,"interventions":7601},"NCT07452003","An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC",[92],"2026-01-03",[7600],"Non-Small Cell Lung Cancer",[7580],{"intervention":7603,"totalTrials":147,"cells":7604},"5-fluorouracil + formyltetrahydrofolate\u002FOxaliplatin + 5-fluorouracil + formyltetrahydrofolate\u002FIrinotecan + 5-fluorouracil + formyltetrahydrofolate\u002FCetuximab + 5-fluorouracil + formyltetrahydrofolate",{"EARLY_PHASE1":7605,"PHASE1":7607,"PHASE2":7609,"PHASE3":7611,"PHASE4":7613,"NA":7615},{"trials":7606,"activeCount":100},[],{"trials":7608,"activeCount":100},[],{"trials":7610,"activeCount":100},[],{"trials":7612,"activeCount":100},[],{"trials":7614,"activeCount":100},[],{"trials":7616,"activeCount":147,"soonestReadout":704},[7617],{"nctId":7618,"briefTitle":7619,"status":137,"phases":7620,"primaryCompletion":704,"completion":2171,"start":757,"enrollment":324,"conditions":7621,"interventions":7625},"NCT05424692","Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer",[92],[2767,4738,7622,7623,7624],"Chemotherapy Effect","PTC","Exon Mutation",[7603],{"intervention":7627,"totalTrials":147,"cells":7628},"DZD9008",{"EARLY_PHASE1":7629,"PHASE1":7631,"PHASE2":7633,"PHASE3":7635,"PHASE4":7637,"NA":7639},{"trials":7630,"activeCount":100},[],{"trials":7632,"activeCount":100},[],{"trials":7634,"activeCount":100},[],{"trials":7636,"activeCount":100},[],{"trials":7638,"activeCount":100},[],{"trials":7640,"activeCount":147,"soonestReadout":333},[7641],{"nctId":7642,"briefTitle":7643,"status":137,"phases":7644,"primaryCompletion":333,"completion":2015,"start":2670,"enrollment":7645,"conditions":7646,"interventions":7647},"NCT05559645","Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)",[92],180,[2867],[7627,7627],{"intervention":41,"totalTrials":147,"cells":7649},{"EARLY_PHASE1":7650,"PHASE1":7652,"PHASE2":7654,"PHASE3":7656,"PHASE4":7658,"NA":7660},{"trials":7651,"activeCount":100},[],{"trials":7653,"activeCount":100},[],{"trials":7655,"activeCount":100},[],{"trials":7657,"activeCount":100},[],{"trials":7659,"activeCount":100},[],{"trials":7661,"activeCount":147,"soonestReadout":40},[7662],{"nctId":38,"briefTitle":39,"status":137,"phases":7663,"primaryCompletion":40,"completion":1817,"start":7664,"enrollment":7665,"conditions":7666,"interventions":7670},[92],"2021-07-01",297,[7667,7668,7669],"Postoperative Infection","Lactate","Antibiotics",[41],{"intervention":7672,"totalTrials":1606,"cells":7673},"Tacrolimus",{"EARLY_PHASE1":7674,"PHASE1":7676,"PHASE2":7678,"PHASE3":7688,"PHASE4":7706,"NA":7728},{"trials":7675,"activeCount":100},[],{"trials":7677,"activeCount":100},[],{"trials":7679,"activeCount":100},[7680],{"nctId":7681,"briefTitle":7682,"status":443,"phases":7683,"primaryCompletion":7684,"completion":2917,"start":3212,"enrollment":1819,"conditions":7685,"interventions":7687},"NCT04403321","Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients",[89],"2022-07-30",[22,7686],"Drug Effect",[7672],{"trials":7689,"activeCount":100},[7690,7698],{"nctId":7691,"briefTitle":7692,"status":108,"phases":7693,"primaryCompletion":2381,"completion":2544,"start":7694,"enrollment":597,"conditions":7695,"interventions":7697},"NCT05678335","Tacrolimus for Thrombocytopenia in SS",[89,90],"2023-02",[7696],"Sjogren Syndrome With Other Organ Involvement",[3620,7672],{"nctId":7699,"briefTitle":7700,"status":108,"phases":7701,"primaryCompletion":7702,"completion":527,"start":7694,"enrollment":3224,"conditions":7703,"interventions":7704},"NCT05694130","Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS",[89,90],"2024-09",[7696],[7705,7672],"Prednisolone",{"trials":7707,"activeCount":100},[7708,7719],{"nctId":7709,"briefTitle":7710,"status":108,"phases":7711,"primaryCompletion":7712,"completion":7713,"start":7714,"enrollment":957,"conditions":7715,"interventions":7717},"NCT03540472","Tacrolimus Treatment for Refractory PRCA",[91],"2018-12-10","2020-06-10","2018-06-10",[7716],"Pure Red Cell Aplasia",[7718],"tacrolimus",{"nctId":7720,"briefTitle":7721,"status":108,"phases":7722,"primaryCompletion":7723,"completion":1412,"start":7724,"enrollment":1206,"conditions":7725,"interventions":7727},"NCT03918265","Tacrolimus Treatment for Refractory Autoimmune Cytopenia",[91],"2020-08-10","2019-05-04",[7255,7716,7726],"Evans Syndrome",[7672],{"trials":7729,"activeCount":100},[],{"intervention":534,"totalTrials":184,"cells":7731},{"EARLY_PHASE1":7732,"PHASE1":7734,"PHASE2":7736,"PHASE3":7746,"PHASE4":7748,"NA":7762},{"trials":7733,"activeCount":100},[],{"trials":7735,"activeCount":100},[],{"trials":7737,"activeCount":100},[7738],{"nctId":7739,"briefTitle":7740,"status":108,"phases":7741,"primaryCompletion":278,"completion":1921,"start":7742,"enrollment":957,"conditions":7743,"interventions":7744},"NCT06004752","Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly",[89],"2023-08-17",[22],[534,7745],"Avatrombopag",{"trials":7747,"activeCount":100},[],{"trials":7749,"activeCount":100},[7750,7758],{"nctId":7751,"briefTitle":7752,"status":443,"phases":7753,"primaryCompletion":5965,"completion":7138,"start":7754,"enrollment":1911,"conditions":7755,"interventions":7756},"NCT05996393","CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly",[91],"2023-09-15",[22],[534,7745,7757],"Anti-Human Thymocyte Immunoglobulin, Rabbit",{"nctId":524,"briefTitle":525,"status":108,"phases":7759,"primaryCompletion":527,"completion":528,"start":529,"enrollment":530,"conditions":7760,"interventions":7761},[91],[532],[503,534],{"trials":7763,"activeCount":100},[],{"intervention":7745,"totalTrials":184,"cells":7765},{"EARLY_PHASE1":7766,"PHASE1":7768,"PHASE2":7770,"PHASE3":7784,"PHASE4":7786,"NA":7792},{"trials":7767,"activeCount":100},[],{"trials":7769,"activeCount":100},[],{"trials":7771,"activeCount":100},[7772,7776],{"nctId":7739,"briefTitle":7740,"status":108,"phases":7773,"primaryCompletion":278,"completion":1921,"start":7742,"enrollment":957,"conditions":7774,"interventions":7775},[89],[22],[534,7745],{"nctId":7777,"briefTitle":7778,"status":108,"phases":7779,"primaryCompletion":7780,"completion":7780,"start":7781,"enrollment":957,"conditions":7782,"interventions":7783},"NCT04896528","Efficacy and Safety of Avatrombopag in Cancer Patients With Thrombocytopenia",[89],"2021-12-31","2021-06-06",[844,7745],[7745],{"trials":7785,"activeCount":100},[],{"trials":7787,"activeCount":100},[7788],{"nctId":7751,"briefTitle":7752,"status":443,"phases":7789,"primaryCompletion":5965,"completion":7138,"start":7754,"enrollment":1911,"conditions":7790,"interventions":7791},[91],[22],[534,7745,7757],{"trials":7793,"activeCount":100},[],{"intervention":3216,"totalTrials":372,"cells":7795},{"EARLY_PHASE1":7796,"PHASE1":7798,"PHASE2":7800,"PHASE3":7802,"PHASE4":7804,"NA":7818},{"trials":7797,"activeCount":100},[],{"trials":7799,"activeCount":100},[],{"trials":7801,"activeCount":100},[],{"trials":7803,"activeCount":100},[],{"trials":7805,"activeCount":100},[7806,7810],{"nctId":3208,"briefTitle":3209,"status":108,"phases":7807,"primaryCompletion":3211,"completion":3211,"start":3212,"enrollment":127,"conditions":7808,"interventions":7809},[91],[3214],[3181,3216],{"nctId":7811,"briefTitle":7812,"status":108,"phases":7813,"primaryCompletion":3211,"completion":3211,"start":7814,"enrollment":127,"conditions":7815,"interventions":7816},"NCT04762810","A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis",[91],"2020-01-03",[3214],[7817,3216],"Cyclophosphamide and glucocorticoids",{"trials":7819,"activeCount":100},[],{"intervention":7821,"totalTrials":372,"cells":7822},"Melatonin",{"EARLY_PHASE1":7823,"PHASE1":7825,"PHASE2":7827,"PHASE3":7829,"PHASE4":7831,"NA":7851},{"trials":7824,"activeCount":100},[],{"trials":7826,"activeCount":100},[],{"trials":7828,"activeCount":100},[],{"trials":7830,"activeCount":100},[],{"trials":7832,"activeCount":100},[7833,7843],{"nctId":7834,"briefTitle":7835,"status":443,"phases":7836,"primaryCompletion":7837,"completion":7838,"start":7839,"enrollment":2353,"conditions":7840,"interventions":7842},"NCT03115034","Melatonin in Patients Under Carotid Endarterectomy",[91],"2017-06-01","2017-11-01","2016-06-01",[7841],"Carotid Stenosis",[7821],{"nctId":7844,"briefTitle":7845,"status":108,"phases":7846,"primaryCompletion":7847,"completion":7847,"start":7848,"enrollment":2353,"conditions":7849,"interventions":7850},"NCT03419767","Insulin Resistance in Patients After Carotid Revascularization",[91],"2018-06-01","2017-08-01",[7841],[7821],{"trials":7852,"activeCount":100},[],{"intervention":7854,"totalTrials":372,"cells":7855},"Telitacicept",{"EARLY_PHASE1":7856,"PHASE1":7858,"PHASE2":7860,"PHASE3":7869,"PHASE4":7871,"NA":7880},{"trials":7857,"activeCount":100},[],{"trials":7859,"activeCount":100},[],{"trials":7861,"activeCount":100},[7862],{"nctId":7863,"briefTitle":7864,"status":309,"phases":7865,"primaryCompletion":193,"completion":2588,"start":7664,"enrollment":142,"conditions":7866,"interventions":7868},"NCT05078710","Telitacicept in Primary APS Patients",[89],[7867],"Anti Phospholipid Syndrome",[7854],{"trials":7870,"activeCount":100},[],{"trials":7872,"activeCount":100},[7873],{"nctId":7874,"briefTitle":7875,"status":108,"phases":7876,"primaryCompletion":5722,"completion":704,"start":3193,"enrollment":7645,"conditions":7877,"interventions":7878},"NCT05899907","Efficacy and Safety of Telitacicept in Early SLE",[91],[760],[7854,7879],"Standard of Care",{"trials":7881,"activeCount":100},[],{"intervention":7883,"totalTrials":372,"cells":7884},"Dapagliflozin",{"EARLY_PHASE1":7885,"PHASE1":7887,"PHASE2":7889,"PHASE3":7891,"PHASE4":7893,"NA":7920},{"trials":7886,"activeCount":100},[],{"trials":7888,"activeCount":100},[],{"trials":7890,"activeCount":100},[],{"trials":7892,"activeCount":100},[],{"trials":7894,"activeCount":100},[7895,7906],{"nctId":7896,"briefTitle":7897,"status":108,"phases":7898,"primaryCompletion":7899,"completion":7899,"start":7900,"enrollment":127,"conditions":7901,"interventions":7903},"NCT04014192","Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus",[91],"2020-07-31","2019-09-01",[7902],"Type 2 Diabetes Mellitus",[7883,7904,7905],"Empagliflozin","Canagliflozin",{"nctId":7907,"briefTitle":7908,"status":108,"phases":7909,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":7645,"conditions":7912,"interventions":7914},"NCT04287387","Response of Gut Microbiota in Type 2 Diabetes to Hypoglycemic Agents",[91],"2021-03-02","2020-03-02",[7913],"Type2 Diabetes Mellitus",[7915,7916,7917,7883,7918,7919],"Glucophage 500Mg","Acarbose","Sitagliptin","Pioglitazone","Glimepiride",{"trials":7921,"activeCount":100},[],{"intervention":7923,"totalTrials":372,"cells":7924},"Parecoxib sodium",{"EARLY_PHASE1":7925,"PHASE1":7927,"PHASE2":7929,"PHASE3":7931,"PHASE4":7933,"NA":7955},{"trials":7926,"activeCount":100},[],{"trials":7928,"activeCount":100},[],{"trials":7930,"activeCount":100},[],{"trials":7932,"activeCount":100},[],{"trials":7934,"activeCount":100},[7935,7945],{"nctId":7936,"briefTitle":7937,"status":443,"phases":7938,"primaryCompletion":7939,"completion":7939,"start":7940,"enrollment":4579,"conditions":7941,"interventions":7943},"NCT02272660","Parecoxib for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty",[91],"2015-08","2014-10",[7942],"Pain, Postoperative",[7923,7944],"Normal saline",{"nctId":7946,"briefTitle":7947,"status":108,"phases":7948,"primaryCompletion":7939,"start":7949,"enrollment":811,"conditions":7950,"interventions":7953},"NCT02204878","Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy",[91],"2014-07",[7951,7952],"Hepatic Hemangioma Located in the Right Liver","Laparotomy Surgery",[7954],"Parecoxib Sodium",{"trials":7956,"activeCount":100},[],{"intervention":762,"totalTrials":372,"cells":7958},{"EARLY_PHASE1":7959,"PHASE1":7961,"PHASE2":7963,"PHASE3":7965,"PHASE4":7967,"NA":7977},{"trials":7960,"activeCount":100},[],{"trials":7962,"activeCount":100},[],{"trials":7964,"activeCount":100},[],{"trials":7966,"activeCount":100},[],{"trials":7968,"activeCount":100},[7969,7973],{"nctId":753,"briefTitle":754,"status":443,"phases":7970,"primaryCompletion":756,"completion":756,"start":757,"enrollment":758,"conditions":7971,"interventions":7972},[91],[760],[339,762],{"nctId":7874,"briefTitle":7875,"status":108,"phases":7974,"primaryCompletion":5722,"completion":704,"start":3193,"enrollment":7645,"conditions":7975,"interventions":7976},[91],[760],[7854,7879],{"trials":7978,"activeCount":100},[],{"intervention":7980,"totalTrials":372,"cells":7981},"Xiangshao granules",{"EARLY_PHASE1":7982,"PHASE1":7984,"PHASE2":7986,"PHASE3":7988,"PHASE4":7990,"NA":8012},{"trials":7983,"activeCount":100},[],{"trials":7985,"activeCount":100},[],{"trials":7987,"activeCount":100},[],{"trials":7989,"activeCount":100},[],{"trials":7991,"activeCount":100},[7992,8002],{"nctId":7993,"briefTitle":7994,"status":108,"phases":7995,"primaryCompletion":3666,"completion":3862,"start":124,"enrollment":7645,"conditions":7996,"interventions":7999},"NCT06117969","the Effects of Different Therapy Regimens on Menopausal Sleep Disorders",[91],[7997,7998],"Menopause","Sleep Disorder",[8000,7980,8001],"Tibolone","Tibolone plus Xiangshao granules",{"nctId":8003,"briefTitle":8004,"status":108,"phases":8005,"primaryCompletion":809,"completion":2543,"start":8006,"enrollment":9,"conditions":8007,"interventions":8009},"NCT05003336","Effects of Xiangshao Granules on Anxiety in Menopausal Women.",[91],"2021-12-23",[8008,7997],"Anxiety",[8010,8011],"Xiangshao Granules","Xiangshao Granules Placebo",{"trials":8013,"activeCount":100},[],{"intervention":116,"totalTrials":372,"cells":8015},{"EARLY_PHASE1":8016,"PHASE1":8018,"PHASE2":8020,"PHASE3":8026,"PHASE4":8028,"NA":8039},{"trials":8017,"activeCount":100},[],{"trials":8019,"activeCount":100},[],{"trials":8021,"activeCount":100},[8022],{"nctId":106,"briefTitle":107,"status":108,"phases":8023,"primaryCompletion":110,"completion":111,"start":112,"enrollment":113,"conditions":8024,"interventions":8025},[89],[25,115,116,117,118],[116,95],{"trials":8027,"activeCount":100},[],{"trials":8029,"activeCount":100},[8030],{"nctId":8031,"briefTitle":8032,"status":108,"phases":8033,"primaryCompletion":8034,"completion":2392,"start":8035,"enrollment":1206,"conditions":8036,"interventions":8037},"NCT04029272","Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight\u002FObese PCOS Patients",[91],"2020-02-28","2019-07-20",[1235],[116,8038],"Exenatide 2 MG",{"trials":8040,"activeCount":100},[],{"intervention":8042,"totalTrials":372,"cells":8043},"Propofol",{"EARLY_PHASE1":8044,"PHASE1":8046,"PHASE2":8048,"PHASE3":8050,"PHASE4":8062,"NA":8076},{"trials":8045,"activeCount":100},[],{"trials":8047,"activeCount":100},[],{"trials":8049,"activeCount":100},[],{"trials":8051,"activeCount":100},[8052],{"nctId":8053,"briefTitle":8054,"status":108,"phases":8055,"primaryCompletion":2681,"completion":3193,"start":757,"enrollment":8056,"conditions":8057,"interventions":8060},"NCT04947345","The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients",[90],84,[8058,8059],"Analgesia","Postoperative Pain",[8061,8042],"Remimazolam Besylate",{"trials":8063,"activeCount":100},[8064],{"nctId":8065,"briefTitle":8066,"status":443,"phases":8067,"primaryCompletion":8068,"completion":8069,"start":8070,"enrollment":8071,"conditions":8072,"interventions":8073},"NCT05822817","Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery",[91],"2024-04-29","2024-08-14","2023-05-03",252,[5691],[8074,8075],"sevoflurane","propofol",{"trials":8077,"activeCount":100},[],{"intervention":1951,"totalTrials":372,"cells":8079},{"EARLY_PHASE1":8080,"PHASE1":8082,"PHASE2":8084,"PHASE3":8094,"PHASE4":8096,"NA":8102},{"trials":8081,"activeCount":100},[],{"trials":8083,"activeCount":100},[],{"trials":8085,"activeCount":100},[8086],{"nctId":8087,"briefTitle":8088,"status":309,"phases":8089,"primaryCompletion":6029,"completion":6029,"start":8090,"enrollment":404,"conditions":8091,"interventions":8093},"NCT05010460","Study of Roxadustat for Reducing the Incidence of Acute Kidney Injury After Coronary Artery Bypass Grafting",[89],"2021-09-30",[8092],"Coronary Artery Bypass",[1951],{"trials":8095,"activeCount":100},[],{"trials":8097,"activeCount":100},[8098],{"nctId":1945,"briefTitle":1946,"status":108,"phases":8099,"primaryCompletion":278,"completion":1921,"start":529,"enrollment":1948,"conditions":8100,"interventions":8101},[91],[1924],[1951,1656],{"trials":8103,"activeCount":100},[],{"intervention":8105,"totalTrials":147,"cells":8106},"non-smoker oral melatonin",{"EARLY_PHASE1":8107,"PHASE1":8109,"PHASE2":8111,"PHASE3":8113,"PHASE4":8115,"NA":8129},{"trials":8108,"activeCount":100},[],{"trials":8110,"activeCount":100},[],{"trials":8112,"activeCount":100},[],{"trials":8114,"activeCount":100},[],{"trials":8116,"activeCount":100},[8117],{"nctId":8118,"briefTitle":8119,"status":443,"phases":8120,"primaryCompletion":8121,"completion":8122,"start":8123,"enrollment":3195,"conditions":8124,"interventions":8127},"NCT02591238","Melatonin in Smoke-induced Vascular Injury",[91],"2015-07","2015-10","2015-06",[8125,8126],"Smoking","Vascular System Injuries",[8105,8128],"smoker oral melatonin",{"trials":8130,"activeCount":100},[],{"intervention":8128,"totalTrials":147,"cells":8132},{"EARLY_PHASE1":8133,"PHASE1":8135,"PHASE2":8137,"PHASE3":8139,"PHASE4":8141,"NA":8147},{"trials":8134,"activeCount":100},[],{"trials":8136,"activeCount":100},[],{"trials":8138,"activeCount":100},[],{"trials":8140,"activeCount":100},[],{"trials":8142,"activeCount":100},[8143],{"nctId":8118,"briefTitle":8119,"status":443,"phases":8144,"primaryCompletion":8121,"completion":8122,"start":8123,"enrollment":3195,"conditions":8145,"interventions":8146},[91],[8125,8126],[8105,8128],{"trials":8148,"activeCount":100},[],{"intervention":8150,"totalTrials":147,"cells":8151},"CsA+ATG+Herombopag",{"EARLY_PHASE1":8152,"PHASE1":8154,"PHASE2":8156,"PHASE3":8158,"PHASE4":8160,"NA":8173},{"trials":8153,"activeCount":100},[],{"trials":8155,"activeCount":100},[],{"trials":8157,"activeCount":100},[],{"trials":8159,"activeCount":100},[],{"trials":8161,"activeCount":100},[8162],{"nctId":8163,"briefTitle":8164,"status":108,"phases":8165,"primaryCompletion":5964,"completion":8166,"start":8167,"enrollment":381,"conditions":8168,"interventions":8171},"NCT06009965","Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System",[91],"2025-01-31","2023-01-20",[22,8169,8170],"CSA","Drug Therapy",[8150,8172],"CsA+Herombopag",{"trials":8174,"activeCount":100},[],{"intervention":8172,"totalTrials":147,"cells":8176},{"EARLY_PHASE1":8177,"PHASE1":8179,"PHASE2":8181,"PHASE3":8183,"PHASE4":8185,"NA":8191},{"trials":8178,"activeCount":100},[],{"trials":8180,"activeCount":100},[],{"trials":8182,"activeCount":100},[],{"trials":8184,"activeCount":100},[],{"trials":8186,"activeCount":100},[8187],{"nctId":8163,"briefTitle":8164,"status":108,"phases":8188,"primaryCompletion":5964,"completion":8166,"start":8167,"enrollment":381,"conditions":8189,"interventions":8190},[91],[22,8169,8170],[8150,8172],{"trials":8192,"activeCount":100},[],{"intervention":8194,"totalTrials":147,"cells":8195},"alendronate sodium vitamin D3",{"EARLY_PHASE1":8196,"PHASE1":8198,"PHASE2":8200,"PHASE3":8202,"PHASE4":8204,"NA":8215},{"trials":8197,"activeCount":100},[],{"trials":8199,"activeCount":100},[],{"trials":8201,"activeCount":100},[],{"trials":8203,"activeCount":100},[],{"trials":8205,"activeCount":100},[8206],{"nctId":8207,"briefTitle":8208,"status":108,"phases":8209,"primaryCompletion":3327,"completion":8210,"start":8211,"enrollment":2353,"conditions":8212,"interventions":8214},"NCT04739592","A Study of Alendronate Sodium Vitamin D3 Tablets on Knee Osteoarthritis",[91],"2024-07","2021-07-07",[8213],"Knee Osteoarthritis",[8194],{"trials":8216,"activeCount":100},[],{"intervention":7757,"totalTrials":147,"cells":8218},{"EARLY_PHASE1":8219,"PHASE1":8221,"PHASE2":8223,"PHASE3":8225,"PHASE4":8227,"NA":8233},{"trials":8220,"activeCount":100},[],{"trials":8222,"activeCount":100},[],{"trials":8224,"activeCount":100},[],{"trials":8226,"activeCount":100},[],{"trials":8228,"activeCount":100},[8229],{"nctId":7751,"briefTitle":7752,"status":443,"phases":8230,"primaryCompletion":5965,"completion":7138,"start":7754,"enrollment":1911,"conditions":8231,"interventions":8232},[91],[22],[534,7745,7757],{"trials":8234,"activeCount":100},[],{"intervention":8236,"totalTrials":147,"cells":8237},"Calcitriol",{"EARLY_PHASE1":8238,"PHASE1":8240,"PHASE2":8242,"PHASE3":8244,"PHASE4":8246,"NA":8256},{"trials":8239,"activeCount":100},[],{"trials":8241,"activeCount":100},[],{"trials":8243,"activeCount":100},[],{"trials":8245,"activeCount":100},[],{"trials":8247,"activeCount":100},[8248],{"nctId":8249,"briefTitle":8250,"status":108,"phases":8251,"primaryCompletion":7780,"completion":1858,"start":8252,"enrollment":811,"conditions":8253,"interventions":8255},"NCT03820518","Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia",[91],"2017-01-01",[8254],"X-linked Hypophosphatemia",[8236],{"trials":8257,"activeCount":100},[],{"intervention":8259,"totalTrials":147,"cells":8260},"Sr-89",{"EARLY_PHASE1":8261,"PHASE1":8263,"PHASE2":8265,"PHASE3":8267,"PHASE4":8269,"NA":8282},{"trials":8262,"activeCount":100},[],{"trials":8264,"activeCount":100},[],{"trials":8266,"activeCount":100},[],{"trials":8268,"activeCount":100},[],{"trials":8270,"activeCount":100},[8271],{"nctId":8272,"briefTitle":8273,"status":108,"phases":8274,"primaryCompletion":8275,"completion":8276,"start":8277,"enrollment":142,"conditions":8278,"interventions":8281},"NCT05466812","Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases",[91],"2024-07-13","2025-07-13","2022-07-13",[8279,8280],"Thyroid Neoplasm Follicular","Bone Metastases",[8259],{"trials":8283,"activeCount":100},[],{"intervention":8285,"totalTrials":147,"cells":8286},"Alendronate",{"EARLY_PHASE1":8287,"PHASE1":8289,"PHASE2":8291,"PHASE3":8293,"PHASE4":8295,"NA":8308},{"trials":8288,"activeCount":100},[],{"trials":8290,"activeCount":100},[],{"trials":8292,"activeCount":100},[],{"trials":8294,"activeCount":100},[],{"trials":8296,"activeCount":100},[8297],{"nctId":8298,"briefTitle":8299,"status":443,"phases":8300,"primaryCompletion":8301,"completion":8302,"start":8303,"enrollment":8304,"conditions":8305,"interventions":8307},"NCT02303873","Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta",[91],"2011-07","2014-08","2007-03",99,[8306],"Osteogenesis Imperfecta",[8285],{"trials":8309,"activeCount":100},[],{"intervention":8311,"totalTrials":147,"cells":8312},"Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live",{"EARLY_PHASE1":8313,"PHASE1":8315,"PHASE2":8317,"PHASE3":8319,"PHASE4":8321,"NA":8332},{"trials":8314,"activeCount":100},[],{"trials":8316,"activeCount":100},[],{"trials":8318,"activeCount":100},[],{"trials":8320,"activeCount":100},[],{"trials":8322,"activeCount":100},[8323],{"nctId":8324,"briefTitle":8325,"status":108,"phases":8326,"primaryCompletion":2917,"completion":2917,"start":8327,"enrollment":167,"conditions":8328,"interventions":8330},"NCT04982380","Efficacy and Safety of Bifidobacterium Quadruple Live Tablets in Patients With T2DM and Constipation",[91],"2021-07-31",[8329],"Type 2 Diabetes Mellitus With Complication",[8311,8331],"Siliankang simulating",{"trials":8333,"activeCount":100},[],{"intervention":8331,"totalTrials":147,"cells":8335},{"EARLY_PHASE1":8336,"PHASE1":8338,"PHASE2":8340,"PHASE3":8342,"PHASE4":8344,"NA":8350},{"trials":8337,"activeCount":100},[],{"trials":8339,"activeCount":100},[],{"trials":8341,"activeCount":100},[],{"trials":8343,"activeCount":100},[],{"trials":8345,"activeCount":100},[8346],{"nctId":8324,"briefTitle":8325,"status":108,"phases":8347,"primaryCompletion":2917,"completion":2917,"start":8327,"enrollment":167,"conditions":8348,"interventions":8349},[91],[8329],[8311,8331],{"trials":8351,"activeCount":100},[],{"intervention":8353,"totalTrials":147,"cells":8354},"estradiol valerate",{"EARLY_PHASE1":8355,"PHASE1":8357,"PHASE2":8359,"PHASE3":8361,"PHASE4":8363,"NA":8375},{"trials":8356,"activeCount":100},[],{"trials":8358,"activeCount":100},[],{"trials":8360,"activeCount":100},[],{"trials":8362,"activeCount":100},[],{"trials":8364,"activeCount":100},[8365],{"nctId":8366,"briefTitle":8367,"status":443,"phases":8368,"primaryCompletion":8369,"completion":8370,"start":8371,"enrollment":8372,"conditions":8373,"interventions":8374},"NCT00860964","A Study of Prevention and Treatment of Postmenopausal Osteoporosis in Chinese Women",[91],"2003-02","2006-12","1998-02",221,[7432],[8353],{"trials":8376,"activeCount":100},[],{"intervention":7904,"totalTrials":147,"cells":8378},{"EARLY_PHASE1":8379,"PHASE1":8381,"PHASE2":8383,"PHASE3":8385,"PHASE4":8387,"NA":8393},{"trials":8380,"activeCount":100},[],{"trials":8382,"activeCount":100},[],{"trials":8384,"activeCount":100},[],{"trials":8386,"activeCount":100},[],{"trials":8388,"activeCount":100},[8389],{"nctId":7896,"briefTitle":7897,"status":108,"phases":8390,"primaryCompletion":7899,"completion":7899,"start":7900,"enrollment":127,"conditions":8391,"interventions":8392},[91],[7902],[7883,7904,7905],{"trials":8394,"activeCount":100},[],{"intervention":7905,"totalTrials":147,"cells":8396},{"EARLY_PHASE1":8397,"PHASE1":8399,"PHASE2":8401,"PHASE3":8403,"PHASE4":8405,"NA":8411},{"trials":8398,"activeCount":100},[],{"trials":8400,"activeCount":100},[],{"trials":8402,"activeCount":100},[],{"trials":8404,"activeCount":100},[],{"trials":8406,"activeCount":100},[8407],{"nctId":7896,"briefTitle":7897,"status":108,"phases":8408,"primaryCompletion":7899,"completion":7899,"start":7900,"enrollment":127,"conditions":8409,"interventions":8410},[91],[7902],[7883,7904,7905],{"trials":8412,"activeCount":100},[],{"intervention":8414,"totalTrials":147,"cells":8415},"Vaginal Cream with Applicator [Dose Form]",{"EARLY_PHASE1":8416,"PHASE1":8418,"PHASE2":8420,"PHASE3":8422,"PHASE4":8424,"NA":8434},{"trials":8417,"activeCount":100},[],{"trials":8419,"activeCount":100},[],{"trials":8421,"activeCount":100},[],{"trials":8423,"activeCount":100},[],{"trials":8425,"activeCount":100},[8426],{"nctId":8427,"briefTitle":8428,"status":108,"phases":8429,"primaryCompletion":1735,"completion":3193,"start":8430,"enrollment":893,"conditions":8431,"interventions":8433},"NCT04393194","The Effect of Intra-vaginal Conjugated Estrogen Cream on Ring Pessary Use for Pelvic Organ Prolapse",[91],"2020-05-24",[8432],"Pelvic Floor Prolapse",[8414],{"trials":8435,"activeCount":100},[],{"intervention":8437,"totalTrials":147,"cells":8438},"Toremifene; Anastrozole",{"EARLY_PHASE1":8439,"PHASE1":8441,"PHASE2":8443,"PHASE3":8445,"PHASE4":8447,"NA":8459},{"trials":8440,"activeCount":100},[],{"trials":8442,"activeCount":100},[],{"trials":8444,"activeCount":100},[],{"trials":8446,"activeCount":100},[],{"trials":8448,"activeCount":100},[8449],{"nctId":8450,"briefTitle":8451,"status":108,"phases":8452,"primaryCompletion":8453,"start":8454,"enrollment":8455,"conditions":8456,"interventions":8458},"NCT02089854","Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer",[91],"2019-04","2014-11",800,[8457],"Female Breast Cancer",[8437],{"trials":8460,"activeCount":100},[],{"intervention":8462,"totalTrials":147,"cells":8463},"methylprednisolone",{"EARLY_PHASE1":8464,"PHASE1":8466,"PHASE2":8468,"PHASE3":8470,"PHASE4":8472,"NA":8484},{"trials":8465,"activeCount":100},[],{"trials":8467,"activeCount":100},[],{"trials":8469,"activeCount":100},[],{"trials":8471,"activeCount":100},[],{"trials":8473,"activeCount":100},[8474],{"nctId":8475,"briefTitle":8476,"status":108,"phases":8477,"primaryCompletion":8478,"completion":8478,"start":8479,"enrollment":8480,"conditions":8481,"interventions":8483},"NCT02552342","Corticosteroid Therapy for Severe Community-Acquired Pneumonia",[91],"2017-05","2015-05",610,[8482],"Community Acquired Pneumonia",[8462,7944],{"trials":8485,"activeCount":100},[],{"intervention":8487,"totalTrials":147,"cells":8488},"Zidovudine",{"EARLY_PHASE1":8489,"PHASE1":8491,"PHASE2":8493,"PHASE3":8495,"PHASE4":8497,"NA":8509},{"trials":8490,"activeCount":100},[],{"trials":8492,"activeCount":100},[],{"trials":8494,"activeCount":100},[],{"trials":8496,"activeCount":100},[],{"trials":8498,"activeCount":100},[8499],{"nctId":8500,"briefTitle":8501,"status":443,"phases":8502,"primaryCompletion":8503,"start":8504,"enrollment":2110,"conditions":8505,"interventions":8507},"NCT00618176","Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort",[91],"2006-09","2005-01",[8506],"HIV Infections",[8487,8508,8487],"Stavudine",{"trials":8510,"activeCount":100},[],{"intervention":8508,"totalTrials":147,"cells":8512},{"EARLY_PHASE1":8513,"PHASE1":8515,"PHASE2":8517,"PHASE3":8519,"PHASE4":8521,"NA":8527},{"trials":8514,"activeCount":100},[],{"trials":8516,"activeCount":100},[],{"trials":8518,"activeCount":100},[],{"trials":8520,"activeCount":100},[],{"trials":8522,"activeCount":100},[8523],{"nctId":8500,"briefTitle":8501,"status":443,"phases":8524,"primaryCompletion":8503,"start":8504,"enrollment":2110,"conditions":8525,"interventions":8526},[91],[8506],[8487,8508,8487],{"trials":8528,"activeCount":100},[],{"intervention":8530,"totalTrials":147,"cells":8531},"99Tc methylene diphosphonate",{"EARLY_PHASE1":8532,"PHASE1":8534,"PHASE2":8536,"PHASE3":8538,"PHASE4":8540,"NA":8549},{"trials":8533,"activeCount":100},[],{"trials":8535,"activeCount":100},[],{"trials":8537,"activeCount":100},[],{"trials":8539,"activeCount":100},[],{"trials":8541,"activeCount":100},[8542],{"nctId":8543,"briefTitle":8544,"status":443,"phases":8545,"primaryCompletion":7664,"completion":7664,"start":1737,"enrollment":142,"conditions":8546,"interventions":8548},"NCT05000086","A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis",[91],[8547],"Arthritis, Psoriatic",[8530],{"trials":8550,"activeCount":100},[],{"intervention":8552,"totalTrials":147,"cells":8553},"Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone",{"EARLY_PHASE1":8554,"PHASE1":8556,"PHASE2":8558,"PHASE3":8560,"PHASE4":8562,"NA":8572},{"trials":8555,"activeCount":100},[],{"trials":8557,"activeCount":100},[],{"trials":8559,"activeCount":100},[],{"trials":8561,"activeCount":100},[],{"trials":8563,"activeCount":100},[8564],{"nctId":8565,"briefTitle":8566,"status":108,"phases":8567,"primaryCompletion":8568,"completion":8568,"start":8569,"enrollment":2353,"conditions":8570,"interventions":8571},"NCT04989140","Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide",[91],"2024-07-26","2021-07-26",[196],[8552],{"trials":8573,"activeCount":100},[],{"intervention":8575,"totalTrials":147,"cells":8576},"Fibrinogen Concentrate Human",{"EARLY_PHASE1":8577,"PHASE1":8579,"PHASE2":8581,"PHASE3":8583,"PHASE4":8585,"NA":8597},{"trials":8578,"activeCount":100},[],{"trials":8580,"activeCount":100},[],{"trials":8582,"activeCount":100},[],{"trials":8584,"activeCount":100},[],{"trials":8586,"activeCount":100},[8587],{"nctId":8588,"briefTitle":8589,"status":443,"phases":8590,"primaryCompletion":8591,"completion":8591,"start":8592,"enrollment":8593,"conditions":8594,"interventions":8596},"NCT03183479","The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery",[91],"2019-08-31","2017-06-14",102,[1370,8595,32],"Bleeding",[8575,7944],{"trials":8598,"activeCount":100},[],{"intervention":8600,"totalTrials":147,"cells":8601},"mirabegron",{"EARLY_PHASE1":8602,"PHASE1":8604,"PHASE2":8606,"PHASE3":8608,"PHASE4":8610,"NA":8621},{"trials":8603,"activeCount":100},[],{"trials":8605,"activeCount":100},[],{"trials":8607,"activeCount":100},[],{"trials":8609,"activeCount":100},[],{"trials":8611,"activeCount":100},[8612],{"nctId":8613,"briefTitle":8614,"status":108,"phases":8615,"primaryCompletion":8616,"completion":8616,"start":8617,"enrollment":2196,"conditions":8618,"interventions":8620},"NCT05452434","Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study",[91],"2023-07-15","2022-07-15",[8619],"Overactive Bladder",[8600],{"trials":8622,"activeCount":100},[],{"intervention":8624,"totalTrials":147,"cells":8625},"DING KUN DAN",{"EARLY_PHASE1":8626,"PHASE1":8628,"PHASE2":8630,"PHASE3":8632,"PHASE4":8634,"NA":8649},{"trials":8627,"activeCount":100},[],{"trials":8629,"activeCount":100},[],{"trials":8631,"activeCount":100},[],{"trials":8633,"activeCount":100},[],{"trials":8635,"activeCount":100},[8636],{"nctId":8637,"briefTitle":8638,"status":108,"phases":8639,"primaryCompletion":8640,"completion":8640,"start":8641,"enrollment":8642,"conditions":8643,"interventions":8646},"NCT03953716","Traditional Chinese Medicine, Western Medicine and Low-level Light Therapy（LLLT） for Primary Dysmenorrhea（PD）",[91],"2020-06-30","2019-06-22",480,[8644,343,8645],"Primary Dysmenorrhea","Light",[8624,8647,8648],"Simulated drug of DING KUN DAN","Marvelon",{"trials":8650,"activeCount":100},[],{"intervention":8647,"totalTrials":147,"cells":8652},{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8657,"PHASE3":8659,"PHASE4":8661,"NA":8667},{"trials":8654,"activeCount":100},[],{"trials":8656,"activeCount":100},[],{"trials":8658,"activeCount":100},[],{"trials":8660,"activeCount":100},[],{"trials":8662,"activeCount":100},[8663],{"nctId":8637,"briefTitle":8638,"status":108,"phases":8664,"primaryCompletion":8640,"completion":8640,"start":8641,"enrollment":8642,"conditions":8665,"interventions":8666},[91],[8644,343,8645],[8624,8647,8648],{"trials":8668,"activeCount":100},[],{"intervention":8648,"totalTrials":147,"cells":8670},{"EARLY_PHASE1":8671,"PHASE1":8673,"PHASE2":8675,"PHASE3":8677,"PHASE4":8679,"NA":8685},{"trials":8672,"activeCount":100},[],{"trials":8674,"activeCount":100},[],{"trials":8676,"activeCount":100},[],{"trials":8678,"activeCount":100},[],{"trials":8680,"activeCount":100},[8681],{"nctId":8637,"briefTitle":8638,"status":108,"phases":8682,"primaryCompletion":8640,"completion":8640,"start":8641,"enrollment":8642,"conditions":8683,"interventions":8684},[91],[8644,343,8645],[8624,8647,8648],{"trials":8686,"activeCount":100},[],{"intervention":8688,"totalTrials":147,"cells":8689},"estradiol plus MPA",{"EARLY_PHASE1":8690,"PHASE1":8692,"PHASE2":8694,"PHASE3":8696,"PHASE4":8698,"NA":8712},{"trials":8691,"activeCount":100},[],{"trials":8693,"activeCount":100},[],{"trials":8695,"activeCount":100},[],{"trials":8697,"activeCount":100},[],{"trials":8699,"activeCount":100},[8700],{"nctId":8701,"briefTitle":8702,"status":108,"phases":8703,"primaryCompletion":8704,"start":8705,"enrollment":2172,"conditions":8706,"interventions":8709},"NCT01698164","Multi-centre Clinical Trial on Hormone Replacement Treatment in China",[91],"2012-10","2008-12",[8707,8708,7432,16],"Menopausal Syndrome","Cardiovascular Disease",[8688,8710,8711],"Ximingting","estradiol plus progesterone",{"trials":8713,"activeCount":100},[],{"intervention":8710,"totalTrials":147,"cells":8715},{"EARLY_PHASE1":8716,"PHASE1":8718,"PHASE2":8720,"PHASE3":8722,"PHASE4":8724,"NA":8730},{"trials":8717,"activeCount":100},[],{"trials":8719,"activeCount":100},[],{"trials":8721,"activeCount":100},[],{"trials":8723,"activeCount":100},[],{"trials":8725,"activeCount":100},[8726],{"nctId":8701,"briefTitle":8702,"status":108,"phases":8727,"primaryCompletion":8704,"start":8705,"enrollment":2172,"conditions":8728,"interventions":8729},[91],[8707,8708,7432,16],[8688,8710,8711],{"trials":8731,"activeCount":100},[],{"intervention":8711,"totalTrials":147,"cells":8733},{"EARLY_PHASE1":8734,"PHASE1":8736,"PHASE2":8738,"PHASE3":8740,"PHASE4":8742,"NA":8748},{"trials":8735,"activeCount":100},[],{"trials":8737,"activeCount":100},[],{"trials":8739,"activeCount":100},[],{"trials":8741,"activeCount":100},[],{"trials":8743,"activeCount":100},[8744],{"nctId":8701,"briefTitle":8702,"status":108,"phases":8745,"primaryCompletion":8704,"start":8705,"enrollment":2172,"conditions":8746,"interventions":8747},[91],[8707,8708,7432,16],[8688,8710,8711],{"trials":8749,"activeCount":100},[],{"intervention":8000,"totalTrials":147,"cells":8751},{"EARLY_PHASE1":8752,"PHASE1":8754,"PHASE2":8756,"PHASE3":8758,"PHASE4":8760,"NA":8766},{"trials":8753,"activeCount":100},[],{"trials":8755,"activeCount":100},[],{"trials":8757,"activeCount":100},[],{"trials":8759,"activeCount":100},[],{"trials":8761,"activeCount":100},[8762],{"nctId":7993,"briefTitle":7994,"status":108,"phases":8763,"primaryCompletion":3666,"completion":3862,"start":124,"enrollment":7645,"conditions":8764,"interventions":8765},[91],[7997,7998],[8000,7980,8001],{"trials":8767,"activeCount":100},[],{"intervention":8001,"totalTrials":147,"cells":8769},{"EARLY_PHASE1":8770,"PHASE1":8772,"PHASE2":8774,"PHASE3":8776,"PHASE4":8778,"NA":8784},{"trials":8771,"activeCount":100},[],{"trials":8773,"activeCount":100},[],{"trials":8775,"activeCount":100},[],{"trials":8777,"activeCount":100},[],{"trials":8779,"activeCount":100},[8780],{"nctId":7993,"briefTitle":7994,"status":108,"phases":8781,"primaryCompletion":3666,"completion":3862,"start":124,"enrollment":7645,"conditions":8782,"interventions":8783},[91],[7997,7998],[8000,7980,8001],{"trials":8785,"activeCount":100},[],{"intervention":8787,"totalTrials":147,"cells":8788},"first line ARV",{"EARLY_PHASE1":8789,"PHASE1":8791,"PHASE2":8793,"PHASE3":8795,"PHASE4":8797,"NA":8810},{"trials":8790,"activeCount":100},[],{"trials":8792,"activeCount":100},[],{"trials":8794,"activeCount":100},[],{"trials":8796,"activeCount":100},[],{"trials":8798,"activeCount":100},[8799],{"nctId":8800,"briefTitle":8801,"status":108,"phases":8802,"primaryCompletion":8803,"completion":6668,"start":8804,"enrollment":8805,"conditions":8806,"interventions":8808},"NCT00872417","Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV\u002FAIDS Patients",[91],"2009-12","2009-03",750,[8807,8506],"Acquired Immune Deficiency Syndrome",[8787,8809],"second line ARV therapy",{"trials":8811,"activeCount":100},[],{"intervention":8809,"totalTrials":147,"cells":8813},{"EARLY_PHASE1":8814,"PHASE1":8816,"PHASE2":8818,"PHASE3":8820,"PHASE4":8822,"NA":8828},{"trials":8815,"activeCount":100},[],{"trials":8817,"activeCount":100},[],{"trials":8819,"activeCount":100},[],{"trials":8821,"activeCount":100},[],{"trials":8823,"activeCount":100},[8824],{"nctId":8800,"briefTitle":8801,"status":108,"phases":8825,"primaryCompletion":8803,"completion":6668,"start":8804,"enrollment":8805,"conditions":8826,"interventions":8827},[91],[8807,8506],[8787,8809],{"trials":8829,"activeCount":100},[],{"intervention":8831,"totalTrials":147,"cells":8832},"Hydrocortisone Butyrate",{"EARLY_PHASE1":8833,"PHASE1":8835,"PHASE2":8837,"PHASE3":8839,"PHASE4":8841,"NA":8851},{"trials":8834,"activeCount":100},[],{"trials":8836,"activeCount":100},[],{"trials":8838,"activeCount":100},[],{"trials":8840,"activeCount":100},[],{"trials":8842,"activeCount":100},[8843],{"nctId":8844,"briefTitle":8845,"status":108,"phases":8846,"primaryCompletion":2644,"completion":8847,"start":8252,"enrollment":811,"conditions":8848,"interventions":8850},"NCT02959580","Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis",[91],"2020-09",[8849],"Granulomatous Mastitis",[8831],{"trials":8852,"activeCount":100},[],{"intervention":8854,"totalTrials":147,"cells":8855},"B\u002FF\u002FTAF",{"EARLY_PHASE1":8856,"PHASE1":8858,"PHASE2":8860,"PHASE3":8862,"PHASE4":8864,"NA":8876},{"trials":8857,"activeCount":100},[],{"trials":8859,"activeCount":100},[],{"trials":8861,"activeCount":100},[],{"trials":8863,"activeCount":100},[],{"trials":8865,"activeCount":100},[8866],{"nctId":8867,"briefTitle":8868,"status":108,"phases":8869,"primaryCompletion":8870,"completion":2749,"start":8871,"enrollment":1738,"conditions":8872,"interventions":8874},"NCT04296695","Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection",[91],"2022-12-13","2021-07-14",[8873],"HIV-1-infection",[8854,8875],"TDF\u002F3TC\u002FEFV",{"trials":8877,"activeCount":100},[],{"intervention":8875,"totalTrials":147,"cells":8879},{"EARLY_PHASE1":8880,"PHASE1":8882,"PHASE2":8884,"PHASE3":8886,"PHASE4":8888,"NA":8894},{"trials":8881,"activeCount":100},[],{"trials":8883,"activeCount":100},[],{"trials":8885,"activeCount":100},[],{"trials":8887,"activeCount":100},[],{"trials":8889,"activeCount":100},[8890],{"nctId":8867,"briefTitle":8868,"status":108,"phases":8891,"primaryCompletion":8870,"completion":2749,"start":8871,"enrollment":1738,"conditions":8892,"interventions":8893},[91],[8873],[8854,8875],{"trials":8895,"activeCount":100},[],{"intervention":8897,"totalTrials":147,"cells":8898},"Enoxaparin",{"EARLY_PHASE1":8899,"PHASE1":8901,"PHASE2":8903,"PHASE3":8905,"PHASE4":8907,"NA":8918},{"trials":8900,"activeCount":100},[],{"trials":8902,"activeCount":100},[],{"trials":8904,"activeCount":100},[],{"trials":8906,"activeCount":100},[],{"trials":8908,"activeCount":100},[8909],{"nctId":8910,"briefTitle":8911,"status":443,"phases":8912,"primaryCompletion":8913,"completion":3616,"start":8914,"enrollment":8915,"conditions":8916,"interventions":8917},"NCT03145675","Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)",[91],"2022-04-20","2017-05-12",378,[463,433],[8897,8897,8897,8897],{"trials":8919,"activeCount":100},[],{"intervention":8921,"totalTrials":147,"cells":8922},"Hydroxychloroquine Sulfate",{"EARLY_PHASE1":8923,"PHASE1":8925,"PHASE2":8927,"PHASE3":8929,"PHASE4":8931,"NA":8943},{"trials":8924,"activeCount":100},[],{"trials":8926,"activeCount":100},[],{"trials":8928,"activeCount":100},[],{"trials":8930,"activeCount":100},[],{"trials":8932,"activeCount":100},[8933],{"nctId":8934,"briefTitle":8935,"status":108,"phases":8936,"primaryCompletion":8937,"completion":8938,"start":495,"enrollment":404,"conditions":8939,"interventions":8941},"NCT02765594","Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy",[91],"2019-05","2019-06",[8940],"Primary IgA Nephropathy",[8921,8942],"Valsartan",{"trials":8944,"activeCount":100},[],{"intervention":8942,"totalTrials":147,"cells":8946},{"EARLY_PHASE1":8947,"PHASE1":8949,"PHASE2":8951,"PHASE3":8953,"PHASE4":8955,"NA":8961},{"trials":8948,"activeCount":100},[],{"trials":8950,"activeCount":100},[],{"trials":8952,"activeCount":100},[],{"trials":8954,"activeCount":100},[],{"trials":8956,"activeCount":100},[8957],{"nctId":8934,"briefTitle":8935,"status":108,"phases":8958,"primaryCompletion":8937,"completion":8938,"start":495,"enrollment":404,"conditions":8959,"interventions":8960},[91],[8940],[8921,8942],{"trials":8962,"activeCount":100},[],{"intervention":8964,"totalTrials":147,"cells":8965},"CEE 0.625 mg\u002FMP 100mg",{"EARLY_PHASE1":8966,"PHASE1":8968,"PHASE2":8970,"PHASE3":8972,"PHASE4":8974,"NA":8987},{"trials":8967,"activeCount":100},[],{"trials":8969,"activeCount":100},[],{"trials":8971,"activeCount":100},[],{"trials":8973,"activeCount":100},[],{"trials":8975,"activeCount":100},[8976],{"nctId":8977,"briefTitle":8978,"status":108,"phases":8979,"primaryCompletion":7847,"completion":8980,"start":8981,"enrollment":167,"conditions":8982,"interventions":8984},"NCT03436303","The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome",[91],"2018-12-01","2014-02-01",[8983],"Menopause Syndrome",[8964,8985,8986],"CEE 0.3 mg\u002FMP 100mg","CEE 0.625mg\u002Fdydrogesterone",{"trials":8988,"activeCount":100},[],{"intervention":8985,"totalTrials":147,"cells":8990},{"EARLY_PHASE1":8991,"PHASE1":8993,"PHASE2":8995,"PHASE3":8997,"PHASE4":8999,"NA":9005},{"trials":8992,"activeCount":100},[],{"trials":8994,"activeCount":100},[],{"trials":8996,"activeCount":100},[],{"trials":8998,"activeCount":100},[],{"trials":9000,"activeCount":100},[9001],{"nctId":8977,"briefTitle":8978,"status":108,"phases":9002,"primaryCompletion":7847,"completion":8980,"start":8981,"enrollment":167,"conditions":9003,"interventions":9004},[91],[8983],[8964,8985,8986],{"trials":9006,"activeCount":100},[],{"intervention":8986,"totalTrials":147,"cells":9008},{"EARLY_PHASE1":9009,"PHASE1":9011,"PHASE2":9013,"PHASE3":9015,"PHASE4":9017,"NA":9023},{"trials":9010,"activeCount":100},[],{"trials":9012,"activeCount":100},[],{"trials":9014,"activeCount":100},[],{"trials":9016,"activeCount":100},[],{"trials":9018,"activeCount":100},[9019],{"nctId":8977,"briefTitle":8978,"status":108,"phases":9020,"primaryCompletion":7847,"completion":8980,"start":8981,"enrollment":167,"conditions":9021,"interventions":9022},[91],[8983],[8964,8985,8986],{"trials":9024,"activeCount":100},[],{"intervention":9026,"totalTrials":147,"cells":9027},"Lusutrombopag",{"EARLY_PHASE1":9028,"PHASE1":9030,"PHASE2":9032,"PHASE3":9034,"PHASE4":9036,"NA":9046},{"trials":9029,"activeCount":100},[],{"trials":9031,"activeCount":100},[],{"trials":9033,"activeCount":100},[],{"trials":9035,"activeCount":100},[],{"trials":9037,"activeCount":100},[9038],{"nctId":9039,"briefTitle":9040,"status":108,"phases":9041,"primaryCompletion":9042,"completion":1921,"start":9043,"enrollment":127,"conditions":9044,"interventions":9045},"NCT06426043","A Prospective Study on the Treatment of Recurrent\u002FRefractory\u002FIntolerable NSAA With Lusutrombopag",[91],"2025-06","2024-06",[22],[9026],{"trials":9047,"activeCount":100},[],{"intervention":9049,"totalTrials":147,"cells":9050},"Dydrogesterone",{"EARLY_PHASE1":9051,"PHASE1":9053,"PHASE2":9055,"PHASE3":9057,"PHASE4":9059,"NA":9070},{"trials":9052,"activeCount":100},[],{"trials":9054,"activeCount":100},[],{"trials":9056,"activeCount":100},[],{"trials":9058,"activeCount":100},[],{"trials":9060,"activeCount":100},[9061],{"nctId":9062,"briefTitle":9063,"status":443,"phases":9064,"primaryCompletion":3120,"completion":9065,"start":9066,"enrollment":2353,"conditions":9067,"interventions":9069},"NCT03790215","Dydrogesterone in the Treatment of Endometrial Polyps",[91],"2019-12-31","2019-02-01",[9068],"Endometrial Polyp",[9049],{"trials":9071,"activeCount":100},[],{"intervention":3380,"totalTrials":147,"cells":9073},{"EARLY_PHASE1":9074,"PHASE1":9076,"PHASE2":9078,"PHASE3":9080,"PHASE4":9082,"NA":9088},{"trials":9075,"activeCount":100},[],{"trials":9077,"activeCount":100},[],{"trials":9079,"activeCount":100},[],{"trials":9081,"activeCount":100},[],{"trials":9083,"activeCount":100},[9084],{"nctId":3372,"briefTitle":3373,"status":443,"phases":9085,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":3377,"conditions":9086,"interventions":9087},[91],[196],[3380,282],{"trials":9089,"activeCount":100},[],{"intervention":9091,"totalTrials":147,"cells":9092},"Solifenacin Succinate",{"EARLY_PHASE1":9093,"PHASE1":9095,"PHASE2":9097,"PHASE3":9099,"PHASE4":9101,"NA":9114},{"trials":9094,"activeCount":100},[],{"trials":9096,"activeCount":100},[],{"trials":9098,"activeCount":100},[],{"trials":9100,"activeCount":100},[],{"trials":9102,"activeCount":100},[9103],{"nctId":9104,"briefTitle":9105,"status":443,"phases":9106,"primaryCompletion":9107,"completion":9107,"start":9108,"enrollment":324,"conditions":9109,"interventions":9112},"NCT01833663","Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women",[91],"2013-10","2011-10",[8619,9110,9111],"Postmenopausal Disorder","Urination Disorders",[9091,9113],"Estrogen",{"trials":9115,"activeCount":100},[],{"intervention":9113,"totalTrials":147,"cells":9117},{"EARLY_PHASE1":9118,"PHASE1":9120,"PHASE2":9122,"PHASE3":9124,"PHASE4":9126,"NA":9132},{"trials":9119,"activeCount":100},[],{"trials":9121,"activeCount":100},[],{"trials":9123,"activeCount":100},[],{"trials":9125,"activeCount":100},[],{"trials":9127,"activeCount":100},[9128],{"nctId":9104,"briefTitle":9105,"status":443,"phases":9129,"primaryCompletion":9107,"completion":9107,"start":9108,"enrollment":324,"conditions":9130,"interventions":9131},[91],[8619,9110,9111],[9091,9113],{"trials":9133,"activeCount":100},[],{"intervention":9135,"totalTrials":147,"cells":9136},"Insulin",{"EARLY_PHASE1":9137,"PHASE1":9139,"PHASE2":9141,"PHASE3":9143,"PHASE4":9145,"NA":9157},{"trials":9138,"activeCount":100},[],{"trials":9140,"activeCount":100},[],{"trials":9142,"activeCount":100},[],{"trials":9144,"activeCount":100},[],{"trials":9146,"activeCount":100},[9147],{"nctId":9148,"briefTitle":9149,"status":108,"phases":9150,"primaryCompletion":9151,"completion":9152,"start":9153,"enrollment":2574,"conditions":9154,"interventions":9156},"NCT03342807","Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis",[91],"2019-11","2020-11","2017-11",[9155,1510],"Pancreatitis, Acute",[9135],{"trials":9158,"activeCount":100},[],{"intervention":9160,"totalTrials":147,"cells":9161},"Benzathine Penicillin G",{"EARLY_PHASE1":9162,"PHASE1":9164,"PHASE2":9166,"PHASE3":9168,"PHASE4":9170,"NA":9181},{"trials":9163,"activeCount":100},[],{"trials":9165,"activeCount":100},[],{"trials":9167,"activeCount":100},[],{"trials":9169,"activeCount":100},[],{"trials":9171,"activeCount":100},[9172],{"nctId":9173,"briefTitle":9174,"status":108,"phases":9175,"primaryCompletion":9176,"completion":9176,"start":9177,"enrollment":5179,"conditions":9178,"interventions":9180},"NCT02871505","The Association Between Molecular Typing of Treponema Pallidum and Treatment Efficacy and Clinical Findings",[91],"2020-08","2016-08",[9179],"Syphilis",[9160],{"trials":9182,"activeCount":100},[],{"intervention":8038,"totalTrials":147,"cells":9184},{"EARLY_PHASE1":9185,"PHASE1":9187,"PHASE2":9189,"PHASE3":9191,"PHASE4":9193,"NA":9199},{"trials":9186,"activeCount":100},[],{"trials":9188,"activeCount":100},[],{"trials":9190,"activeCount":100},[],{"trials":9192,"activeCount":100},[],{"trials":9194,"activeCount":100},[9195],{"nctId":8031,"briefTitle":8032,"status":108,"phases":9196,"primaryCompletion":8034,"completion":2392,"start":8035,"enrollment":1206,"conditions":9197,"interventions":9198},[91],[1235],[116,8038],{"trials":9200,"activeCount":100},[],{"intervention":9202,"totalTrials":147,"cells":9203},"Somatostatin",{"EARLY_PHASE1":9204,"PHASE1":9206,"PHASE2":9208,"PHASE3":9210,"PHASE4":9212,"NA":9224},{"trials":9205,"activeCount":100},[],{"trials":9207,"activeCount":100},[],{"trials":9209,"activeCount":100},[],{"trials":9211,"activeCount":100},[],{"trials":9213,"activeCount":100},[9214],{"nctId":9215,"briefTitle":9216,"status":443,"phases":9217,"primaryCompletion":9218,"completion":9218,"start":9219,"enrollment":9220,"conditions":9221,"interventions":9223},"NCT03349424","Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy",[91],"2019-05-24","2018-06-22",205,[9222],"Pancreatic Fistula",[9202],{"trials":9225,"activeCount":100},[],{"intervention":9227,"totalTrials":147,"cells":9228},"Parecoxib and Celecoxib",{"EARLY_PHASE1":9229,"PHASE1":9231,"PHASE2":9233,"PHASE3":9235,"PHASE4":9237,"NA":9249},{"trials":9230,"activeCount":100},[],{"trials":9232,"activeCount":100},[],{"trials":9234,"activeCount":100},[],{"trials":9236,"activeCount":100},[],{"trials":9238,"activeCount":100},[9239],{"nctId":9240,"briefTitle":9241,"status":443,"phases":9242,"primaryCompletion":9243,"completion":3472,"start":9244,"enrollment":9245,"conditions":9246,"interventions":9248},"NCT02198924","Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients",[91],"2016-11","2014-12",246,[9247,6539],"Pain",[9227],{"trials":9250,"activeCount":100},[],{"intervention":2385,"totalTrials":147,"cells":9252},{"EARLY_PHASE1":9253,"PHASE1":9255,"PHASE2":9257,"PHASE3":9259,"PHASE4":9261,"NA":9267},{"trials":9254,"activeCount":100},[],{"trials":9256,"activeCount":100},[],{"trials":9258,"activeCount":100},[],{"trials":9260,"activeCount":100},[],{"trials":9262,"activeCount":100},[9263],{"nctId":2377,"briefTitle":2378,"status":108,"phases":9264,"primaryCompletion":2380,"completion":2381,"start":2382,"enrollment":2353,"conditions":9265,"interventions":9266},[91],[2368],[2385,250],{"trials":9268,"activeCount":100},[],{"intervention":9270,"totalTrials":147,"cells":9271},"benzathine penicillin",{"EARLY_PHASE1":9272,"PHASE1":9274,"PHASE2":9276,"PHASE3":9278,"PHASE4":9280,"NA":9288},{"trials":9273,"activeCount":100},[],{"trials":9275,"activeCount":100},[],{"trials":9277,"activeCount":100},[],{"trials":9279,"activeCount":100},[],{"trials":9281,"activeCount":100},[9282],{"nctId":9283,"briefTitle":9284,"status":108,"phases":9285,"primaryCompletion":8847,"completion":8847,"start":9177,"enrollment":5179,"conditions":9286,"interventions":9287},"NCT02884115","Serological Response to Retreatment of Serofast Early Syphilis Cases With Benzathine Penicillin",[91],[9179],[9270],{"trials":9289,"activeCount":100},[],{"intervention":7915,"totalTrials":147,"cells":9291},{"EARLY_PHASE1":9292,"PHASE1":9294,"PHASE2":9296,"PHASE3":9298,"PHASE4":9300,"NA":9306},{"trials":9293,"activeCount":100},[],{"trials":9295,"activeCount":100},[],{"trials":9297,"activeCount":100},[],{"trials":9299,"activeCount":100},[],{"trials":9301,"activeCount":100},[9302],{"nctId":7907,"briefTitle":7908,"status":108,"phases":9303,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":7645,"conditions":9304,"interventions":9305},[91],[7913],[7915,7916,7917,7883,7918,7919],{"trials":9307,"activeCount":100},[],{"intervention":7916,"totalTrials":147,"cells":9309},{"EARLY_PHASE1":9310,"PHASE1":9312,"PHASE2":9314,"PHASE3":9316,"PHASE4":9318,"NA":9324},{"trials":9311,"activeCount":100},[],{"trials":9313,"activeCount":100},[],{"trials":9315,"activeCount":100},[],{"trials":9317,"activeCount":100},[],{"trials":9319,"activeCount":100},[9320],{"nctId":7907,"briefTitle":7908,"status":108,"phases":9321,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":7645,"conditions":9322,"interventions":9323},[91],[7913],[7915,7916,7917,7883,7918,7919],{"trials":9325,"activeCount":100},[],{"intervention":7917,"totalTrials":147,"cells":9327},{"EARLY_PHASE1":9328,"PHASE1":9330,"PHASE2":9332,"PHASE3":9334,"PHASE4":9336,"NA":9342},{"trials":9329,"activeCount":100},[],{"trials":9331,"activeCount":100},[],{"trials":9333,"activeCount":100},[],{"trials":9335,"activeCount":100},[],{"trials":9337,"activeCount":100},[9338],{"nctId":7907,"briefTitle":7908,"status":108,"phases":9339,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":7645,"conditions":9340,"interventions":9341},[91],[7913],[7915,7916,7917,7883,7918,7919],{"trials":9343,"activeCount":100},[],{"intervention":7918,"totalTrials":147,"cells":9345},{"EARLY_PHASE1":9346,"PHASE1":9348,"PHASE2":9350,"PHASE3":9352,"PHASE4":9354,"NA":9360},{"trials":9347,"activeCount":100},[],{"trials":9349,"activeCount":100},[],{"trials":9351,"activeCount":100},[],{"trials":9353,"activeCount":100},[],{"trials":9355,"activeCount":100},[9356],{"nctId":7907,"briefTitle":7908,"status":108,"phases":9357,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":7645,"conditions":9358,"interventions":9359},[91],[7913],[7915,7916,7917,7883,7918,7919],{"trials":9361,"activeCount":100},[],{"intervention":7919,"totalTrials":147,"cells":9363},{"EARLY_PHASE1":9364,"PHASE1":9366,"PHASE2":9368,"PHASE3":9370,"PHASE4":9372,"NA":9378},{"trials":9365,"activeCount":100},[],{"trials":9367,"activeCount":100},[],{"trials":9369,"activeCount":100},[],{"trials":9371,"activeCount":100},[],{"trials":9373,"activeCount":100},[9374],{"nctId":7907,"briefTitle":7908,"status":108,"phases":9375,"primaryCompletion":7910,"completion":7910,"start":7911,"enrollment":7645,"conditions":9376,"interventions":9377},[91],[7913],[7915,7916,7917,7883,7918,7919],{"trials":9379,"activeCount":100},[],{"intervention":9381,"totalTrials":147,"cells":9382},"norepinephrine+vasopressin",{"EARLY_PHASE1":9383,"PHASE1":9385,"PHASE2":9387,"PHASE3":9389,"PHASE4":9391,"NA":9401},{"trials":9384,"activeCount":100},[],{"trials":9386,"activeCount":100},[],{"trials":9388,"activeCount":100},[],{"trials":9390,"activeCount":100},[],{"trials":9392,"activeCount":100},[9393],{"nctId":9394,"briefTitle":9395,"status":108,"phases":9396,"primaryCompletion":3147,"completion":3862,"start":2800,"enrollment":2353,"conditions":9397,"interventions":9399},"NCT05886192","The Construction and Application of Therapeutic System of Intelligent Decision-Oriented Hemodynamic Organized Therapy for Shock Patients",[91],[9398],"Septic Shock",[9381,9400],"Norepinephrine",{"trials":9402,"activeCount":100},[],{"intervention":9400,"totalTrials":147,"cells":9404},{"EARLY_PHASE1":9405,"PHASE1":9407,"PHASE2":9409,"PHASE3":9411,"PHASE4":9413,"NA":9419},{"trials":9406,"activeCount":100},[],{"trials":9408,"activeCount":100},[],{"trials":9410,"activeCount":100},[],{"trials":9412,"activeCount":100},[],{"trials":9414,"activeCount":100},[9415],{"nctId":9394,"briefTitle":9395,"status":108,"phases":9416,"primaryCompletion":3147,"completion":3862,"start":2800,"enrollment":2353,"conditions":9417,"interventions":9418},[91],[9398],[9381,9400],{"trials":9420,"activeCount":100},[],{"intervention":7817,"totalTrials":147,"cells":9422},{"EARLY_PHASE1":9423,"PHASE1":9425,"PHASE2":9427,"PHASE3":9429,"PHASE4":9431,"NA":9437},{"trials":9424,"activeCount":100},[],{"trials":9426,"activeCount":100},[],{"trials":9428,"activeCount":100},[],{"trials":9430,"activeCount":100},[],{"trials":9432,"activeCount":100},[9433],{"nctId":7811,"briefTitle":7812,"status":108,"phases":9434,"primaryCompletion":3211,"completion":3211,"start":7814,"enrollment":127,"conditions":9435,"interventions":9436},[91],[3214],[7817,3216],{"trials":9438,"activeCount":100},[],{"intervention":9440,"totalTrials":147,"cells":9441},"KANG FU PEN",{"EARLY_PHASE1":9442,"PHASE1":9444,"PHASE2":9446,"PHASE3":9448,"PHASE4":9450,"NA":9461},{"trials":9443,"activeCount":100},[],{"trials":9445,"activeCount":100},[],{"trials":9447,"activeCount":100},[],{"trials":9449,"activeCount":100},[],{"trials":9451,"activeCount":100},[9452],{"nctId":9453,"briefTitle":9454,"status":108,"phases":9455,"primaryCompletion":5489,"completion":5722,"start":3109,"enrollment":9456,"conditions":9457,"interventions":9460},"NCT04819685","Application of KANG FU PEN in Radical Concurrent Radiotherapy and Chemotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Rectal Injury",[91],520,[25,9458,9459],"Radiotherapy Side Effect","Radiotherapy; Complications",[9440],{"trials":9462,"activeCount":100},[],{"intervention":9464,"totalTrials":147,"cells":9465},"ulinastatin",{"EARLY_PHASE1":9466,"PHASE1":9468,"PHASE2":9470,"PHASE3":9472,"PHASE4":9474,"NA":9484},{"trials":9467,"activeCount":100},[],{"trials":9469,"activeCount":100},[],{"trials":9471,"activeCount":100},[],{"trials":9473,"activeCount":100},[],{"trials":9475,"activeCount":100},[9476],{"nctId":9477,"briefTitle":9478,"status":443,"phases":9479,"primaryCompletion":2507,"completion":2813,"start":3472,"enrollment":9480,"conditions":9481,"interventions":9483},"NCT02647554","Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China",[91],347,[9482,9398],"Sepsis",[9464],{"trials":9485,"activeCount":100},[],{"intervention":9487,"totalTrials":147,"cells":9488},"Compound Betamethasone",{"EARLY_PHASE1":9489,"PHASE1":9491,"PHASE2":9493,"PHASE3":9495,"PHASE4":9497,"NA":9508},{"trials":9490,"activeCount":100},[],{"trials":9492,"activeCount":100},[],{"trials":9494,"activeCount":100},[],{"trials":9496,"activeCount":100},[],{"trials":9498,"activeCount":100},[9499],{"nctId":9500,"briefTitle":9501,"status":108,"phases":9502,"primaryCompletion":2382,"completion":9503,"start":9504,"enrollment":811,"conditions":9505,"interventions":9506},"NCT03766997","Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)",[91],"2022-01","2019-02-19",[8849],[9487,9507],"Hydrocortisone Butyrate 0.1% Cream",{"trials":9509,"activeCount":100},[],{"intervention":9507,"totalTrials":147,"cells":9511},{"EARLY_PHASE1":9512,"PHASE1":9514,"PHASE2":9516,"PHASE3":9518,"PHASE4":9520,"NA":9526},{"trials":9513,"activeCount":100},[],{"trials":9515,"activeCount":100},[],{"trials":9517,"activeCount":100},[],{"trials":9519,"activeCount":100},[],{"trials":9521,"activeCount":100},[9522],{"nctId":9500,"briefTitle":9501,"status":108,"phases":9523,"primaryCompletion":2382,"completion":9503,"start":9504,"enrollment":811,"conditions":9524,"interventions":9525},[91],[8849],[9487,9507],{"trials":9527,"activeCount":100},[],{"intervention":3343,"totalTrials":147,"cells":9529},{"EARLY_PHASE1":9530,"PHASE1":9532,"PHASE2":9534,"PHASE3":9536,"PHASE4":9538,"NA":9544},{"trials":9531,"activeCount":100},[],{"trials":9533,"activeCount":100},[],{"trials":9535,"activeCount":100},[],{"trials":9537,"activeCount":100},[],{"trials":9539,"activeCount":100},[9540],{"nctId":3334,"briefTitle":3335,"status":443,"phases":9541,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":9542,"interventions":9543},[91],[3318],[3343,235,3344],{"trials":9545,"activeCount":100},[],{"intervention":3344,"totalTrials":147,"cells":9547},{"EARLY_PHASE1":9548,"PHASE1":9550,"PHASE2":9552,"PHASE3":9554,"PHASE4":9556,"NA":9562},{"trials":9549,"activeCount":100},[],{"trials":9551,"activeCount":100},[],{"trials":9553,"activeCount":100},[],{"trials":9555,"activeCount":100},[],{"trials":9557,"activeCount":100},[9558],{"nctId":3334,"briefTitle":3335,"status":443,"phases":9559,"primaryCompletion":3337,"completion":3338,"start":3339,"enrollment":3340,"conditions":9560,"interventions":9561},[91],[3318],[3343,235,3344],{"trials":9563,"activeCount":100},[],{"intervention":9565,"totalTrials":147,"cells":9566},"Herombopag + CsA",{"EARLY_PHASE1":9567,"PHASE1":9569,"PHASE2":9571,"PHASE3":9573,"PHASE4":9575,"NA":9585},{"trials":9568,"activeCount":100},[],{"trials":9570,"activeCount":100},[],{"trials":9572,"activeCount":100},[],{"trials":9574,"activeCount":100},[],{"trials":9576,"activeCount":100},[9577],{"nctId":9578,"briefTitle":9579,"status":108,"phases":9580,"primaryCompletion":278,"completion":9581,"start":529,"enrollment":357,"conditions":9582,"interventions":9583},"NCT06004791","A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA",[91],"2025-08-31",[22,7686],[9565,9584],"rhTPO combined with Herombopag + CsA",{"trials":9586,"activeCount":100},[],{"intervention":9584,"totalTrials":147,"cells":9588},{"EARLY_PHASE1":9589,"PHASE1":9591,"PHASE2":9593,"PHASE3":9595,"PHASE4":9597,"NA":9603},{"trials":9590,"activeCount":100},[],{"trials":9592,"activeCount":100},[],{"trials":9594,"activeCount":100},[],{"trials":9596,"activeCount":100},[],{"trials":9598,"activeCount":100},[9599],{"nctId":9578,"briefTitle":9579,"status":108,"phases":9600,"primaryCompletion":278,"completion":9581,"start":529,"enrollment":357,"conditions":9601,"interventions":9602},[91],[22,7686],[9565,9584],{"trials":9604,"activeCount":100},[],{"intervention":8074,"totalTrials":147,"cells":9606},{"EARLY_PHASE1":9607,"PHASE1":9609,"PHASE2":9611,"PHASE3":9613,"PHASE4":9615,"NA":9621},{"trials":9608,"activeCount":100},[],{"trials":9610,"activeCount":100},[],{"trials":9612,"activeCount":100},[],{"trials":9614,"activeCount":100},[],{"trials":9616,"activeCount":100},[9617],{"nctId":8065,"briefTitle":8066,"status":443,"phases":9618,"primaryCompletion":8068,"completion":8069,"start":8070,"enrollment":8071,"conditions":9619,"interventions":9620},[91],[5691],[8074,8075],{"trials":9622,"activeCount":100},[],{"intervention":499,"totalTrials":147,"cells":9624},{"EARLY_PHASE1":9625,"PHASE1":9627,"PHASE2":9629,"PHASE3":9631,"PHASE4":9633,"NA":9639},{"trials":9626,"activeCount":100},[],{"trials":9628,"activeCount":100},[],{"trials":9630,"activeCount":100},[],{"trials":9632,"activeCount":100},[],{"trials":9634,"activeCount":100},[9635],{"nctId":491,"briefTitle":492,"status":443,"phases":9636,"primaryCompletion":494,"completion":494,"start":495,"enrollment":127,"conditions":9637,"interventions":9638},[91],[463,497],[499,436,390],{"trials":9640,"activeCount":100},[],{"intervention":8011,"totalTrials":147,"cells":9642},{"EARLY_PHASE1":9643,"PHASE1":9645,"PHASE2":9647,"PHASE3":9649,"PHASE4":9651,"NA":9657},{"trials":9644,"activeCount":100},[],{"trials":9646,"activeCount":100},[],{"trials":9648,"activeCount":100},[],{"trials":9650,"activeCount":100},[],{"trials":9652,"activeCount":100},[9653],{"nctId":8003,"briefTitle":8004,"status":108,"phases":9654,"primaryCompletion":809,"completion":2543,"start":8006,"enrollment":9,"conditions":9655,"interventions":9656},[91],[8008,7997],[8010,8011],{"trials":9658,"activeCount":100},[],{"intervention":9660,"totalTrials":147,"cells":9661},"ropivacaine, fentanyl, adrenaline",{"EARLY_PHASE1":9662,"PHASE1":9664,"PHASE2":9666,"PHASE3":9668,"PHASE4":9670,"NA":9679},{"trials":9663,"activeCount":100},[],{"trials":9665,"activeCount":100},[],{"trials":9667,"activeCount":100},[],{"trials":9669,"activeCount":100},[],{"trials":9671,"activeCount":100},[9672],{"nctId":9673,"briefTitle":9674,"status":443,"phases":9675,"primaryCompletion":7939,"completion":7939,"start":9676,"enrollment":3909,"conditions":9677,"interventions":9678},"NCT02270437","Safety and Efficacy of Cocktail Periarticular Injection in Simultaneous Total Knee Arthroplasty",[91],"2014-06",[7942],[9660],{"trials":9680,"activeCount":100},[],{"intervention":9682,"totalTrials":372,"cells":9683},"Docetaxel, Doxorubicin, Cyclophosphamide",{"EARLY_PHASE1":9684,"PHASE1":9686,"PHASE2":9688,"PHASE3":9699,"PHASE4":9710,"NA":9712},{"trials":9685,"activeCount":100},[],{"trials":9687,"activeCount":100},[],{"trials":9689,"activeCount":100},[9690],{"nctId":9691,"briefTitle":9692,"status":443,"phases":9693,"primaryCompletion":9694,"start":9695,"enrollment":705,"conditions":9696,"interventions":9697},"NCT02838225","DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer",[89],"2016-01","2009-01",[16],[9698,9682],"Docetaxel, Doxorubicin",{"trials":9700,"activeCount":100},[9701],{"nctId":9702,"briefTitle":9703,"status":443,"phases":9704,"primaryCompletion":2381,"completion":2381,"start":9705,"enrollment":9706,"conditions":9707,"interventions":9708},"NCT01354522","TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer",[90],"2011-05",204,[16],[9682,9709],"Docetaxel, Cyclophosphamide, Capecitabine",{"trials":9711,"activeCount":100},[],{"trials":9713,"activeCount":100},[],{"intervention":3620,"totalTrials":372,"cells":9715},{"EARLY_PHASE1":9716,"PHASE1":9718,"PHASE2":9720,"PHASE3":9726,"PHASE4":9732,"NA":9734},{"trials":9717,"activeCount":100},[],{"trials":9719,"activeCount":100},[],{"trials":9721,"activeCount":100},[9722],{"nctId":3611,"briefTitle":3612,"status":443,"phases":9723,"primaryCompletion":3614,"completion":3615,"start":3616,"enrollment":3617,"conditions":9724,"interventions":9725},[89],[336],[3403,3620],{"trials":9727,"activeCount":100},[9728],{"nctId":7691,"briefTitle":7692,"status":108,"phases":9729,"primaryCompletion":2381,"completion":2544,"start":7694,"enrollment":597,"conditions":9730,"interventions":9731},[89,90],[7696],[3620,7672],{"trials":9733,"activeCount":100},[],{"trials":9735,"activeCount":100},[],{"intervention":1713,"totalTrials":372,"cells":9737},{"EARLY_PHASE1":9738,"PHASE1":9740,"PHASE2":9742,"PHASE3":9744,"PHASE4":9754,"NA":9756},{"trials":9739,"activeCount":100},[],{"trials":9741,"activeCount":100},[],{"trials":9743,"activeCount":100},[],{"trials":9745,"activeCount":100},[9746,9750],{"nctId":1705,"briefTitle":1706,"status":108,"phases":9747,"primaryCompletion":1708,"completion":841,"start":1709,"enrollment":1413,"conditions":9748,"interventions":9749},[89,90],[1711],[1713,247,1714],{"nctId":3311,"briefTitle":3312,"status":443,"phases":9751,"primaryCompletion":3314,"completion":3314,"start":3315,"enrollment":3316,"conditions":9752,"interventions":9753},[89,90],[3318],[1713,235],{"trials":9755,"activeCount":100},[],{"trials":9757,"activeCount":100},[],{"intervention":9759,"totalTrials":372,"cells":9760},"Goserelin",{"EARLY_PHASE1":9761,"PHASE1":9763,"PHASE2":9765,"PHASE3":9767,"PHASE4":9787,"NA":9789},{"trials":9762,"activeCount":100},[],{"trials":9764,"activeCount":100},[],{"trials":9766,"activeCount":100},[],{"trials":9768,"activeCount":100},[9769,9779],{"nctId":9770,"briefTitle":9771,"status":108,"phases":9772,"primaryCompletion":1652,"start":9773,"enrollment":705,"conditions":9774,"interventions":9777},"NCT02132390","Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea",[90],"2014-05",[16,9775,9776],"Chemotherapy Induced Amenorrhea","Ovarian Function Suppression",[9759,9778],"Toremifene",{"nctId":9780,"briefTitle":9781,"status":443,"phases":9782,"primaryCompletion":9243,"completion":9243,"start":8123,"enrollment":404,"conditions":9783,"interventions":9784},"NCT02483767","Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer",[90],[16],[9785,9786],"goserelin","standard chemotherapy",{"trials":9788,"activeCount":100},[],{"trials":9790,"activeCount":100},[],{"intervention":9778,"totalTrials":372,"cells":9792},{"EARLY_PHASE1":9793,"PHASE1":9795,"PHASE2":9797,"PHASE3":9799,"PHASE4":9814,"NA":9816},{"trials":9794,"activeCount":100},[],{"trials":9796,"activeCount":100},[],{"trials":9798,"activeCount":100},[],{"trials":9800,"activeCount":100},[9801,9805],{"nctId":9770,"briefTitle":9771,"status":108,"phases":9802,"primaryCompletion":1652,"start":9773,"enrollment":705,"conditions":9803,"interventions":9804},[90],[16,9775,9776],[9759,9778],{"nctId":9806,"briefTitle":9807,"status":108,"phases":9808,"primaryCompletion":2544,"start":9809,"enrollment":2196,"conditions":9810,"interventions":9811},"NCT02097459","Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer",[90],"2014-03",[16],[9812,9813,9778],"Anastrozole","Tamoxifen",{"trials":9815,"activeCount":100},[],{"trials":9817,"activeCount":100},[],{"intervention":6628,"totalTrials":372,"cells":9819},{"EARLY_PHASE1":9820,"PHASE1":9822,"PHASE2":9824,"PHASE3":9826,"PHASE4":9839,"NA":9841},{"trials":9821,"activeCount":100},[],{"trials":9823,"activeCount":100},[],{"trials":9825,"activeCount":100},[],{"trials":9827,"activeCount":100},[9828,9835],{"nctId":9829,"briefTitle":9830,"status":108,"phases":9831,"primaryCompletion":2800,"completion":2800,"start":7664,"enrollment":811,"conditions":9832,"interventions":9833},"NCT05841992","Al18F-PSMA-617 and 68Ga-PSMA-617 PET\u002FCT Imaging in the Same Group of Prostate Cancer Patients",[89,90],[5664],[9834,6628],"Al18F-PSMA-617",{"nctId":6622,"briefTitle":6623,"status":108,"phases":9836,"primaryCompletion":2813,"completion":2701,"start":6625,"enrollment":194,"conditions":9837,"interventions":9838},[89,90],[5664],[6628,5710],{"trials":9840,"activeCount":100},[],{"trials":9842,"activeCount":100},[],{"intervention":9844,"totalTrials":372,"cells":9845},"Hetrombopag",{"EARLY_PHASE1":9846,"PHASE1":9848,"PHASE2":9850,"PHASE3":9852,"PHASE4":9867,"NA":9869},{"trials":9847,"activeCount":100},[],{"trials":9849,"activeCount":100},[],{"trials":9851,"activeCount":100},[],{"trials":9853,"activeCount":100},[9854,9861],{"nctId":9855,"briefTitle":9856,"status":108,"phases":9857,"primaryCompletion":3908,"completion":1736,"start":2659,"enrollment":194,"conditions":9858,"interventions":9859},"NCT05024877","Hetrombopag for Low\u002FIntermediate-1 Risk MDS With Thrombocytopenia",[89,90],[3867],[9844,9860],"Stanozolol",{"nctId":9862,"briefTitle":9863,"status":108,"phases":9864,"primaryCompletion":3908,"completion":1736,"start":2659,"enrollment":127,"conditions":9865,"interventions":9866},"NCT05018936","Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia",[89,90],[22,7686],[9844],{"trials":9868,"activeCount":100},[],{"trials":9870,"activeCount":100},[],{"intervention":9872,"totalTrials":372,"cells":9873},"AngongNiuhuang pill",{"EARLY_PHASE1":9874,"PHASE1":9876,"PHASE2":9878,"PHASE3":9880,"PHASE4":9897,"NA":9899},{"trials":9875,"activeCount":100},[],{"trials":9877,"activeCount":100},[],{"trials":9879,"activeCount":100},[],{"trials":9881,"activeCount":100},[9882,9890],{"nctId":9883,"briefTitle":9884,"status":108,"phases":9885,"primaryCompletion":9886,"completion":9886,"start":8980,"enrollment":811,"conditions":9887,"interventions":9889},"NCT03733002","Efficacy and Safety of AngongNiuhuang Pill for the Treatment of Patients With Acute Ischemic Stroke.",[90],"2019-12-30",[9888],"Acute Ischemic Stroke",[9872],{"nctId":9891,"briefTitle":9892,"status":443,"phases":9893,"primaryCompletion":9894,"completion":7684,"start":6625,"enrollment":167,"conditions":9895,"interventions":9896},"NCT04475328","Efficacy and Safety of AngongNiuhuang Pill in Patients With Acute Ischemic Stroke (ANGONG TRIAL)",[90],"2022-05-01",[9888],[9872],{"trials":9898,"activeCount":100},[],{"trials":9900,"activeCount":100},[],{"intervention":9902,"totalTrials":147,"cells":9903},"sirolimus and ATRA",{"EARLY_PHASE1":9904,"PHASE1":9906,"PHASE2":9908,"PHASE3":9910,"PHASE4":9920,"NA":9922},{"trials":9905,"activeCount":100},[],{"trials":9907,"activeCount":100},[],{"trials":9909,"activeCount":100},[],{"trials":9911,"activeCount":100},[9912],{"nctId":9913,"briefTitle":9914,"status":108,"phases":9915,"primaryCompletion":648,"completion":177,"start":9916,"enrollment":194,"conditions":9917,"interventions":9919},"NCT04324411","Sirolimus Combined With ATRA for the Treatment of Auto-Immune Anemia",[89,90],"2020-04-01",[9918],"Autoimmune Anemia",[9902],{"trials":9921,"activeCount":100},[],{"trials":9923,"activeCount":100},[],{"intervention":9925,"totalTrials":147,"cells":9926},"Danazol + rhTPO",{"EARLY_PHASE1":9927,"PHASE1":9929,"PHASE2":9931,"PHASE3":9933,"PHASE4":9944,"NA":9946},{"trials":9928,"activeCount":100},[],{"trials":9930,"activeCount":100},[],{"trials":9932,"activeCount":100},[],{"trials":9934,"activeCount":100},[9935],{"nctId":9936,"briefTitle":9937,"status":108,"phases":9938,"primaryCompletion":2681,"completion":177,"start":3533,"enrollment":9939,"conditions":9940,"interventions":9942},"NCT04324060","A Randomized Trial of rhTPO Versus Placebo for Low\u002FIntermediate-1 Risk MDS With Thrombocytopenia",[89,90],75,[9941],"Low\u002FIntermediate Risk-1 MDS",[9925,9943],"Danazol + sodium chloride",{"trials":9945,"activeCount":100},[],{"trials":9947,"activeCount":100},[],{"intervention":9943,"totalTrials":147,"cells":9949},{"EARLY_PHASE1":9950,"PHASE1":9952,"PHASE2":9954,"PHASE3":9956,"PHASE4":9962,"NA":9964},{"trials":9951,"activeCount":100},[],{"trials":9953,"activeCount":100},[],{"trials":9955,"activeCount":100},[],{"trials":9957,"activeCount":100},[9958],{"nctId":9936,"briefTitle":9937,"status":108,"phases":9959,"primaryCompletion":2681,"completion":177,"start":3533,"enrollment":9939,"conditions":9960,"interventions":9961},[89,90],[9941],[9925,9943],{"trials":9963,"activeCount":100},[],{"trials":9965,"activeCount":100},[],{"intervention":9967,"totalTrials":147,"cells":9968},"Esmolol",{"EARLY_PHASE1":9969,"PHASE1":9971,"PHASE2":9973,"PHASE3":9975,"PHASE4":9984,"NA":9986},{"trials":9970,"activeCount":100},[],{"trials":9972,"activeCount":100},[],{"trials":9974,"activeCount":100},[],{"trials":9976,"activeCount":100},[9977],{"nctId":9978,"briefTitle":9979,"status":108,"phases":9980,"primaryCompletion":3472,"completion":3472,"start":9244,"enrollment":2556,"conditions":9981,"interventions":9983},"NCT02842983","Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients",[89,90],[9982],"Shock, Septic",[9967],{"trials":9985,"activeCount":100},[],{"trials":9987,"activeCount":100},[],{"intervention":9989,"totalTrials":147,"cells":9990},"Triptolide Wilfordii",{"EARLY_PHASE1":9991,"PHASE1":9993,"PHASE2":9995,"PHASE3":9997,"PHASE4":10008,"NA":10010},{"trials":9992,"activeCount":100},[],{"trials":9994,"activeCount":100},[],{"trials":9996,"activeCount":100},[],{"trials":9998,"activeCount":100},[9999],{"nctId":10000,"briefTitle":10001,"status":443,"phases":10002,"primaryCompletion":2736,"completion":2736,"start":10003,"enrollment":10004,"conditions":10005,"interventions":10007},"NCT03403569","Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection",[90],"2018-09-01",353,[10006],"HIV-infection\u002FAIDS",[9989],{"trials":10009,"activeCount":100},[],{"trials":10011,"activeCount":100},[],{"intervention":10013,"totalTrials":147,"cells":10014},"Bisoprolol Fumarate",{"EARLY_PHASE1":10015,"PHASE1":10017,"PHASE2":10019,"PHASE3":10021,"PHASE4":10032,"NA":10034},{"trials":10016,"activeCount":100},[],{"trials":10018,"activeCount":100},[],{"trials":10020,"activeCount":100},[],{"trials":10022,"activeCount":100},[10023],{"nctId":10024,"briefTitle":10025,"status":108,"phases":10026,"primaryCompletion":40,"completion":55,"start":10027,"enrollment":269,"conditions":10028,"interventions":10031},"NCT03779646","Bisoprolol in DMD Early Cardiomyopathy",[89,90],"2019-01-16",[10029,10030],"Duchenne Muscular Dystrophy","Cardiomyopathy, Dilated",[10013],{"trials":10033,"activeCount":100},[],{"trials":10035,"activeCount":100},[],{"intervention":10037,"totalTrials":147,"cells":10038},"Triplitode",{"EARLY_PHASE1":10039,"PHASE1":10041,"PHASE2":10043,"PHASE3":10045,"PHASE4":10057,"NA":10059},{"trials":10040,"activeCount":100},[],{"trials":10042,"activeCount":100},[],{"trials":10044,"activeCount":100},[],{"trials":10046,"activeCount":100},[10047],{"nctId":10048,"briefTitle":10049,"status":108,"phases":10050,"primaryCompletion":10051,"completion":10052,"start":7949,"enrollment":1765,"conditions":10053,"interventions":10055},"NCT02219672","Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection",[90],"2016-07","2017-07",[10054],"AIDS\u002FHIV PROBLEM",[10037,10056],"Tenofovir plus lamivudine plus Lopinavir \u002F ritonavir plus raltegravir",{"trials":10058,"activeCount":100},[],{"trials":10060,"activeCount":100},[],{"intervention":10056,"totalTrials":147,"cells":10062},{"EARLY_PHASE1":10063,"PHASE1":10065,"PHASE2":10067,"PHASE3":10069,"PHASE4":10075,"NA":10077},{"trials":10064,"activeCount":100},[],{"trials":10066,"activeCount":100},[],{"trials":10068,"activeCount":100},[],{"trials":10070,"activeCount":100},[10071],{"nctId":10048,"briefTitle":10049,"status":108,"phases":10072,"primaryCompletion":10051,"completion":10052,"start":7949,"enrollment":1765,"conditions":10073,"interventions":10074},[90],[10054],[10037,10056],{"trials":10076,"activeCount":100},[],{"trials":10078,"activeCount":100},[],{"intervention":1714,"totalTrials":147,"cells":10080},{"EARLY_PHASE1":10081,"PHASE1":10083,"PHASE2":10085,"PHASE3":10087,"PHASE4":10093,"NA":10095},{"trials":10082,"activeCount":100},[],{"trials":10084,"activeCount":100},[],{"trials":10086,"activeCount":100},[],{"trials":10088,"activeCount":100},[10089],{"nctId":1705,"briefTitle":1706,"status":108,"phases":10090,"primaryCompletion":1708,"completion":841,"start":1709,"enrollment":1413,"conditions":10091,"interventions":10092},[89,90],[1711],[1713,247,1714],{"trials":10094,"activeCount":100},[],{"trials":10096,"activeCount":100},[],{"intervention":10098,"totalTrials":147,"cells":10099},"Radiotherapy plus temozolomide",{"EARLY_PHASE1":10100,"PHASE1":10102,"PHASE2":10104,"PHASE3":10106,"PHASE4":10116,"NA":10118},{"trials":10101,"activeCount":100},[],{"trials":10103,"activeCount":100},[],{"trials":10105,"activeCount":100},[],{"trials":10107,"activeCount":100},[10108],{"nctId":10109,"briefTitle":10110,"status":108,"phases":10111,"primaryCompletion":177,"completion":1736,"start":10112,"enrollment":5179,"conditions":10113,"interventions":10115},"NCT04244708","The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas",[89,90],"2020-02-10",[10114],"Pituitary Adenomas",[10098],{"trials":10117,"activeCount":100},[],{"trials":10119,"activeCount":100},[],{"intervention":10121,"totalTrials":147,"cells":10122},"Capecitabine +\u002F- Oxaliplatin",{"EARLY_PHASE1":10123,"PHASE1":10125,"PHASE2":10127,"PHASE3":10129,"PHASE4":10137,"NA":10139},{"trials":10124,"activeCount":100},[],{"trials":10126,"activeCount":100},[],{"trials":10128,"activeCount":100},[],{"trials":10130,"activeCount":100},[10131],{"nctId":10132,"briefTitle":10133,"status":108,"phases":10134,"primaryCompletion":5593,"completion":5594,"start":5595,"enrollment":705,"conditions":10135,"interventions":10136},"NCT03038217","Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer",[90],[5597,5598],[10121],{"trials":10138,"activeCount":100},[],{"trials":10140,"activeCount":100},[],{"intervention":9834,"totalTrials":147,"cells":10142},{"EARLY_PHASE1":10143,"PHASE1":10145,"PHASE2":10147,"PHASE3":10149,"PHASE4":10155,"NA":10157},{"trials":10144,"activeCount":100},[],{"trials":10146,"activeCount":100},[],{"trials":10148,"activeCount":100},[],{"trials":10150,"activeCount":100},[10151],{"nctId":9829,"briefTitle":9830,"status":108,"phases":10152,"primaryCompletion":2800,"completion":2800,"start":7664,"enrollment":811,"conditions":10153,"interventions":10154},[89,90],[5664],[9834,6628],{"trials":10156,"activeCount":100},[],{"trials":10158,"activeCount":100},[],{"intervention":10160,"totalTrials":147,"cells":10161},"Avatrombopag 20 MG",{"EARLY_PHASE1":10162,"PHASE1":10164,"PHASE2":10166,"PHASE3":10168,"PHASE4":10177,"NA":10179},{"trials":10163,"activeCount":100},[],{"trials":10165,"activeCount":100},[],{"trials":10167,"activeCount":100},[],{"trials":10169,"activeCount":100},[10170],{"nctId":10171,"briefTitle":10172,"status":108,"phases":10173,"primaryCompletion":1858,"completion":778,"start":10174,"enrollment":127,"conditions":10175,"interventions":10176},"NCT04728789","Avatrombopag Usage in NSAA",[89,90],"2021-02-01",[22,7686],[10160],{"trials":10178,"activeCount":100},[],{"trials":10180,"activeCount":100},[],{"intervention":9860,"totalTrials":147,"cells":10182},{"EARLY_PHASE1":10183,"PHASE1":10185,"PHASE2":10187,"PHASE3":10189,"PHASE4":10195,"NA":10197},{"trials":10184,"activeCount":100},[],{"trials":10186,"activeCount":100},[],{"trials":10188,"activeCount":100},[],{"trials":10190,"activeCount":100},[10191],{"nctId":9855,"briefTitle":9856,"status":108,"phases":10192,"primaryCompletion":3908,"completion":1736,"start":2659,"enrollment":194,"conditions":10193,"interventions":10194},[89,90],[3867],[9844,9860],{"trials":10196,"activeCount":100},[],{"trials":10198,"activeCount":100},[],{"intervention":10200,"totalTrials":147,"cells":10201},"concurrent",{"EARLY_PHASE1":10202,"PHASE1":10204,"PHASE2":10206,"PHASE3":10208,"PHASE4":10217,"NA":10219},{"trials":10203,"activeCount":100},[],{"trials":10205,"activeCount":100},[],{"trials":10207,"activeCount":100},[],{"trials":10209,"activeCount":100},[10210],{"nctId":10211,"briefTitle":10212,"status":443,"phases":10213,"primaryCompletion":9177,"completion":9177,"start":9705,"enrollment":3316,"conditions":10214,"interventions":10215},"NCT01413828","Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer",[89,90],[16],[10200,10216],"sequential",{"trials":10218,"activeCount":100},[],{"trials":10220,"activeCount":100},[],{"intervention":10216,"totalTrials":147,"cells":10222},{"EARLY_PHASE1":10223,"PHASE1":10225,"PHASE2":10227,"PHASE3":10229,"PHASE4":10235,"NA":10237},{"trials":10224,"activeCount":100},[],{"trials":10226,"activeCount":100},[],{"trials":10228,"activeCount":100},[],{"trials":10230,"activeCount":100},[10231],{"nctId":10211,"briefTitle":10212,"status":443,"phases":10232,"primaryCompletion":9177,"completion":9177,"start":9705,"enrollment":3316,"conditions":10233,"interventions":10234},[89,90],[16],[10200,10216],{"trials":10236,"activeCount":100},[],{"trials":10238,"activeCount":100},[],{"intervention":9812,"totalTrials":147,"cells":10240},{"EARLY_PHASE1":10241,"PHASE1":10243,"PHASE2":10245,"PHASE3":10247,"PHASE4":10253,"NA":10255},{"trials":10242,"activeCount":100},[],{"trials":10244,"activeCount":100},[],{"trials":10246,"activeCount":100},[],{"trials":10248,"activeCount":100},[10249],{"nctId":9806,"briefTitle":9807,"status":108,"phases":10250,"primaryCompletion":2544,"start":9809,"enrollment":2196,"conditions":10251,"interventions":10252},[90],[16],[9812,9813,9778],{"trials":10254,"activeCount":100},[],{"trials":10256,"activeCount":100},[],{"intervention":9813,"totalTrials":147,"cells":10258},{"EARLY_PHASE1":10259,"PHASE1":10261,"PHASE2":10263,"PHASE3":10265,"PHASE4":10271,"NA":10273},{"trials":10260,"activeCount":100},[],{"trials":10262,"activeCount":100},[],{"trials":10264,"activeCount":100},[],{"trials":10266,"activeCount":100},[10267],{"nctId":9806,"briefTitle":9807,"status":108,"phases":10268,"primaryCompletion":2544,"start":9809,"enrollment":2196,"conditions":10269,"interventions":10270},[90],[16],[9812,9813,9778],{"trials":10272,"activeCount":100},[],{"trials":10274,"activeCount":100},[],{"intervention":10276,"totalTrials":147,"cells":10277},"Trimethoprim\u002FSulfamethoxazole",{"EARLY_PHASE1":10278,"PHASE1":10280,"PHASE2":10282,"PHASE3":10284,"PHASE4":10295,"NA":10297},{"trials":10279,"activeCount":100},[],{"trials":10281,"activeCount":100},[],{"trials":10283,"activeCount":100},[],{"trials":10285,"activeCount":100},[10286],{"nctId":10287,"briefTitle":10288,"status":108,"phases":10289,"primaryCompletion":3314,"completion":840,"start":10290,"enrollment":1206,"conditions":10291,"interventions":10294},"NCT01747278","Study of Trimethoprim\u002FSulfamethoxazole as PCP Prophylaxis in CTD Patients",[89,90],"2012-08",[10292,10293],"Pneumonia, Pneumocystis","Prevention & Control",[10276],{"trials":10296,"activeCount":100},[],{"trials":10298,"activeCount":100},[],{"intervention":7705,"totalTrials":147,"cells":10300},{"EARLY_PHASE1":10301,"PHASE1":10303,"PHASE2":10305,"PHASE3":10307,"PHASE4":10313,"NA":10315},{"trials":10302,"activeCount":100},[],{"trials":10304,"activeCount":100},[],{"trials":10306,"activeCount":100},[],{"trials":10308,"activeCount":100},[10309],{"nctId":7699,"briefTitle":7700,"status":108,"phases":10310,"primaryCompletion":7702,"completion":527,"start":7694,"enrollment":3224,"conditions":10311,"interventions":10312},[89,90],[7696],[7705,7672],{"trials":10314,"activeCount":100},[],{"trials":10316,"activeCount":100},[],{"intervention":10318,"totalTrials":147,"cells":10319},"Tucidinostat, Azacitidine combined with CHOP",{"EARLY_PHASE1":10320,"PHASE1":10322,"PHASE2":10324,"PHASE3":10326,"PHASE4":10337,"NA":10339},{"trials":10321,"activeCount":100},[],{"trials":10323,"activeCount":100},[],{"trials":10325,"activeCount":100},[],{"trials":10327,"activeCount":100},[10328],{"nctId":10329,"briefTitle":10330,"status":108,"phases":10331,"primaryCompletion":10332,"completion":70,"start":2659,"enrollment":10333,"conditions":10334,"interventions":10336},"NCT05075460","Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma",[90],"2024-05-30",107,[10335],"T-cell Lymphoma",[10318],{"trials":10338,"activeCount":100},[],{"trials":10340,"activeCount":100},[],{"intervention":10342,"totalTrials":147,"cells":10343},"lapatinib\u002Fherceptin",{"EARLY_PHASE1":10344,"PHASE1":10346,"PHASE2":10348,"PHASE3":10350,"PHASE4":10361,"NA":10363},{"trials":10345,"activeCount":100},[],{"trials":10347,"activeCount":100},[],{"trials":10349,"activeCount":100},[],{"trials":10351,"activeCount":100},[10352],{"nctId":10353,"briefTitle":10354,"status":108,"phases":10355,"primaryCompletion":10356,"completion":3109,"start":10357,"enrollment":10358,"conditions":10359,"interventions":10360},"NCT03085368","A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin",[89,90],"2018-05-01","2017-03-01",482,[1741],[10342],{"trials":10362,"activeCount":100},[],{"trials":10364,"activeCount":100},[],{"intervention":10366,"totalTrials":147,"cells":10367},"statins",{"EARLY_PHASE1":10368,"PHASE1":10370,"PHASE2":10372,"PHASE3":10374,"PHASE4":10386,"NA":10388},{"trials":10369,"activeCount":100},[],{"trials":10371,"activeCount":100},[],{"trials":10373,"activeCount":100},[],{"trials":10375,"activeCount":100},[10376],{"nctId":10377,"briefTitle":10378,"status":108,"phases":10379,"primaryCompletion":10380,"completion":10381,"start":10382,"enrollment":10383,"conditions":10384,"interventions":10385},"NCT03971019","Survival Benefits of Statins in Breast Cancer Patients",[90],"2024-05-28","2024-06-28","2019-03-28",314,[1740],[10366],{"trials":10387,"activeCount":100},[],{"trials":10389,"activeCount":100},[],{"intervention":10391,"totalTrials":147,"cells":10392},"Probiotic Agent",{"EARLY_PHASE1":10393,"PHASE1":10395,"PHASE2":10397,"PHASE3":10399,"PHASE4":10409,"NA":10411},{"trials":10394,"activeCount":100},[],{"trials":10396,"activeCount":100},[],{"trials":10398,"activeCount":100},[],{"trials":10400,"activeCount":100},[10401],{"nctId":10402,"briefTitle":10403,"status":108,"phases":10404,"primaryCompletion":8640,"completion":2392,"start":10405,"enrollment":324,"conditions":10406,"interventions":10407},"NCT03843736","The Role of Dysbiosis of Gut Microbiota in the Pathogenesis of PCOS.",[90],"2019-02-21",[1235],[10391,10408],"Oral contraceptive",{"trials":10410,"activeCount":100},[],{"trials":10412,"activeCount":100},[],{"intervention":10408,"totalTrials":147,"cells":10414},{"EARLY_PHASE1":10415,"PHASE1":10417,"PHASE2":10419,"PHASE3":10421,"PHASE4":10427,"NA":10429},{"trials":10416,"activeCount":100},[],{"trials":10418,"activeCount":100},[],{"trials":10420,"activeCount":100},[],{"trials":10422,"activeCount":100},[10423],{"nctId":10402,"briefTitle":10403,"status":108,"phases":10424,"primaryCompletion":8640,"completion":2392,"start":10405,"enrollment":324,"conditions":10425,"interventions":10426},[90],[1235],[10391,10408],{"trials":10428,"activeCount":100},[],{"trials":10430,"activeCount":100},[],{"intervention":9786,"totalTrials":147,"cells":10432},{"EARLY_PHASE1":10433,"PHASE1":10435,"PHASE2":10437,"PHASE3":10439,"PHASE4":10445,"NA":10447},{"trials":10434,"activeCount":100},[],{"trials":10436,"activeCount":100},[],{"trials":10438,"activeCount":100},[],{"trials":10440,"activeCount":100},[10441],{"nctId":9780,"briefTitle":9781,"status":443,"phases":10442,"primaryCompletion":9243,"completion":9243,"start":8123,"enrollment":404,"conditions":10443,"interventions":10444},[90],[16],[9785,9786],{"trials":10446,"activeCount":100},[],{"trials":10448,"activeCount":100},[],{"intervention":9709,"totalTrials":147,"cells":10450},{"EARLY_PHASE1":10451,"PHASE1":10453,"PHASE2":10455,"PHASE3":10457,"PHASE4":10463,"NA":10465},{"trials":10452,"activeCount":100},[],{"trials":10454,"activeCount":100},[],{"trials":10456,"activeCount":100},[],{"trials":10458,"activeCount":100},[10459],{"nctId":9702,"briefTitle":9703,"status":443,"phases":10460,"primaryCompletion":2381,"completion":2381,"start":9705,"enrollment":9706,"conditions":10461,"interventions":10462},[90],[16],[9682,9709],{"trials":10464,"activeCount":100},[],{"trials":10466,"activeCount":100},[],{"intervention":10468,"totalTrials":147,"cells":10469},"methylprednisolone therapy",{"EARLY_PHASE1":10470,"PHASE1":10472,"PHASE2":10474,"PHASE3":10476,"PHASE4":10487,"NA":10489},{"trials":10471,"activeCount":100},[],{"trials":10473,"activeCount":100},[],{"trials":10475,"activeCount":100},[],{"trials":10477,"activeCount":100},[10478],{"nctId":10479,"briefTitle":10480,"status":443,"phases":10481,"primaryCompletion":10482,"completion":10482,"start":10483,"enrollment":1206,"conditions":10484,"interventions":10486},"NCT04244591","Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure",[89,90],"2020-04-13","2020-01-26",[10485],"COVID-19 Infections",[10468],{"trials":10488,"activeCount":100},[],{"trials":10490,"activeCount":100},[],{"intervention":10492,"totalTrials":147,"cells":10493},"Intravenous Immunoglobulin",{"EARLY_PHASE1":10494,"PHASE1":10496,"PHASE2":10498,"PHASE3":10500,"PHASE4":10510,"NA":10512},{"trials":10495,"activeCount":100},[],{"trials":10497,"activeCount":100},[],{"trials":10499,"activeCount":100},[],{"trials":10501,"activeCount":100},[10502],{"nctId":10503,"briefTitle":10504,"status":108,"phases":10505,"primaryCompletion":10506,"completion":8640,"start":10112,"enrollment":1206,"conditions":10507,"interventions":10509},"NCT04261426","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia",[89,90],"2020-04-30",[10508],"2019-nCoV",[10492],{"trials":10511,"activeCount":100},[],{"trials":10513,"activeCount":100},[],{"intervention":10515,"totalTrials":147,"cells":10516},"Doxorubicin, Cyclophosphamide",{"EARLY_PHASE1":10517,"PHASE1":10519,"PHASE2":10521,"PHASE3":10523,"PHASE4":10534,"NA":10536},{"trials":10518,"activeCount":100},[],{"trials":10520,"activeCount":100},[],{"trials":10522,"activeCount":100},[],{"trials":10524,"activeCount":100},[10525],{"nctId":10526,"briefTitle":10527,"status":108,"phases":10528,"primaryCompletion":10529,"start":10530,"enrollment":705,"conditions":10531,"interventions":10532},"NCT01415336","AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer",[89,90],"2013-03","2010-03",[16],[10515,10533],"doxorubicin, Capecitabine",{"trials":10535,"activeCount":100},[],{"trials":10537,"activeCount":100},[],{"intervention":10533,"totalTrials":147,"cells":10539},{"EARLY_PHASE1":10540,"PHASE1":10542,"PHASE2":10544,"PHASE3":10546,"PHASE4":10552,"NA":10554},{"trials":10541,"activeCount":100},[],{"trials":10543,"activeCount":100},[],{"trials":10545,"activeCount":100},[],{"trials":10547,"activeCount":100},[10548],{"nctId":10526,"briefTitle":10527,"status":108,"phases":10549,"primaryCompletion":10529,"start":10530,"enrollment":705,"conditions":10550,"interventions":10551},[89,90],[16],[10515,10533],{"trials":10553,"activeCount":100},[],{"trials":10555,"activeCount":100},[],{"intervention":451,"totalTrials":147,"cells":10557},{"EARLY_PHASE1":10558,"PHASE1":10560,"PHASE2":10562,"PHASE3":10564,"PHASE4":10570,"NA":10572},{"trials":10559,"activeCount":100},[],{"trials":10561,"activeCount":100},[],{"trials":10563,"activeCount":100},[],{"trials":10565,"activeCount":100},[10566],{"nctId":441,"briefTitle":442,"status":443,"phases":10567,"primaryCompletion":445,"completion":445,"start":446,"enrollment":447,"conditions":10568,"interventions":10569},[90],[449],[451,390,436],{"trials":10571,"activeCount":100},[],{"trials":10573,"activeCount":100},[],{"intervention":10575,"totalTrials":147,"cells":10576},"Interferon Alfa-2A",{"EARLY_PHASE1":10577,"PHASE1":10579,"PHASE2":10581,"PHASE3":10583,"PHASE4":10596,"NA":10598},{"trials":10578,"activeCount":100},[],{"trials":10580,"activeCount":100},[],{"trials":10582,"activeCount":100},[],{"trials":10584,"activeCount":100},[10585],{"nctId":10586,"briefTitle":10587,"status":443,"phases":10588,"primaryCompletion":10589,"completion":10590,"start":10591,"enrollment":780,"conditions":10592,"interventions":10594},"NCT03209219","Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis",[90],"2020-08-31","2021-01-31","2017-06-30",[10593,1415],"Behçet Disease",[10575,10595],"Cyclosporine Pill",{"trials":10597,"activeCount":100},[],{"trials":10599,"activeCount":100},[],{"intervention":10595,"totalTrials":147,"cells":10601},{"EARLY_PHASE1":10602,"PHASE1":10604,"PHASE2":10606,"PHASE3":10608,"PHASE4":10614,"NA":10616},{"trials":10603,"activeCount":100},[],{"trials":10605,"activeCount":100},[],{"trials":10607,"activeCount":100},[],{"trials":10609,"activeCount":100},[10610],{"nctId":10586,"briefTitle":10587,"status":443,"phases":10611,"primaryCompletion":10589,"completion":10590,"start":10591,"enrollment":780,"conditions":10612,"interventions":10613},[90],[10593,1415],[10575,10595],{"trials":10615,"activeCount":100},[],{"trials":10617,"activeCount":100},[],{"intervention":10619,"totalTrials":147,"cells":10620},"COX-2 inhibitor",{"EARLY_PHASE1":10621,"PHASE1":10623,"PHASE2":10625,"PHASE3":10627,"PHASE4":10636,"NA":10638},{"trials":10622,"activeCount":100},[],{"trials":10624,"activeCount":100},[],{"trials":10626,"activeCount":100},[],{"trials":10628,"activeCount":100},[10629],{"nctId":10630,"briefTitle":10631,"status":108,"phases":10632,"primaryCompletion":8121,"completion":10051,"start":2366,"enrollment":957,"conditions":10633,"interventions":10635},"NCT02438709","Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy",[90],[10634],"Primary Hypertrophic Osteoarthropathy",[10619],{"trials":10637,"activeCount":100},[],{"trials":10639,"activeCount":100},[],{"intervention":10641,"totalTrials":147,"cells":10642},"intravitreal injection of Conbercept",{"EARLY_PHASE1":10643,"PHASE1":10645,"PHASE2":10647,"PHASE3":10649,"PHASE4":10663,"NA":10665},{"trials":10644,"activeCount":100},[],{"trials":10646,"activeCount":100},[],{"trials":10648,"activeCount":100},[],{"trials":10650,"activeCount":100},[10651],{"nctId":10652,"briefTitle":10653,"status":309,"phases":10654,"primaryCompletion":10655,"completion":10656,"start":10657,"enrollment":1606,"conditions":10658,"interventions":10662},"NCT04296838","Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF",[89,90],"2020-04-12","2022-02-12","2019-10-12",[1415,10659,10660,10661],"Macular Edema","Vascular Endothelial Growth Factor","Effect of Drugs",[10641],{"trials":10664,"activeCount":100},[],{"trials":10666,"activeCount":100},[],{"intervention":815,"totalTrials":1606,"cells":10668},{"EARLY_PHASE1":10669,"PHASE1":10671,"PHASE2":10673,"PHASE3":10700,"PHASE4":10702,"NA":10704},{"trials":10670,"activeCount":100},[],{"trials":10672,"activeCount":100},[],{"trials":10674,"activeCount":100},[10675,10684,10688,10692,10696],{"nctId":10676,"briefTitle":10677,"status":108,"phases":10678,"primaryCompletion":10679,"completion":2555,"start":10680,"enrollment":780,"conditions":10681,"interventions":10682},"NCT05076786","Chidamide Plus Etoposide and Cisplatin\u002FCarboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma",[89],"2022-10-15","2021-10-27",[5422,5424],[815,10683],"Etoposide + Cisplatin\u002FCarboplatin",{"nctId":805,"briefTitle":806,"status":108,"phases":10685,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":10686,"interventions":10687},[88,89],[813],[815,247,248,249,681,250],{"nctId":1894,"briefTitle":1895,"status":108,"phases":10689,"primaryCompletion":1897,"completion":1898,"start":1680,"enrollment":142,"conditions":10690,"interventions":10691},[89],[1900],[1885,815],{"nctId":5396,"briefTitle":5397,"status":108,"phases":10693,"primaryCompletion":2380,"completion":527,"start":2661,"enrollment":5399,"conditions":10694,"interventions":10695},[89],[5401],[653,815],{"nctId":5414,"briefTitle":5415,"status":108,"phases":10697,"primaryCompletion":5417,"completion":5418,"start":5419,"enrollment":5420,"conditions":10698,"interventions":10699},[89],[5422,5423,5424,5425],[815,653],{"trials":10701,"activeCount":100},[],{"trials":10703,"activeCount":100},[],{"trials":10705,"activeCount":100},[],{"intervention":2754,"totalTrials":184,"cells":10707},{"EARLY_PHASE1":10708,"PHASE1":10710,"PHASE2":10712,"PHASE3":10734,"PHASE4":10736,"NA":10738},{"trials":10709,"activeCount":100},[],{"trials":10711,"activeCount":100},[],{"trials":10713,"activeCount":100},[10714,10724,10730],{"nctId":10715,"briefTitle":10716,"status":443,"phases":10717,"primaryCompletion":2701,"completion":1681,"start":10718,"enrollment":1948,"conditions":10719,"interventions":10723},"NCT05858177","The Efficacy and Safety of Temozolomide in Patients With MPPGL",[89],"2019-10-01",[10720,10721,10722],"Pheochromocytoma, Metastatic","Paraganglioma, Malignant","Pheochromocytoma Malignant",[2754],{"nctId":10725,"briefTitle":10726,"status":108,"phases":10727,"primaryCompletion":3495,"completion":3495,"start":240,"enrollment":142,"conditions":10728,"interventions":10729},"NCT05885386","A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL",[89],[5857,5858],[2754],{"nctId":2746,"briefTitle":2747,"status":108,"phases":10731,"primaryCompletion":124,"completion":2749,"start":2750,"enrollment":269,"conditions":10732,"interventions":10733},[89],[2752],[2462,2754],{"trials":10735,"activeCount":100},[],{"trials":10737,"activeCount":100},[],{"trials":10739,"activeCount":100},[],{"intervention":10741,"totalTrials":184,"cells":10742},"Anlotinib hydrochloride",{"EARLY_PHASE1":10743,"PHASE1":10745,"PHASE2":10747,"PHASE3":10777,"PHASE4":10779,"NA":10781},{"trials":10744,"activeCount":100},[],{"trials":10746,"activeCount":100},[],{"trials":10748,"activeCount":100},[10749,10759,10765],{"nctId":10750,"briefTitle":10751,"status":108,"phases":10752,"primaryCompletion":10753,"completion":10754,"start":10755,"enrollment":269,"conditions":10756,"interventions":10757},"NCT04952493","Anlotinib or Penpulimab in Combination With RAI for DTC",[89],"2023-07-20","2024-07-20","2021-09-15",[3439],[10741,10758,665],"Sodium Iodide I 131",{"nctId":10760,"briefTitle":10761,"status":108,"phases":10762,"primaryCompletion":1736,"completion":1898,"start":9894,"enrollment":215,"conditions":10763,"interventions":10764},"NCT05883085","A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL",[89],[5857,5858],[10741],{"nctId":10766,"briefTitle":10767,"status":443,"phases":10768,"primaryCompletion":10769,"completion":10769,"start":10770,"enrollment":4605,"conditions":10771,"interventions":10775},"NCT04860700","The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma",[89],"2023-10-17","2021-04-30",[10772,10773,10720,10721,10774],"Malignant Adrenal Gland Pheochromocytoma","Malignant Paraganglioma","Paraganglioma, Extra-Adrenal",[10776],"anlotinib hydrochloride",{"trials":10778,"activeCount":100},[],{"trials":10780,"activeCount":100},[],{"trials":10782,"activeCount":100},[],{"intervention":665,"totalTrials":184,"cells":10784},{"EARLY_PHASE1":10785,"PHASE1":10787,"PHASE2":10789,"PHASE3":10805,"PHASE4":10807,"NA":10809},{"trials":10786,"activeCount":100},[],{"trials":10788,"activeCount":100},[],{"trials":10790,"activeCount":100},[10791,10795,10799],{"nctId":10750,"briefTitle":10751,"status":108,"phases":10792,"primaryCompletion":10753,"completion":10754,"start":10755,"enrollment":269,"conditions":10793,"interventions":10794},[89],[3439],[10741,10758,665],{"nctId":655,"briefTitle":656,"status":108,"phases":10796,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":10797,"interventions":10798},[89],[663],[636,665],{"nctId":10800,"briefTitle":10801,"status":108,"phases":10802,"primaryCompletion":5722,"completion":5722,"start":240,"enrollment":1606,"conditions":10803,"interventions":10804},"NCT05885399","The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment",[89],[10720,10722,10721],[665],{"trials":10806,"activeCount":100},[],{"trials":10808,"activeCount":100},[],{"trials":10810,"activeCount":100},[],{"intervention":10812,"totalTrials":372,"cells":10813},"Niraparib",{"EARLY_PHASE1":10814,"PHASE1":10816,"PHASE2":10818,"PHASE3":10835,"PHASE4":10837,"NA":10839},{"trials":10815,"activeCount":100},[],{"trials":10817,"activeCount":100},[],{"trials":10819,"activeCount":100},[10820,10827],{"nctId":10821,"briefTitle":10822,"status":108,"phases":10823,"primaryCompletion":2681,"completion":1735,"start":10824,"enrollment":2556,"conditions":10825,"interventions":10826},"NCT04217798","Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant\u002FRefractory Recurrent Ovarian Cancer",[89],"2020-05-21",[5626],[10812],{"nctId":10828,"briefTitle":10829,"status":108,"phases":10830,"primaryCompletion":2544,"completion":7702,"start":10831,"enrollment":2814,"conditions":10832,"interventions":10834},"NCT05385068","A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi",[89],"2022-06",[10833],"Epithelial Ovarian Cancer",[10812],{"trials":10836,"activeCount":100},[],{"trials":10838,"activeCount":100},[],{"trials":10840,"activeCount":100},[],{"intervention":785,"totalTrials":372,"cells":10842},{"EARLY_PHASE1":10843,"PHASE1":10845,"PHASE2":10847,"PHASE3":10860,"PHASE4":10862,"NA":10864},{"trials":10844,"activeCount":100},[],{"trials":10846,"activeCount":100},[],{"trials":10848,"activeCount":100},[10849,10856],{"nctId":10850,"briefTitle":10851,"status":108,"phases":10852,"primaryCompletion":841,"completion":9244,"start":2366,"enrollment":2353,"conditions":10853,"interventions":10854},"NCT01755923","Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC",[89],[1767],[10855,785],"Gefitinib",{"nctId":774,"briefTitle":775,"status":443,"phases":10857,"primaryCompletion":777,"completion":778,"start":779,"enrollment":780,"conditions":10858,"interventions":10859},[89],[782],[46,784,785],{"trials":10861,"activeCount":100},[],{"trials":10863,"activeCount":100},[],{"trials":10865,"activeCount":100},[],{"intervention":1747,"totalTrials":372,"cells":10867},{"EARLY_PHASE1":10868,"PHASE1":10870,"PHASE2":10872,"PHASE3":10886,"PHASE4":10888,"NA":10890},{"trials":10869,"activeCount":100},[],{"trials":10871,"activeCount":100},[],{"trials":10873,"activeCount":100},[10874,10882],{"nctId":10875,"briefTitle":10876,"status":108,"phases":10877,"primaryCompletion":3148,"completion":3148,"start":10718,"enrollment":127,"conditions":10878,"interventions":10879},"NCT03994107","Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer",[88,89],[16],[10880,10881,1747],"Pegylated Liposomal Doxorubicin","Albumin-bound paclitaxel",{"nctId":1732,"briefTitle":1733,"status":108,"phases":10883,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":10884,"interventions":10885},[89],[1740,1741,1742,1743,1744,1745],[159,1747,1748],{"trials":10887,"activeCount":100},[],{"trials":10889,"activeCount":100},[],{"trials":10891,"activeCount":100},[],{"intervention":10893,"totalTrials":372,"cells":10894},"Toripalimab plus Lenvatinib",{"EARLY_PHASE1":10895,"PHASE1":10897,"PHASE2":10899,"PHASE3":10918,"PHASE4":10920,"NA":10922},{"trials":10896,"activeCount":100},[],{"trials":10898,"activeCount":100},[],{"trials":10900,"activeCount":100},[10901,10910],{"nctId":10902,"briefTitle":10903,"status":108,"phases":10904,"primaryCompletion":10905,"completion":1910,"start":10906,"enrollment":10907,"conditions":10908,"interventions":10909},"NCT04368078","Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma",[89],"2024-04","2020-07-11",76,[27],[10893],{"nctId":10911,"briefTitle":10912,"status":108,"phases":10913,"primaryCompletion":8210,"completion":527,"start":10914,"enrollment":530,"conditions":10915,"interventions":10917},"NCT04211168","Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers",[89],"2020-08-11",[10916],"Advanced Biliary Tract Cancer",[10893],{"trials":10919,"activeCount":100},[],{"trials":10921,"activeCount":100},[],{"trials":10923,"activeCount":100},[],{"intervention":248,"totalTrials":372,"cells":10925},{"EARLY_PHASE1":10926,"PHASE1":10928,"PHASE2":10930,"PHASE3":10940,"PHASE4":10942,"NA":10944},{"trials":10927,"activeCount":100},[],{"trials":10929,"activeCount":100},[],{"trials":10931,"activeCount":100},[10932,10936],{"nctId":805,"briefTitle":806,"status":108,"phases":10933,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":10934,"interventions":10935},[88,89],[813],[815,247,248,249,681,250],{"nctId":237,"briefTitle":238,"status":108,"phases":10937,"primaryCompletion":240,"completion":241,"start":242,"enrollment":142,"conditions":10938,"interventions":10939},[89],[244],[246,214,247,248,249,250],{"trials":10941,"activeCount":100},[],{"trials":10943,"activeCount":100},[],{"trials":10945,"activeCount":100},[],{"intervention":249,"totalTrials":372,"cells":10947},{"EARLY_PHASE1":10948,"PHASE1":10950,"PHASE2":10952,"PHASE3":10962,"PHASE4":10964,"NA":10966},{"trials":10949,"activeCount":100},[],{"trials":10951,"activeCount":100},[],{"trials":10953,"activeCount":100},[10954,10958],{"nctId":805,"briefTitle":806,"status":108,"phases":10955,"primaryCompletion":808,"completion":809,"start":810,"enrollment":811,"conditions":10956,"interventions":10957},[88,89],[813],[815,247,248,249,681,250],{"nctId":237,"briefTitle":238,"status":108,"phases":10959,"primaryCompletion":240,"completion":241,"start":242,"enrollment":142,"conditions":10960,"interventions":10961},[89],[244],[246,214,247,248,249,250],{"trials":10963,"activeCount":100},[],{"trials":10965,"activeCount":100},[],{"trials":10967,"activeCount":100},[],{"intervention":10969,"totalTrials":372,"cells":10970},"Linperlisib in combined with Chidamide",{"EARLY_PHASE1":10971,"PHASE1":10973,"PHASE2":10975,"PHASE3":10994,"PHASE4":10996,"NA":10998},{"trials":10972,"activeCount":100},[],{"trials":10974,"activeCount":100},[],{"trials":10976,"activeCount":100},[10977,10987],{"nctId":10978,"briefTitle":10979,"status":108,"phases":10980,"primaryCompletion":10981,"completion":10982,"start":10983,"enrollment":661,"conditions":10984,"interventions":10986},"NCT06083701","Phase I\u002FII Study of Linperlisib Plus Chidamide for R\u002FR Peripheral T-cell Lymphoma: a Prospective, Multi-center Study",[88,89],"2024-09-25","2025-09-25","2023-09-25",[10985],"Peripheral T Cell Lymphoma",[10969],{"nctId":10988,"briefTitle":10989,"status":108,"phases":10990,"primaryCompletion":8210,"completion":10991,"start":40,"enrollment":2480,"conditions":10992,"interventions":10993},"NCT06037239","Phase I\u002FII Study of Linperlisib Plus Chidamide for R\u002FR Cutaneous T-cell Lymphoma: a Prospective, Single-center Study",[88,89],"2025-07",[5401],[10969],{"trials":10995,"activeCount":100},[],{"trials":10997,"activeCount":100},[],{"trials":10999,"activeCount":100},[],{"intervention":5548,"totalTrials":372,"cells":11001},{"EARLY_PHASE1":11002,"PHASE1":11004,"PHASE2":11006,"PHASE3":11021,"PHASE4":11023,"NA":11025},{"trials":11003,"activeCount":100},[],{"trials":11005,"activeCount":100},[],{"trials":11007,"activeCount":100},[11008,11012],{"nctId":5540,"briefTitle":5541,"status":108,"phases":11009,"primaryCompletion":5543,"completion":4675,"start":5544,"enrollment":142,"conditions":11010,"interventions":11011},[89],[5546],[5548,5549,2474],{"nctId":11013,"briefTitle":11014,"status":108,"phases":11015,"primaryCompletion":11016,"completion":11017,"start":810,"enrollment":3224,"conditions":11018,"interventions":11020},"NCT02754180","Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and\u002For Positive Lymph Nodes",[89],"2019-03","2021-03",[11019],"Pancreatic Neoplasms",[5548],{"trials":11022,"activeCount":100},[],{"trials":11024,"activeCount":100},[],{"trials":11026,"activeCount":100},[],{"intervention":11028,"totalTrials":372,"cells":11029},"Nab-paclitaxel and S-1",{"EARLY_PHASE1":11030,"PHASE1":11032,"PHASE2":11034,"PHASE3":11050,"PHASE4":11052,"NA":11054},{"trials":11031,"activeCount":100},[],{"trials":11033,"activeCount":100},[],{"trials":11035,"activeCount":100},[11036,11043],{"nctId":11037,"briefTitle":11038,"status":108,"phases":11039,"primaryCompletion":11040,"completion":5523,"start":2776,"enrollment":2353,"conditions":11041,"interventions":11042},"NCT03885219","Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer",[89],"2022-03",[4039],[11028],{"nctId":11044,"briefTitle":11045,"status":108,"phases":11046,"primaryCompletion":11040,"completion":5523,"start":2776,"enrollment":2353,"conditions":11047,"interventions":11048},"NCT03850769","Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer",[89],[4846],[11049],"nab-paclitaxel and S-1",{"trials":11051,"activeCount":100},[],{"trials":11053,"activeCount":100},[],{"trials":11055,"activeCount":100},[],{"intervention":9698,"totalTrials":147,"cells":11057},{"EARLY_PHASE1":11058,"PHASE1":11060,"PHASE2":11062,"PHASE3":11068,"PHASE4":11070,"NA":11072},{"trials":11059,"activeCount":100},[],{"trials":11061,"activeCount":100},[],{"trials":11063,"activeCount":100},[11064],{"nctId":9691,"briefTitle":9692,"status":443,"phases":11065,"primaryCompletion":9694,"start":9695,"enrollment":705,"conditions":11066,"interventions":11067},[89],[16],[9698,9682],{"trials":11069,"activeCount":100},[],{"trials":11071,"activeCount":100},[],{"trials":11073,"activeCount":100},[],{"intervention":234,"totalTrials":147,"cells":11075},{"EARLY_PHASE1":11076,"PHASE1":11078,"PHASE2":11080,"PHASE3":11086,"PHASE4":11088,"NA":11090},{"trials":11077,"activeCount":100},[],{"trials":11079,"activeCount":100},[],{"trials":11081,"activeCount":100},[11082],{"nctId":224,"briefTitle":225,"status":108,"phases":11083,"primaryCompletion":227,"completion":228,"start":229,"enrollment":194,"conditions":11084,"interventions":11085},[89],[231],[233,234,214,235],{"trials":11087,"activeCount":100},[],{"trials":11089,"activeCount":100},[],{"trials":11091,"activeCount":100},[],{"intervention":11093,"totalTrials":147,"cells":11094},"lenalidomide and dexamethasone",{"EARLY_PHASE1":11095,"PHASE1":11097,"PHASE2":11099,"PHASE3":11109,"PHASE4":11111,"NA":11113},{"trials":11096,"activeCount":100},[],{"trials":11098,"activeCount":100},[],{"trials":11100,"activeCount":100},[11101],{"nctId":11102,"briefTitle":11103,"status":108,"phases":11104,"primaryCompletion":2749,"completion":80,"start":11105,"enrollment":758,"conditions":11106,"interventions":11108},"NCT04924647","Lenalidomide and Dexamethasone for Rosai-Dorfman Disease",[89],"2021-06-08",[11107],"Rosai-Dorfman Disease",[11093],{"trials":11110,"activeCount":100},[],{"trials":11112,"activeCount":100},[],{"trials":11114,"activeCount":100},[],{"intervention":11116,"totalTrials":147,"cells":11117},"liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin",{"EARLY_PHASE1":11118,"PHASE1":11120,"PHASE2":11122,"PHASE3":11131,"PHASE4":11133,"NA":11135},{"trials":11119,"activeCount":100},[],{"trials":11121,"activeCount":100},[],{"trials":11123,"activeCount":100},[11124],{"nctId":11125,"briefTitle":11126,"status":108,"phases":11127,"primaryCompletion":3174,"completion":3174,"start":9894,"enrollment":2353,"conditions":11128,"interventions":11130},"NCT05441761","Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed\u002FRefractory PTCL",[88,89],[11129,5156],"Treatment",[11116],{"trials":11132,"activeCount":100},[],{"trials":11134,"activeCount":100},[],{"trials":11136,"activeCount":100},[],{"intervention":11138,"totalTrials":147,"cells":11139},"Idarubicin and cytarabine induction",{"EARLY_PHASE1":11140,"PHASE1":11142,"PHASE2":11144,"PHASE3":11155,"PHASE4":11157,"NA":11159},{"trials":11141,"activeCount":100},[],{"trials":11143,"activeCount":100},[],{"trials":11145,"activeCount":100},[11146],{"nctId":11147,"briefTitle":11148,"status":108,"phases":11149,"primaryCompletion":11150,"completion":7780,"start":11151,"enrollment":269,"conditions":11152,"interventions":11154},"NCT04069208","IA14 Induction in Young Acute Myeloid Leukemia",[89],"2021-10-31","2019-09-03",[11153],"Acute Myeloid Leukemia",[11138],{"trials":11156,"activeCount":100},[],{"trials":11158,"activeCount":100},[],{"trials":11160,"activeCount":100},[],{"intervention":10855,"totalTrials":147,"cells":11162},{"EARLY_PHASE1":11163,"PHASE1":11165,"PHASE2":11167,"PHASE3":11173,"PHASE4":11175,"NA":11177},{"trials":11164,"activeCount":100},[],{"trials":11166,"activeCount":100},[],{"trials":11168,"activeCount":100},[11169],{"nctId":10850,"briefTitle":10851,"status":108,"phases":11170,"primaryCompletion":841,"completion":9244,"start":2366,"enrollment":2353,"conditions":11171,"interventions":11172},[89],[1767],[10855,785],{"trials":11174,"activeCount":100},[],{"trials":11176,"activeCount":100},[],{"trials":11178,"activeCount":100},[],{"intervention":10880,"totalTrials":147,"cells":11180},{"EARLY_PHASE1":11181,"PHASE1":11183,"PHASE2":11185,"PHASE3":11191,"PHASE4":11193,"NA":11195},{"trials":11182,"activeCount":100},[],{"trials":11184,"activeCount":100},[],{"trials":11186,"activeCount":100},[11187],{"nctId":10875,"briefTitle":10876,"status":108,"phases":11188,"primaryCompletion":3148,"completion":3148,"start":10718,"enrollment":127,"conditions":11189,"interventions":11190},[88,89],[16],[10880,10881,1747],{"trials":11192,"activeCount":100},[],{"trials":11194,"activeCount":100},[],{"trials":11196,"activeCount":100},[],{"intervention":10881,"totalTrials":147,"cells":11198},{"EARLY_PHASE1":11199,"PHASE1":11201,"PHASE2":11203,"PHASE3":11209,"PHASE4":11211,"NA":11213},{"trials":11200,"activeCount":100},[],{"trials":11202,"activeCount":100},[],{"trials":11204,"activeCount":100},[11205],{"nctId":10875,"briefTitle":10876,"status":108,"phases":11206,"primaryCompletion":3148,"completion":3148,"start":10718,"enrollment":127,"conditions":11207,"interventions":11208},[88,89],[16],[10880,10881,1747],{"trials":11210,"activeCount":100},[],{"trials":11212,"activeCount":100},[],{"trials":11214,"activeCount":100},[],{"intervention":11216,"totalTrials":147,"cells":11217},"Gefitinib group",{"EARLY_PHASE1":11218,"PHASE1":11220,"PHASE2":11222,"PHASE3":11232,"PHASE4":11234,"NA":11236},{"trials":11219,"activeCount":100},[],{"trials":11221,"activeCount":100},[],{"trials":11223,"activeCount":100},[11224],{"nctId":11225,"briefTitle":11226,"status":108,"phases":11227,"primaryCompletion":3472,"completion":5674,"start":2366,"enrollment":167,"conditions":11228,"interventions":11230},"NCT01749072","Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients",[89],[1767,11229],"Effects of Chemotherapy",[11216,11231],"Vinorelbine, Ifosfamide, Mesna",{"trials":11233,"activeCount":100},[],{"trials":11235,"activeCount":100},[],{"trials":11237,"activeCount":100},[],{"intervention":11231,"totalTrials":147,"cells":11239},{"EARLY_PHASE1":11240,"PHASE1":11242,"PHASE2":11244,"PHASE3":11250,"PHASE4":11252,"NA":11254},{"trials":11241,"activeCount":100},[],{"trials":11243,"activeCount":100},[],{"trials":11245,"activeCount":100},[11246],{"nctId":11225,"briefTitle":11226,"status":108,"phases":11247,"primaryCompletion":3472,"completion":5674,"start":2366,"enrollment":167,"conditions":11248,"interventions":11249},[89],[1767,11229],[11216,11231],{"trials":11251,"activeCount":100},[],{"trials":11253,"activeCount":100},[],{"trials":11255,"activeCount":100},[],{"intervention":10758,"totalTrials":147,"cells":11257},{"EARLY_PHASE1":11258,"PHASE1":11260,"PHASE2":11262,"PHASE3":11268,"PHASE4":11270,"NA":11272},{"trials":11259,"activeCount":100},[],{"trials":11261,"activeCount":100},[],{"trials":11263,"activeCount":100},[11264],{"nctId":10750,"briefTitle":10751,"status":108,"phases":11265,"primaryCompletion":10753,"completion":10754,"start":10755,"enrollment":269,"conditions":11266,"interventions":11267},[89],[3439],[10741,10758,665],{"trials":11269,"activeCount":100},[],{"trials":11271,"activeCount":100},[],{"trials":11273,"activeCount":100},[],{"intervention":11275,"totalTrials":147,"cells":11276},"Tranilast",{"EARLY_PHASE1":11277,"PHASE1":11279,"PHASE2":11281,"PHASE3":11293,"PHASE4":11295,"NA":11297},{"trials":11278,"activeCount":100},[],{"trials":11280,"activeCount":100},[],{"trials":11282,"activeCount":100},[11283],{"nctId":11284,"briefTitle":11285,"status":108,"phases":11286,"primaryCompletion":10905,"completion":11287,"start":11288,"enrollment":11289,"conditions":11290,"interventions":11292},"NCT03923140","A Clinical Study of Tranilast in the Treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)",[89],"2024-10","2019-05-23",71,[11291],"Cryopyrin-Associated Periodic Syndromes",[11275],{"trials":11294,"activeCount":100},[],{"trials":11296,"activeCount":100},[],{"trials":11298,"activeCount":100},[],{"intervention":11300,"totalTrials":147,"cells":11301},"Buxue Yimu Pills",{"EARLY_PHASE1":11302,"PHASE1":11304,"PHASE2":11306,"PHASE3":11318,"PHASE4":11320,"NA":11322},{"trials":11303,"activeCount":100},[],{"trials":11305,"activeCount":100},[],{"trials":11307,"activeCount":100},[11308],{"nctId":11309,"briefTitle":11310,"status":108,"phases":11311,"primaryCompletion":3119,"completion":11312,"start":7837,"enrollment":7645,"conditions":11313,"interventions":11315},"NCT03232554","Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia",[89],"2019-02-28",[11314],"Iron-Deficiency Anemia",[11300,11316,11317],"Buxue Yimu Pills &Ferrous Sulfate","Ferrous Sulfate",{"trials":11319,"activeCount":100},[],{"trials":11321,"activeCount":100},[],{"trials":11323,"activeCount":100},[],{"intervention":11316,"totalTrials":147,"cells":11325},{"EARLY_PHASE1":11326,"PHASE1":11328,"PHASE2":11330,"PHASE3":11336,"PHASE4":11338,"NA":11340},{"trials":11327,"activeCount":100},[],{"trials":11329,"activeCount":100},[],{"trials":11331,"activeCount":100},[11332],{"nctId":11309,"briefTitle":11310,"status":108,"phases":11333,"primaryCompletion":3119,"completion":11312,"start":7837,"enrollment":7645,"conditions":11334,"interventions":11335},[89],[11314],[11300,11316,11317],{"trials":11337,"activeCount":100},[],{"trials":11339,"activeCount":100},[],{"trials":11341,"activeCount":100},[],{"intervention":11317,"totalTrials":147,"cells":11343},{"EARLY_PHASE1":11344,"PHASE1":11346,"PHASE2":11348,"PHASE3":11354,"PHASE4":11356,"NA":11358},{"trials":11345,"activeCount":100},[],{"trials":11347,"activeCount":100},[],{"trials":11349,"activeCount":100},[11350],{"nctId":11309,"briefTitle":11310,"status":108,"phases":11351,"primaryCompletion":3119,"completion":11312,"start":7837,"enrollment":7645,"conditions":11352,"interventions":11353},[89],[11314],[11300,11316,11317],{"trials":11355,"activeCount":100},[],{"trials":11357,"activeCount":100},[],{"trials":11359,"activeCount":100},[],{"intervention":11361,"totalTrials":147,"cells":11362},"Albumin Paclitaxel",{"EARLY_PHASE1":11363,"PHASE1":11365,"PHASE2":11367,"PHASE3":11377,"PHASE4":11379,"NA":11381},{"trials":11364,"activeCount":100},[],{"trials":11366,"activeCount":100},[],{"trials":11368,"activeCount":100},[11369],{"nctId":11370,"briefTitle":11371,"status":108,"phases":11372,"primaryCompletion":1898,"completion":11373,"start":2507,"enrollment":142,"conditions":11374,"interventions":11375},"NCT04646837","Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models",[88,89],"2025-03",[1767],[132,11361,11376],"Carboplatin\u002FCisplatin",{"trials":11378,"activeCount":100},[],{"trials":11380,"activeCount":100},[],{"trials":11382,"activeCount":100},[],{"intervention":11376,"totalTrials":147,"cells":11384},{"EARLY_PHASE1":11385,"PHASE1":11387,"PHASE2":11389,"PHASE3":11395,"PHASE4":11397,"NA":11399},{"trials":11386,"activeCount":100},[],{"trials":11388,"activeCount":100},[],{"trials":11390,"activeCount":100},[11391],{"nctId":11370,"briefTitle":11371,"status":108,"phases":11392,"primaryCompletion":1898,"completion":11373,"start":2507,"enrollment":142,"conditions":11393,"interventions":11394},[88,89],[1767],[132,11361,11376],{"trials":11396,"activeCount":100},[],{"trials":11398,"activeCount":100},[],{"trials":11400,"activeCount":100},[],{"intervention":11402,"totalTrials":147,"cells":11403},"Carboplatin",{"EARLY_PHASE1":11404,"PHASE1":11406,"PHASE2":11408,"PHASE3":11417,"PHASE4":11419,"NA":11421},{"trials":11405,"activeCount":100},[],{"trials":11407,"activeCount":100},[],{"trials":11409,"activeCount":100},[11410],{"nctId":11411,"briefTitle":11412,"status":443,"phases":11413,"primaryCompletion":1736,"completion":1897,"start":11414,"enrollment":2353,"conditions":11415,"interventions":11416},"NCT04568200","Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma",[89],"2020-06-19",[782],[132,11402,2817],{"trials":11418,"activeCount":100},[],{"trials":11420,"activeCount":100},[],{"trials":11422,"activeCount":100},[],{"intervention":11424,"totalTrials":147,"cells":11425},"Camrelizumab+S-1",{"EARLY_PHASE1":11426,"PHASE1":11428,"PHASE2":11430,"PHASE3":11441,"PHASE4":11443,"NA":11445},{"trials":11427,"activeCount":100},[],{"trials":11429,"activeCount":100},[],{"trials":11431,"activeCount":100},[11432],{"nctId":11433,"briefTitle":11434,"status":108,"phases":11435,"primaryCompletion":5000,"completion":11436,"start":11437,"enrollment":269,"conditions":11438,"interventions":11440},"NCT05170542","The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.",[89],"2026-01-24","2021-12-24",[11439],"Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC",[11424],{"trials":11442,"activeCount":100},[],{"trials":11444,"activeCount":100},[],{"trials":11446,"activeCount":100},[],{"intervention":10683,"totalTrials":147,"cells":11448},{"EARLY_PHASE1":11449,"PHASE1":11451,"PHASE2":11453,"PHASE3":11459,"PHASE4":11461,"NA":11463},{"trials":11450,"activeCount":100},[],{"trials":11452,"activeCount":100},[],{"trials":11454,"activeCount":100},[11455],{"nctId":10676,"briefTitle":10677,"status":108,"phases":11456,"primaryCompletion":10679,"completion":2555,"start":10680,"enrollment":780,"conditions":11457,"interventions":11458},[89],[5422,5424],[815,10683],{"trials":11460,"activeCount":100},[],{"trials":11462,"activeCount":100},[],{"trials":11464,"activeCount":100},[],{"intervention":3429,"totalTrials":147,"cells":11466},{"EARLY_PHASE1":11467,"PHASE1":11469,"PHASE2":11471,"PHASE3":11477,"PHASE4":11479,"NA":11481},{"trials":11468,"activeCount":100},[],{"trials":11470,"activeCount":100},[],{"trials":11472,"activeCount":100},[11473],{"nctId":3423,"briefTitle":3424,"status":108,"phases":11474,"primaryCompletion":2543,"completion":2543,"start":2606,"enrollment":2353,"conditions":11475,"interventions":11476},[89],[3427],[3429,3430,3431,2473],{"trials":11478,"activeCount":100},[],{"trials":11480,"activeCount":100},[],{"trials":11482,"activeCount":100},[],{"intervention":3430,"totalTrials":147,"cells":11484},{"EARLY_PHASE1":11485,"PHASE1":11487,"PHASE2":11489,"PHASE3":11495,"PHASE4":11497,"NA":11499},{"trials":11486,"activeCount":100},[],{"trials":11488,"activeCount":100},[],{"trials":11490,"activeCount":100},[11491],{"nctId":3423,"briefTitle":3424,"status":108,"phases":11492,"primaryCompletion":2543,"completion":2543,"start":2606,"enrollment":2353,"conditions":11493,"interventions":11494},[89],[3427],[3429,3430,3431,2473],{"trials":11496,"activeCount":100},[],{"trials":11498,"activeCount":100},[],{"trials":11500,"activeCount":100},[],{"intervention":3431,"totalTrials":147,"cells":11502},{"EARLY_PHASE1":11503,"PHASE1":11505,"PHASE2":11507,"PHASE3":11513,"PHASE4":11515,"NA":11517},{"trials":11504,"activeCount":100},[],{"trials":11506,"activeCount":100},[],{"trials":11508,"activeCount":100},[11509],{"nctId":3423,"briefTitle":3424,"status":108,"phases":11510,"primaryCompletion":2543,"completion":2543,"start":2606,"enrollment":2353,"conditions":11511,"interventions":11512},[89],[3427],[3429,3430,3431,2473],{"trials":11514,"activeCount":100},[],{"trials":11516,"activeCount":100},[],{"trials":11518,"activeCount":100},[],{"intervention":11520,"totalTrials":147,"cells":11521},"JS016",{"EARLY_PHASE1":11522,"PHASE1":11524,"PHASE2":11526,"PHASE3":11537,"PHASE4":11539,"NA":11541},{"trials":11523,"activeCount":100},[],{"trials":11525,"activeCount":100},[],{"trials":11527,"activeCount":100},[11528],{"nctId":11529,"briefTitle":11530,"status":108,"phases":11531,"primaryCompletion":7780,"completion":1858,"start":11532,"enrollment":324,"conditions":11533,"interventions":11536},"NCT04931238","Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19)",[89],"2021-01-20",[11534,11535],"COVID-19","SARS-CoV-2",[11520],{"trials":11538,"activeCount":100},[],{"trials":11540,"activeCount":100},[],{"trials":11542,"activeCount":100},[],{"intervention":2549,"totalTrials":147,"cells":11544},{"EARLY_PHASE1":11545,"PHASE1":11547,"PHASE2":11549,"PHASE3":11555,"PHASE4":11557,"NA":11559},{"trials":11546,"activeCount":100},[],{"trials":11548,"activeCount":100},[],{"trials":11550,"activeCount":100},[11551],{"nctId":2540,"briefTitle":2541,"status":108,"phases":11552,"primaryCompletion":2543,"completion":2544,"start":2545,"enrollment":127,"conditions":11553,"interventions":11554},[89],[2547],[2549,303,2531],{"trials":11556,"activeCount":100},[],{"trials":11558,"activeCount":100},[],{"trials":11560,"activeCount":100},[],{"intervention":11562,"totalTrials":147,"cells":11563},"RC48-ADC",{"EARLY_PHASE1":11564,"PHASE1":11566,"PHASE2":11568,"PHASE3":11579,"PHASE4":11581,"NA":11583},{"trials":11565,"activeCount":100},[],{"trials":11567,"activeCount":100},[],{"trials":11569,"activeCount":100},[11570],{"nctId":11571,"briefTitle":11572,"status":108,"phases":11573,"primaryCompletion":11574,"completion":2749,"start":11575,"enrollment":215,"conditions":11576,"interventions":11578},"NCT05601401","Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2",[89],"2023-03-31","2022-03-31",[11577],"Salivary Gland Tumors",[11562],{"trials":11580,"activeCount":100},[],{"trials":11582,"activeCount":100},[],{"trials":11584,"activeCount":100},[],{"intervention":11586,"totalTrials":147,"cells":11587},"Paclitaxel\u002FDDP",{"EARLY_PHASE1":11588,"PHASE1":11590,"PHASE2":11592,"PHASE3":11603,"PHASE4":11605,"NA":11607},{"trials":11589,"activeCount":100},[],{"trials":11591,"activeCount":100},[],{"trials":11593,"activeCount":100},[11594],{"nctId":11595,"briefTitle":11596,"status":108,"phases":11597,"primaryCompletion":277,"completion":529,"start":11598,"enrollment":2353,"conditions":11599,"interventions":11601},"NCT03322969","Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy",[89],"2017-08-23",[11600],"Locally Advanced Gastric Cancer",[11586,11602],"XELOX\u002FSOX",{"trials":11604,"activeCount":100},[],{"trials":11606,"activeCount":100},[],{"trials":11608,"activeCount":100},[],{"intervention":11602,"totalTrials":147,"cells":11610},{"EARLY_PHASE1":11611,"PHASE1":11613,"PHASE2":11615,"PHASE3":11621,"PHASE4":11623,"NA":11625},{"trials":11612,"activeCount":100},[],{"trials":11614,"activeCount":100},[],{"trials":11616,"activeCount":100},[11617],{"nctId":11595,"briefTitle":11596,"status":108,"phases":11618,"primaryCompletion":277,"completion":529,"start":11598,"enrollment":2353,"conditions":11619,"interventions":11620},[89],[11600],[11586,11602],{"trials":11622,"activeCount":100},[],{"trials":11624,"activeCount":100},[],{"trials":11626,"activeCount":100},[],{"intervention":11628,"totalTrials":147,"cells":11629},"Toripalimab + ScTIL",{"EARLY_PHASE1":11630,"PHASE1":11632,"PHASE2":11634,"PHASE3":11645,"PHASE4":11647,"NA":11649},{"trials":11631,"activeCount":100},[],{"trials":11633,"activeCount":100},[],{"trials":11635,"activeCount":100},[11636],{"nctId":11637,"briefTitle":11638,"status":108,"phases":11639,"primaryCompletion":11640,"completion":5895,"start":11641,"enrollment":957,"conditions":11642,"interventions":11644},"NCT05342506","Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies",[89],"2024-02-28","2022-04-18",[25,5626,11643],"Malignant Trophoblastic Tumor",[11628],{"trials":11646,"activeCount":100},[],{"trials":11648,"activeCount":100},[],{"trials":11650,"activeCount":100},[],{"intervention":11652,"totalTrials":147,"cells":11653},"Iguratimod",{"EARLY_PHASE1":11654,"PHASE1":11656,"PHASE2":11658,"PHASE3":11668,"PHASE4":11670,"NA":11672},{"trials":11655,"activeCount":100},[],{"trials":11657,"activeCount":100},[],{"trials":11659,"activeCount":100},[11660],{"nctId":11661,"briefTitle":11662,"status":108,"phases":11663,"primaryCompletion":11664,"completion":11665,"start":5595,"enrollment":957,"conditions":11666,"interventions":11667},"NCT03023592","Study of Iguratimod in Sjögren's Syndrome",[88,89],"2018-02","2018-04",[336],[11652],{"trials":11669,"activeCount":100},[],{"trials":11671,"activeCount":100},[],{"trials":11673,"activeCount":100},[],{"intervention":1748,"totalTrials":147,"cells":11675},{"EARLY_PHASE1":11676,"PHASE1":11678,"PHASE2":11680,"PHASE3":11686,"PHASE4":11688,"NA":11690},{"trials":11677,"activeCount":100},[],{"trials":11679,"activeCount":100},[],{"trials":11681,"activeCount":100},[11682],{"nctId":1732,"briefTitle":1733,"status":108,"phases":11683,"primaryCompletion":1735,"completion":1736,"start":1737,"enrollment":1738,"conditions":11684,"interventions":11685},[89],[1740,1741,1742,1743,1744,1745],[159,1747,1748],{"trials":11687,"activeCount":100},[],{"trials":11689,"activeCount":100},[],{"trials":11691,"activeCount":100},[],{"intervention":11693,"totalTrials":147,"cells":11694},"Apatinib plus Camrelizumab",{"EARLY_PHASE1":11695,"PHASE1":11697,"PHASE2":11699,"PHASE3":11709,"PHASE4":11711,"NA":11713},{"trials":11696,"activeCount":100},[],{"trials":11698,"activeCount":100},[],{"trials":11700,"activeCount":100},[11701],{"nctId":11702,"briefTitle":11703,"status":443,"phases":11704,"primaryCompletion":2506,"completion":3148,"start":8980,"enrollment":299,"conditions":11705,"interventions":11708},"NCT04642664","Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer",[89],[2457,2510,11706,11707],"Biomarker","Hepatobiliary Neoplasm",[11693],{"trials":11710,"activeCount":100},[],{"trials":11712,"activeCount":100},[],{"trials":11714,"activeCount":100},[],{"intervention":11716,"totalTrials":147,"cells":11717},"Nab-paclitaxel in combination with pyrotinib",{"EARLY_PHASE1":11718,"PHASE1":11720,"PHASE2":11722,"PHASE3":11732,"PHASE4":11734,"NA":11736},{"trials":11719,"activeCount":100},[],{"trials":11721,"activeCount":100},[],{"trials":11723,"activeCount":100},[11724],{"nctId":11725,"briefTitle":11726,"status":108,"phases":11727,"primaryCompletion":10831,"completion":9042,"start":2382,"enrollment":11728,"conditions":11729,"interventions":11731},"NCT04659499","Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer",[89],261,[11730],"Early Breast Cancer",[11716],{"trials":11733,"activeCount":100},[],{"trials":11735,"activeCount":100},[],{"trials":11737,"activeCount":100},[],{"intervention":11739,"totalTrials":147,"cells":11740},"Furmonertinib 160 mg, Q.D.",{"EARLY_PHASE1":11741,"PHASE1":11743,"PHASE2":11745,"PHASE3":11756,"PHASE4":11758,"NA":11760},{"trials":11742,"activeCount":100},[],{"trials":11744,"activeCount":100},[],{"trials":11746,"activeCount":100},[11747],{"nctId":11748,"briefTitle":11749,"status":443,"phases":11750,"primaryCompletion":1046,"completion":1046,"start":11751,"enrollment":430,"conditions":11752,"interventions":11755},"NCT05465343","Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)",[89],"2022-07-11",[1805,11753,2880,11754],"EGFR-mutation","Brain Metastases",[11739],{"trials":11757,"activeCount":100},[],{"trials":11759,"activeCount":100},[],{"trials":11761,"activeCount":100},[],{"intervention":11763,"totalTrials":147,"cells":11764},"Lenvatinib Plus Tislelizumab",{"EARLY_PHASE1":11765,"PHASE1":11767,"PHASE2":11769,"PHASE3":11777,"PHASE4":11779,"NA":11781},{"trials":11766,"activeCount":100},[],{"trials":11768,"activeCount":100},[],{"trials":11770,"activeCount":100},[11771],{"nctId":11772,"briefTitle":11773,"status":108,"phases":11774,"primaryCompletion":112,"completion":5418,"start":3193,"enrollment":2353,"conditions":11775,"interventions":11776},"NCT05842317","Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC",[88,89],[27],[11763],{"trials":11778,"activeCount":100},[],{"trials":11780,"activeCount":100},[],{"trials":11782,"activeCount":100},[],{"intervention":11784,"totalTrials":147,"cells":11785},"mFOLFOX6 regimen",{"EARLY_PHASE1":11786,"PHASE1":11788,"PHASE2":11790,"PHASE3":11799,"PHASE4":11801,"NA":11803},{"trials":11787,"activeCount":100},[],{"trials":11789,"activeCount":100},[],{"trials":11791,"activeCount":100},[11792],{"nctId":11793,"briefTitle":11794,"status":108,"phases":11795,"primaryCompletion":9244,"start":9107,"enrollment":9939,"conditions":11796,"interventions":11798},"NCT02226380","FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer",[89],[11797,11229,32],"Gastric Cancer",[11784],{"trials":11800,"activeCount":100},[],{"trials":11802,"activeCount":100},[],{"trials":11804,"activeCount":100},[],{"intervention":411,"totalTrials":147,"cells":11806},{"EARLY_PHASE1":11807,"PHASE1":11809,"PHASE2":11811,"PHASE3":11817,"PHASE4":11819,"NA":11821},{"trials":11808,"activeCount":100},[],{"trials":11810,"activeCount":100},[],{"trials":11812,"activeCount":100},[11813],{"nctId":399,"briefTitle":400,"status":108,"phases":11814,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":11815,"interventions":11816},[89],[406,390,407,408,409],[390,411],{"trials":11818,"activeCount":100},[],{"trials":11820,"activeCount":100},[],{"trials":11822,"activeCount":100},[],{"intervention":11824,"totalTrials":147,"cells":11825},"Xinmailong",{"EARLY_PHASE1":11826,"PHASE1":11828,"PHASE2":11830,"PHASE3":11841,"PHASE4":11843,"NA":11845},{"trials":11827,"activeCount":100},[],{"trials":11829,"activeCount":100},[],{"trials":11831,"activeCount":100},[11832],{"nctId":11833,"briefTitle":11834,"status":108,"phases":11835,"primaryCompletion":3533,"completion":5722,"start":1682,"enrollment":2353,"conditions":11836,"interventions":11840},"NCT03785704","Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer",[89],[11837,11838,11839],"Breast Neoplasms","Cardiac Event","Chemotherapeutic Toxicity",[11824],{"trials":11842,"activeCount":100},[],{"trials":11844,"activeCount":100},[],{"trials":11846,"activeCount":100},[],{"intervention":11848,"totalTrials":147,"cells":11849},"Tegafur, Gimeracil and Oteracil Potassium",{"EARLY_PHASE1":11850,"PHASE1":11852,"PHASE2":11854,"PHASE3":11863,"PHASE4":11865,"NA":11867},{"trials":11851,"activeCount":100},[],{"trials":11853,"activeCount":100},[],{"trials":11855,"activeCount":100},[11856],{"nctId":11857,"briefTitle":11858,"status":108,"phases":11859,"primaryCompletion":112,"completion":11860,"start":297,"enrollment":324,"conditions":11861,"interventions":11862},"NCT04310774","CCRT Followed by Tegafur, Gimeracil and Oteracil Potassium in Cervical Cancer",[88,89],"2026-04-15",[25,95],[11848],{"trials":11864,"activeCount":100},[],{"trials":11866,"activeCount":100},[],{"trials":11868,"activeCount":100},[],{"intervention":11870,"totalTrials":147,"cells":11871},"Donafenib",{"EARLY_PHASE1":11872,"PHASE1":11874,"PHASE2":11876,"PHASE3":11884,"PHASE4":11886,"NA":11888},{"trials":11873,"activeCount":100},[],{"trials":11875,"activeCount":100},[],{"trials":11877,"activeCount":100},[11878],{"nctId":11879,"briefTitle":11880,"status":108,"phases":11881,"primaryCompletion":2381,"completion":527,"start":5594,"enrollment":957,"conditions":11882,"interventions":11883},"NCT05161143","Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma",[89],[27],[11870],{"trials":11885,"activeCount":100},[],{"trials":11887,"activeCount":100},[],{"trials":11889,"activeCount":100},[],{"intervention":6726,"totalTrials":147,"cells":11891},{"EARLY_PHASE1":11892,"PHASE1":11894,"PHASE2":11896,"PHASE3":11902,"PHASE4":11904,"NA":11906},{"trials":11893,"activeCount":100},[],{"trials":11895,"activeCount":100},[],{"trials":11897,"activeCount":100},[11898],{"nctId":6719,"briefTitle":6720,"status":108,"phases":11899,"primaryCompletion":177,"completion":177,"start":6722,"enrollment":957,"conditions":11900,"interventions":11901},[88,89],[6724],[6644,6726],{"trials":11903,"activeCount":100},[],{"trials":11905,"activeCount":100},[],{"trials":11907,"activeCount":100},[],{"intervention":11909,"totalTrials":147,"cells":11910},"smart soup",{"EARLY_PHASE1":11911,"PHASE1":11913,"PHASE2":11915,"PHASE3":11927,"PHASE4":11929,"NA":11931},{"trials":11912,"activeCount":100},[],{"trials":11914,"activeCount":100},[],{"trials":11916,"activeCount":100},[11917],{"nctId":11918,"briefTitle":11919,"status":108,"phases":11920,"primaryCompletion":9043,"completion":9043,"start":1735,"enrollment":7645,"conditions":11921,"interventions":11924},"NCT05538507","Efficacy of Chinese Traditional Medicine \"Smart Soup\" in Cognition and Behavior Regulation in Alzheimer's Disease",[89],[11922,11923],"Alzheimer Disease","Mild Cognitive Impairment",[11909,11925,11926],"Donepezil","Memantine",{"trials":11928,"activeCount":100},[],{"trials":11930,"activeCount":100},[],{"trials":11932,"activeCount":100},[],{"intervention":11925,"totalTrials":147,"cells":11934},{"EARLY_PHASE1":11935,"PHASE1":11937,"PHASE2":11939,"PHASE3":11945,"PHASE4":11947,"NA":11949},{"trials":11936,"activeCount":100},[],{"trials":11938,"activeCount":100},[],{"trials":11940,"activeCount":100},[11941],{"nctId":11918,"briefTitle":11919,"status":108,"phases":11942,"primaryCompletion":9043,"completion":9043,"start":1735,"enrollment":7645,"conditions":11943,"interventions":11944},[89],[11922,11923],[11909,11925,11926],{"trials":11946,"activeCount":100},[],{"trials":11948,"activeCount":100},[],{"trials":11950,"activeCount":100},[],{"intervention":11926,"totalTrials":147,"cells":11952},{"EARLY_PHASE1":11953,"PHASE1":11955,"PHASE2":11957,"PHASE3":11963,"PHASE4":11965,"NA":11967},{"trials":11954,"activeCount":100},[],{"trials":11956,"activeCount":100},[],{"trials":11958,"activeCount":100},[11959],{"nctId":11918,"briefTitle":11919,"status":108,"phases":11960,"primaryCompletion":9043,"completion":9043,"start":1735,"enrollment":7645,"conditions":11961,"interventions":11962},[89],[11922,11923],[11909,11925,11926],{"trials":11964,"activeCount":100},[],{"trials":11966,"activeCount":100},[],{"trials":11968,"activeCount":100},[],{"intervention":2501,"totalTrials":147,"cells":11970},{"EARLY_PHASE1":11971,"PHASE1":11973,"PHASE2":11975,"PHASE3":11981,"PHASE4":11983,"NA":11985},{"trials":11972,"activeCount":100},[],{"trials":11974,"activeCount":100},[],{"trials":11976,"activeCount":100},[11977],{"nctId":2492,"briefTitle":2493,"status":108,"phases":11978,"primaryCompletion":2495,"completion":2496,"start":2497,"enrollment":705,"conditions":11979,"interventions":11980},[89],[2499],[2461,2440,2501],{"trials":11982,"activeCount":100},[],{"trials":11984,"activeCount":100},[],{"trials":11986,"activeCount":100},[],{"intervention":11988,"totalTrials":147,"cells":11989},"Vaccine",{"EARLY_PHASE1":11990,"PHASE1":11992,"PHASE2":11994,"PHASE3":12003,"PHASE4":12005,"NA":12007},{"trials":11991,"activeCount":100},[],{"trials":11993,"activeCount":100},[],{"trials":11995,"activeCount":100},[11996],{"nctId":11997,"briefTitle":11998,"status":108,"phases":11999,"primaryCompletion":2381,"completion":527,"start":529,"enrollment":142,"conditions":12000,"interventions":12002},"NCT05986981","MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers",[89],[12001],"Solid Tumor, Adult",[11988],{"trials":12004,"activeCount":100},[],{"trials":12006,"activeCount":100},[],{"trials":12008,"activeCount":100},[],{"intervention":12010,"totalTrials":147,"cells":12011},"TMZ",{"EARLY_PHASE1":12012,"PHASE1":12014,"PHASE2":12016,"PHASE3":12026,"PHASE4":12028,"NA":12030},{"trials":12013,"activeCount":100},[],{"trials":12015,"activeCount":100},[],{"trials":12017,"activeCount":100},[12018],{"nctId":12019,"briefTitle":12020,"status":108,"phases":12021,"primaryCompletion":8302,"start":10290,"enrollment":167,"conditions":12022,"interventions":12024},"NCT01670890","Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas",[89],[12023],"Malignant Gliomas",[12010,12025],"TMZ plus CDDP",{"trials":12027,"activeCount":100},[],{"trials":12029,"activeCount":100},[],{"trials":12031,"activeCount":100},[],{"intervention":12025,"totalTrials":147,"cells":12033},{"EARLY_PHASE1":12034,"PHASE1":12036,"PHASE2":12038,"PHASE3":12044,"PHASE4":12046,"NA":12048},{"trials":12035,"activeCount":100},[],{"trials":12037,"activeCount":100},[],{"trials":12039,"activeCount":100},[12040],{"nctId":12019,"briefTitle":12020,"status":108,"phases":12041,"primaryCompletion":8302,"start":10290,"enrollment":167,"conditions":12042,"interventions":12043},[89],[12023],[12010,12025],{"trials":12045,"activeCount":100},[],{"trials":12047,"activeCount":100},[],{"trials":12049,"activeCount":100},[],{"intervention":12051,"totalTrials":147,"cells":12052},"temozolomide or dacarbazine-based chemotherapy, endostatin",{"EARLY_PHASE1":12053,"PHASE1":12055,"PHASE2":12057,"PHASE3":12069,"PHASE4":12071,"NA":12073},{"trials":12054,"activeCount":100},[],{"trials":12056,"activeCount":100},[],{"trials":12058,"activeCount":100},[12059],{"nctId":12060,"briefTitle":12061,"status":443,"phases":12062,"primaryCompletion":12063,"completion":12064,"start":12065,"enrollment":1756,"conditions":12066,"interventions":12068},"NCT01845675","Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor",[89],"2016-11-30","2017-03-31","2013-04",[12067],"Advanced Well-differentiated Pancreatic Neuroendocrine Tumor",[12051],{"trials":12070,"activeCount":100},[],{"trials":12072,"activeCount":100},[],{"trials":12074,"activeCount":100},[],{"intervention":133,"totalTrials":147,"cells":12076},{"EARLY_PHASE1":12077,"PHASE1":12079,"PHASE2":12081,"PHASE3":12087,"PHASE4":12089,"NA":12091},{"trials":12078,"activeCount":100},[],{"trials":12080,"activeCount":100},[],{"trials":12082,"activeCount":100},[12083],{"nctId":121,"briefTitle":122,"status":108,"phases":12084,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":12085,"interventions":12086},[89],[129,130],[132,133,95],{"trials":12088,"activeCount":100},[],{"trials":12090,"activeCount":100},[],{"trials":12092,"activeCount":100},[],{"intervention":5549,"totalTrials":147,"cells":12094},{"EARLY_PHASE1":12095,"PHASE1":12097,"PHASE2":12099,"PHASE3":12105,"PHASE4":12107,"NA":12109},{"trials":12096,"activeCount":100},[],{"trials":12098,"activeCount":100},[],{"trials":12100,"activeCount":100},[12101],{"nctId":5540,"briefTitle":5541,"status":108,"phases":12102,"primaryCompletion":5543,"completion":4675,"start":5544,"enrollment":142,"conditions":12103,"interventions":12104},[89],[5546],[5548,5549,2474],{"trials":12106,"activeCount":100},[],{"trials":12108,"activeCount":100},[],{"trials":12110,"activeCount":100},[],{"intervention":1686,"totalTrials":147,"cells":12112},{"EARLY_PHASE1":12113,"PHASE1":12115,"PHASE2":12117,"PHASE3":12123,"PHASE4":12125,"NA":12127},{"trials":12114,"activeCount":100},[],{"trials":12116,"activeCount":100},[],{"trials":12118,"activeCount":100},[12119],{"nctId":1677,"briefTitle":1678,"status":108,"phases":12120,"primaryCompletion":1680,"completion":1681,"start":1682,"enrollment":957,"conditions":12121,"interventions":12122},[89],[1684],[303,247,1686],{"trials":12124,"activeCount":100},[],{"trials":12126,"activeCount":100},[],{"trials":12128,"activeCount":100},[],{"intervention":12130,"totalTrials":147,"cells":12131},"TA or TAC",{"EARLY_PHASE1":12132,"PHASE1":12134,"PHASE2":12136,"PHASE3":12145,"PHASE4":12147,"NA":12149},{"trials":12133,"activeCount":100},[],{"trials":12135,"activeCount":100},[],{"trials":12137,"activeCount":100},[12138],{"nctId":12139,"briefTitle":12140,"status":108,"phases":12141,"primaryCompletion":5576,"start":2364,"enrollment":1048,"conditions":12142,"interventions":12143},"NCT02842099","Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer",[89],[16],[12130,12144],"X",{"trials":12146,"activeCount":100},[],{"trials":12148,"activeCount":100},[],{"trials":12150,"activeCount":100},[],{"intervention":12144,"totalTrials":147,"cells":12152},{"EARLY_PHASE1":12153,"PHASE1":12155,"PHASE2":12157,"PHASE3":12163,"PHASE4":12165,"NA":12167},{"trials":12154,"activeCount":100},[],{"trials":12156,"activeCount":100},[],{"trials":12158,"activeCount":100},[12159],{"nctId":12139,"briefTitle":12140,"status":108,"phases":12160,"primaryCompletion":5576,"start":2364,"enrollment":1048,"conditions":12161,"interventions":12162},[89],[16],[12130,12144],{"trials":12164,"activeCount":100},[],{"trials":12166,"activeCount":100},[],{"trials":12168,"activeCount":100},[],{"intervention":12170,"totalTrials":147,"cells":12171},"Cytarabine",{"EARLY_PHASE1":12172,"PHASE1":12174,"PHASE2":12176,"PHASE3":12184,"PHASE4":12186,"NA":12188},{"trials":12173,"activeCount":100},[],{"trials":12175,"activeCount":100},[],{"trials":12177,"activeCount":100},[12178],{"nctId":12179,"briefTitle":12180,"status":108,"phases":12181,"primaryCompletion":7780,"completion":7780,"start":10718,"enrollment":127,"conditions":12182,"interventions":12183},"NCT04121819","AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis",[89],[3278],[12170],{"trials":12185,"activeCount":100},[],{"trials":12187,"activeCount":100},[],{"trials":12189,"activeCount":100},[],{"intervention":12191,"totalTrials":147,"cells":12192},"177Lu-LNC1011",{"EARLY_PHASE1":12193,"PHASE1":12195,"PHASE2":12197,"PHASE3":12205,"PHASE4":12207,"NA":12209},{"trials":12194,"activeCount":100},[],{"trials":12196,"activeCount":100},[],{"trials":12198,"activeCount":100},[12199],{"nctId":12200,"briefTitle":12201,"status":108,"phases":12202,"primaryCompletion":241,"completion":3495,"start":2800,"enrollment":209,"conditions":12203,"interventions":12204},"NCT06250244","177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer",[88,89],[5987],[12191],{"trials":12206,"activeCount":100},[],{"trials":12208,"activeCount":100},[],{"trials":12210,"activeCount":100},[],{"intervention":12212,"totalTrials":147,"cells":12213},"axitinib plus toripalimab",{"EARLY_PHASE1":12214,"PHASE1":12216,"PHASE2":12218,"PHASE3":12228,"PHASE4":12230,"NA":12232},{"trials":12215,"activeCount":100},[],{"trials":12217,"activeCount":100},[],{"trials":12219,"activeCount":100},[12220],{"nctId":12221,"briefTitle":12222,"status":108,"phases":12223,"primaryCompletion":1897,"completion":3375,"start":12224,"enrollment":2353,"conditions":12225,"interventions":12227},"NCT04010071","Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors",[89],"2020-05-01",[11707,12226,129],"Liver Neoplasm",[12212],{"trials":12229,"activeCount":100},[],{"trials":12231,"activeCount":100},[],{"trials":12233,"activeCount":100},[],{"intervention":12235,"totalTrials":147,"cells":12236},"thalidomide combined with dexamethasone and cyclophosphamide",{"EARLY_PHASE1":12237,"PHASE1":12239,"PHASE2":12241,"PHASE3":12250,"PHASE4":12252,"NA":12254},{"trials":12238,"activeCount":100},[],{"trials":12240,"activeCount":100},[],{"trials":12242,"activeCount":100},[12243],{"nctId":12244,"briefTitle":12245,"status":108,"phases":12246,"primaryCompletion":7780,"completion":7780,"start":12247,"enrollment":142,"conditions":12248,"interventions":12249},"NCT04120519","Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent\u002FRefractory Adult Langerhans Cell Histiocytosis",[89],"2019-10-10",[3278],[12235],{"trials":12251,"activeCount":100},[],{"trials":12253,"activeCount":100},[],{"trials":12255,"activeCount":100},[],{"intervention":12257,"totalTrials":147,"cells":12258},"induction chemotherapy",{"EARLY_PHASE1":12259,"PHASE1":12261,"PHASE2":12263,"PHASE3":12272,"PHASE4":12274,"NA":12276},{"trials":12260,"activeCount":100},[],{"trials":12262,"activeCount":100},[],{"trials":12264,"activeCount":100},[12265],{"nctId":12266,"briefTitle":12267,"status":108,"phases":12268,"primaryCompletion":11040,"completion":809,"start":808,"enrollment":811,"conditions":12269,"interventions":12271},"NCT04296747","Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer",[89],[12270],"Hypopharyngeal Squamous Cell Carcinoma",[12257],{"trials":12273,"activeCount":100},[],{"trials":12275,"activeCount":100},[],{"trials":12277,"activeCount":100},[],{"intervention":12279,"totalTrials":147,"cells":12280},"SHR-1210 plus Anlotinib",{"EARLY_PHASE1":12281,"PHASE1":12283,"PHASE2":12285,"PHASE3":12295,"PHASE4":12297,"NA":12299},{"trials":12282,"activeCount":100},[],{"trials":12284,"activeCount":100},[],{"trials":12286,"activeCount":100},[12287],{"nctId":12288,"briefTitle":12289,"status":108,"phases":12290,"primaryCompletion":529,"completion":278,"start":11017,"enrollment":2519,"conditions":12291,"interventions":12294},"NCT04797507","SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer",[89],[12292,636,12293],"SHR-1210","Advanced Esophageal Squamous Cell Cancer",[12279],{"trials":12296,"activeCount":100},[],{"trials":12298,"activeCount":100},[],{"trials":12300,"activeCount":100},[],{"intervention":2818,"totalTrials":147,"cells":12302},{"EARLY_PHASE1":12303,"PHASE1":12305,"PHASE2":12307,"PHASE3":12313,"PHASE4":12315,"NA":12317},{"trials":12304,"activeCount":100},[],{"trials":12306,"activeCount":100},[],{"trials":12308,"activeCount":100},[12309],{"nctId":2810,"briefTitle":2811,"status":108,"phases":12310,"primaryCompletion":177,"completion":1736,"start":2813,"enrollment":2814,"conditions":12311,"interventions":12312},[89],[25],[2461,2817,2818,2472],{"trials":12314,"activeCount":100},[],{"trials":12316,"activeCount":100},[],{"trials":12318,"activeCount":100},[],{"intervention":12320,"totalTrials":147,"cells":12321},"Pembrolizumab in Combination with Plinabulin and Docetaxel",{"EARLY_PHASE1":12322,"PHASE1":12324,"PHASE2":12326,"PHASE3":12336,"PHASE4":12338,"NA":12340},{"trials":12323,"activeCount":100},[],{"trials":12325,"activeCount":100},[],{"trials":12327,"activeCount":100},[12328],{"nctId":12329,"briefTitle":12330,"status":108,"phases":12331,"primaryCompletion":12332,"completion":333,"start":2680,"enrollment":258,"conditions":12333,"interventions":12335},"NCT05599789","Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)",[89],"2025-01-21",[12334],"Non Small Cell Lung Cancer Metastatic",[12320],{"trials":12337,"activeCount":100},[],{"trials":12339,"activeCount":100},[],{"trials":12341,"activeCount":100},[],{"intervention":12343,"totalTrials":147,"cells":12344},"Thalidomide, cyclophosphamide and prednisone",{"EARLY_PHASE1":12345,"PHASE1":12347,"PHASE2":12349,"PHASE3":12358,"PHASE4":12360,"NA":12362},{"trials":12346,"activeCount":100},[],{"trials":12348,"activeCount":100},[],{"trials":12350,"activeCount":100},[12351],{"nctId":12352,"briefTitle":12353,"status":108,"phases":12354,"primaryCompletion":7274,"completion":3148,"start":8252,"enrollment":1860,"conditions":12355,"interventions":12357},"NCT03043105","TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial",[89],[12356],"Multicentric Castleman Disease",[12343],{"trials":12359,"activeCount":100},[],{"trials":12361,"activeCount":100},[],{"trials":12363,"activeCount":100},[],{"intervention":12365,"totalTrials":147,"cells":12366},"Crinone 8%",{"EARLY_PHASE1":12367,"PHASE1":12369,"PHASE2":12371,"PHASE3":12382,"PHASE4":12384,"NA":12386},{"trials":12368,"activeCount":100},[],{"trials":12370,"activeCount":100},[],{"trials":12372,"activeCount":100},[12373],{"nctId":12374,"briefTitle":12375,"status":443,"phases":12376,"primaryCompletion":471,"completion":12377,"start":8803,"enrollment":113,"conditions":12378,"interventions":12380},"NCT01057511","Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration",[88,89],"2012-02",[12379],"Postmenopausal Endometrium",[12365,12381],"Progesterone",{"trials":12383,"activeCount":100},[],{"trials":12385,"activeCount":100},[],{"trials":12387,"activeCount":100},[],{"intervention":12389,"totalTrials":147,"cells":12390},"Anlotinib plus AK105",{"EARLY_PHASE1":12391,"PHASE1":12393,"PHASE2":12395,"PHASE3":12408,"PHASE4":12410,"NA":12412},{"trials":12392,"activeCount":100},[],{"trials":12394,"activeCount":100},[],{"trials":12396,"activeCount":100},[12397],{"nctId":12398,"briefTitle":12399,"status":108,"phases":12400,"primaryCompletion":11640,"completion":12401,"start":12402,"enrollment":12403,"conditions":12404,"interventions":12407},"NCT04803851","Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer",[88,89],"2024-06-29","2021-05-12",29,[636,12405,12406],"Anti-PD-1 Antibody","Advanced Pancreatic Cancer",[12389],{"trials":12409,"activeCount":100},[],{"trials":12411,"activeCount":100},[],{"trials":12413,"activeCount":100},[],{"intervention":12415,"totalTrials":147,"cells":12416},"Fruquintinib in Combination with S-1",{"EARLY_PHASE1":12417,"PHASE1":12419,"PHASE2":12421,"PHASE3":12433,"PHASE4":12435,"NA":12437},{"trials":12418,"activeCount":100},[],{"trials":12420,"activeCount":100},[],{"trials":12422,"activeCount":100},[12423],{"nctId":12424,"briefTitle":12425,"status":108,"phases":12426,"primaryCompletion":12427,"completion":12428,"start":12429,"enrollment":12430,"conditions":12431,"interventions":12432},"NCT05636150","A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma",[89],"2024-03-30","2024-08-30","2022-03-30",48,[782],[12415],{"trials":12434,"activeCount":100},[],{"trials":12436,"activeCount":100},[],{"trials":12438,"activeCount":100},[],{"intervention":12440,"totalTrials":147,"cells":12441},"Lenalidomide, Dexamethasone",{"EARLY_PHASE1":12442,"PHASE1":12444,"PHASE2":12446,"PHASE3":12457,"PHASE4":12459,"NA":12461},{"trials":12443,"activeCount":100},[],{"trials":12445,"activeCount":100},[],{"trials":12447,"activeCount":100},[12448],{"nctId":12449,"briefTitle":12450,"status":443,"phases":12451,"primaryCompletion":8122,"completion":12452,"start":9809,"enrollment":12453,"conditions":12454,"interventions":12456},"NCT01816620","Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome",[89],"2017-04",41,[12455],"POEMS Syndrome",[12440],{"trials":12458,"activeCount":100},[],{"trials":12460,"activeCount":100},[],{"trials":12462,"activeCount":100},[],{"intervention":12464,"totalTrials":147,"cells":12465},"combined group",{"EARLY_PHASE1":12466,"PHASE1":12468,"PHASE2":12470,"PHASE3":12479,"PHASE4":12481,"NA":12483},{"trials":12467,"activeCount":100},[],{"trials":12469,"activeCount":100},[],{"trials":12471,"activeCount":100},[12472],{"nctId":12473,"briefTitle":12474,"status":108,"phases":12475,"primaryCompletion":8122,"completion":495,"start":8704,"enrollment":2353,"conditions":12476,"interventions":12477},"NCT01746277","Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy",[89],[2867],[12464,12478],"Sequenced group",{"trials":12480,"activeCount":100},[],{"trials":12482,"activeCount":100},[],{"trials":12484,"activeCount":100},[],{"intervention":12478,"totalTrials":147,"cells":12486},{"EARLY_PHASE1":12487,"PHASE1":12489,"PHASE2":12491,"PHASE3":12497,"PHASE4":12499,"NA":12501},{"trials":12488,"activeCount":100},[],{"trials":12490,"activeCount":100},[],{"trials":12492,"activeCount":100},[12493],{"nctId":12473,"briefTitle":12474,"status":108,"phases":12494,"primaryCompletion":8122,"completion":495,"start":8704,"enrollment":2353,"conditions":12495,"interventions":12496},[89],[2867],[12464,12478],{"trials":12498,"activeCount":100},[],{"trials":12500,"activeCount":100},[],{"trials":12502,"activeCount":100},[],{"intervention":12504,"totalTrials":147,"cells":12505},"combination of a single dose anti-CD20 antibody and bortezomib",{"EARLY_PHASE1":12506,"PHASE1":12508,"PHASE2":12510,"PHASE3":12522,"PHASE4":12524,"NA":12526},{"trials":12507,"activeCount":100},[],{"trials":12509,"activeCount":100},[],{"trials":12511,"activeCount":100},[12512],{"nctId":12513,"briefTitle":12514,"status":443,"phases":12515,"primaryCompletion":12516,"completion":12517,"start":12518,"enrollment":2519,"conditions":12519,"interventions":12521},"NCT04083014","Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia",[89],"2024-03-01","2024-03-20","2019-08-20",[7255,12520],"Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia",[12504],{"trials":12523,"activeCount":100},[],{"trials":12525,"activeCount":100},[],{"trials":12527,"activeCount":100},[],{"intervention":2882,"totalTrials":147,"cells":12529},{"EARLY_PHASE1":12530,"PHASE1":12532,"PHASE2":12534,"PHASE3":12540,"PHASE4":12542,"NA":12544},{"trials":12531,"activeCount":100},[],{"trials":12533,"activeCount":100},[],{"trials":12535,"activeCount":100},[12536],{"nctId":2872,"briefTitle":2873,"status":108,"phases":12537,"primaryCompletion":2875,"completion":2876,"start":2877,"enrollment":2878,"conditions":12538,"interventions":12539},[89],[2880],[2882,46],{"trials":12541,"activeCount":100},[],{"trials":12543,"activeCount":100},[],{"trials":12545,"activeCount":100},[],{"intervention":12547,"totalTrials":147,"cells":12548},"Baricitinib 2 MG",{"EARLY_PHASE1":12549,"PHASE1":12551,"PHASE2":12553,"PHASE3":12564,"PHASE4":12566,"NA":12568},{"trials":12550,"activeCount":100},[],{"trials":12552,"activeCount":100},[],{"trials":12554,"activeCount":100},[12555],{"nctId":12556,"briefTitle":12557,"status":443,"phases":12558,"primaryCompletion":12559,"completion":12560,"start":12561,"enrollment":33,"conditions":12562,"interventions":12563},"NCT04916756","A Prospective Pilot Study to Explore Efficacy and Safety of Baricitinib in Active Primary Sjogren's Syndrome Patients",[88,89],"2020-12-24","2021-03-25","2020-01-16",[336],[12547],{"trials":12565,"activeCount":100},[],{"trials":12567,"activeCount":100},[],{"trials":12569,"activeCount":100},[],{"intervention":12571,"totalTrials":147,"cells":12572},"Lenvatinib+Toripalimab.",{"EARLY_PHASE1":12573,"PHASE1":12575,"PHASE2":12577,"PHASE3":12587,"PHASE4":12589,"NA":12591},{"trials":12574,"activeCount":100},[],{"trials":12576,"activeCount":100},[],{"trials":12578,"activeCount":100},[12579],{"nctId":12580,"briefTitle":12581,"status":108,"phases":12582,"primaryCompletion":80,"completion":333,"start":2680,"enrollment":12583,"conditions":12584,"interventions":12586},"NCT06241105","Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer",[89],69,[12585],"Recurrent Ovarian Carcinoma",[12571],{"trials":12588,"activeCount":100},[],{"trials":12590,"activeCount":100},[],{"trials":12592,"activeCount":100},[],{"intervention":12594,"totalTrials":147,"cells":12595},"Lenvatinib plus Pembrolizumab",{"EARLY_PHASE1":12596,"PHASE1":12598,"PHASE2":12600,"PHASE3":12611,"PHASE4":12613,"NA":12615},{"trials":12597,"activeCount":100},[],{"trials":12599,"activeCount":100},[],{"trials":12601,"activeCount":100},[12602],{"nctId":12603,"briefTitle":12604,"status":443,"phases":12605,"primaryCompletion":242,"completion":2813,"start":12606,"enrollment":661,"conditions":12607,"interventions":12610},"NCT03895970","Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors",[89],"2019-04-20",[12608,2510,12609,11706],"Liver Neoplasm Malignant Primary","Combinational Immunotherapy",[12594],{"trials":12612,"activeCount":100},[],{"trials":12614,"activeCount":100},[],{"trials":12616,"activeCount":100},[],{"intervention":12618,"totalTrials":147,"cells":12619},"GM-CSF",{"EARLY_PHASE1":12620,"PHASE1":12622,"PHASE2":12624,"PHASE3":12634,"PHASE4":12636,"NA":12638},{"trials":12621,"activeCount":100},[],{"trials":12623,"activeCount":100},[],{"trials":12625,"activeCount":100},[12626],{"nctId":12627,"briefTitle":12628,"status":108,"phases":12629,"primaryCompletion":12630,"completion":12630,"start":8302,"enrollment":269,"conditions":12631,"interventions":12633},"NCT02243228","Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)",[89],"2017-08",[12632],"Autoimmune Pulmonary Alveolar Proteinosis",[12618],{"trials":12635,"activeCount":100},[],{"trials":12637,"activeCount":100},[],{"trials":12639,"activeCount":100},[],{"intervention":12641,"totalTrials":184,"cells":12642},"68Ga-NOTA-RM26",{"EARLY_PHASE1":12643,"PHASE1":12662,"PHASE2":12670,"PHASE3":12672,"PHASE4":12674,"NA":12676},{"trials":12644,"activeCount":100},[12645,12654],{"nctId":12646,"briefTitle":12647,"status":108,"phases":12648,"primaryCompletion":12649,"completion":12649,"start":12650,"enrollment":957,"conditions":12651,"interventions":12653},"NCT03347864","68Ga-NOTA-RM26 PET\u002FCT in Breast Tumor Patients",[87],"2018-10","2016-10",[12652],"Breast Tumor",[12641],{"nctId":12655,"briefTitle":12656,"status":108,"phases":12657,"primaryCompletion":12658,"completion":12658,"start":2507,"enrollment":957,"conditions":12659,"interventions":12661},"NCT05001204","68Ga-NOTA-RM26 PET\u002FCT for the Detection of Gastrointestinal Stromal Tumor",[87],"2022-08-31",[12660],"Gastrointestinal Stromal Tumors",[12641],{"trials":12663,"activeCount":100},[12664],{"nctId":12665,"briefTitle":12666,"status":108,"phases":12667,"primaryCompletion":5688,"completion":5688,"start":9243,"enrollment":957,"conditions":12668,"interventions":12669},"NCT03164837","68Ga-NOTA-RM26 PET\u002FCT in Prostate Cancer Patients",[88],[5664],[12641],{"trials":12671,"activeCount":100},[],{"trials":12673,"activeCount":100},[],{"trials":12675,"activeCount":100},[],{"trials":12677,"activeCount":100},[],{"intervention":12679,"totalTrials":372,"cells":12680},"68Ga-NEB",{"EARLY_PHASE1":12681,"PHASE1":12683,"PHASE2":12702,"PHASE3":12704,"PHASE4":12706,"NA":12708},{"trials":12682,"activeCount":100},[],{"trials":12684,"activeCount":100},[12685,12695],{"nctId":12686,"briefTitle":12687,"status":108,"phases":12688,"primaryCompletion":5674,"completion":5674,"start":2364,"enrollment":2061,"conditions":12689,"interventions":12694},"NCT02496013","Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB",[88],[12690,12691,12692,12693],"Arteriovenous Malformation","Hemangioma","Neoplasms Lymph Nodes","Lymphedema",[12679],{"nctId":12696,"briefTitle":12697,"status":108,"phases":12698,"primaryCompletion":1858,"completion":1858,"start":10718,"enrollment":357,"conditions":12699,"interventions":12701},"NCT04273334","Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders",[88],[12700],"Lymphatic Disorders",[12679],{"trials":12703,"activeCount":100},[],{"trials":12705,"activeCount":100},[],{"trials":12707,"activeCount":100},[],{"trials":12709,"activeCount":100},[],{"intervention":12711,"totalTrials":372,"cells":12712},"68Ga-NOTA-BBN-RGD",{"EARLY_PHASE1":12713,"PHASE1":12721,"PHASE2":12730,"PHASE3":12732,"PHASE4":12734,"NA":12736},{"trials":12714,"activeCount":100},[12715],{"nctId":12716,"briefTitle":12717,"status":108,"phases":12718,"primaryCompletion":10052,"start":7949,"enrollment":957,"conditions":12719,"interventions":12720},"NCT02747290","68Ga-NOTA-BBN-RGD PET\u002FCT in Prostate Cancer Patients",[87],[5664],[12711],{"trials":12722,"activeCount":100},[12723],{"nctId":12724,"briefTitle":12725,"status":108,"phases":12726,"primaryCompletion":12727,"start":8121,"enrollment":127,"conditions":12728,"interventions":12729},"NCT02749019","Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients",[88],"2018-07",[16],[12711],{"trials":12731,"activeCount":100},[],{"trials":12733,"activeCount":100},[],{"trials":12735,"activeCount":100},[],{"trials":12737,"activeCount":100},[],{"intervention":12739,"totalTrials":147,"cells":12740},"1.11GBq of 177Lu-EB-PSMA-617",{"EARLY_PHASE1":12741,"PHASE1":12743,"PHASE2":12754,"PHASE3":12756,"PHASE4":12758,"NA":12760},{"trials":12742,"activeCount":100},[],{"trials":12744,"activeCount":100},[12745],{"nctId":12746,"briefTitle":12747,"status":108,"phases":12748,"primaryCompletion":2644,"completion":177,"start":12749,"enrollment":194,"conditions":12750,"interventions":12751},"NCT03780075","Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer",[88],"2018-04-15",[5987],[12739,12752,12753],"2.00 GBq of 177Lu-EB-PSMA-617","3.70GBq of 177Lu-EB-PSMA-617",{"trials":12755,"activeCount":100},[],{"trials":12757,"activeCount":100},[],{"trials":12759,"activeCount":100},[],{"trials":12761,"activeCount":100},[],{"intervention":12752,"totalTrials":147,"cells":12763},{"EARLY_PHASE1":12764,"PHASE1":12766,"PHASE2":12772,"PHASE3":12774,"PHASE4":12776,"NA":12778},{"trials":12765,"activeCount":100},[],{"trials":12767,"activeCount":100},[12768],{"nctId":12746,"briefTitle":12747,"status":108,"phases":12769,"primaryCompletion":2644,"completion":177,"start":12749,"enrollment":194,"conditions":12770,"interventions":12771},[88],[5987],[12739,12752,12753],{"trials":12773,"activeCount":100},[],{"trials":12775,"activeCount":100},[],{"trials":12777,"activeCount":100},[],{"trials":12779,"activeCount":100},[],{"intervention":12753,"totalTrials":147,"cells":12781},{"EARLY_PHASE1":12782,"PHASE1":12784,"PHASE2":12790,"PHASE3":12792,"PHASE4":12794,"NA":12796},{"trials":12783,"activeCount":100},[],{"trials":12785,"activeCount":100},[12786],{"nctId":12746,"briefTitle":12747,"status":108,"phases":12787,"primaryCompletion":2644,"completion":177,"start":12749,"enrollment":194,"conditions":12788,"interventions":12789},[88],[5987],[12739,12752,12753],{"trials":12791,"activeCount":100},[],{"trials":12793,"activeCount":100},[],{"trials":12795,"activeCount":100},[],{"trials":12797,"activeCount":100},[],{"intervention":12799,"totalTrials":147,"cells":12800},"IM21 CAR-T cells",{"EARLY_PHASE1":12801,"PHASE1":12803,"PHASE2":12814,"PHASE3":12816,"PHASE4":12818,"NA":12820},{"trials":12802,"activeCount":100},[],{"trials":12804,"activeCount":100},[12805],{"nctId":12806,"briefTitle":12807,"status":108,"phases":12808,"primaryCompletion":12809,"completion":12810,"start":12811,"enrollment":23,"conditions":12812,"interventions":12813},"NCT03711864","Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma",[88],"2021-10-10","2021-12-20","2019-02-25",[196],[12799],{"trials":12815,"activeCount":100},[],{"trials":12817,"activeCount":100},[],{"trials":12819,"activeCount":100},[],{"trials":12821,"activeCount":100},[],{"intervention":12823,"totalTrials":147,"cells":12824},"177Lu-DOTA-EB-TATE 1",{"EARLY_PHASE1":12825,"PHASE1":12827,"PHASE2":12840,"PHASE3":12842,"PHASE4":12844,"NA":12846},{"trials":12826,"activeCount":100},[],{"trials":12828,"activeCount":100},[12829],{"nctId":12830,"briefTitle":12831,"status":108,"phases":12832,"primaryCompletion":1858,"completion":2800,"start":12833,"enrollment":2353,"conditions":12834,"interventions":12835},"NCT03478358","Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors",[88],"2017-04-30",[5422],[12823,12836,12837,12838,12839,12839],"177Lu-DOTA-TATE","177Lu-DOTA-EB-TATE 2","177Lu-DOTA-EB-TATE 3","3.7 GBq",{"trials":12841,"activeCount":100},[],{"trials":12843,"activeCount":100},[],{"trials":12845,"activeCount":100},[],{"trials":12847,"activeCount":100},[],{"intervention":12836,"totalTrials":147,"cells":12849},{"EARLY_PHASE1":12850,"PHASE1":12852,"PHASE2":12858,"PHASE3":12860,"PHASE4":12862,"NA":12864},{"trials":12851,"activeCount":100},[],{"trials":12853,"activeCount":100},[12854],{"nctId":12830,"briefTitle":12831,"status":108,"phases":12855,"primaryCompletion":1858,"completion":2800,"start":12833,"enrollment":2353,"conditions":12856,"interventions":12857},[88],[5422],[12823,12836,12837,12838,12839,12839],{"trials":12859,"activeCount":100},[],{"trials":12861,"activeCount":100},[],{"trials":12863,"activeCount":100},[],{"trials":12865,"activeCount":100},[],{"intervention":12837,"totalTrials":147,"cells":12867},{"EARLY_PHASE1":12868,"PHASE1":12870,"PHASE2":12876,"PHASE3":12878,"PHASE4":12880,"NA":12882},{"trials":12869,"activeCount":100},[],{"trials":12871,"activeCount":100},[12872],{"nctId":12830,"briefTitle":12831,"status":108,"phases":12873,"primaryCompletion":1858,"completion":2800,"start":12833,"enrollment":2353,"conditions":12874,"interventions":12875},[88],[5422],[12823,12836,12837,12838,12839,12839],{"trials":12877,"activeCount":100},[],{"trials":12879,"activeCount":100},[],{"trials":12881,"activeCount":100},[],{"trials":12883,"activeCount":100},[],{"intervention":12838,"totalTrials":147,"cells":12885},{"EARLY_PHASE1":12886,"PHASE1":12888,"PHASE2":12894,"PHASE3":12896,"PHASE4":12898,"NA":12900},{"trials":12887,"activeCount":100},[],{"trials":12889,"activeCount":100},[12890],{"nctId":12830,"briefTitle":12831,"status":108,"phases":12891,"primaryCompletion":1858,"completion":2800,"start":12833,"enrollment":2353,"conditions":12892,"interventions":12893},[88],[5422],[12823,12836,12837,12838,12839,12839],{"trials":12895,"activeCount":100},[],{"trials":12897,"activeCount":100},[],{"trials":12899,"activeCount":100},[],{"trials":12901,"activeCount":100},[],{"intervention":12839,"totalTrials":147,"cells":12903},{"EARLY_PHASE1":12904,"PHASE1":12906,"PHASE2":12912,"PHASE3":12914,"PHASE4":12916,"NA":12918},{"trials":12905,"activeCount":100},[],{"trials":12907,"activeCount":100},[12908],{"nctId":12830,"briefTitle":12831,"status":108,"phases":12909,"primaryCompletion":1858,"completion":2800,"start":12833,"enrollment":2353,"conditions":12910,"interventions":12911},[88],[5422],[12823,12836,12837,12838,12839,12839],{"trials":12913,"activeCount":100},[],{"trials":12915,"activeCount":100},[],{"trials":12917,"activeCount":100},[],{"trials":12919,"activeCount":100},[],{"intervention":12921,"totalTrials":147,"cells":12922},"IPM001",{"EARLY_PHASE1":12923,"PHASE1":12925,"PHASE2":12934,"PHASE3":12936,"PHASE4":12938,"NA":12940},{"trials":12924,"activeCount":100},[],{"trials":12926,"activeCount":100},[12927],{"nctId":12928,"briefTitle":12929,"status":108,"phases":12930,"primaryCompletion":12931,"completion":12931,"start":2701,"enrollment":430,"conditions":12932,"interventions":12933},"NCT05536427","Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma",[88],"2024-10-31",[27],[12921],{"trials":12935,"activeCount":100},[],{"trials":12937,"activeCount":100},[],{"trials":12939,"activeCount":100},[],{"trials":12941,"activeCount":100},[],{"intervention":12943,"totalTrials":147,"cells":12944},"C-CAR088",{"EARLY_PHASE1":12945,"PHASE1":12947,"PHASE2":12957,"PHASE3":12959,"PHASE4":12961,"NA":12963},{"trials":12946,"activeCount":100},[],{"trials":12948,"activeCount":100},[12949],{"nctId":12950,"briefTitle":12951,"status":108,"phases":12952,"primaryCompletion":12953,"completion":5594,"start":12954,"enrollment":215,"conditions":12955,"interventions":12956},"NCT04295018","A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r\u002Fr Multiple Myeloma",[88],"2021-09","2019-10-23",[196],[12943],{"trials":12958,"activeCount":100},[],{"trials":12960,"activeCount":100},[],{"trials":12962,"activeCount":100},[],{"trials":12964,"activeCount":100},[],{"intervention":12966,"totalTrials":147,"cells":12967},"68Ga-NYM096 PET\u002FCT and 177Lu-NYM096",{"EARLY_PHASE1":12968,"PHASE1":12970,"PHASE2":12981,"PHASE3":12983,"PHASE4":12985,"NA":12987},{"trials":12969,"activeCount":100},[],{"trials":12971,"activeCount":100},[12972],{"nctId":12973,"briefTitle":12974,"status":12975,"phases":12976,"primaryCompletion":2572,"completion":12977,"start":12978,"enrollment":142,"conditions":12979,"interventions":12980},"NCT06649682","68Ga-NYM096\u002F177Lu-NYM096 in Metastatic ccRCC","SUSPENDED",[88],"2027-10","2024-11-21",[3724],[12966],{"trials":12982,"activeCount":100},[],{"trials":12984,"activeCount":100},[],{"trials":12986,"activeCount":100},[],{"trials":12988,"activeCount":100},[],{"intervention":5874,"totalTrials":147,"cells":12990},{"EARLY_PHASE1":12991,"PHASE1":12993,"PHASE2":12999,"PHASE3":13001,"PHASE4":13003,"NA":13005},{"trials":12992,"activeCount":100},[],{"trials":12994,"activeCount":100},[12995],{"nctId":5865,"briefTitle":5866,"status":108,"phases":12996,"primaryCompletion":5868,"completion":5869,"start":5870,"enrollment":194,"conditions":12997,"interventions":12998},[88],[5872],[5861,5874],{"trials":13000,"activeCount":100},[],{"trials":13002,"activeCount":100},[],{"trials":13004,"activeCount":100},[],{"trials":13006,"activeCount":100},[],{"intervention":13008,"totalTrials":147,"cells":13009},"higenamine",{"EARLY_PHASE1":13010,"PHASE1":13012,"PHASE2":13023,"PHASE3":13025,"PHASE4":13027,"NA":13029},{"trials":13011,"activeCount":100},[],{"trials":13013,"activeCount":100},[13014],{"nctId":13015,"briefTitle":13016,"status":443,"phases":13017,"primaryCompletion":13018,"completion":13018,"start":13019,"enrollment":215,"conditions":13020,"interventions":13022},"NCT01451229","Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects",[88],"2009-08","2009-06",[13021],"Healthy",[13008],{"trials":13024,"activeCount":100},[],{"trials":13026,"activeCount":100},[],{"trials":13028,"activeCount":100},[],{"trials":13030,"activeCount":100},[],{"intervention":13032,"totalTrials":147,"cells":13033},"pamidronate disodium",{"EARLY_PHASE1":13034,"PHASE1":13036,"PHASE2":13044,"PHASE3":13046,"PHASE4":13048,"NA":13050},{"trials":13035,"activeCount":100},[],{"trials":13037,"activeCount":100},[13038],{"nctId":13039,"briefTitle":13040,"status":443,"phases":13041,"primaryCompletion":12650,"completion":12650,"start":8122,"enrollment":957,"conditions":13042,"interventions":13043},"NCT02544659","Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome",[88],[2608],[13032],{"trials":13045,"activeCount":100},[],{"trials":13047,"activeCount":100},[],{"trials":13049,"activeCount":100},[],{"trials":13051,"activeCount":100},[],{"intervention":13053,"totalTrials":147,"cells":13054},"177Lu-EB-PSMA-617",{"EARLY_PHASE1":13055,"PHASE1":13057,"PHASE2":13066,"PHASE3":13068,"PHASE4":13070,"NA":13072},{"trials":13056,"activeCount":100},[],{"trials":13058,"activeCount":100},[13059],{"nctId":13060,"briefTitle":13061,"status":108,"phases":13062,"primaryCompletion":8980,"completion":8980,"start":13063,"enrollment":957,"conditions":13064,"interventions":13065},"NCT03403595","177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer",[88],"2017-12-01",[5987],[13053],{"trials":13067,"activeCount":100},[],{"trials":13069,"activeCount":100},[],{"trials":13071,"activeCount":100},[],{"trials":13073,"activeCount":100},[],{"intervention":13075,"totalTrials":147,"cells":13076},"CD19-directed CAR-T cells",{"EARLY_PHASE1":13077,"PHASE1":13079,"PHASE2":13091,"PHASE3":13093,"PHASE4":13095,"NA":13097},{"trials":13078,"activeCount":100},[],{"trials":13080,"activeCount":100},[13081],{"nctId":13082,"briefTitle":13083,"status":443,"phases":13084,"primaryCompletion":13085,"completion":13086,"start":13087,"enrollment":1660,"conditions":13088,"interventions":13090},"NCT03483688","A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects",[88],"2019-12-10","2020-01-10","2018-03-06",[13089],"B-cell Non-Hodgkin Lymphoma",[13075],{"trials":13092,"activeCount":100},[],{"trials":13094,"activeCount":100},[],{"trials":13096,"activeCount":100},[],{"trials":13098,"activeCount":100},[],{"intervention":13100,"totalTrials":147,"cells":13101},"177Lu-DOTA-EB-TATE",{"EARLY_PHASE1":13102,"PHASE1":13104,"PHASE2":13112,"PHASE3":13114,"PHASE4":13116,"NA":13118},{"trials":13103,"activeCount":100},[],{"trials":13105,"activeCount":100},[13106],{"nctId":13107,"briefTitle":13108,"status":108,"phases":13109,"primaryCompletion":10356,"completion":10356,"start":12833,"enrollment":957,"conditions":13110,"interventions":13111},"NCT03308682","177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors",[88],[5422],[13100],{"trials":13113,"activeCount":100},[],{"trials":13115,"activeCount":100},[],{"trials":13117,"activeCount":100},[],{"trials":13119,"activeCount":100},[],{"intervention":13121,"totalTrials":147,"cells":13122},"Prizloncabtagene Autoleucel",{"EARLY_PHASE1":13123,"PHASE1":13125,"PHASE2":13135,"PHASE3":13137,"PHASE4":13139,"NA":13141},{"trials":13124,"activeCount":100},[],{"trials":13126,"activeCount":100},[13127],{"nctId":13128,"briefTitle":13129,"status":443,"phases":13130,"primaryCompletion":11640,"completion":3375,"start":13131,"enrollment":215,"conditions":13132,"interventions":13134},"NCT04655677","A Study of C-CAR039 Treatment in Subjects With r\u002Fr NHL SubjectsNon-Hodgkin's Lymphoma",[88],"2020-10-30",[13133],"B-cell Non-Hodgkin's Lymphoma",[13121],{"trials":13136,"activeCount":100},[],{"trials":13138,"activeCount":100},[],{"trials":13140,"activeCount":100},[],{"trials":13142,"activeCount":100},[],{"intervention":13144,"totalTrials":147,"cells":13145},"SCG101",{"EARLY_PHASE1":13146,"PHASE1":13148,"PHASE2":13157,"PHASE3":13159,"PHASE4":13161,"NA":13163},{"trials":13147,"activeCount":100},[],{"trials":13149,"activeCount":100},[13150],{"nctId":13151,"briefTitle":13152,"status":108,"phases":13153,"primaryCompletion":3327,"completion":2381,"start":313,"enrollment":2556,"conditions":13154,"interventions":13155},"NCT05339321","Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC",[88],[27],[13144,13156],"PD1\u002FPD-L1 checkpoint inhibitor",{"trials":13158,"activeCount":100},[],{"trials":13160,"activeCount":100},[],{"trials":13162,"activeCount":100},[],{"trials":13164,"activeCount":100},[],{"intervention":13156,"totalTrials":147,"cells":13166},{"EARLY_PHASE1":13167,"PHASE1":13169,"PHASE2":13175,"PHASE3":13177,"PHASE4":13179,"NA":13181},{"trials":13168,"activeCount":100},[],{"trials":13170,"activeCount":100},[13171],{"nctId":13151,"briefTitle":13152,"status":108,"phases":13172,"primaryCompletion":3327,"completion":2381,"start":313,"enrollment":2556,"conditions":13173,"interventions":13174},[88],[27],[13144,13156],{"trials":13176,"activeCount":100},[],{"trials":13178,"activeCount":100},[],{"trials":13180,"activeCount":100},[],{"trials":13182,"activeCount":100},[],{"intervention":3264,"totalTrials":147,"cells":13184},{"EARLY_PHASE1":13185,"PHASE1":13187,"PHASE2":13193,"PHASE3":13195,"PHASE4":13197,"NA":13199},{"trials":13186,"activeCount":100},[],{"trials":13188,"activeCount":100},[13189],{"nctId":3258,"briefTitle":3259,"status":108,"phases":13190,"primaryCompletion":2918,"completion":1858,"start":3261,"enrollment":2353,"conditions":13191,"interventions":13192},[88],[2638],[3264,3265,235],{"trials":13194,"activeCount":100},[],{"trials":13196,"activeCount":100},[],{"trials":13198,"activeCount":100},[],{"trials":13200,"activeCount":100},[],{"intervention":3265,"totalTrials":147,"cells":13202},{"EARLY_PHASE1":13203,"PHASE1":13205,"PHASE2":13211,"PHASE3":13213,"PHASE4":13215,"NA":13217},{"trials":13204,"activeCount":100},[],{"trials":13206,"activeCount":100},[13207],{"nctId":3258,"briefTitle":3259,"status":108,"phases":13208,"primaryCompletion":2918,"completion":1858,"start":3261,"enrollment":2353,"conditions":13209,"interventions":13210},[88],[2638],[3264,3265,235],{"trials":13212,"activeCount":100},[],{"trials":13214,"activeCount":100},[],{"trials":13216,"activeCount":100},[],{"trials":13218,"activeCount":100},[],{"intervention":13220,"totalTrials":1606,"cells":13221},"68Ga-BNOTA-PRGD2",{"EARLY_PHASE1":13222,"PHASE1":13254,"PHASE2":13256,"PHASE3":13258,"PHASE4":13260,"NA":13262},{"trials":13223,"activeCount":100},[13224,13230,13236,13242,13248],{"nctId":13225,"briefTitle":13226,"status":108,"phases":13227,"primaryCompletion":5674,"completion":5674,"start":8704,"enrollment":957,"conditions":13228,"interventions":13229},"NCT01801371","68Ga-BNOTA-PRGD2 PET\u002FCT in Diagnosis and Evaluation of Glioma",[87],[5897],[13220],{"nctId":13231,"briefTitle":13232,"status":108,"phases":13233,"primaryCompletion":5674,"completion":5674,"start":12377,"enrollment":194,"conditions":13234,"interventions":13235},"NCT01542073","68Ga-BNOTA-PRGD2 PET\u002FCT in Evaluation of Myocardial Infarction",[87],[463],[13220],{"nctId":13237,"briefTitle":13238,"status":108,"phases":13239,"primaryCompletion":5674,"completion":5674,"start":5845,"enrollment":811,"conditions":13240,"interventions":13241},"NCT01527058","68Ga-BNOTA-PRGD2 PET\u002FCT in Healthy Volunteers and Lung Cancer Patients",[87],[29],[13220],{"nctId":13243,"briefTitle":13244,"status":108,"phases":13245,"primaryCompletion":5674,"completion":5674,"start":12377,"enrollment":194,"conditions":13246,"interventions":13247},"NCT01656785","68Ga-BNOTA-PRGD2 PET\u002FCT in Evaluation of Stroke",[87],[475],[13220],{"nctId":13249,"briefTitle":13250,"status":108,"phases":13251,"primaryCompletion":9153,"completion":5674,"start":12377,"enrollment":194,"conditions":13252,"interventions":13253},"NCT01940926","68Ga-BNOTA-PRGD2 PET\u002FCT in Patients With Rheumatoid Arthritis",[87],[5491],[13220],{"trials":13255,"activeCount":100},[],{"trials":13257,"activeCount":100},[],{"trials":13259,"activeCount":100},[],{"trials":13261,"activeCount":100},[],{"trials":13263,"activeCount":100},[],{"intervention":13265,"totalTrials":147,"cells":13266},"68Ga-NOTA-PRGD2",{"EARLY_PHASE1":13267,"PHASE1":13276,"PHASE2":13278,"PHASE3":13280,"PHASE4":13282,"NA":13284},{"trials":13268,"activeCount":100},[13269],{"nctId":13270,"briefTitle":13271,"status":108,"phases":13272,"primaryCompletion":5674,"completion":5674,"start":8479,"enrollment":957,"conditions":13273,"interventions":13275},"NCT02511197","68Ga-NOTA-PRGD2 PET\u002FCT in Patients With Lung Injury and Pulmonary Fibrosis",[87],[13274],"Pulmonary Fibrosis, Unspecified",[13265],{"trials":13277,"activeCount":100},[],{"trials":13279,"activeCount":100},[],{"trials":13281,"activeCount":100},[],{"trials":13283,"activeCount":100},[],{"trials":13285,"activeCount":100},[],{"intervention":13287,"totalTrials":147,"cells":13288},"68Ga-NOTA-Aca-BBN",{"EARLY_PHASE1":13289,"PHASE1":13298,"PHASE2":13300,"PHASE3":13302,"PHASE4":13304,"NA":13306},{"trials":13290,"activeCount":100},[13291],{"nctId":13292,"briefTitle":13293,"status":108,"phases":13294,"primaryCompletion":5674,"completion":5674,"start":13295,"enrollment":957,"conditions":13296,"interventions":13297},"NCT02520882","68Ga-NOTA-Aca-BBN(7-14) PET\u002FCT in Patients With Primary Gliomas",[87],"2015-01",[5897],[13287],{"trials":13299,"activeCount":100},[],{"trials":13301,"activeCount":100},[],{"trials":13303,"activeCount":100},[],{"trials":13305,"activeCount":100},[],{"trials":13307,"activeCount":100},[],{"intervention":13309,"totalTrials":147,"cells":13310},"11C-Choline",{"EARLY_PHASE1":13311,"PHASE1":13322,"PHASE2":13324,"PHASE3":13326,"PHASE4":13328,"NA":13330},{"trials":13312,"activeCount":100},[13313],{"nctId":13314,"briefTitle":13315,"status":108,"phases":13316,"primaryCompletion":13317,"completion":4867,"start":13318,"enrollment":194,"conditions":13319,"interventions":13321},"NCT05087134","Characterizing LAM With 11C-Choline PET\u002FCT",[87],"2022-09","2021-11",[13320],"Lymphangioleiomyomatosis",[13309],{"trials":13323,"activeCount":100},[],{"trials":13325,"activeCount":100},[],{"trials":13327,"activeCount":100},[],{"trials":13329,"activeCount":100},[],{"trials":13331,"activeCount":100},[],{"intervention":13333,"totalTrials":147,"cells":13334},"68Ga-A3",{"EARLY_PHASE1":13335,"PHASE1":13345,"PHASE2":13347,"PHASE3":13349,"PHASE4":13351,"NA":13353},{"trials":13336,"activeCount":100},[13337],{"nctId":13338,"briefTitle":13339,"status":108,"phases":13340,"primaryCompletion":13341,"completion":5479,"start":5407,"enrollment":142,"conditions":13342,"interventions":13344},"NCT06194630","Application of 68Ga-labeled ACE2 Targeting Probe PET\u002FCT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer",[87],"2023-12-12",[29,13343],"Healthy Human",[13333],{"trials":13346,"activeCount":100},[],{"trials":13348,"activeCount":100},[],{"trials":13350,"activeCount":100},[],{"trials":13352,"activeCount":100},[],{"trials":13354,"activeCount":100},[],{"intervention":13356,"totalTrials":147,"cells":13357},"68Ga-BMV101",{"EARLY_PHASE1":13358,"PHASE1":13367,"PHASE2":13369,"PHASE3":13371,"PHASE4":13373,"NA":13375},{"trials":13359,"activeCount":100},[13360],{"nctId":13361,"briefTitle":13362,"status":108,"phases":13363,"primaryCompletion":5674,"completion":5674,"start":13295,"enrollment":142,"conditions":13364,"interventions":13366},"NCT02485886","68Ga-BMV101 PET\u002FCT in Patients With Idiopathic Pulmonary Fibrosis",[87],[13365],"Idiopathic Pulmonary Fibrosis",[13356],{"trials":13368,"activeCount":100},[],{"trials":13370,"activeCount":100},[],{"trials":13372,"activeCount":100},[],{"trials":13374,"activeCount":100},[],{"trials":13376,"activeCount":100},[],{"intervention":13378,"totalTrials":147,"cells":13379},"2.0 GBq of 177Lu-EB-PSMA",{"EARLY_PHASE1":13380,"PHASE1":13389,"PHASE2":13391,"PHASE3":13393,"PHASE4":13395,"NA":13397},{"trials":13381,"activeCount":100},[13382],{"nctId":13383,"briefTitle":13384,"status":108,"phases":13385,"primaryCompletion":3193,"completion":177,"start":13386,"enrollment":957,"conditions":13387,"interventions":13388},"NCT04996602","Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC",[87],"2019-01-14",[5664],[13378],{"trials":13390,"activeCount":100},[],{"trials":13392,"activeCount":100},[],{"trials":13394,"activeCount":100},[],{"trials":13396,"activeCount":100},[],{"trials":13398,"activeCount":100},[],{"intervention":13400,"totalTrials":147,"cells":13401},"68Ga-NOTA-3P-TATE-RGD",{"EARLY_PHASE1":13402,"PHASE1":13410,"PHASE2":13412,"PHASE3":13414,"PHASE4":13416,"NA":13418},{"trials":13403,"activeCount":100},[13404],{"nctId":13405,"briefTitle":13406,"status":108,"phases":13407,"primaryCompletion":2506,"completion":1858,"start":7839,"enrollment":811,"conditions":13408,"interventions":13409},"NCT02817945","Dual SSTR2 and Integrin αvβ3 Targeting PET\u002FCT Imaging",[87],[29,5425],[13400],{"trials":13411,"activeCount":100},[],{"trials":13413,"activeCount":100},[],{"trials":13415,"activeCount":100},[],{"trials":13417,"activeCount":100},[],{"trials":13419,"activeCount":100},[],{"intervention":13421,"totalTrials":147,"cells":13422},"68Ga-FAPI-04",{"EARLY_PHASE1":13423,"PHASE1":13432,"PHASE2":13434,"PHASE3":13436,"PHASE4":13438,"NA":13440},{"trials":13424,"activeCount":100},[13425],{"nctId":13426,"briefTitle":13427,"status":108,"phases":13428,"primaryCompletion":177,"completion":177,"start":242,"enrollment":957,"conditions":13429,"interventions":13431},"NCT05003427","68Ga-FAPI-04 PET\u002FCT for the Detection of Oral Carcinoma",[87],[13430],"Oral Carcinoma",[13421],{"trials":13433,"activeCount":100},[],{"trials":13435,"activeCount":100},[],{"trials":13437,"activeCount":100},[],{"trials":13439,"activeCount":100},[],{"trials":13441,"activeCount":100},[],{"intervention":3544,"totalTrials":147,"cells":13443},{"EARLY_PHASE1":13444,"PHASE1":13450,"PHASE2":13452,"PHASE3":13454,"PHASE4":13456,"NA":13458},{"trials":13445,"activeCount":100},[13446],{"nctId":3538,"briefTitle":3539,"status":108,"phases":13447,"primaryCompletion":278,"completion":278,"start":3541,"enrollment":811,"conditions":13448,"interventions":13449},[87],[196],[3544,3517],{"trials":13451,"activeCount":100},[],{"trials":13453,"activeCount":100},[],{"trials":13455,"activeCount":100},[],{"trials":13457,"activeCount":100},[],{"trials":13459,"activeCount":100},[],{"intervention":13461,"totalTrials":147,"cells":13462},"GD-iExo-001",{"EARLY_PHASE1":13463,"PHASE1":13473,"PHASE2":13475,"PHASE3":13477,"PHASE4":13479,"NA":13481},{"trials":13464,"activeCount":100},[13465],{"nctId":13466,"briefTitle":13467,"status":108,"phases":13468,"primaryCompletion":5543,"completion":595,"start":13469,"enrollment":142,"conditions":13470,"interventions":13472},"NCT05969717","Induced Pluripotent Stem Cell Derived Exosomes for the Treatment of Atopic Dermatitis",[87],"2023-04-12",[13471],"Atopic Dermatitis",[13461],{"trials":13474,"activeCount":100},[],{"trials":13476,"activeCount":100},[],{"trials":13478,"activeCount":100},[],{"trials":13480,"activeCount":100},[],{"trials":13482,"activeCount":100},[],{"intervention":13484,"totalTrials":147,"cells":13485},"Intravenous injection of 68Ga-PMD22",{"EARLY_PHASE1":13486,"PHASE1":13496,"PHASE2":13498,"PHASE3":13500,"PHASE4":13502,"NA":13504},{"trials":13487,"activeCount":100},[13488],{"nctId":13489,"briefTitle":13490,"status":108,"phases":13491,"primaryCompletion":1323,"completion":1323,"start":13492,"enrollment":215,"conditions":13493,"interventions":13495},"NCT05937919","68Ga-PMD22 PET\u002FCT Examination Targeting CLDN18.2",[87],"2023-05-28",[13494],"Gastrointestinal Cancer",[13484],{"trials":13497,"activeCount":100},[],{"trials":13499,"activeCount":100},[],{"trials":13501,"activeCount":100},[],{"trials":13503,"activeCount":100},[],{"trials":13505,"activeCount":100},[],{"intervention":13507,"totalTrials":147,"cells":13508},"99mTc-HPArk2",{"EARLY_PHASE1":13509,"PHASE1":13518,"PHASE2":13520,"PHASE3":13522,"PHASE4":13524,"NA":13526},{"trials":13510,"activeCount":100},[13511],{"nctId":13512,"briefTitle":13513,"status":443,"phases":13514,"primaryCompletion":2392,"completion":2392,"start":13515,"enrollment":3460,"conditions":13516,"interventions":13517},"NCT04267900","99mTc-HPArk2 SPECT\u002FCT for the Detection of HER2-positive Breast Cancer",[87],"2019-12-07",[16],[13507],{"trials":13519,"activeCount":100},[],{"trials":13521,"activeCount":100},[],{"trials":13523,"activeCount":100},[],{"trials":13525,"activeCount":100},[],{"trials":13527,"activeCount":100},[],{"intervention":13529,"totalTrials":147,"cells":13530},"99mTc-3PRGD2",{"EARLY_PHASE1":13531,"PHASE1":13539,"PHASE2":13541,"PHASE3":13543,"PHASE4":13545,"NA":13547},{"trials":13532,"activeCount":100},[13533],{"nctId":13534,"briefTitle":13535,"status":108,"phases":13536,"primaryCompletion":5674,"completion":5674,"start":842,"enrollment":811,"conditions":13537,"interventions":13538},"NCT01737112","99mTc-3PRGD2 SPECT\u002FCT in Lung Cancer Patients",[87],[29],[13529],{"trials":13540,"activeCount":100},[],{"trials":13542,"activeCount":100},[],{"trials":13544,"activeCount":100},[],{"trials":13546,"activeCount":100},[],{"trials":13548,"activeCount":100},[],{"intervention":13550,"totalTrials":147,"cells":13551},"Ezetimibe+Simvastatin Drug Combination",{"EARLY_PHASE1":13552,"PHASE1":13560,"PHASE2":13562,"PHASE3":13564,"PHASE4":13566,"NA":13568},{"trials":13553,"activeCount":100},[13554],{"nctId":13555,"briefTitle":13556,"status":108,"phases":13557,"primaryCompletion":12650,"completion":3472,"start":2352,"enrollment":957,"conditions":13558,"interventions":13559},"NCT02548936","Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE",[87],[2617],[13550],{"trials":13561,"activeCount":100},[],{"trials":13563,"activeCount":100},[],{"trials":13565,"activeCount":100},[],{"trials":13567,"activeCount":100},[],{"trials":13569,"activeCount":100},[],{"intervention":13571,"totalTrials":147,"cells":13572},"CNCT19 cell",{"EARLY_PHASE1":13573,"PHASE1":13584,"PHASE2":13586,"PHASE3":13588,"PHASE4":13590,"NA":13592},{"trials":13574,"activeCount":100},[13575],{"nctId":13576,"briefTitle":13577,"status":108,"phases":13578,"primaryCompletion":10332,"completion":13579,"start":13580,"enrollment":209,"conditions":13581,"interventions":13583},"NCT05930314","CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus",[87],"2025-05-30","2023-06-19",[13582,3099,420],"Refractory Systemic Lupus Erythematosus",[13571],{"trials":13585,"activeCount":100},[],{"trials":13587,"activeCount":100},[],{"trials":13589,"activeCount":100},[],{"trials":13591,"activeCount":100},[],{"trials":13593,"activeCount":100},[],{"intervention":13595,"totalTrials":147,"cells":13596},"[68Ga]Ga-HBED-CC-exendin-4",{"EARLY_PHASE1":13597,"PHASE1":13608,"PHASE2":13610,"PHASE3":13612,"PHASE4":13614,"NA":13616},{"trials":13598,"activeCount":100},[13599],{"nctId":13600,"briefTitle":13601,"status":108,"phases":13602,"primaryCompletion":13603,"completion":1693,"start":2659,"enrollment":142,"conditions":13604,"interventions":13606},"NCT05034783","[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET\u002FCT Imaging in the Same Group of Insulinoma Patients",[87],"2022-10-13",[13605],"Insulinoma",[13595,13607],"[68Ga]Ga-NOTA-exendin-4",{"trials":13609,"activeCount":100},[],{"trials":13611,"activeCount":100},[],{"trials":13613,"activeCount":100},[],{"trials":13615,"activeCount":100},[],{"trials":13617,"activeCount":100},[],{"intervention":13607,"totalTrials":147,"cells":13619},{"EARLY_PHASE1":13620,"PHASE1":13626,"PHASE2":13628,"PHASE3":13630,"PHASE4":13632,"NA":13634},{"trials":13621,"activeCount":100},[13622],{"nctId":13600,"briefTitle":13601,"status":108,"phases":13623,"primaryCompletion":13603,"completion":1693,"start":2659,"enrollment":142,"conditions":13624,"interventions":13625},[87],[13605],[13595,13607],{"trials":13627,"activeCount":100},[],{"trials":13629,"activeCount":100},[],{"trials":13631,"activeCount":100},[],{"trials":13633,"activeCount":100},[],{"trials":13635,"activeCount":100},[],{"intervention":13637,"totalTrials":147,"cells":13638},"68Ga-NOTA-exendin-4",{"EARLY_PHASE1":13639,"PHASE1":13649,"PHASE2":13651,"PHASE3":13653,"PHASE4":13655,"NA":13657},{"trials":13640,"activeCount":100},[13641],{"nctId":13642,"briefTitle":13643,"status":108,"phases":13644,"primaryCompletion":3472,"completion":3472,"start":13645,"enrollment":811,"conditions":13646,"interventions":13648},"NCT02560376","68Ga-NOTA-exendin-4 PET\u002FCT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis",[87],"2014-02",[13605,13647],"Nesidioblastosis",[13637],{"trials":13650,"activeCount":100},[],{"trials":13652,"activeCount":100},[],{"trials":13654,"activeCount":100},[],{"trials":13656,"activeCount":100},[],{"trials":13658,"activeCount":100},[],{"intervention":13660,"totalTrials":147,"cells":13661},"68Ga-EB-ss-CPT",{"EARLY_PHASE1":13662,"PHASE1":13672,"PHASE2":13674,"PHASE3":13676,"PHASE4":13678,"NA":13680},{"trials":13663,"activeCount":100},[13664],{"nctId":13665,"briefTitle":13666,"status":108,"phases":13667,"primaryCompletion":1323,"completion":1323,"start":13668,"enrollment":215,"conditions":13669,"interventions":13670},"NCT05891028","64Cu\u002F68Ga Labelled EB-ss-CPT PET\u002FCT Scan in Colorectal Cancer",[87],"2023-05-07",[663],[13660,13671],"64Cu-EB-ss-CPT",{"trials":13673,"activeCount":100},[],{"trials":13675,"activeCount":100},[],{"trials":13677,"activeCount":100},[],{"trials":13679,"activeCount":100},[],{"trials":13681,"activeCount":100},[],{"intervention":13671,"totalTrials":147,"cells":13683},{"EARLY_PHASE1":13684,"PHASE1":13690,"PHASE2":13692,"PHASE3":13694,"PHASE4":13696,"NA":13698},{"trials":13685,"activeCount":100},[13686],{"nctId":13665,"briefTitle":13666,"status":108,"phases":13687,"primaryCompletion":1323,"completion":1323,"start":13668,"enrollment":215,"conditions":13688,"interventions":13689},[87],[663],[13660,13671],{"trials":13691,"activeCount":100},[],{"trials":13693,"activeCount":100},[],{"trials":13695,"activeCount":100},[],{"trials":13697,"activeCount":100},[],{"trials":13699,"activeCount":100},[],{"intervention":13701,"totalTrials":147,"cells":13702},"iPSC-Exos",{"EARLY_PHASE1":13703,"PHASE1":13715,"PHASE2":13717,"PHASE3":13719,"PHASE4":13721,"NA":13723},{"trials":13704,"activeCount":100},[13705],{"nctId":13706,"briefTitle":13707,"status":108,"phases":13708,"primaryCompletion":13709,"completion":13710,"start":13711,"enrollment":3460,"conditions":13712,"interventions":13714},"NCT05886205","Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy",[87],"2025-06-13","2025-11-13","2023-06-05",[13713],"Refractory Focal Epilepsy",[13701],{"trials":13716,"activeCount":100},[],{"trials":13718,"activeCount":100},[],{"trials":13720,"activeCount":100},[],{"trials":13722,"activeCount":100},[],{"trials":13724,"activeCount":100},[],{"intervention":13726,"totalTrials":147,"cells":13727},"18F-FDS",{"EARLY_PHASE1":13728,"PHASE1":13739,"PHASE2":13741,"PHASE3":13743,"PHASE4":13745,"NA":13747},{"trials":13729,"activeCount":100},[13730],{"nctId":13731,"briefTitle":13732,"status":108,"phases":13733,"primaryCompletion":13734,"completion":13735,"start":13295,"enrollment":957,"conditions":13736,"interventions":13738},"NCT02450942","18F-FDS PET\u002FCT in Healthy Volunteers and Patients With Suspected Infection",[87],"2018-01","2018-03",[13737],"Enterobacteriaceae Infections",[13726],{"trials":13740,"activeCount":100},[],{"trials":13742,"activeCount":100},[],{"trials":13744,"activeCount":100},[],{"trials":13746,"activeCount":100},[],{"trials":13748,"activeCount":100},[],{"intervention":13750,"totalTrials":147,"cells":13751},"99mTc-MIRC213",{"EARLY_PHASE1":13752,"PHASE1":13761,"PHASE2":13763,"PHASE3":13765,"PHASE4":13767,"NA":13769},{"trials":13753,"activeCount":100},[13754],{"nctId":13755,"briefTitle":13756,"status":108,"phases":13757,"primaryCompletion":2749,"completion":2749,"start":13758,"enrollment":957,"conditions":13759,"interventions":13760},"NCT05622240","99mTc-MIRC213 SPECT\u002FCT for the Detection of HER2-positive Breast Cancer",[87],"2022-09-07",[16],[13750],{"trials":13762,"activeCount":100},[],{"trials":13764,"activeCount":100},[],{"trials":13766,"activeCount":100},[],{"trials":13768,"activeCount":100},[],{"trials":13770,"activeCount":100},[],{"intervention":13772,"totalTrials":147,"cells":13773},"18F-FMPP",{"EARLY_PHASE1":13774,"PHASE1":13783,"PHASE2":13785,"PHASE3":13787,"PHASE4":13789,"NA":13791},{"trials":13775,"activeCount":100},[13776],{"nctId":13777,"briefTitle":13778,"status":108,"phases":13779,"primaryCompletion":10831,"completion":13317,"start":2919,"enrollment":811,"conditions":13780,"interventions":13782},"NCT04596527","18F-FMPP PET MPI in the Detection of Coronary Artery Disease",[87],[13781],"Coronary Disease",[13772],{"trials":13784,"activeCount":100},[],{"trials":13786,"activeCount":100},[],{"trials":13788,"activeCount":100},[],{"trials":13790,"activeCount":100},[],{"trials":13792,"activeCount":100},[],{"intervention":13794,"totalTrials":147,"cells":13795},"68Ga-NY104",{"EARLY_PHASE1":13796,"PHASE1":13806,"PHASE2":13808,"PHASE3":13810,"PHASE4":13812,"NA":13814},{"trials":13797,"activeCount":100},[13798],{"nctId":13799,"briefTitle":13800,"status":443,"phases":13801,"primaryCompletion":13802,"completion":13802,"start":13803,"enrollment":184,"conditions":13804,"interventions":13805},"NCT05728515","A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma",[87],"2022-03-04","2021-12-25",[3724],[13794],{"trials":13807,"activeCount":100},[],{"trials":13809,"activeCount":100},[],{"trials":13811,"activeCount":100},[],{"trials":13813,"activeCount":100},[],{"trials":13815,"activeCount":100},[],{"intervention":7944,"totalTrials":605,"cells":13817},{"EARLY_PHASE1":13818,"PHASE1":13820,"PHASE2":13822,"PHASE3":13824,"PHASE4":13826,"NA":13840},{"trials":13819,"activeCount":100},[],{"trials":13821,"activeCount":100},[],{"trials":13823,"activeCount":100},[],{"trials":13825,"activeCount":100},[],{"trials":13827,"activeCount":100},[13828,13832,13836],{"nctId":7936,"briefTitle":7937,"status":443,"phases":13829,"primaryCompletion":7939,"completion":7939,"start":7940,"enrollment":4579,"conditions":13830,"interventions":13831},[91],[7942],[7923,7944],{"nctId":8475,"briefTitle":8476,"status":108,"phases":13833,"primaryCompletion":8478,"completion":8478,"start":8479,"enrollment":8480,"conditions":13834,"interventions":13835},[91],[8482],[8462,7944],{"nctId":8588,"briefTitle":8589,"status":443,"phases":13837,"primaryCompletion":8591,"completion":8591,"start":8592,"enrollment":8593,"conditions":13838,"interventions":13839},[91],[1370,8595,32],[8575,7944],{"trials":13841,"activeCount":100},[13842],{"nctId":13843,"briefTitle":13844,"status":108,"phases":13845,"primaryCompletion":3326,"completion":3326,"start":13846,"enrollment":13847,"conditions":13848,"interventions":13850},"NCT04621565","Hydrocortisone Use During Peri-operation for Pituitary Adenomas",[92],"2020-11-01",436,[5691,13849,32],"Adrenal Insufficiency",[7944,13851],"Hydrocortisone",{"intervention":132,"totalTrials":605,"cells":13853},{"EARLY_PHASE1":13854,"PHASE1":13856,"PHASE2":13858,"PHASE3":13872,"PHASE4":13874,"NA":13876},{"trials":13855,"activeCount":100},[],{"trials":13857,"activeCount":100},[],{"trials":13859,"activeCount":100},[13860,13864,13868],{"nctId":11370,"briefTitle":11371,"status":108,"phases":13861,"primaryCompletion":1898,"completion":11373,"start":2507,"enrollment":142,"conditions":13862,"interventions":13863},[88,89],[1767],[132,11361,11376],{"nctId":11411,"briefTitle":11412,"status":443,"phases":13865,"primaryCompletion":1736,"completion":1897,"start":11414,"enrollment":2353,"conditions":13866,"interventions":13867},[89],[782],[132,11402,2817],{"nctId":121,"briefTitle":122,"status":108,"phases":13869,"primaryCompletion":124,"completion":125,"start":126,"enrollment":127,"conditions":13870,"interventions":13871},[89],[129,130],[132,133,95],{"trials":13873,"activeCount":100},[],{"trials":13875,"activeCount":100},[],{"trials":13877,"activeCount":100},[13878],{"nctId":13879,"briefTitle":13880,"status":108,"phases":13881,"primaryCompletion":2604,"completion":11287,"start":13882,"enrollment":811,"conditions":13883,"interventions":13886},"NCT04672759","A Real-world Study of Durvalumab for Lung Cancer in China",[],"2020-07-28",[13884,13885],"Non Small Cell Lung Cancer Stage III","Small-Cell Lung Cancer",[132,132],{"intervention":12381,"totalTrials":184,"cells":13888},{"EARLY_PHASE1":13889,"PHASE1":13899,"PHASE2":13901,"PHASE3":13907,"PHASE4":13909,"NA":13911},{"trials":13890,"activeCount":100},[13891],{"nctId":13892,"briefTitle":13893,"status":108,"phases":13894,"primaryCompletion":298,"completion":13895,"start":298,"enrollment":2814,"conditions":13896,"interventions":13898},"NCT03687021","Clinical Study on Endometrial Receptivity",[87],"2018-11-10",[13897],"Endometrial Receptivity;RNA; Progesterone",[12381],{"trials":13900,"activeCount":100},[],{"trials":13902,"activeCount":100},[13903],{"nctId":12374,"briefTitle":12375,"status":443,"phases":13904,"primaryCompletion":471,"completion":12377,"start":8803,"enrollment":113,"conditions":13905,"interventions":13906},[88,89],[12379],[12365,12381],{"trials":13908,"activeCount":100},[],{"trials":13910,"activeCount":100},[],{"trials":13912,"activeCount":100},[13913],{"nctId":13914,"briefTitle":13915,"status":108,"phases":13916,"primaryCompletion":13917,"completion":778,"start":5869,"enrollment":13918,"conditions":13919,"interventions":13921},"NCT05312190","Clinical and Basic Researches Related to ZhenQi Buxue Oral Liquid in Treating Menstrual Disorders",[92],"2022-12-30",330,[13920],"Menstrual Disorders",[13922,12381],"ZhenQi BuXue KouFuYe",{"intervention":2817,"totalTrials":184,"cells":13924},{"EARLY_PHASE1":13925,"PHASE1":13927,"PHASE2":13929,"PHASE3":13939,"PHASE4":13941,"NA":13943},{"trials":13926,"activeCount":100},[],{"trials":13928,"activeCount":100},[],{"trials":13930,"activeCount":100},[13931,13935],{"nctId":11411,"briefTitle":11412,"status":443,"phases":13932,"primaryCompletion":1736,"completion":1897,"start":11414,"enrollment":2353,"conditions":13933,"interventions":13934},[89],[782],[132,11402,2817],{"nctId":2810,"briefTitle":2811,"status":108,"phases":13936,"primaryCompletion":177,"completion":1736,"start":2813,"enrollment":2814,"conditions":13937,"interventions":13938},[89],[25],[2461,2817,2818,2472],{"trials":13940,"activeCount":100},[],{"trials":13942,"activeCount":100},[],{"trials":13944,"activeCount":100},[13945],{"nctId":13946,"briefTitle":13947,"status":108,"phases":13948,"primaryCompletion":3212,"completion":3212,"start":1682,"enrollment":194,"conditions":13949,"interventions":13951},"NCT03544047","Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model",[92],[13950],"Organoid",[2817],{"intervention":13953,"totalTrials":372,"cells":13954},"68Ga-PSMA",{"EARLY_PHASE1":13955,"PHASE1":13965,"PHASE2":13967,"PHASE3":13969,"PHASE4":13971,"NA":13973},{"trials":13956,"activeCount":100},[13957],{"nctId":13958,"briefTitle":13959,"status":108,"phases":13960,"primaryCompletion":3193,"completion":1858,"start":2644,"enrollment":127,"conditions":13961,"interventions":13963},"NCT04801264","Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617",[87],[13962],"Adenoid Cystic Carcinoma",[13953,13964],"1.85GBq (50 mCi) of 177Lu-EB-PSMA-617",{"trials":13966,"activeCount":100},[],{"trials":13968,"activeCount":100},[],{"trials":13970,"activeCount":100},[],{"trials":13972,"activeCount":100},[],{"trials":13974,"activeCount":100},[13975],{"nctId":13976,"briefTitle":13977,"status":108,"phases":13978,"primaryCompletion":2701,"completion":40,"start":2660,"enrollment":127,"conditions":13979,"interventions":13981},"NCT05170555","Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617",[92],[13980],"Renal Cell Carcinoma",[13953,13964],{"intervention":13964,"totalTrials":372,"cells":13983},{"EARLY_PHASE1":13984,"PHASE1":13990,"PHASE2":13992,"PHASE3":13994,"PHASE4":13996,"NA":13998},{"trials":13985,"activeCount":100},[13986],{"nctId":13958,"briefTitle":13959,"status":108,"phases":13987,"primaryCompletion":3193,"completion":1858,"start":2644,"enrollment":127,"conditions":13988,"interventions":13989},[87],[13962],[13953,13964],{"trials":13991,"activeCount":100},[],{"trials":13993,"activeCount":100},[],{"trials":13995,"activeCount":100},[],{"trials":13997,"activeCount":100},[],{"trials":13999,"activeCount":100},[14000],{"nctId":13976,"briefTitle":13977,"status":108,"phases":14001,"primaryCompletion":2701,"completion":40,"start":2660,"enrollment":127,"conditions":14002,"interventions":14003},[92],[13980],[13953,13964],{"intervention":478,"totalTrials":372,"cells":14005},{"EARLY_PHASE1":14006,"PHASE1":14008,"PHASE2":14010,"PHASE3":14012,"PHASE4":14014,"NA":14020},{"trials":14007,"activeCount":100},[],{"trials":14009,"activeCount":100},[],{"trials":14011,"activeCount":100},[],{"trials":14013,"activeCount":100},[],{"trials":14015,"activeCount":100},[14016],{"nctId":467,"briefTitle":468,"status":108,"phases":14017,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":14018,"interventions":14019},[91],[475,476],[478,390],{"trials":14021,"activeCount":100},[14022],{"nctId":14023,"briefTitle":14024,"status":108,"phases":14025,"primaryCompletion":14026,"completion":10831,"start":14027,"enrollment":705,"conditions":14028,"interventions":14030},"NCT04078204","A Clinical Study on the Treatment of Cerebral Small Vascular Disease",[92],"2022-02","2018-04-25",[14029],"Cerebral Small Vessel Diseases",[478],{"intervention":2780,"totalTrials":372,"cells":14032},{"EARLY_PHASE1":14033,"PHASE1":14035,"PHASE2":14037,"PHASE3":14043,"PHASE4":14045,"NA":14047},{"trials":14034,"activeCount":100},[],{"trials":14036,"activeCount":100},[],{"trials":14038,"activeCount":100},[14039],{"nctId":3575,"briefTitle":3576,"status":108,"phases":14040,"primaryCompletion":3223,"completion":956,"start":2659,"enrollment":142,"conditions":14041,"interventions":14042},[89],[27,2780,3579],[2780,56],{"trials":14044,"activeCount":100},[],{"trials":14046,"activeCount":100},[],{"trials":14048,"activeCount":100},[14049],{"nctId":2771,"briefTitle":2772,"status":108,"phases":14050,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":14051,"interventions":14052},[],[2778],[2780,2781,46,2462,653,2461,2474],{"intervention":14054,"totalTrials":372,"cells":14055},"infliximab",{"EARLY_PHASE1":14056,"PHASE1":14058,"PHASE2":14060,"PHASE3":14062,"PHASE4":14064,"NA":14075},{"trials":14057,"activeCount":100},[],{"trials":14059,"activeCount":100},[],{"trials":14061,"activeCount":100},[],{"trials":14063,"activeCount":100},[],{"trials":14065,"activeCount":100},[14066],{"nctId":14067,"briefTitle":14068,"status":108,"phases":14069,"start":6667,"enrollment":14070,"conditions":14071,"interventions":14074},"NCT01282528","Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis",[91],85,[5491,14072,14073],"Ultrasonography","Infliximab",[14054],{"trials":14076,"activeCount":100},[14077],{"nctId":14078,"briefTitle":14079,"status":108,"phases":14080,"primaryCompletion":4867,"completion":2381,"start":14081,"enrollment":324,"conditions":14082,"interventions":14085},"NCT05386290","A Multicentered Prospective Cohort Study of Chinese IBD Patients",[],"2020-07-09",[14083,14084],"Ulcerative Colitis","Crohn Disease",[14073,14086,14087,14088],"Vedolizumab","Ustekinumab","conventional treatment",{"intervention":14090,"totalTrials":372,"cells":14091},"99mTc-ABH2",{"EARLY_PHASE1":14092,"PHASE1":14103,"PHASE2":14105,"PHASE3":14107,"PHASE4":14109,"NA":14111},{"trials":14093,"activeCount":100},[14094],{"nctId":14095,"briefTitle":14096,"status":443,"phases":14097,"primaryCompletion":14098,"completion":14099,"start":14100,"enrollment":661,"conditions":14101,"interventions":14102},"NCT03546478","99mTc Labelled Affibody SPECT\u002FCT Imaging for Breast Cancer HER2 Characterization",[87],"2017-05-24","2018-05-18","2015-06-24",[16],[14090],{"trials":14104,"activeCount":100},[],{"trials":14106,"activeCount":100},[],{"trials":14108,"activeCount":100},[],{"trials":14110,"activeCount":100},[],{"trials":14112,"activeCount":100},[14113],{"nctId":14114,"briefTitle":14115,"status":108,"phases":14116,"primaryCompletion":124,"completion":14117,"start":14118,"enrollment":127,"conditions":14119,"interventions":14120},"NCT06194565","99mTc-ABH2 SPECT\u002FCT in Breast Cancer",[92],"2024-01-30","2023-03-20",[16],[14090],{"intervention":14122,"totalTrials":372,"cells":14123},"Efavirenz 400mg",{"EARLY_PHASE1":14124,"PHASE1":14126,"PHASE2":14128,"PHASE3":14130,"PHASE4":14132,"NA":14134},{"trials":14125,"activeCount":100},[],{"trials":14127,"activeCount":100},[],{"trials":14129,"activeCount":100},[],{"trials":14131,"activeCount":100},[],{"trials":14133,"activeCount":100},[],{"trials":14135,"activeCount":100},[14136,14143],{"nctId":14137,"briefTitle":14138,"status":443,"phases":14139,"primaryCompletion":14140,"completion":9886,"start":7837,"enrollment":1860,"conditions":14141,"interventions":14142},"NCT04596488","Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients",[92],"2018-12-30",[8873],[14122],{"nctId":14144,"briefTitle":14145,"status":108,"phases":14146,"primaryCompletion":5593,"completion":14147,"start":14148,"enrollment":1048,"conditions":14149,"interventions":14152},"NCT04463784","Efficacy of Efavirenz 400mg vs. 600mg Combined With Lamivudine and Tenofovir in Treatment Naive HIV Infection",[92],"2021-08","2018-04-01",[14150,14151],"HIV\u002FAIDS","Mental Impairment",[14153,14154],"Efavirenz 400Mg Oral","Efavirenz 600Mg Oral",{"intervention":14156,"totalTrials":372,"cells":14157},"Prednisone and Mycophenolate Mofetil",{"EARLY_PHASE1":14158,"PHASE1":14160,"PHASE2":14162,"PHASE3":14168,"PHASE4":14170,"NA":14172},{"trials":14159,"activeCount":100},[],{"trials":14161,"activeCount":100},[],{"trials":14163,"activeCount":100},[14164],{"nctId":2347,"briefTitle":2348,"status":108,"phases":14165,"primaryCompletion":2350,"completion":2351,"start":2352,"enrollment":2353,"conditions":14166,"interventions":14167},[89],[2355],[250,2357],{"trials":14169,"activeCount":100},[],{"trials":14171,"activeCount":100},[],{"trials":14173,"activeCount":100},[14174],{"nctId":14175,"briefTitle":14176,"status":108,"phases":14177,"primaryCompletion":80,"completion":80,"start":193,"enrollment":2353,"conditions":14178,"interventions":14179},"NCT05789017","Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement",[92],[7319],[14156,14180,14181],"Mycophenolate Mofetil","Leflunomide",{"intervention":14180,"totalTrials":372,"cells":14183},{"EARLY_PHASE1":14184,"PHASE1":14186,"PHASE2":14188,"PHASE3":14190,"PHASE4":14192,"NA":14194},{"trials":14185,"activeCount":100},[],{"trials":14187,"activeCount":100},[],{"trials":14189,"activeCount":100},[],{"trials":14191,"activeCount":100},[],{"trials":14193,"activeCount":100},[],{"trials":14195,"activeCount":100},[14196,14200],{"nctId":14175,"briefTitle":14176,"status":108,"phases":14197,"primaryCompletion":80,"completion":80,"start":193,"enrollment":2353,"conditions":14198,"interventions":14199},[92],[7319],[14156,14180,14181],{"nctId":14201,"briefTitle":14202,"status":108,"phases":14203,"primaryCompletion":528,"completion":528,"start":14204,"enrollment":14205,"conditions":14206,"interventions":14207},"NCT05974683","Treatment Strategies in IgG4-RD Patients With Re-elevation of Serum IgG4 Level During Maintenance Remission Period",[92],"2023-08-01",108,[7319],[14208],"mycophenolate mofetil",{"intervention":14210,"totalTrials":372,"cells":14211},"Remimazolam besylate",{"EARLY_PHASE1":14212,"PHASE1":14214,"PHASE2":14216,"PHASE3":14218,"PHASE4":14224,"NA":14226},{"trials":14213,"activeCount":100},[],{"trials":14215,"activeCount":100},[],{"trials":14217,"activeCount":100},[],{"trials":14219,"activeCount":100},[14220],{"nctId":8053,"briefTitle":8054,"status":108,"phases":14221,"primaryCompletion":2681,"completion":3193,"start":757,"enrollment":8056,"conditions":14222,"interventions":14223},[90],[8058,8059],[8061,8042],{"trials":14225,"activeCount":100},[],{"trials":14227,"activeCount":100},[14228],{"nctId":14229,"briefTitle":14230,"status":108,"phases":14231,"primaryCompletion":240,"completion":3908,"start":11641,"enrollment":5179,"conditions":14232,"interventions":14236},"NCT05350085","Remimazolam in the Extraction of Impacted Wisdom Teeth",[92],[14233,14234,14235],"Dental Anxiety","Sedation Complication","Anterograde Amnesia",[14210,14237],"Midazolam",{"intervention":14239,"totalTrials":372,"cells":14240},"Corticosteroids",{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14245,"PHASE3":14247,"PHASE4":14249,"NA":14251},{"trials":14242,"activeCount":100},[],{"trials":14244,"activeCount":100},[],{"trials":14246,"activeCount":100},[],{"trials":14248,"activeCount":100},[],{"trials":14250,"activeCount":100},[],{"trials":14252,"activeCount":100},[14253,14262],{"nctId":14254,"briefTitle":14255,"status":108,"phases":14256,"primaryCompletion":5722,"completion":595,"start":14257,"enrollment":2353,"conditions":14258,"interventions":14260},"NCT05899725","The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia",[92],"2023-04-14",[14259],"Severe Checkpoint Inhibitor Pneumonitis",[14239,14261],"Corticosteroids and Ruxolitinib",{"nctId":14263,"briefTitle":14264,"status":108,"phases":14265,"primaryCompletion":5594,"completion":5594,"start":14266,"enrollment":957,"conditions":14267,"interventions":14271},"NCT02797665","Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and\u002For Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids",[92],"2016-05",[14268,14269,14270],"Autoimmune Pancreatitis","IgG4-related Sclerosing Cholangitis","Obstructive Jaundice",[14272],"corticosteroids",{"intervention":14274,"totalTrials":147,"cells":14275},"Drug free, IS monotherapy and GC combined with IS",{"EARLY_PHASE1":14276,"PHASE1":14278,"PHASE2":14280,"PHASE3":14282,"PHASE4":14284,"NA":14286},{"trials":14277,"activeCount":100},[],{"trials":14279,"activeCount":100},[],{"trials":14281,"activeCount":100},[],{"trials":14283,"activeCount":100},[],{"trials":14285,"activeCount":100},[],{"trials":14287,"activeCount":100},[14288],{"nctId":14289,"briefTitle":14290,"status":108,"phases":14291,"primaryCompletion":13917,"completion":778,"start":14292,"enrollment":1922,"conditions":14293,"interventions":14294},"NCT04124861","Withdraw Drug in Stable IgG4-Related Disease",[92],"2020-06-23",[7319],[14274],{"intervention":13922,"totalTrials":147,"cells":14296},{"EARLY_PHASE1":14297,"PHASE1":14299,"PHASE2":14301,"PHASE3":14303,"PHASE4":14305,"NA":14307},{"trials":14298,"activeCount":100},[],{"trials":14300,"activeCount":100},[],{"trials":14302,"activeCount":100},[],{"trials":14304,"activeCount":100},[],{"trials":14306,"activeCount":100},[],{"trials":14308,"activeCount":100},[14309],{"nctId":13914,"briefTitle":13915,"status":108,"phases":14310,"primaryCompletion":13917,"completion":778,"start":5869,"enrollment":13918,"conditions":14311,"interventions":14312},[92],[13920],[13922,12381],{"intervention":14314,"totalTrials":147,"cells":14315},"Precision oncology including targeted therapy and immunotherapy",{"EARLY_PHASE1":14316,"PHASE1":14318,"PHASE2":14320,"PHASE3":14322,"PHASE4":14324,"NA":14326},{"trials":14317,"activeCount":100},[],{"trials":14319,"activeCount":100},[],{"trials":14321,"activeCount":100},[],{"trials":14323,"activeCount":100},[],{"trials":14325,"activeCount":100},[],{"trials":14327,"activeCount":100},[14328],{"nctId":14329,"briefTitle":14330,"status":108,"phases":14331,"primaryCompletion":3908,"completion":333,"start":14332,"enrollment":7186,"conditions":14333,"interventions":14341},"NCT03892577","Real-world Study for Patients With Advanced Hepatobiliary Tumors",[],"2017-07-01",[14334,14335,14336,14337,14338,14339,14340],"Objective Response Rate","Progression-free Survival","Overall Survival","Disease Control Rate","Duration of Response","Five-year Survival Rate","Quality of Life",[14314],{"intervention":14343,"totalTrials":147,"cells":14344},"99mTc-HFAPI",{"EARLY_PHASE1":14345,"PHASE1":14347,"PHASE2":14349,"PHASE3":14351,"PHASE4":14353,"NA":14355},{"trials":14346,"activeCount":100},[],{"trials":14348,"activeCount":100},[],{"trials":14350,"activeCount":100},[],{"trials":14352,"activeCount":100},[],{"trials":14354,"activeCount":100},[],{"trials":14356,"activeCount":100},[14357],{"nctId":14358,"briefTitle":14359,"status":108,"phases":14360,"primaryCompletion":40,"completion":55,"start":14361,"enrollment":5179,"conditions":14362,"interventions":14363},"NCT05859763","99mTc-HFAPI SPECT\u002FCT in Pulmonary Fibrosis",[92],"2021-12-12",[2672],[14343],{"intervention":14365,"totalTrials":147,"cells":14366},"Euthyrox",{"EARLY_PHASE1":14367,"PHASE1":14369,"PHASE2":14371,"PHASE3":14373,"PHASE4":14375,"NA":14377},{"trials":14368,"activeCount":100},[],{"trials":14370,"activeCount":100},[],{"trials":14372,"activeCount":100},[],{"trials":14374,"activeCount":100},[],{"trials":14376,"activeCount":100},[],{"trials":14378,"activeCount":100},[14379],{"nctId":14380,"briefTitle":14381,"status":108,"phases":14382,"primaryCompletion":2588,"completion":333,"start":14383,"enrollment":811,"conditions":14384,"interventions":14389},"NCT06353555","Efficacy of Thyroid Hormone Replacement for Secondary Hypothyroidism Following Intracerebral Hemorrhage",[92],"2023-10-11",[14385,14386,14387,14388],"Intracerebral Hemorrhage","Low T3 Syndrome","Neurocritical Care","Hormone Replacement Therapy",[14365,14365],{"intervention":14391,"totalTrials":147,"cells":14392},"rHuEPO",{"EARLY_PHASE1":14393,"PHASE1":14395,"PHASE2":14397,"PHASE3":14399,"PHASE4":14401,"NA":14403},{"trials":14394,"activeCount":100},[],{"trials":14396,"activeCount":100},[],{"trials":14398,"activeCount":100},[],{"trials":14400,"activeCount":100},[],{"trials":14402,"activeCount":100},[],{"trials":14404,"activeCount":100},[14405],{"nctId":14406,"briefTitle":14407,"status":108,"phases":14408,"primaryCompletion":14409,"completion":3120,"start":14410,"enrollment":14411,"conditions":14412,"interventions":14414},"NCT03917394","Erythropoietin And\u002FOr Iron Sucrose For Perioperative Anemia Management In Hip and Knee Arthroplasty",[],"2019-05-30","2019-04-24",780,[14413],"Anemia, Iron Deficiency",[14391,14415],"Iron sucrose",{"intervention":14415,"totalTrials":147,"cells":14417},{"EARLY_PHASE1":14418,"PHASE1":14420,"PHASE2":14422,"PHASE3":14424,"PHASE4":14426,"NA":14428},{"trials":14419,"activeCount":100},[],{"trials":14421,"activeCount":100},[],{"trials":14423,"activeCount":100},[],{"trials":14425,"activeCount":100},[],{"trials":14427,"activeCount":100},[],{"trials":14429,"activeCount":100},[14430],{"nctId":14406,"briefTitle":14407,"status":108,"phases":14431,"primaryCompletion":14409,"completion":3120,"start":14410,"enrollment":14411,"conditions":14432,"interventions":14433},[],[14413],[14391,14415],{"intervention":14435,"totalTrials":147,"cells":14436},"Antiretroviral Therapy",{"EARLY_PHASE1":14437,"PHASE1":14439,"PHASE2":14441,"PHASE3":14443,"PHASE4":14445,"NA":14447},{"trials":14438,"activeCount":100},[],{"trials":14440,"activeCount":100},[],{"trials":14442,"activeCount":100},[],{"trials":14444,"activeCount":100},[],{"trials":14446,"activeCount":100},[],{"trials":14448,"activeCount":100},[14449],{"nctId":14450,"briefTitle":14451,"status":443,"phases":14452,"primaryCompletion":9065,"completion":9065,"start":14453,"enrollment":194,"conditions":14454,"interventions":14455},"NCT04297501","Gut Microbiota Changes of HIV Patients Before and After One Year of ART",[],"2018-03-01",[8506],[14435],{"intervention":13851,"totalTrials":147,"cells":14457},{"EARLY_PHASE1":14458,"PHASE1":14460,"PHASE2":14462,"PHASE3":14464,"PHASE4":14466,"NA":14468},{"trials":14459,"activeCount":100},[],{"trials":14461,"activeCount":100},[],{"trials":14463,"activeCount":100},[],{"trials":14465,"activeCount":100},[],{"trials":14467,"activeCount":100},[],{"trials":14469,"activeCount":100},[14470],{"nctId":13843,"briefTitle":13844,"status":108,"phases":14471,"primaryCompletion":3326,"completion":3326,"start":13846,"enrollment":13847,"conditions":14472,"interventions":14473},[92],[5691,13849,32],[7944,13851],{"intervention":14475,"totalTrials":147,"cells":14476},"Aspirin \u002F Clopidogrel, Atorvastatin \u002F Simvastatin",{"EARLY_PHASE1":14477,"PHASE1":14479,"PHASE2":14481,"PHASE3":14483,"PHASE4":14485,"NA":14487},{"trials":14478,"activeCount":100},[],{"trials":14480,"activeCount":100},[],{"trials":14482,"activeCount":100},[],{"trials":14484,"activeCount":100},[],{"trials":14486,"activeCount":100},[],{"trials":14488,"activeCount":100},[14489],{"nctId":14490,"briefTitle":14491,"status":443,"phases":14492,"primaryCompletion":6668,"completion":14493,"start":14494,"enrollment":14495,"conditions":14496,"interventions":14497},"NCT00664846","Standard Medical Management in Secondary Prevention of Ischemic Stroke in China",[92],"2011-04","2008-04",4000,[475],[14475,14498],"Asprin \u002F Clopidogrel, Atorvastatin \u002F Simvastatin",{"intervention":14498,"totalTrials":147,"cells":14500},{"EARLY_PHASE1":14501,"PHASE1":14503,"PHASE2":14505,"PHASE3":14507,"PHASE4":14509,"NA":14511},{"trials":14502,"activeCount":100},[],{"trials":14504,"activeCount":100},[],{"trials":14506,"activeCount":100},[],{"trials":14508,"activeCount":100},[],{"trials":14510,"activeCount":100},[],{"trials":14512,"activeCount":100},[14513],{"nctId":14490,"briefTitle":14491,"status":443,"phases":14514,"primaryCompletion":6668,"completion":14493,"start":14494,"enrollment":14495,"conditions":14515,"interventions":14516},[92],[475],[14475,14498],{"intervention":14518,"totalTrials":147,"cells":14519},"Bisphosphonate",{"EARLY_PHASE1":14520,"PHASE1":14522,"PHASE2":14524,"PHASE3":14526,"PHASE4":14528,"NA":14530},{"trials":14521,"activeCount":100},[],{"trials":14523,"activeCount":100},[],{"trials":14525,"activeCount":100},[],{"trials":14527,"activeCount":100},[],{"trials":14529,"activeCount":100},[],{"trials":14531,"activeCount":100},[14532],{"nctId":14533,"briefTitle":14534,"status":108,"phases":14535,"primaryCompletion":14536,"completion":956,"start":648,"enrollment":473,"conditions":14537,"interventions":14538},"NCT05680194","Prospective Research for Elderly (≥65 Years Old) Early Breast Cancer Patients",[],"2025-03-31",[1740],[14518],{"intervention":14540,"totalTrials":147,"cells":14541},"Tocilizumab monotherapy",{"EARLY_PHASE1":14542,"PHASE1":14544,"PHASE2":14546,"PHASE3":14548,"PHASE4":14550,"NA":14552},{"trials":14543,"activeCount":100},[],{"trials":14545,"activeCount":100},[],{"trials":14547,"activeCount":100},[],{"trials":14549,"activeCount":100},[],{"trials":14551,"activeCount":100},[],{"trials":14553,"activeCount":100},[14554],{"nctId":14555,"briefTitle":14556,"status":443,"phases":14557,"primaryCompletion":13917,"completion":13917,"start":14558,"enrollment":209,"conditions":14559,"interventions":14562},"NCT05133895","Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis",[],"2020-07-15",[14560,14561],"Chronic Periaortitis","Tocilizumab Monotherapy",[14540],{"intervention":14564,"totalTrials":147,"cells":14565},"Wound topically irrigated with 500mg TXA",{"EARLY_PHASE1":14566,"PHASE1":14568,"PHASE2":14570,"PHASE3":14572,"PHASE4":14574,"NA":14576},{"trials":14567,"activeCount":100},[],{"trials":14569,"activeCount":100},[],{"trials":14571,"activeCount":100},[],{"trials":14573,"activeCount":100},[],{"trials":14575,"activeCount":100},[],{"trials":14577,"activeCount":100},[14578],{"nctId":14579,"briefTitle":14580,"status":108,"phases":14581,"primaryCompletion":494,"start":5595,"enrollment":14582,"conditions":14583,"interventions":14586},"NCT03011866","Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries",[92],176,[14584,14585],"Spinal Stenosis","Intervertebral Disc Displacement",[14564,14587],"1mg\u002Fkg\u002Fhr TXA intravenous infusion till the last suture",{"intervention":14587,"totalTrials":147,"cells":14589},{"EARLY_PHASE1":14590,"PHASE1":14592,"PHASE2":14594,"PHASE3":14596,"PHASE4":14598,"NA":14600},{"trials":14591,"activeCount":100},[],{"trials":14593,"activeCount":100},[],{"trials":14595,"activeCount":100},[],{"trials":14597,"activeCount":100},[],{"trials":14599,"activeCount":100},[],{"trials":14601,"activeCount":100},[14602],{"nctId":14579,"briefTitle":14580,"status":108,"phases":14603,"primaryCompletion":494,"start":5595,"enrollment":14582,"conditions":14604,"interventions":14605},[92],[14584,14585],[14564,14587],{"intervention":14607,"totalTrials":147,"cells":14608},"[18F]Florbetazine",{"EARLY_PHASE1":14609,"PHASE1":14611,"PHASE2":14613,"PHASE3":14615,"PHASE4":14617,"NA":14619},{"trials":14610,"activeCount":100},[],{"trials":14612,"activeCount":100},[],{"trials":14614,"activeCount":100},[],{"trials":14616,"activeCount":100},[],{"trials":14618,"activeCount":100},[],{"trials":14620,"activeCount":100},[14621],{"nctId":14622,"briefTitle":14623,"status":108,"phases":14624,"primaryCompletion":80,"completion":333,"start":14625,"enrollment":5179,"conditions":14626,"interventions":14628},"NCT06141356","[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease",[],"2023-01-30",[14627],"Alzheimer's Disease",[14607,14629],"[11C]PIB",{"intervention":14629,"totalTrials":147,"cells":14631},{"EARLY_PHASE1":14632,"PHASE1":14634,"PHASE2":14636,"PHASE3":14638,"PHASE4":14640,"NA":14642},{"trials":14633,"activeCount":100},[],{"trials":14635,"activeCount":100},[],{"trials":14637,"activeCount":100},[],{"trials":14639,"activeCount":100},[],{"trials":14641,"activeCount":100},[],{"trials":14643,"activeCount":100},[14644],{"nctId":14622,"briefTitle":14623,"status":108,"phases":14645,"primaryCompletion":80,"completion":333,"start":14625,"enrollment":5179,"conditions":14646,"interventions":14647},[],[14627],[14607,14629],{"intervention":14649,"totalTrials":147,"cells":14650},"sodium lactate Ringer's",{"EARLY_PHASE1":14651,"PHASE1":14653,"PHASE2":14655,"PHASE3":14657,"PHASE4":14659,"NA":14661},{"trials":14652,"activeCount":100},[],{"trials":14654,"activeCount":100},[],{"trials":14656,"activeCount":100},[],{"trials":14658,"activeCount":100},[],{"trials":14660,"activeCount":100},[],{"trials":14662,"activeCount":100},[14663],{"nctId":14664,"briefTitle":14665,"status":108,"phases":14666,"primaryCompletion":3472,"completion":3472,"start":14667,"conditions":14668,"interventions":14670},"NCT02449928","Using Sodium Lactate Ringer's Injection Resuscitate Septic Shock Patients",[92],"2015-09",[14669,7668],"Severe Sepsis With Septic Shock",[14649,14671],"Compound Sodium Chloride",{"intervention":14671,"totalTrials":147,"cells":14673},{"EARLY_PHASE1":14674,"PHASE1":14676,"PHASE2":14678,"PHASE3":14680,"PHASE4":14682,"NA":14684},{"trials":14675,"activeCount":100},[],{"trials":14677,"activeCount":100},[],{"trials":14679,"activeCount":100},[],{"trials":14681,"activeCount":100},[],{"trials":14683,"activeCount":100},[],{"trials":14685,"activeCount":100},[14686],{"nctId":14664,"briefTitle":14665,"status":108,"phases":14687,"primaryCompletion":3472,"completion":3472,"start":14667,"conditions":14688,"interventions":14689},[92],[14669,7668],[14649,14671],{"intervention":14691,"totalTrials":147,"cells":14692},"oral nutritional supplements",{"EARLY_PHASE1":14693,"PHASE1":14695,"PHASE2":14697,"PHASE3":14699,"PHASE4":14701,"NA":14703},{"trials":14694,"activeCount":100},[],{"trials":14696,"activeCount":100},[],{"trials":14698,"activeCount":100},[],{"trials":14700,"activeCount":100},[],{"trials":14702,"activeCount":100},[],{"trials":14704,"activeCount":100},[14705],{"nctId":14706,"briefTitle":14707,"status":108,"phases":14708,"primaryCompletion":14709,"completion":5407,"start":14710,"enrollment":14711,"conditions":14712,"interventions":14715},"NCT06062914","Health Economic Research on Oral Nutritional Supplements for Hospitalized Patients With Nutritional Risk",[],"2023-11-07","2023-10-07",30000,[14713,14714],"Malnutrition","Nutritional Risk",[14691],{"intervention":14717,"totalTrials":147,"cells":14718},"different volume of 0.5% ropivacaine",{"EARLY_PHASE1":14719,"PHASE1":14721,"PHASE2":14723,"PHASE3":14725,"PHASE4":14727,"NA":14729},{"trials":14720,"activeCount":100},[],{"trials":14722,"activeCount":100},[],{"trials":14724,"activeCount":100},[],{"trials":14726,"activeCount":100},[],{"trials":14728,"activeCount":100},[],{"trials":14730,"activeCount":100},[14731],{"nctId":14732,"briefTitle":14733,"status":108,"phases":14734,"primaryCompletion":14735,"completion":14736,"start":14737,"enrollment":597,"conditions":14738,"interventions":14740},"NCT05012137","The MEV of 0.5% Ropivacaine in Ultrasound-guided SASIS-FICB",[92],"2021-10-25","2021-11-25","2021-08-25",[14739],"Nerve Block",[14717],{"intervention":14742,"totalTrials":147,"cells":14743},"Anlotinib Hydrochloride Capsule and Penpulimab",{"EARLY_PHASE1":14744,"PHASE1":14746,"PHASE2":14748,"PHASE3":14750,"PHASE4":14752,"NA":14754},{"trials":14745,"activeCount":100},[],{"trials":14747,"activeCount":100},[],{"trials":14749,"activeCount":100},[],{"trials":14751,"activeCount":100},[],{"trials":14753,"activeCount":100},[],{"trials":14755,"activeCount":100},[14756],{"nctId":14757,"briefTitle":14758,"status":108,"phases":14759,"primaryCompletion":312,"completion":14760,"start":14761,"enrollment":215,"conditions":14762,"interventions":14764},"NCT06062563","Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer",[92],"2025-08-20","2023-11-11",[14763],"Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma",[14742],{"intervention":14766,"totalTrials":147,"cells":14767},"Tianqi",{"EARLY_PHASE1":14768,"PHASE1":14770,"PHASE2":14772,"PHASE3":14774,"PHASE4":14776,"NA":14778},{"trials":14769,"activeCount":100},[],{"trials":14771,"activeCount":100},[],{"trials":14773,"activeCount":100},[],{"trials":14775,"activeCount":100},[],{"trials":14777,"activeCount":100},[],{"trials":14779,"activeCount":100},[14780],{"nctId":14781,"briefTitle":14782,"status":108,"phases":14783,"primaryCompletion":5674,"completion":11664,"start":9694,"enrollment":811,"conditions":14784,"interventions":14785},"NCT02617732","Effects of Tianqi Capsule on Glucose Variability in Patients With Type 2 Diabetes.",[92],[7902],[14766],{"intervention":14787,"totalTrials":147,"cells":14788},"Polyethylene Glycols",{"EARLY_PHASE1":14789,"PHASE1":14791,"PHASE2":14793,"PHASE3":14795,"PHASE4":14797,"NA":14799},{"trials":14790,"activeCount":100},[],{"trials":14792,"activeCount":100},[],{"trials":14794,"activeCount":100},[],{"trials":14796,"activeCount":100},[],{"trials":14798,"activeCount":100},[],{"trials":14800,"activeCount":100},[14801],{"nctId":14802,"briefTitle":14803,"status":108,"phases":14804,"primaryCompletion":14805,"completion":80,"start":3193,"enrollment":1829,"conditions":14806,"interventions":14808},"NCT05485103","A Prospective Study of the Effect of Modified Colonoscopy Bowel Preparation Program on Intestinal Cleaning, Examination and Disease in Patients With Inflammatory Bowel Disease",[92],"2024-07-31",[14807],"Inflammatory Bowel Diseases",[14787],{"intervention":14810,"totalTrials":147,"cells":14811},"deep neuromuscular block",{"EARLY_PHASE1":14812,"PHASE1":14814,"PHASE2":14816,"PHASE3":14818,"PHASE4":14820,"NA":14822},{"trials":14813,"activeCount":100},[],{"trials":14815,"activeCount":100},[],{"trials":14817,"activeCount":100},[],{"trials":14819,"activeCount":100},[],{"trials":14821,"activeCount":100},[],{"trials":14823,"activeCount":100},[14824],{"nctId":14825,"briefTitle":14826,"status":108,"phases":14827,"primaryCompletion":3908,"completion":1736,"start":6625,"enrollment":14828,"conditions":14829,"interventions":14832},"NCT04259112","Effect of Pneumoperitoneum and Neuromuscular Block on Renal Function in Diabetes Patients",[92],648,[6969,197,14830,14831],"Laparoscopic Surgical Procedure","Neuromuscular Blockade",[14810,14833],"moderate neuromuscular block",{"intervention":14833,"totalTrials":147,"cells":14835},{"EARLY_PHASE1":14836,"PHASE1":14838,"PHASE2":14840,"PHASE3":14842,"PHASE4":14844,"NA":14846},{"trials":14837,"activeCount":100},[],{"trials":14839,"activeCount":100},[],{"trials":14841,"activeCount":100},[],{"trials":14843,"activeCount":100},[],{"trials":14845,"activeCount":100},[],{"trials":14847,"activeCount":100},[14848],{"nctId":14825,"briefTitle":14826,"status":108,"phases":14849,"primaryCompletion":3908,"completion":1736,"start":6625,"enrollment":14828,"conditions":14850,"interventions":14851},[92],[6969,197,14830,14831],[14810,14833],{"intervention":14853,"totalTrials":147,"cells":14854},"HCQ",{"EARLY_PHASE1":14855,"PHASE1":14857,"PHASE2":14859,"PHASE3":14861,"PHASE4":14863,"NA":14865},{"trials":14856,"activeCount":100},[],{"trials":14858,"activeCount":100},[],{"trials":14860,"activeCount":100},[],{"trials":14862,"activeCount":100},[],{"trials":14864,"activeCount":100},[],{"trials":14866,"activeCount":100},[14867],{"nctId":14868,"briefTitle":14869,"status":443,"phases":14870,"primaryCompletion":14871,"completion":14871,"start":12650,"enrollment":14872,"conditions":14873,"interventions":14875},"NCT02842814","Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus",[92],"2022-09-28",333,[14874],"Systemic Lupus Erythematosus",[14853,14876],"GC+HCQ",{"intervention":14876,"totalTrials":147,"cells":14878},{"EARLY_PHASE1":14879,"PHASE1":14881,"PHASE2":14883,"PHASE3":14885,"PHASE4":14887,"NA":14889},{"trials":14880,"activeCount":100},[],{"trials":14882,"activeCount":100},[],{"trials":14884,"activeCount":100},[],{"trials":14886,"activeCount":100},[],{"trials":14888,"activeCount":100},[],{"trials":14890,"activeCount":100},[14891],{"nctId":14868,"briefTitle":14869,"status":443,"phases":14892,"primaryCompletion":14871,"completion":14871,"start":12650,"enrollment":14872,"conditions":14893,"interventions":14894},[92],[14874],[14853,14876],{"intervention":14896,"totalTrials":147,"cells":14897},"Pranoprofen",{"EARLY_PHASE1":14898,"PHASE1":14900,"PHASE2":14902,"PHASE3":14904,"PHASE4":14906,"NA":14908},{"trials":14899,"activeCount":100},[],{"trials":14901,"activeCount":100},[],{"trials":14903,"activeCount":100},[],{"trials":14905,"activeCount":100},[],{"trials":14907,"activeCount":100},[],{"trials":14909,"activeCount":100},[14910],{"nctId":14911,"briefTitle":14912,"status":108,"phases":14913,"primaryCompletion":13735,"completion":14914,"start":9243,"enrollment":811,"conditions":14915,"interventions":14917},"NCT03013959","Observation on the Herpes Simplex Keratitis",[],"2018-09",[14916],"Keratitis, Herpetic",[14896],{"intervention":14919,"totalTrials":147,"cells":14920},"Neoantigen vaccine, I.M",{"EARLY_PHASE1":14921,"PHASE1":14923,"PHASE2":14925,"PHASE3":14927,"PHASE4":14929,"NA":14931},{"trials":14922,"activeCount":100},[],{"trials":14924,"activeCount":100},[],{"trials":14926,"activeCount":100},[],{"trials":14928,"activeCount":100},[],{"trials":14930,"activeCount":100},[],{"trials":14932,"activeCount":100},[14933],{"nctId":14934,"briefTitle":14935,"status":108,"phases":14936,"primaryCompletion":80,"completion":333,"start":14937,"enrollment":12430,"conditions":14938,"interventions":14940},"NCT05981066","A Clinical Study of mRNA Vaccine (ABOR2014\u002FIPM511) in Patients With Advanced Hepatocellular Carcinoma",[92],"2023-07-10",[14939],"Advanced Hepatocellular Carcinoma",[14919],{"intervention":14942,"totalTrials":147,"cells":14943},"Lamivudine and Dotiravir Sodium",{"EARLY_PHASE1":14944,"PHASE1":14946,"PHASE2":14948,"PHASE3":14950,"PHASE4":14952,"NA":14954},{"trials":14945,"activeCount":100},[],{"trials":14947,"activeCount":100},[],{"trials":14949,"activeCount":100},[],{"trials":14951,"activeCount":100},[],{"trials":14953,"activeCount":100},[],{"trials":14955,"activeCount":100},[14956],{"nctId":14957,"briefTitle":14958,"status":108,"phases":14959,"primaryCompletion":1735,"completion":14960,"start":9894,"enrollment":324,"conditions":14961,"interventions":14962},"NCT05332470","A Real-world Study of Lamivudine and Dotiravir Sodium Tablets in the Treatment-naïve HIV-1 Infected Patients",[],"2025-05-31",[8873],[14942],{"intervention":2781,"totalTrials":147,"cells":14964},{"EARLY_PHASE1":14965,"PHASE1":14967,"PHASE2":14969,"PHASE3":14971,"PHASE4":14973,"NA":14975},{"trials":14966,"activeCount":100},[],{"trials":14968,"activeCount":100},[],{"trials":14970,"activeCount":100},[],{"trials":14972,"activeCount":100},[],{"trials":14974,"activeCount":100},[],{"trials":14976,"activeCount":100},[14977],{"nctId":2771,"briefTitle":2772,"status":108,"phases":14978,"primaryCompletion":2774,"completion":2775,"start":2776,"enrollment":811,"conditions":14979,"interventions":14980},[],[2778],[2780,2781,46,2462,653,2461,2474],{"intervention":14982,"totalTrials":147,"cells":14983},"TDF+3TC+EFV",{"EARLY_PHASE1":14984,"PHASE1":14986,"PHASE2":14988,"PHASE3":14990,"PHASE4":14992,"NA":14994},{"trials":14985,"activeCount":100},[],{"trials":14987,"activeCount":100},[],{"trials":14989,"activeCount":100},[],{"trials":14991,"activeCount":100},[],{"trials":14993,"activeCount":100},[],{"trials":14995,"activeCount":100},[14996],{"nctId":14997,"briefTitle":14998,"status":108,"phases":14999,"primaryCompletion":8122,"completion":15000,"start":15001,"enrollment":1048,"conditions":15002,"interventions":15003},"NCT01844297","Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy",[92],"2015-12","2013-05",[10054],[14982],{"intervention":15005,"totalTrials":147,"cells":15006},"Human Papillomavirus",{"EARLY_PHASE1":15007,"PHASE1":15009,"PHASE2":15011,"PHASE3":15013,"PHASE4":15015,"NA":15017},{"trials":15008,"activeCount":100},[],{"trials":15010,"activeCount":100},[],{"trials":15012,"activeCount":100},[],{"trials":15014,"activeCount":100},[],{"trials":15016,"activeCount":100},[],{"trials":15018,"activeCount":100},[15019],{"nctId":15020,"briefTitle":15021,"status":108,"phases":15022,"primaryCompletion":15023,"completion":15024,"start":10003,"enrollment":15025,"conditions":15026,"interventions":15028},"NCT03548740","Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection",[],"2020-01-20","2020-05-20",151,[15027],"Papillomavirus Infections",[15005],{"intervention":15030,"totalTrials":147,"cells":15031},"sugammadex as reversal drugs",{"EARLY_PHASE1":15032,"PHASE1":15034,"PHASE2":15036,"PHASE3":15038,"PHASE4":15040,"NA":15042},{"trials":15033,"activeCount":100},[],{"trials":15035,"activeCount":100},[],{"trials":15037,"activeCount":100},[],{"trials":15039,"activeCount":100},[],{"trials":15041,"activeCount":100},[],{"trials":15043,"activeCount":100},[15044],{"nctId":15045,"briefTitle":15046,"status":108,"phases":15047,"primaryCompletion":3326,"completion":13317,"start":15048,"enrollment":15049,"conditions":15050,"interventions":15052},"NCT05040490","Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography",[92],"2021-08-31",414,[15051],"Postoperative Pulmonary Complications",[15030],{"intervention":15054,"totalTrials":147,"cells":15055},"Intravitreal injection of methotrexate",{"EARLY_PHASE1":15056,"PHASE1":15058,"PHASE2":15060,"PHASE3":15062,"PHASE4":15064,"NA":15066},{"trials":15057,"activeCount":100},[],{"trials":15059,"activeCount":100},[],{"trials":15061,"activeCount":100},[],{"trials":15063,"activeCount":100},[],{"trials":15065,"activeCount":100},[],{"trials":15067,"activeCount":100},[15068],{"nctId":15069,"briefTitle":15070,"status":108,"phases":15071,"primaryCompletion":527,"completion":2563,"start":2701,"enrollment":811,"conditions":15072,"interventions":15073},"NCT05950490","Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma",[],[271],[15054],{"intervention":15075,"totalTrials":147,"cells":15076},"Golimumab",{"EARLY_PHASE1":15077,"PHASE1":15079,"PHASE2":15081,"PHASE3":15083,"PHASE4":15085,"NA":15087},{"trials":15078,"activeCount":100},[],{"trials":15080,"activeCount":100},[],{"trials":15082,"activeCount":100},[],{"trials":15084,"activeCount":100},[],{"trials":15086,"activeCount":100},[],{"trials":15088,"activeCount":100},[15089],{"nctId":15090,"briefTitle":15091,"status":108,"phases":15092,"primaryCompletion":3109,"completion":3109,"start":15093,"enrollment":324,"conditions":15094,"interventions":15095},"NCT04188249","Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis",[],"2019-07-01",[3318],[15075],{"intervention":15097,"totalTrials":147,"cells":15098},"adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro",{"EARLY_PHASE1":15099,"PHASE1":15101,"PHASE2":15103,"PHASE3":15105,"PHASE4":15107,"NA":15109},{"trials":15100,"activeCount":100},[],{"trials":15102,"activeCount":100},[],{"trials":15104,"activeCount":100},[],{"trials":15106,"activeCount":100},[],{"trials":15108,"activeCount":100},[],{"trials":15110,"activeCount":100},[15111],{"nctId":15112,"briefTitle":15113,"status":108,"phases":15114,"primaryCompletion":3862,"completion":3862,"start":15115,"enrollment":5179,"conditions":15116,"interventions":15118},"NCT05978349","PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer",[92],"2022-02-14",[15117],"Colo-rectal Cancer",[15097],{"intervention":14086,"totalTrials":147,"cells":15120},{"EARLY_PHASE1":15121,"PHASE1":15123,"PHASE2":15125,"PHASE3":15127,"PHASE4":15129,"NA":15131},{"trials":15122,"activeCount":100},[],{"trials":15124,"activeCount":100},[],{"trials":15126,"activeCount":100},[],{"trials":15128,"activeCount":100},[],{"trials":15130,"activeCount":100},[],{"trials":15132,"activeCount":100},[15133],{"nctId":14078,"briefTitle":14079,"status":108,"phases":15134,"primaryCompletion":4867,"completion":2381,"start":14081,"enrollment":324,"conditions":15135,"interventions":15136},[],[14083,14084],[14073,14086,14087,14088],{"intervention":14087,"totalTrials":147,"cells":15138},{"EARLY_PHASE1":15139,"PHASE1":15141,"PHASE2":15143,"PHASE3":15145,"PHASE4":15147,"NA":15149},{"trials":15140,"activeCount":100},[],{"trials":15142,"activeCount":100},[],{"trials":15144,"activeCount":100},[],{"trials":15146,"activeCount":100},[],{"trials":15148,"activeCount":100},[],{"trials":15150,"activeCount":100},[15151],{"nctId":14078,"briefTitle":14079,"status":108,"phases":15152,"primaryCompletion":4867,"completion":2381,"start":14081,"enrollment":324,"conditions":15153,"interventions":15154},[],[14083,14084],[14073,14086,14087,14088],{"intervention":14088,"totalTrials":147,"cells":15156},{"EARLY_PHASE1":15157,"PHASE1":15159,"PHASE2":15161,"PHASE3":15163,"PHASE4":15165,"NA":15167},{"trials":15158,"activeCount":100},[],{"trials":15160,"activeCount":100},[],{"trials":15162,"activeCount":100},[],{"trials":15164,"activeCount":100},[],{"trials":15166,"activeCount":100},[],{"trials":15168,"activeCount":100},[15169],{"nctId":14078,"briefTitle":14079,"status":108,"phases":15170,"primaryCompletion":4867,"completion":2381,"start":14081,"enrollment":324,"conditions":15171,"interventions":15172},[],[14083,14084],[14073,14086,14087,14088],{"intervention":15174,"totalTrials":147,"cells":15175},"steroid",{"EARLY_PHASE1":15176,"PHASE1":15178,"PHASE2":15180,"PHASE3":15182,"PHASE4":15184,"NA":15186},{"trials":15177,"activeCount":100},[],{"trials":15179,"activeCount":100},[],{"trials":15181,"activeCount":100},[],{"trials":15183,"activeCount":100},[],{"trials":15185,"activeCount":100},[],{"trials":15187,"activeCount":100},[15188],{"nctId":15189,"briefTitle":15190,"status":443,"phases":15191,"primaryCompletion":15192,"completion":15193,"start":15194,"enrollment":96,"conditions":15195,"interventions":15198},"NCT05933291","Single-cell Landscape of BALF in Patients With Severe ARDS and CARDS",[],"2023-02-09","2023-03-15","2022-09-24",[15196,15197],"ARDS: Acute Respiratory Distress Syndrome","Covid19",[15174],{"intervention":15200,"totalTrials":147,"cells":15201},"endometriosis",{"EARLY_PHASE1":15202,"PHASE1":15204,"PHASE2":15206,"PHASE3":15208,"PHASE4":15210,"NA":15212},{"trials":15203,"activeCount":100},[],{"trials":15205,"activeCount":100},[],{"trials":15207,"activeCount":100},[],{"trials":15209,"activeCount":100},[],{"trials":15211,"activeCount":100},[],{"trials":15213,"activeCount":100},[15214],{"nctId":15215,"briefTitle":15216,"status":108,"phases":15217,"primaryCompletion":8980,"completion":14140,"start":15218,"enrollment":127,"conditions":15219,"interventions":15221},"NCT03682341","Oxidative Stress Gene Polymorphism and Ovarian Reserve Functione",[],"2018-09-20",[15220],"Recruitment",[15200],{"intervention":14181,"totalTrials":147,"cells":15223},{"EARLY_PHASE1":15224,"PHASE1":15226,"PHASE2":15228,"PHASE3":15230,"PHASE4":15232,"NA":15234},{"trials":15225,"activeCount":100},[],{"trials":15227,"activeCount":100},[],{"trials":15229,"activeCount":100},[],{"trials":15231,"activeCount":100},[],{"trials":15233,"activeCount":100},[],{"trials":15235,"activeCount":100},[15236],{"nctId":14175,"briefTitle":14176,"status":108,"phases":15237,"primaryCompletion":80,"completion":80,"start":193,"enrollment":2353,"conditions":15238,"interventions":15239},[92],[7319],[14156,14180,14181],{"intervention":15241,"totalTrials":147,"cells":15242},"low dose of dexmedetomidine with sufentanil",{"EARLY_PHASE1":15243,"PHASE1":15245,"PHASE2":15247,"PHASE3":15249,"PHASE4":15251,"NA":15253},{"trials":15244,"activeCount":100},[],{"trials":15246,"activeCount":100},[],{"trials":15248,"activeCount":100},[],{"trials":15250,"activeCount":100},[],{"trials":15252,"activeCount":100},[],{"trials":15254,"activeCount":100},[15255],{"nctId":15256,"briefTitle":15257,"status":108,"phases":15258,"primaryCompletion":333,"completion":333,"start":5042,"enrollment":8056,"conditions":15259,"interventions":15260},"NCT05249153","Dexmedetomidine and Sufentanil Effect in PCA on Pediatric Patients Undergoing Scoliosis Surgery",[92],[1444],[15241,15261],"high dose of dexmedetomidine with sufentanil",{"intervention":15261,"totalTrials":147,"cells":15263},{"EARLY_PHASE1":15264,"PHASE1":15266,"PHASE2":15268,"PHASE3":15270,"PHASE4":15272,"NA":15274},{"trials":15265,"activeCount":100},[],{"trials":15267,"activeCount":100},[],{"trials":15269,"activeCount":100},[],{"trials":15271,"activeCount":100},[],{"trials":15273,"activeCount":100},[],{"trials":15275,"activeCount":100},[15276],{"nctId":15256,"briefTitle":15257,"status":108,"phases":15277,"primaryCompletion":333,"completion":333,"start":5042,"enrollment":8056,"conditions":15278,"interventions":15279},[92],[1444],[15241,15261],{"intervention":15281,"totalTrials":147,"cells":15282},"Conbercept",{"EARLY_PHASE1":15283,"PHASE1":15285,"PHASE2":15287,"PHASE3":15289,"PHASE4":15291,"NA":15293},{"trials":15284,"activeCount":100},[],{"trials":15286,"activeCount":100},[],{"trials":15288,"activeCount":100},[],{"trials":15290,"activeCount":100},[],{"trials":15292,"activeCount":100},[],{"trials":15294,"activeCount":100},[15295],{"nctId":15296,"briefTitle":15297,"status":443,"phases":15298,"primaryCompletion":15299,"completion":15300,"start":10356,"enrollment":1048,"conditions":15301,"interventions":15303},"NCT05229237","Conbercept for Polypoidal Choroidal Vasculopathy（START Study）",[],"2021-06-05","2021-12-05",[15302,15281],"Polypoidal Choroidal Vasculopathy",[15281],{"intervention":14237,"totalTrials":147,"cells":15305},{"EARLY_PHASE1":15306,"PHASE1":15308,"PHASE2":15310,"PHASE3":15312,"PHASE4":15314,"NA":15316},{"trials":15307,"activeCount":100},[],{"trials":15309,"activeCount":100},[],{"trials":15311,"activeCount":100},[],{"trials":15313,"activeCount":100},[],{"trials":15315,"activeCount":100},[],{"trials":15317,"activeCount":100},[15318],{"nctId":14229,"briefTitle":14230,"status":108,"phases":15319,"primaryCompletion":240,"completion":3908,"start":11641,"enrollment":5179,"conditions":15320,"interventions":15321},[92],[14233,14234,14235],[14210,14237],{"intervention":15323,"totalTrials":147,"cells":15324},"Moxifloxacin Hydrochloride and Sodium Chloride",{"EARLY_PHASE1":15325,"PHASE1":15327,"PHASE2":15329,"PHASE3":15331,"PHASE4":15333,"NA":15335},{"trials":15326,"activeCount":100},[],{"trials":15328,"activeCount":100},[],{"trials":15330,"activeCount":100},[],{"trials":15332,"activeCount":100},[],{"trials":15334,"activeCount":100},[],{"trials":15336,"activeCount":100},[15337],{"nctId":15338,"briefTitle":15339,"status":108,"phases":15340,"primaryCompletion":8591,"completion":15341,"start":403,"enrollment":10383,"conditions":15342,"interventions":15344},"NCT03280004","Reason Evaluation of Initial Treatment Failure in Patients With CAP",[],"2019-11-30",[15343],"Community-acquired Pneumonia",[15323],{"intervention":15346,"totalTrials":147,"cells":15347},"Amphotericin B colloidal dispersion（ABCD）",{"EARLY_PHASE1":15348,"PHASE1":15350,"PHASE2":15352,"PHASE3":15354,"PHASE4":15356,"NA":15358},{"trials":15349,"activeCount":100},[],{"trials":15351,"activeCount":100},[],{"trials":15353,"activeCount":100},[],{"trials":15355,"activeCount":100},[],{"trials":15357,"activeCount":100},[],{"trials":15359,"activeCount":100},[15360],{"nctId":15361,"briefTitle":15362,"status":108,"phases":15363,"primaryCompletion":1858,"completion":2634,"start":15364,"enrollment":1048,"conditions":15365,"interventions":15367},"NCT05116059","To Evaluate the Efficacy and Safety of ABCD in the Treatment of IFD",[],"2021-10-22",[15366],"Invasive Fungal Disease",[15346],{"intervention":15369,"totalTrials":147,"cells":15370},"Indocyanine Green (ICG) Fluorescence Cholangiography",{"EARLY_PHASE1":15371,"PHASE1":15373,"PHASE2":15375,"PHASE3":15377,"PHASE4":15379,"NA":15381},{"trials":15372,"activeCount":100},[],{"trials":15374,"activeCount":100},[],{"trials":15376,"activeCount":100},[],{"trials":15378,"activeCount":100},[],{"trials":15380,"activeCount":100},[],{"trials":15382,"activeCount":100},[15383],{"nctId":15384,"briefTitle":15385,"status":443,"phases":15386,"primaryCompletion":15387,"completion":15388,"start":15389,"enrollment":15390,"conditions":15391,"interventions":15393},"NCT07551388","CBD Wall-Thickness Adjusted ICG Microdosing for Fluorescence Cholangiography in Moderate-to-Severe Acute Cholecystitis: A Single-Center Prospective Study",[92],"2025-04-20","2025-10-31","2025-01-08",21,[15392],"Acute Cholecystitis",[15369],{"intervention":15395,"totalTrials":147,"cells":15396},"early vaginal administration of carboprost methylate",{"EARLY_PHASE1":15397,"PHASE1":15399,"PHASE2":15401,"PHASE3":15403,"PHASE4":15405,"NA":15407},{"trials":15398,"activeCount":100},[],{"trials":15400,"activeCount":100},[],{"trials":15402,"activeCount":100},[],{"trials":15404,"activeCount":100},[],{"trials":15406,"activeCount":100},[],{"trials":15408,"activeCount":100},[15409],{"nctId":15410,"briefTitle":15411,"status":443,"phases":15412,"primaryCompletion":1858,"completion":11574,"start":1680,"enrollment":167,"conditions":15413,"interventions":15415},"NCT05834361","The Time Point of Carboprost Methylate Administration and Perioperative Complications",[92],[15414],"Artificial Abortion, PONV(Post Operative Nausea and Vomiting)",[15395,15416],"delayed vaginal administration of carboprost methylate",{"intervention":15416,"totalTrials":147,"cells":15418},{"EARLY_PHASE1":15419,"PHASE1":15421,"PHASE2":15423,"PHASE3":15425,"PHASE4":15427,"NA":15429},{"trials":15420,"activeCount":100},[],{"trials":15422,"activeCount":100},[],{"trials":15424,"activeCount":100},[],{"trials":15426,"activeCount":100},[],{"trials":15428,"activeCount":100},[],{"trials":15430,"activeCount":100},[15431],{"nctId":15410,"briefTitle":15411,"status":443,"phases":15432,"primaryCompletion":1858,"completion":11574,"start":1680,"enrollment":167,"conditions":15433,"interventions":15434},[92],[15414],[15395,15416],{"intervention":15436,"totalTrials":147,"cells":15437},"single adductor-canal-block",{"EARLY_PHASE1":15438,"PHASE1":15440,"PHASE2":15442,"PHASE3":15444,"PHASE4":15446,"NA":15448},{"trials":15439,"activeCount":100},[],{"trials":15441,"activeCount":100},[],{"trials":15443,"activeCount":100},[],{"trials":15445,"activeCount":100},[],{"trials":15447,"activeCount":100},[],{"trials":15449,"activeCount":100},[15450],{"nctId":15451,"briefTitle":15452,"status":108,"phases":15453,"primaryCompletion":5674,"completion":494,"start":15454,"enrollment":324,"conditions":15455,"interventions":15457},"NCT02784041","Single Adductor-canal-block Versus Peri-articular Infiltration on Outcome After Total Knee Arthroplasty",[92],"2016-09",[15456],"Osteoarthritis,Knee",[15436,15458],"periarticular infiltration",{"intervention":15458,"totalTrials":147,"cells":15460},{"EARLY_PHASE1":15461,"PHASE1":15463,"PHASE2":15465,"PHASE3":15467,"PHASE4":15469,"NA":15471},{"trials":15462,"activeCount":100},[],{"trials":15464,"activeCount":100},[],{"trials":15466,"activeCount":100},[],{"trials":15468,"activeCount":100},[],{"trials":15470,"activeCount":100},[],{"trials":15472,"activeCount":100},[15473],{"nctId":15451,"briefTitle":15452,"status":108,"phases":15474,"primaryCompletion":5674,"completion":494,"start":15454,"enrollment":324,"conditions":15475,"interventions":15476},[92],[15456],[15436,15458],{"intervention":15478,"totalTrials":147,"cells":15479},"NSAID",{"EARLY_PHASE1":15480,"PHASE1":15482,"PHASE2":15484,"PHASE3":15486,"PHASE4":15488,"NA":15490},{"trials":15481,"activeCount":100},[],{"trials":15483,"activeCount":100},[],{"trials":15485,"activeCount":100},[],{"trials":15487,"activeCount":100},[],{"trials":15489,"activeCount":100},[],{"trials":15491,"activeCount":100},[15492],{"nctId":15493,"briefTitle":15494,"status":108,"phases":15495,"primaryCompletion":15496,"completion":15496,"start":15497,"enrollment":7405,"conditions":15498,"interventions":15499},"NCT04611685","Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas",[92],"2021-10","2020-10-31",[5691,32,9247],[15478,15500],"Tramadol",{"intervention":15500,"totalTrials":147,"cells":15502},{"EARLY_PHASE1":15503,"PHASE1":15505,"PHASE2":15507,"PHASE3":15509,"PHASE4":15511,"NA":15513},{"trials":15504,"activeCount":100},[],{"trials":15506,"activeCount":100},[],{"trials":15508,"activeCount":100},[],{"trials":15510,"activeCount":100},[],{"trials":15512,"activeCount":100},[],{"trials":15514,"activeCount":100},[15515],{"nctId":15493,"briefTitle":15494,"status":108,"phases":15516,"primaryCompletion":15496,"completion":15496,"start":15497,"enrollment":7405,"conditions":15517,"interventions":15518},[92],[5691,32,9247],[15478,15500],{"intervention":5600,"totalTrials":147,"cells":15520},{"EARLY_PHASE1":15521,"PHASE1":15523,"PHASE2":15525,"PHASE3":15527,"PHASE4":15529,"NA":15531},{"trials":15522,"activeCount":100},[],{"trials":15524,"activeCount":100},[],{"trials":15526,"activeCount":100},[],{"trials":15528,"activeCount":100},[],{"trials":15530,"activeCount":100},[],{"trials":15532,"activeCount":100},[15533],{"nctId":5590,"briefTitle":5591,"status":108,"phases":15534,"primaryCompletion":5593,"completion":5594,"start":5595,"enrollment":2172,"conditions":15535,"interventions":15536},[92],[5597,5598],[5600,5601],{"intervention":14154,"totalTrials":147,"cells":15538},{"EARLY_PHASE1":15539,"PHASE1":15541,"PHASE2":15543,"PHASE3":15545,"PHASE4":15547,"NA":15549},{"trials":15540,"activeCount":100},[],{"trials":15542,"activeCount":100},[],{"trials":15544,"activeCount":100},[],{"trials":15546,"activeCount":100},[],{"trials":15548,"activeCount":100},[],{"trials":15550,"activeCount":100},[15551],{"nctId":14144,"briefTitle":14145,"status":108,"phases":15552,"primaryCompletion":5593,"completion":14147,"start":14148,"enrollment":1048,"conditions":15553,"interventions":15554},[92],[14150,14151],[14153,14154],{"intervention":15556,"totalTrials":147,"cells":15557},"Precise treatment",{"EARLY_PHASE1":15558,"PHASE1":15560,"PHASE2":15562,"PHASE3":15564,"PHASE4":15566,"NA":15568},{"trials":15559,"activeCount":100},[],{"trials":15561,"activeCount":100},[],{"trials":15563,"activeCount":100},[],{"trials":15565,"activeCount":100},[],{"trials":15567,"activeCount":100},[],{"trials":15569,"activeCount":100},[15570],{"nctId":15571,"briefTitle":15572,"status":108,"phases":15573,"primaryCompletion":5674,"completion":494,"start":15000,"enrollment":957,"conditions":15574,"interventions":15577},"NCT02715089","Precise Treatment in Hepatobiliary Cancers (PTHBC)",[],[15575,129,15576],"Liver Neoplasms","Hepatobiliary Neoplasms",[15556],{"intervention":15579,"totalTrials":147,"cells":15580},"Qufeng Shengshi Fang and Loratadine",{"EARLY_PHASE1":15581,"PHASE1":15583,"PHASE2":15585,"PHASE3":15587,"PHASE4":15589,"NA":15591},{"trials":15582,"activeCount":100},[],{"trials":15584,"activeCount":100},[],{"trials":15586,"activeCount":100},[],{"trials":15588,"activeCount":100},[],{"trials":15590,"activeCount":100},[],{"trials":15592,"activeCount":100},[15593],{"nctId":15594,"briefTitle":15595,"status":108,"phases":15596,"primaryCompletion":13735,"completion":15597,"start":495,"enrollment":7645,"conditions":15598,"interventions":15600},"NCT02653339","Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.",[92],"2018-08",[15599],"Rhinitis, Allergic, Perennial",[15579,15601],"Loratadine",{"intervention":15601,"totalTrials":147,"cells":15603},{"EARLY_PHASE1":15604,"PHASE1":15606,"PHASE2":15608,"PHASE3":15610,"PHASE4":15612,"NA":15614},{"trials":15605,"activeCount":100},[],{"trials":15607,"activeCount":100},[],{"trials":15609,"activeCount":100},[],{"trials":15611,"activeCount":100},[],{"trials":15613,"activeCount":100},[],{"trials":15615,"activeCount":100},[15616],{"nctId":15594,"briefTitle":15595,"status":108,"phases":15617,"primaryCompletion":13735,"completion":15597,"start":495,"enrollment":7645,"conditions":15618,"interventions":15619},[92],[15599],[15579,15601],{"intervention":15621,"totalTrials":147,"cells":15622},"RAL+TDF+LPV\u002Fr",{"EARLY_PHASE1":15623,"PHASE1":15625,"PHASE2":15627,"PHASE3":15629,"PHASE4":15631,"NA":15633},{"trials":15624,"activeCount":100},[],{"trials":15626,"activeCount":100},[],{"trials":15628,"activeCount":100},[],{"trials":15630,"activeCount":100},[],{"trials":15632,"activeCount":100},[],{"trials":15634,"activeCount":100},[15635],{"nctId":15636,"briefTitle":15637,"status":108,"phases":15638,"primaryCompletion":15000,"completion":15000,"start":15001,"enrollment":705,"conditions":15639,"interventions":15640},"NCT01844310","Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection",[92],[10054],[15621,15641],"3TC+TDF+LPV\u002Fr",{"intervention":15641,"totalTrials":147,"cells":15643},{"EARLY_PHASE1":15644,"PHASE1":15646,"PHASE2":15648,"PHASE3":15650,"PHASE4":15652,"NA":15654},{"trials":15645,"activeCount":100},[],{"trials":15647,"activeCount":100},[],{"trials":15649,"activeCount":100},[],{"trials":15651,"activeCount":100},[],{"trials":15653,"activeCount":100},[],{"trials":15655,"activeCount":100},[15656],{"nctId":15636,"briefTitle":15637,"status":108,"phases":15657,"primaryCompletion":15000,"completion":15000,"start":15001,"enrollment":705,"conditions":15658,"interventions":15659},[92],[10054],[15621,15641],{"intervention":15661,"totalTrials":147,"cells":15662},"Dacomitinib",{"EARLY_PHASE1":15663,"PHASE1":15665,"PHASE2":15667,"PHASE3":15669,"PHASE4":15671,"NA":15673},{"trials":15664,"activeCount":100},[],{"trials":15666,"activeCount":100},[],{"trials":15668,"activeCount":100},[],{"trials":15670,"activeCount":100},[],{"trials":15672,"activeCount":100},[],{"trials":15674,"activeCount":100},[15675],{"nctId":15676,"briefTitle":15677,"status":108,"phases":15678,"primaryCompletion":3375,"completion":12931,"start":2644,"enrollment":15679,"conditions":15680,"interventions":15685},"NCT04768491","Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC",[],82,[15681,15682,15683,15684],"EGFR Activating Mutation","NSCLC Stage IV","NSCLC Stage IIIB","NSCLC, Recurrent",[15661],{"intervention":15687,"totalTrials":147,"cells":15688},"Gonadotropin-releasing Hormone",{"EARLY_PHASE1":15689,"PHASE1":15691,"PHASE2":15693,"PHASE3":15695,"PHASE4":15697,"NA":15699},{"trials":15690,"activeCount":100},[],{"trials":15692,"activeCount":100},[],{"trials":15694,"activeCount":100},[],{"trials":15696,"activeCount":100},[],{"trials":15698,"activeCount":100},[],{"trials":15700,"activeCount":100},[15701],{"nctId":15702,"briefTitle":15703,"status":108,"phases":15704,"primaryCompletion":9177,"completion":12630,"start":9694,"enrollment":142,"conditions":15705,"interventions":15707},"NCT02705014","Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome",[92],[15706],"Hypogonadotropic Hypogonadism",[15687],{"intervention":2396,"totalTrials":147,"cells":15709},{"EARLY_PHASE1":15710,"PHASE1":15712,"PHASE2":15714,"PHASE3":15716,"PHASE4":15718,"NA":15720},{"trials":15711,"activeCount":100},[],{"trials":15713,"activeCount":100},[],{"trials":15715,"activeCount":100},[],{"trials":15717,"activeCount":100},[],{"trials":15719,"activeCount":100},[],{"trials":15721,"activeCount":100},[15722],{"nctId":2389,"briefTitle":2390,"status":108,"phases":15723,"primaryCompletion":2392,"completion":2392,"start":2393,"enrollment":2061,"conditions":15724,"interventions":15725},[92],[2355],[250,2396],{"intervention":15727,"totalTrials":147,"cells":15728},"microparticles packaging methotrexate",{"EARLY_PHASE1":15729,"PHASE1":15731,"PHASE2":15733,"PHASE3":15735,"PHASE4":15737,"NA":15739},{"trials":15730,"activeCount":100},[],{"trials":15732,"activeCount":100},[],{"trials":15734,"activeCount":100},[],{"trials":15736,"activeCount":100},[],{"trials":15738,"activeCount":100},[],{"trials":15740,"activeCount":100},[15741],{"nctId":15742,"briefTitle":15743,"status":108,"phases":15744,"primaryCompletion":15745,"completion":15746,"start":296,"enrollment":15747,"conditions":15748,"interventions":15750},"NCT04131231","Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion",[92],"2021-01-15","2021-06-15",248,[29,16,15749],"Malignant Pleural Effusion",[15727,15751],"recombinant human interleukin-2",{"intervention":15751,"totalTrials":147,"cells":15753},{"EARLY_PHASE1":15754,"PHASE1":15756,"PHASE2":15758,"PHASE3":15760,"PHASE4":15762,"NA":15764},{"trials":15755,"activeCount":100},[],{"trials":15757,"activeCount":100},[],{"trials":15759,"activeCount":100},[],{"trials":15761,"activeCount":100},[],{"trials":15763,"activeCount":100},[],{"trials":15765,"activeCount":100},[15766],{"nctId":15742,"briefTitle":15743,"status":108,"phases":15767,"primaryCompletion":15745,"completion":15746,"start":296,"enrollment":15747,"conditions":15768,"interventions":15769},[92],[29,16,15749],[15727,15751],{"intervention":15771,"totalTrials":147,"cells":15772},"Vinegar 20ml",{"EARLY_PHASE1":15773,"PHASE1":15775,"PHASE2":15777,"PHASE3":15779,"PHASE4":15781,"NA":15783},{"trials":15774,"activeCount":100},[],{"trials":15776,"activeCount":100},[],{"trials":15778,"activeCount":100},[],{"trials":15780,"activeCount":100},[],{"trials":15782,"activeCount":100},[],{"trials":15784,"activeCount":100},[15785],{"nctId":15786,"briefTitle":15787,"status":443,"phases":15788,"primaryCompletion":3174,"completion":333,"start":13917,"enrollment":9939,"conditions":15789,"interventions":15790},"NCT05617872","Vinegar-induced Collection of Duodenal Pancreatic Juice Via Endoscopic Ultrasound",[92],[19],[15771,15791,15792],"Saline","Vinegar 40ml",{"intervention":15791,"totalTrials":147,"cells":15794},{"EARLY_PHASE1":15795,"PHASE1":15797,"PHASE2":15799,"PHASE3":15801,"PHASE4":15803,"NA":15805},{"trials":15796,"activeCount":100},[],{"trials":15798,"activeCount":100},[],{"trials":15800,"activeCount":100},[],{"trials":15802,"activeCount":100},[],{"trials":15804,"activeCount":100},[],{"trials":15806,"activeCount":100},[15807],{"nctId":15786,"briefTitle":15787,"status":443,"phases":15808,"primaryCompletion":3174,"completion":333,"start":13917,"enrollment":9939,"conditions":15809,"interventions":15810},[92],[19],[15771,15791,15792],{"intervention":15792,"totalTrials":147,"cells":15812},{"EARLY_PHASE1":15813,"PHASE1":15815,"PHASE2":15817,"PHASE3":15819,"PHASE4":15821,"NA":15823},{"trials":15814,"activeCount":100},[],{"trials":15816,"activeCount":100},[],{"trials":15818,"activeCount":100},[],{"trials":15820,"activeCount":100},[],{"trials":15822,"activeCount":100},[],{"trials":15824,"activeCount":100},[15825],{"nctId":15786,"briefTitle":15787,"status":443,"phases":15826,"primaryCompletion":3174,"completion":333,"start":13917,"enrollment":9939,"conditions":15827,"interventions":15828},[92],[19],[15771,15791,15792],{"intervention":15830,"totalTrials":147,"cells":15831},"Digital Smoking Cessation",{"EARLY_PHASE1":15832,"PHASE1":15834,"PHASE2":15836,"PHASE3":15838,"PHASE4":15840,"NA":15842},{"trials":15833,"activeCount":100},[],{"trials":15835,"activeCount":100},[],{"trials":15837,"activeCount":100},[],{"trials":15839,"activeCount":100},[],{"trials":15841,"activeCount":100},[],{"trials":15843,"activeCount":100},[15844],{"nctId":15845,"briefTitle":15846,"status":108,"phases":15847,"primaryCompletion":9043,"completion":9043,"start":529,"enrollment":15848,"conditions":15849,"interventions":15853},"NCT05996029","A Joint Real-World Study of Digital Smoking Cessation Interventions",[92],2214,[15850,15851,15852],"Tobacco Smoke Pollution","Passive Smoking","Secondhand Smoking",[15830],{"intervention":15855,"totalTrials":147,"cells":15856},"high risk warm",{"EARLY_PHASE1":15857,"PHASE1":15859,"PHASE2":15861,"PHASE3":15863,"PHASE4":15865,"NA":15867},{"trials":15858,"activeCount":100},[],{"trials":15860,"activeCount":100},[],{"trials":15862,"activeCount":100},[],{"trials":15864,"activeCount":100},[],{"trials":15866,"activeCount":100},[],{"trials":15868,"activeCount":100},[15869],{"nctId":15870,"briefTitle":15871,"status":108,"phases":15872,"primaryCompletion":2775,"completion":15048,"start":3110,"enrollment":8455,"conditions":15873,"interventions":15875},"NCT03878901","Systemic Prevention and Management for Perioperative Hypothermia and Its Effect on Patients Outcome",[92],[15874],"Hypothermia; Anesthesia",[15855,15876,15877],"moderate risk warm","low risk warm",{"intervention":15876,"totalTrials":147,"cells":15879},{"EARLY_PHASE1":15880,"PHASE1":15882,"PHASE2":15884,"PHASE3":15886,"PHASE4":15888,"NA":15890},{"trials":15881,"activeCount":100},[],{"trials":15883,"activeCount":100},[],{"trials":15885,"activeCount":100},[],{"trials":15887,"activeCount":100},[],{"trials":15889,"activeCount":100},[],{"trials":15891,"activeCount":100},[15892],{"nctId":15870,"briefTitle":15871,"status":108,"phases":15893,"primaryCompletion":2775,"completion":15048,"start":3110,"enrollment":8455,"conditions":15894,"interventions":15895},[92],[15874],[15855,15876,15877],{"intervention":15877,"totalTrials":147,"cells":15897},{"EARLY_PHASE1":15898,"PHASE1":15900,"PHASE2":15902,"PHASE3":15904,"PHASE4":15906,"NA":15908},{"trials":15899,"activeCount":100},[],{"trials":15901,"activeCount":100},[],{"trials":15903,"activeCount":100},[],{"trials":15905,"activeCount":100},[],{"trials":15907,"activeCount":100},[],{"trials":15909,"activeCount":100},[15910],{"nctId":15870,"briefTitle":15871,"status":108,"phases":15911,"primaryCompletion":2775,"completion":15048,"start":3110,"enrollment":8455,"conditions":15912,"interventions":15913},[92],[15874],[15855,15876,15877],{"intervention":15915,"totalTrials":147,"cells":15916},"Chemotherapy Drugs, Cancer",{"EARLY_PHASE1":15917,"PHASE1":15919,"PHASE2":15921,"PHASE3":15923,"PHASE4":15925,"NA":15927},{"trials":15918,"activeCount":100},[],{"trials":15920,"activeCount":100},[],{"trials":15922,"activeCount":100},[],{"trials":15924,"activeCount":100},[],{"trials":15926,"activeCount":100},[],{"trials":15928,"activeCount":100},[15929],{"nctId":15930,"briefTitle":15931,"status":108,"phases":15932,"primaryCompletion":428,"completion":15933,"start":8640,"enrollment":705,"conditions":15934,"interventions":15935},"NCT04663438","Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC",[],"2021-05-30",[677],[15915],{"intervention":15937,"totalTrials":147,"cells":15938},"Octreotide",{"EARLY_PHASE1":15939,"PHASE1":15941,"PHASE2":15943,"PHASE3":15945,"PHASE4":15947,"NA":15949},{"trials":15940,"activeCount":100},[],{"trials":15942,"activeCount":100},[],{"trials":15944,"activeCount":100},[],{"trials":15946,"activeCount":100},[],{"trials":15948,"activeCount":100},[],{"trials":15950,"activeCount":100},[15951],{"nctId":15952,"briefTitle":15953,"status":108,"phases":15954,"primaryCompletion":9065,"completion":2392,"start":1682,"enrollment":957,"conditions":15955,"interventions":15957},"NCT03812939","Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs",[],[15956],"Gastric NET",[15937],{"intervention":15959,"totalTrials":147,"cells":15960},"NI group",{"EARLY_PHASE1":15961,"PHASE1":15963,"PHASE2":15965,"PHASE3":15967,"PHASE4":15969,"NA":15971},{"trials":15962,"activeCount":100},[],{"trials":15964,"activeCount":100},[],{"trials":15966,"activeCount":100},[],{"trials":15968,"activeCount":100},[],{"trials":15970,"activeCount":100},[],{"trials":15972,"activeCount":100},[15973],{"nctId":15974,"briefTitle":15975,"status":108,"phases":15976,"primaryCompletion":9244,"completion":15000,"start":2366,"enrollment":2353,"conditions":15977,"interventions":15978},"NCT01752517","Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer",[],[3679],[15959],{"intervention":14261,"totalTrials":147,"cells":15980},{"EARLY_PHASE1":15981,"PHASE1":15983,"PHASE2":15985,"PHASE3":15987,"PHASE4":15989,"NA":15991},{"trials":15982,"activeCount":100},[],{"trials":15984,"activeCount":100},[],{"trials":15986,"activeCount":100},[],{"trials":15988,"activeCount":100},[],{"trials":15990,"activeCount":100},[],{"trials":15992,"activeCount":100},[15993],{"nctId":14254,"briefTitle":14255,"status":108,"phases":15994,"primaryCompletion":5722,"completion":595,"start":14257,"enrollment":2353,"conditions":15995,"interventions":15996},[92],[14259],[14239,14261],{"intervention":15998,"totalTrials":147,"cells":15999},"Ivabradine Oral Product",{"EARLY_PHASE1":16000,"PHASE1":16002,"PHASE2":16004,"PHASE3":16006,"PHASE4":16008,"NA":16010},{"trials":16001,"activeCount":100},[],{"trials":16003,"activeCount":100},[],{"trials":16005,"activeCount":100},[],{"trials":16007,"activeCount":100},[],{"trials":16009,"activeCount":100},[],{"trials":16011,"activeCount":100},[16012],{"nctId":16013,"briefTitle":16014,"status":108,"phases":16015,"primaryCompletion":2392,"completion":2736,"start":1859,"enrollment":2061,"conditions":16016,"interventions":16018},"NCT03367026","Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine",[92],[16017],"Sepsis, Severe",[15998],{"intervention":16020,"totalTrials":147,"cells":16021},"Amphotericin B Colloidal Dispersion",{"EARLY_PHASE1":16022,"PHASE1":16024,"PHASE2":16026,"PHASE3":16028,"PHASE4":16030,"NA":16032},{"trials":16023,"activeCount":100},[],{"trials":16025,"activeCount":100},[],{"trials":16027,"activeCount":100},[],{"trials":16029,"activeCount":100},[],{"trials":16031,"activeCount":100},[],{"trials":16033,"activeCount":100},[16034],{"nctId":16035,"briefTitle":16036,"status":108,"phases":16037,"primaryCompletion":2635,"completion":5544,"start":16038,"enrollment":957,"conditions":16039,"interventions":16041},"NCT05471063","Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis",[92],"2022-08-22",[16040],"Cryptococcal Meningitis",[16020,16042,16043],"flucytosine","fluconazole",{"intervention":16042,"totalTrials":147,"cells":16045},{"EARLY_PHASE1":16046,"PHASE1":16048,"PHASE2":16050,"PHASE3":16052,"PHASE4":16054,"NA":16056},{"trials":16047,"activeCount":100},[],{"trials":16049,"activeCount":100},[],{"trials":16051,"activeCount":100},[],{"trials":16053,"activeCount":100},[],{"trials":16055,"activeCount":100},[],{"trials":16057,"activeCount":100},[16058],{"nctId":16035,"briefTitle":16036,"status":108,"phases":16059,"primaryCompletion":2635,"completion":5544,"start":16038,"enrollment":957,"conditions":16060,"interventions":16061},[92],[16040],[16020,16042,16043],{"intervention":16043,"totalTrials":147,"cells":16063},{"EARLY_PHASE1":16064,"PHASE1":16066,"PHASE2":16068,"PHASE3":16070,"PHASE4":16072,"NA":16074},{"trials":16065,"activeCount":100},[],{"trials":16067,"activeCount":100},[],{"trials":16069,"activeCount":100},[],{"trials":16071,"activeCount":100},[],{"trials":16073,"activeCount":100},[],{"trials":16075,"activeCount":100},[16076],{"nctId":16035,"briefTitle":16036,"status":108,"phases":16077,"primaryCompletion":2635,"completion":5544,"start":16038,"enrollment":957,"conditions":16078,"interventions":16079},[92],[16040],[16020,16042,16043],{"intervention":16081,"totalTrials":147,"cells":16082},"Atorvastatin",{"EARLY_PHASE1":16083,"PHASE1":16085,"PHASE2":16087,"PHASE3":16089,"PHASE4":16091,"NA":16093},{"trials":16084,"activeCount":100},[],{"trials":16086,"activeCount":100},[],{"trials":16088,"activeCount":100},[],{"trials":16090,"activeCount":100},[],{"trials":16092,"activeCount":100},[],{"trials":16094,"activeCount":100},[16095],{"nctId":16096,"briefTitle":16097,"status":443,"phases":16098,"primaryCompletion":1708,"completion":1708,"start":16099,"enrollment":3677,"conditions":16100,"interventions":16101},"NCT01547455","Safety and Efficiency Study of Loading Dose Atorvastatin in Cardiac Surgery",[92],"2012-04",[197],[16081]]